[{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1199261459181645825"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-26T09:46:28.000Z","author_id":"116716199","text":"RT @EUombudsman: üÜï Further to constructive dialogue, @EMA_News agrees:\n\n‚úîÔ∏è to record scientific advice for medicines in market approval pro‚Ä¶","id":"1199263139499560963","conversation_id":"1199263139499560963","entities":{"mentions":[{"start":3,"end":15,"username":"EUombudsman","id":"873777758"},{"start":53,"end":62,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1198904238862147584"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-25T15:28:55.000Z","author_id":"116716199","text":"RT @UMCGlobalSafety: Welcome to #MedSafetyWeek! Join 57 medicines regulators around the globe in raising awareness of side effects and the‚Ä¶","id":"1198986931788492803","conversation_id":"1198986931788492803","entities":{"mentions":[{"start":3,"end":19,"username":"UMCGlobalSafety","id":"3173443348"}],"hashtags":[{"start":32,"end":46,"tag":"MedSafetyWeek"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"quoted","id":"1197522784341151744"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":1,"like_count":31,"quote_count":1},"created_at":"2019-11-22T14:04:20.000Z","author_id":"116716199","text":"At the EMA-@EUnetHTA bilateral meeting yesterday, experts discussed topics such as the use of patient-reported outcomes as part of evidence generation plans; #PatientRegistries; and practices and experiences with combination products/companion diagnostics. https://t.co/yjHUPe8y4k","id":"1197878482937757696","conversation_id":"1197878482937757696","entities":{"mentions":[{"start":11,"end":20,"username":"EUnetHTA","id":"56493220"}],"hashtags":[{"start":158,"end":176,"tag":"PatientRegistries"}],"urls":[{"start":257,"end":280,"url":"https://t.co/yjHUPe8y4k","expanded_url":"https://twitter.com/EUnetHTA/status/1197522784341151744","display_url":"twitter.com/EUnetHTA/statu‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1197522784341151744"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-21T16:36:38.000Z","author_id":"116716199","text":"RT @EUnetHTA: EMA-EUnetHTA Bilateral Meeting\n\n@EUnetHTA  has been delighted to host representatives from the EMA (@EMA_News) at ZIN (@ZiNLA‚Ä¶","id":"1197554424077533184","conversation_id":"1197554424077533184","entities":{"mentions":[{"start":3,"end":12,"username":"EUnetHTA","id":"56493220"},{"start":46,"end":55,"username":"EUnetHTA","id":"56493220"},{"start":114,"end":123,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":[{"start":14,"end":35,"probability":0.3953,"type":"Organization","normalized_text":"EMA-EUnetHTA Bilateral"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":13,"quote_count":2},"created_at":"2019-11-21T13:53:55.000Z","author_id":"116716199","text":"Working together is the best way to combat #AntimicrobialResistance. See the #ICMRA statement on #AMR, which is available in English, French, Spanish &amp; Portuguese: \n\nüëâhttps://t.co/fZb8w71xmV\n\n#AntibioticResistance #OneHealth #HealthForAll #KeepAntibioticsWorking https://t.co/08jMfnhk4z","id":"1197513474525544448","conversation_id":"1197513474525544448","entities":{"mentions":{},"hashtags":[{"start":43,"end":67,"tag":"AntimicrobialResistance"},{"start":77,"end":83,"tag":"ICMRA"},{"start":97,"end":101,"tag":"AMR"},{"start":196,"end":217,"tag":"AntibioticResistance"},{"start":218,"end":228,"tag":"OneHealth"},{"start":229,"end":242,"tag":"HealthForAll"},{"start":243,"end":266,"tag":"KeepAntibioticsWorking"}],"urls":[{"start":171,"end":194,"url":"https://t.co/fZb8w71xmV","expanded_url":"http://www.icmra.info/drupal/en/news","display_url":"icmra.info/drupal/en/news"},{"start":267,"end":290,"url":"https://t.co/08jMfnhk4z","expanded_url":"https://twitter.com/EMA_News/status/1197513474525544448/photo/1","display_url":"pic.twitter.com/08jMfnhk4z"}],"annotations":{}},"attachments":{"media_keys":["3_1197513470209613825"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":4,"quote_count":0},"created_at":"2019-11-21T13:30:40.000Z","author_id":"116716199","text":"How many recommendations for eligibility for EMA's PRIME scheme were granted in November? Follow #PRIME_EMA for the latest updates. \nüëâhttps://t.co/nU3QccfxZi https://t.co/8LwdoSwirv","id":"1197507621986750465","conversation_id":"1197507621986750465","entities":{"mentions":{},"hashtags":[{"start":97,"end":107,"tag":"PRIME_EMA"}],"urls":[{"start":134,"end":157,"url":"https://t.co/nU3QccfxZi","expanded_url":"https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-11-14-november-2019_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":158,"end":181,"url":"https://t.co/8LwdoSwirv","expanded_url":"https://twitter.com/EMA_News/status/1197507621986750465/photo/1","display_url":"pic.twitter.com/8LwdoSwirv"}],"annotations":[{"start":45,"end":47,"probability":0.4222,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1197507617507151874"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":1,"like_count":29,"quote_count":3},"created_at":"2019-11-20T09:47:00.000Z","author_id":"116716199","text":"By 2050, #AntimicrobialResistance could result in a loss of USD$100 trillion and 10 million lives. We‚Äôre committed to the global fight also through #ICMRA: \n\nüëâhttps://t.co/mdMUOxDpWh\n\n#OneHealth #HealthForAll #KeepAntibioticsWorking #AMR #AntibioticResistance https://t.co/KIVMpDIizU","id":"1197088948696354816","conversation_id":"1197088948696354816","entities":{"mentions":{},"hashtags":[{"start":9,"end":33,"tag":"AntimicrobialResistance"},{"start":148,"end":154,"tag":"ICMRA"},{"start":184,"end":194,"tag":"OneHealth"},{"start":195,"end":208,"tag":"HealthForAll"},{"start":209,"end":232,"tag":"KeepAntibioticsWorking"},{"start":233,"end":237,"tag":"AMR"},{"start":238,"end":259,"tag":"AntibioticResistance"}],"urls":[{"start":159,"end":182,"url":"https://t.co/mdMUOxDpWh","expanded_url":"https://www.ema.europa.eu/en/partners-networks/international-activities/multilateral-organisations-initiatives/international-coalition-medicines-regulatory-authorities-icmra#commitment-to-fight-against-antimicrobial-resistance-section","display_url":"ema.europa.eu/en/partners-ne‚Ä¶"},{"start":260,"end":283,"url":"https://t.co/KIVMpDIizU","expanded_url":"https://twitter.com/EMA_News/status/1197088948696354816/photo/1","display_url":"pic.twitter.com/KIVMpDIizU"}],"annotations":{}},"attachments":{"media_keys":["3_1197088940529987584"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":23,"quote_count":2},"created_at":"2019-11-19T13:36:53.000Z","author_id":"116716199","text":"#AntibioticResistance is on the rise and is a major threat to global #PublicHealth. Through #ICMRA and the @WHO, we have joined the international regulatory community in the fight against #AMR:\n\nüëâhttps://t.co/mdMUOxDpWh\n\n#OneHealth #HealthForAll #KeepAntibioticsWorking https://t.co/jvljGC30Ro","id":"1196784410487595008","conversation_id":"1196784410487595008","entities":{"mentions":[{"start":107,"end":111,"username":"WHO","id":"14499829"}],"hashtags":[{"start":0,"end":21,"tag":"AntibioticResistance"},{"start":69,"end":82,"tag":"PublicHealth"},{"start":92,"end":98,"tag":"ICMRA"},{"start":188,"end":192,"tag":"AMR"},{"start":221,"end":231,"tag":"OneHealth"},{"start":232,"end":245,"tag":"HealthForAll"},{"start":246,"end":269,"tag":"KeepAntibioticsWorking"}],"urls":[{"start":196,"end":219,"url":"https://t.co/mdMUOxDpWh","expanded_url":"https://www.ema.europa.eu/en/partners-networks/international-activities/multilateral-organisations-initiatives/international-coalition-medicines-regulatory-authorities-icmra#commitment-to-fight-against-antimicrobial-resistance-section","display_url":"ema.europa.eu/en/partners-ne‚Ä¶"},{"start":270,"end":293,"url":"https://t.co/jvljGC30Ro","expanded_url":"https://twitter.com/EMA_News/status/1196784410487595008/photo/1","display_url":"pic.twitter.com/jvljGC30Ro"}],"annotations":{}},"attachments":{"media_keys":["3_1196784404007464961"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2019-11-19T13:15:34.000Z","author_id":"116716199","text":"Global health leaders and decision-makers can create new incentives and policy tools to foster the development of new medicines to curb #AntibioticResistance: \n\nüëâhttps://t.co/45lFaV6qTv \n\n#ICMRA #EAAD #EAAD2019 #KeepAntibioticsWorking #AMR https://t.co/n0VA9citbz","id":"1196779045104574465","conversation_id":"1196779045104574465","entities":{"mentions":{},"hashtags":[{"start":136,"end":157,"tag":"AntibioticResistance"},{"start":188,"end":194,"tag":"ICMRA"},{"start":195,"end":200,"tag":"EAAD"},{"start":201,"end":210,"tag":"EAAD2019"},{"start":211,"end":234,"tag":"KeepAntibioticsWorking"},{"start":235,"end":239,"tag":"AMR"}],"urls":[{"start":162,"end":185,"url":"https://t.co/45lFaV6qTv","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/antimicrobial-resistance#public-awareness-section","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":240,"end":263,"url":"https://t.co/n0VA9citbz","expanded_url":"https://twitter.com/EMA_News/status/1196779045104574465/photo/1","display_url":"pic.twitter.com/n0VA9citbz"}],"annotations":{}},"attachments":{"media_keys":["3_1196779038909648899"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":15,"quote_count":1},"created_at":"2019-11-19T10:55:44.000Z","author_id":"116716199","text":"Today is the second day of our #RegScience2025 workshop. Watch it live here: \n\nüëâhttps://t.co/lfsMw6oI6U\n\nPlease send any comments and questions to regulatoryscience2025@ema.europa.eu https://t.co/VBxUC18ZQs","id":"1196743854801801216","conversation_id":"1196743854801801216","entities":{"mentions":{},"hashtags":[{"start":31,"end":46,"tag":"RegScience2025"}],"urls":[{"start":80,"end":103,"url":"https://t.co/lfsMw6oI6U","expanded_url":"https://www.ema.europa.eu/en/events/multi-stakeholder-workshop-draft-regulatory-science-2025-strategy-stakeholders-human-medicines","display_url":"ema.europa.eu/en/events/mult‚Ä¶"},{"start":183,"end":206,"url":"https://t.co/VBxUC18ZQs","expanded_url":"https://twitter.com/EMA_News/status/1196743854801801216/photo/1","display_url":"pic.twitter.com/VBxUC18ZQs"}],"annotations":{}},"attachments":{"media_keys":["3_1196743849370095617"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":17,"quote_count":0},"created_at":"2019-11-19T10:37:46.000Z","author_id":"116716199","text":"As a #veterinarian, do you know how you can protect the effectiveness of #antibiotics in animals? \n\nhttps://t.co/45lFaV6qTv\n\n#EAAD #EAAD2019 #KeepAntibioticsWorking #AntibioticResistance #AMR #veterinary https://t.co/ZETDYpD8kk","id":"1196739336932405249","conversation_id":"1196739336932405249","entities":{"mentions":{},"hashtags":[{"start":5,"end":18,"tag":"veterinarian"},{"start":73,"end":85,"tag":"antibiotics"},{"start":125,"end":130,"tag":"EAAD"},{"start":131,"end":140,"tag":"EAAD2019"},{"start":141,"end":164,"tag":"KeepAntibioticsWorking"},{"start":165,"end":186,"tag":"AntibioticResistance"},{"start":187,"end":191,"tag":"AMR"},{"start":192,"end":203,"tag":"veterinary"}],"urls":[{"start":100,"end":123,"url":"https://t.co/45lFaV6qTv","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/antimicrobial-resistance#public-awareness-section","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":204,"end":227,"url":"https://t.co/ZETDYpD8kk","expanded_url":"https://twitter.com/EMA_News/status/1196739336932405249/photo/1","display_url":"pic.twitter.com/ZETDYpD8kk"}],"annotations":{}},"attachments":{"media_keys":["3_1196739331790163968"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":1,"like_count":31,"quote_count":3},"created_at":"2019-11-19T09:17:39.000Z","author_id":"116716199","text":"To fight #AntibioticResistance we need new weapons! The pharmaceutical industry needs to boost its R&amp;D efforts to #KeepAntibioticsWorking  \n#EAAD #EAAD2019 #AMR\nhttps://t.co/45lFaV6qTv https://t.co/ltokxwupvY","id":"1196719173893869569","conversation_id":"1196719173893869569","entities":{"mentions":{},"hashtags":[{"start":9,"end":30,"tag":"AntibioticResistance"},{"start":118,"end":141,"tag":"KeepAntibioticsWorking"},{"start":144,"end":149,"tag":"EAAD"},{"start":150,"end":159,"tag":"EAAD2019"},{"start":160,"end":164,"tag":"AMR"}],"urls":[{"start":165,"end":188,"url":"https://t.co/45lFaV6qTv","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/antimicrobial-resistance#public-awareness-section","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":189,"end":212,"url":"https://t.co/ltokxwupvY","expanded_url":"https://twitter.com/EMA_News/status/1196719173893869569/photo/1","display_url":"pic.twitter.com/ltokxwupvY"}],"annotations":{}},"attachments":{"media_keys":["3_1196719168273424385"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":11,"quote_count":1},"created_at":"2019-11-18T15:42:54.000Z","author_id":"116716199","text":"The live broadcast of our #RegScience2025 workshop had a technical glitch but the issue has now been solved. Both breakout sessions can be followed here: https://t.co/lfsMw6oI6U","id":"1196453737298046978","conversation_id":"1196453737298046978","entities":{"mentions":{},"hashtags":[{"start":26,"end":41,"tag":"RegScience2025"}],"urls":[{"start":154,"end":177,"url":"https://t.co/lfsMw6oI6U","expanded_url":"https://www.ema.europa.eu/en/events/multi-stakeholder-workshop-draft-regulatory-science-2025-strategy-stakeholders-human-medicines","display_url":"ema.europa.eu/en/events/mult‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1196412167941238784"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-18T14:27:58.000Z","author_id":"116716199","text":"RT @EAAD_EU: @EUScienceInnov @EU_Health @ECDC_EU @EU_Commission @EFSA_EU @EMA_News @WHO_Europe @V_Andriukaitis Exploring alternative therap‚Ä¶","id":"1196434879996665857","conversation_id":"1196434879996665857","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"},{"start":13,"end":28,"username":"EUScienceInnov","id":"193301414"},{"start":29,"end":39,"username":"EU_Health","id":"606325697"},{"start":40,"end":48,"username":"ECDC_EU","id":"204752573"},{"start":49,"end":63,"username":"EU_Commission","id":"157981564"},{"start":64,"end":72,"username":"EFSA_EU","id":"84582815"},{"start":73,"end":82,"username":"EMA_News","id":"116716199"},{"start":83,"end":94,"username":"WHO_Europe","id":"125403342"},{"start":95,"end":110,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":0,"like_count":29,"quote_count":8},"created_at":"2019-11-18T13:00:00.000Z","author_id":"116716199","text":"As a #HealthcareProfessional you can promote the responsible use of #antibiotics. Talk to your patients about the dangers of #AntibioticResistance.\n#EAAD #EAAD2019 #KeepAntibioticsWorking #AMR https://t.co/EOhDMNcG5e","id":"1196412740278964224","conversation_id":"1196412740278964224","entities":{"mentions":{},"hashtags":[{"start":5,"end":28,"tag":"HealthcareProfessional"},{"start":68,"end":80,"tag":"antibiotics"},{"start":125,"end":146,"tag":"AntibioticResistance"},{"start":148,"end":153,"tag":"EAAD"},{"start":154,"end":163,"tag":"EAAD2019"},{"start":164,"end":187,"tag":"KeepAntibioticsWorking"},{"start":188,"end":192,"tag":"AMR"}],"urls":[{"start":193,"end":216,"url":"https://t.co/EOhDMNcG5e","expanded_url":"https://twitter.com/EMA_News/status/1196412740278964224/photo/1","display_url":"pic.twitter.com/EOhDMNcG5e"}],"annotations":{}},"attachments":{"media_keys":["3_1196391298397282306"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":1,"like_count":32,"quote_count":4},"created_at":"2019-11-18T12:00:01.000Z","author_id":"116716199","text":"You can now follow live our #RegScience2025 workshop. Among its objectives are discussing the outcome of the public consultation on the draft strategy and identifying concrete actions to implement the core recommendations. https://t.co/lfsMw6oI6U https://t.co/906P3HVH5g","id":"1196397644597407744","conversation_id":"1196397644597407744","entities":{"mentions":{},"hashtags":[{"start":28,"end":43,"tag":"RegScience2025"}],"urls":[{"start":223,"end":246,"url":"https://t.co/lfsMw6oI6U","expanded_url":"https://www.ema.europa.eu/en/events/multi-stakeholder-workshop-draft-regulatory-science-2025-strategy-stakeholders-human-medicines","display_url":"ema.europa.eu/en/events/mult‚Ä¶"},{"start":247,"end":270,"url":"https://t.co/906P3HVH5g","expanded_url":"https://twitter.com/EMA_News/status/1196397644597407744/photo/1","display_url":"pic.twitter.com/906P3HVH5g"}],"annotations":{}},"attachments":{"media_keys":["3_1196380875455418369"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":2,"like_count":35,"quote_count":1},"created_at":"2019-11-18T10:27:31.000Z","author_id":"116716199","text":"Use antibiotics prudently so you can help protect #patients whose immune system is weakened or compromised. \n\n#EAAD #EAAD2019 #KeepAntibioticsWorking #AntibioticResistance #AMR https://t.co/wNJ4XLZcxO","id":"1196374368185704448","conversation_id":"1196374368185704448","entities":{"mentions":{},"hashtags":[{"start":50,"end":59,"tag":"patients"},{"start":110,"end":115,"tag":"EAAD"},{"start":116,"end":125,"tag":"EAAD2019"},{"start":126,"end":149,"tag":"KeepAntibioticsWorking"},{"start":150,"end":171,"tag":"AntibioticResistance"},{"start":172,"end":176,"tag":"AMR"}],"urls":[{"start":177,"end":200,"url":"https://t.co/wNJ4XLZcxO","expanded_url":"https://twitter.com/EMA_News/status/1196374368185704448/photo/1","display_url":"pic.twitter.com/wNJ4XLZcxO"}],"annotations":{}},"attachments":{"media_keys":["3_1196374362707955712"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":269,"reply_count":8,"like_count":359,"quote_count":31},"created_at":"2019-11-18T10:09:29.000Z","author_id":"116716199","text":"Antibiotics are not effective against viral infections. Don‚Äôt use them to treat a cold or flu. \n#EAAD #EAAD2019 #KeepAntibioticsWorking #AntibioticResistance #AMR https://t.co/vu8MTdD53z","id":"1196369828577239041","conversation_id":"1196369828577239041","entities":{"mentions":{},"hashtags":[{"start":96,"end":101,"tag":"EAAD"},{"start":102,"end":111,"tag":"EAAD2019"},{"start":112,"end":135,"tag":"KeepAntibioticsWorking"},{"start":136,"end":157,"tag":"AntibioticResistance"},{"start":158,"end":162,"tag":"AMR"}],"urls":[{"start":163,"end":186,"url":"https://t.co/vu8MTdD53z","expanded_url":"https://twitter.com/EMA_News/status/1196369828577239041/photo/1","display_url":"pic.twitter.com/vu8MTdD53z"}],"annotations":{}},"attachments":{"media_keys":["3_1196369823586045952"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":21,"quote_count":4},"created_at":"2019-11-18T10:02:50.000Z","author_id":"116716199","text":"#DYK that today marks #EAAD? What‚Äôs your role when it comes to the responsible use of #antibiotics? Find out what you can do as a #patient to fight #AntibioticResistance and #KeepAntibioticsWorking: https://t.co/eh0woG5Fj5\n#EAAD2019 #AMR https://t.co/3vvo2jGKt1","id":"1196368154013978624","conversation_id":"1196368154013978624","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":22,"end":27,"tag":"EAAD"},{"start":86,"end":98,"tag":"antibiotics"},{"start":130,"end":138,"tag":"patient"},{"start":148,"end":169,"tag":"AntibioticResistance"},{"start":174,"end":197,"tag":"KeepAntibioticsWorking"},{"start":223,"end":232,"tag":"EAAD2019"},{"start":233,"end":237,"tag":"AMR"}],"urls":[{"start":199,"end":222,"url":"https://t.co/eh0woG5Fj5","expanded_url":"https://www.youtube.com/watch?v=DdBWsP0oyj0","display_url":"youtube.com/watch?v=DdBWsP‚Ä¶"},{"start":238,"end":261,"url":"https://t.co/3vvo2jGKt1","expanded_url":"https://twitter.com/EMA_News/status/1196368154013978624/photo/1","display_url":"pic.twitter.com/3vvo2jGKt1"}],"annotations":{}},"attachments":{"media_keys":["3_1196368149156966400"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1196333467933401088"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":61,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-18T09:52:39.000Z","author_id":"116716199","text":"RT @EAAD_EU: #EAAD is here! And we're opening this year's celebrations in Stockholm with interesting discussions with experts on #Antibioti‚Ä¶","id":"1196365594435739648","conversation_id":"1196365594435739648","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"}],"hashtags":[{"start":13,"end":18,"tag":"EAAD"}],"urls":{},"annotations":[{"start":74,"end":82,"probability":0.9912,"type":"Place","normalized_text":"Stockholm"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1196322144961073152"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":51,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-18T08:56:36.000Z","author_id":"116716199","text":"RT @EAAD_EU: #EAAD is here!\n\nEveryone has a role to play in fighting #AntibioticResistance.\n\nLet‚Äôs #KeepAntibioticsWorking - tell your coll‚Ä¶","id":"1196351486952914944","conversation_id":"1196351486952914944","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"}],"hashtags":[{"start":13,"end":18,"tag":"EAAD"},{"start":69,"end":90,"tag":"AntibioticResistance"},{"start":99,"end":122,"tag":"KeepAntibioticsWorking"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1195364138463174659"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-15T15:43:36.000Z","author_id":"116716199","text":"RT @EU_Health: Next Monday is #EuropeanAntibioticAwarenessDay #EAAD2019 üî¥Follow along live from 9:15 as stakeholders, both at EU/EEA and na‚Ä¶","id":"1195366747966263296","conversation_id":"1195366747966263296","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":30,"end":61,"tag":"EuropeanAntibioticAwarenessDay"},{"start":62,"end":71,"tag":"EAAD2019"}],"urls":{},"annotations":[{"start":127,"end":128,"probability":0.4001,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1195350454974201856"}],"possibly_sensitive":false,"lang":"nl","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-15T14:50:16.000Z","author_id":"116716199","text":"RT @MinVWS: Precies twee jaar nadat duidelijk werd dat het #EMA naar Nederland zou verhuizen is vandaag het nieuwe gebouw op de Amsterdamse‚Ä¶","id":"1195353328256991233","conversation_id":"1195353328256991233","entities":{"mentions":[{"start":3,"end":10,"username":"MinVWS","id":"15581273"}],"hashtags":[{"start":59,"end":63,"tag":"EMA"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":66,"reply_count":5,"like_count":140,"quote_count":6},"created_at":"2019-11-15T14:38:57.000Z","author_id":"116716199","text":"Today, the Dutch authorities have handed over to us the new building located in the Zuidas area of Amsterdam. Our staff will move into their new offices and workspaces in January 2020. https://t.co/Zfo2dxRrmE https://t.co/hHA6XAvrTf","id":"1195350479154434048","conversation_id":"1195350479154434048","entities":{"mentions":{},"hashtags":{},"urls":[{"start":185,"end":208,"url":"https://t.co/Zfo2dxRrmE","expanded_url":"https://www.ema.europa.eu/en/news/dutch-authorities-hand-over-final-building-ema-amsterdam","display_url":"ema.europa.eu/en/news/dutch-‚Ä¶"},{"start":209,"end":232,"url":"https://t.co/hHA6XAvrTf","expanded_url":"https://twitter.com/EMA_News/status/1195350479154434048/photo/1","display_url":"pic.twitter.com/hHA6XAvrTf"}],"annotations":[{"start":84,"end":89,"probability":0.5497,"type":"Place","normalized_text":"Zuidas"},{"start":99,"end":107,"probability":0.9761,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1195350472078565378"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":1,"like_count":25,"quote_count":1},"created_at":"2019-11-15T11:30:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 7 #medicines for approval at its November 2019 meeting: https://t.co/E44BgLeYC3 https://t.co/8S2CY6Oqoq","id":"1195302928522731520","conversation_id":"1195302928522731520","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":107,"end":130,"url":"https://t.co/E44BgLeYC3","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-11-14-november-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":131,"end":154,"url":"https://t.co/8S2CY6Oqoq","expanded_url":"https://twitter.com/EMA_News/status/1195302928522731520/photo/1","display_url":"pic.twitter.com/8S2CY6Oqoq"}],"annotations":[{"start":0,"end":2,"probability":0.4579,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1195301471790813184"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":17,"quote_count":3},"created_at":"2019-11-12T15:28:00.000Z","author_id":"116716199","text":"Regulators‚Äô advice can make a difference for faster patient access to highly innovative therapies ‚Äì Read the perspective article published by EMA and its scientific committees #CAT and #CHMP: https://t.co/EPduulLRVz","id":"1194275658488328192","conversation_id":"1194275658488328192","entities":{"mentions":{},"hashtags":[{"start":176,"end":180,"tag":"CAT"},{"start":185,"end":190,"tag":"CHMP"}],"urls":[{"start":192,"end":215,"url":"https://t.co/EPduulLRVz","expanded_url":"https://www.ema.europa.eu/en/news/regulators-advice-can-make-difference-faster-patient-access-highly-innovative-therapies","display_url":"ema.europa.eu/en/news/regula‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"quoted","id":"1193905146784362496"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":22,"quote_count":2},"created_at":"2019-11-11T15:57:00.000Z","author_id":"116716199","text":"Great news! You can learn more about EMA's role in supporting the development of #Ebola medicines here: https://t.co/m0sS8XDqVQ https://t.co/DmKG6g0Pmt","id":"1193920568812285952","conversation_id":"1193920568812285952","entities":{"mentions":{},"hashtags":[{"start":81,"end":87,"tag":"Ebola"}],"urls":[{"start":104,"end":127,"url":"https://t.co/m0sS8XDqVQ","expanded_url":"https://www.ema.europa.eu/en/documents/leaflet/ebola-vaccine-development-2014-2019_en.pdf","display_url":"ema.europa.eu/en/documents/l‚Ä¶"},{"start":128,"end":151,"url":"https://t.co/DmKG6g0Pmt","expanded_url":"https://twitter.com/V_Andriukaitis/status/1193905146784362496","display_url":"twitter.com/V_Andriukaitis‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":41,"reply_count":0,"like_count":54,"quote_count":7},"created_at":"2019-11-11T14:16:00.000Z","author_id":"116716199","text":"Save the date: #EMA is hosting a multi-stakeholder workshop on the human medicine aspects of its draft ‚ÄòRegulatory Science Strategy to 2025‚Äô on 18-19 November. You can follow the workshop live on the day via our website https://t.co/LUOsM4T5A2 #RegScience2025 https://t.co/zQ6TDW4gCd","id":"1193895151510228993","conversation_id":"1193895151510228993","entities":{"mentions":{},"hashtags":[{"start":15,"end":19,"tag":"EMA"},{"start":244,"end":259,"tag":"RegScience2025"}],"urls":[{"start":220,"end":243,"url":"https://t.co/LUOsM4T5A2","expanded_url":"https://www.ema.europa.eu/en/news/regulatory-science-2025-live-broadcast-post-consultation-workshop","display_url":"ema.europa.eu/en/news/regula‚Ä¶"},{"start":260,"end":283,"url":"https://t.co/zQ6TDW4gCd","expanded_url":"https://twitter.com/EMA_News/status/1193895151510228993/photo/1","display_url":"pic.twitter.com/zQ6TDW4gCd"}],"annotations":{}},"attachments":{"media_keys":["3_1193894021162323968"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":3,"quote_count":0},"created_at":"2019-11-11T11:51:00.000Z","author_id":"116716199","text":"What's on the agenda of the November meeting of EMA's human medicines committee? https://t.co/1nMgwzgOXF #CHMP","id":"1193858660939681792","conversation_id":"1193858660939681792","entities":{"mentions":{},"hashtags":[{"start":105,"end":110,"tag":"CHMP"}],"urls":[{"start":81,"end":104,"url":"https://t.co/1nMgwzgOXF","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-11-14-november-2019-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":[{"start":48,"end":50,"probability":0.3957,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":32,"quote_count":2},"created_at":"2019-11-07T13:35:00.000Z","author_id":"116716199","text":"We have published a summary of the 4th meeting between EMA, the @US_FDA and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) on the development of safe and effective antibacterial medicines: https://t.co/3Iq4zLHCRc #AMR https://t.co/EurD9i2Y6R","id":"1192435282366197761","conversation_id":"1192435282366197761","entities":{"mentions":[{"start":64,"end":71,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":229,"end":233,"tag":"AMR"}],"urls":[{"start":205,"end":228,"url":"https://t.co/3Iq4zLHCRc","expanded_url":"https://www.ema.europa.eu/en/events/tripartite-meeting-held-between-ema-food-drug-administration-fda-pharmaceuticals-medical-devices","display_url":"ema.europa.eu/en/events/trip‚Ä¶"},{"start":234,"end":257,"url":"https://t.co/EurD9i2Y6R","expanded_url":"https://twitter.com/EMA_News/status/1192435282366197761/photo/1","display_url":"pic.twitter.com/EurD9i2Y6R"}],"annotations":{}},"attachments":{"media_keys":["3_1192433966973894663"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1192355824326381568"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-07T08:48:23.000Z","author_id":"116716199","text":"RT @EFSA_EU: Today in Brussels the heads of @EU_ECHA @EMA_News @ECDC_EU @EFSA_EU and @EUEnvironment will address MEPs on the Committee on E‚Ä¶","id":"1192363154291990528","conversation_id":"1192363154291990528","entities":{"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"},{"start":44,"end":52,"username":"EU_ECHA","id":"331604970"},{"start":53,"end":62,"username":"EMA_News","id":"116716199"},{"start":63,"end":71,"username":"ECDC_EU","id":"204752573"},{"start":72,"end":80,"username":"EFSA_EU","id":"84582815"},{"start":85,"end":99,"username":"EUEnvironment","id":"22362552"}],"hashtags":{},"urls":{},"annotations":[{"start":22,"end":29,"probability":0.9763,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":14,"quote_count":0},"created_at":"2019-11-07T08:00:00.000Z","author_id":"116716199","text":"EMA, @EU_ECHA, @EUEnvironment, @ECDC_EU and @EFSA_EU Directors will present the work of the EU Agencies today at the European Parliament Committee on Environment, Public Health and Food Safety. Follow the live broadcast from 10:00 CET https://t.co/ovPJY2z4JF","id":"1192350979124948993","conversation_id":"1192350979124948993","entities":{"mentions":[{"start":5,"end":13,"username":"EU_ECHA","id":"331604970"},{"start":15,"end":29,"username":"EUEnvironment","id":"22362552"},{"start":31,"end":39,"username":"ECDC_EU","id":"204752573"},{"start":44,"end":52,"username":"EFSA_EU","id":"84582815"}],"hashtags":{},"urls":[{"start":235,"end":258,"url":"https://t.co/ovPJY2z4JF","expanded_url":"https://www.europarl.europa.eu/ep-live/en/committees/video?event=20191107-0900-COMMITTEE-ENVI","display_url":"europarl.europa.eu/ep-live/en/com‚Ä¶"}],"annotations":[{"start":92,"end":102,"probability":0.8919,"type":"Organization","normalized_text":"EU Agencies"},{"start":117,"end":145,"probability":0.4938,"type":"Organization","normalized_text":"European Parliament Committee"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1192084348712804358"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-06T15:33:16.000Z","author_id":"116716199","text":"RT @EU_ECHA: üëâFollow online the ENVI committee on 7.11 üîóhttps://t.co/c6TZHWzh3d. Together with @EMA_News, @EUEnvironment, @ECDC_EU and @EFS‚Ä¶","id":"1192102658846400512","conversation_id":"1192102658846400512","entities":{"mentions":[{"start":3,"end":11,"username":"EU_ECHA","id":"331604970"},{"start":95,"end":104,"username":"EMA_News","id":"116716199"},{"start":106,"end":120,"username":"EUEnvironment","id":"22362552"},{"start":122,"end":130,"username":"ECDC_EU","id":"204752573"}],"hashtags":{},"urls":[{"start":56,"end":79,"url":"https://t.co/c6TZHWzh3d","expanded_url":"http://bit.ly/2WLXj8f","display_url":"bit.ly/2WLXj8f"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1192033194733920256"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-11-06T11:21:45.000Z","author_id":"116716199","text":"RT @EUScienceInnov: What are the #EU funding opportunities &amp; support for SMEs?\n\nDon‚Äôt miss our session at #BIOEurope with @StephaneHogan @M‚Ä¶","id":"1192039361304518657","conversation_id":"1192039361304518657","entities":{"mentions":[{"start":3,"end":18,"username":"EUScienceInnov","id":"193301414"},{"start":126,"end":140,"username":"StephaneHogan","id":"429834472"}],"hashtags":[{"start":33,"end":36,"tag":"EU"},{"start":110,"end":120,"tag":"BIOEurope"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":1,"like_count":16,"quote_count":3},"created_at":"2019-10-31T14:58:07.000Z","author_id":"116716199","text":"At its Nov meeting, EMA‚Äôs safety committee (#PRAC) recommended measures to minimise risk of serious #SideEffects with #Lemtrada for #MultipleSclerosis and cautious use of #Xeljanz for all #patients at high risk of blood clots:\nüëâhttps://t.co/eF4Cbp0OUH https://t.co/dtSnP12Kz7","id":"1189919485236514816","conversation_id":"1189919485236514816","entities":{"mentions":{},"hashtags":[{"start":44,"end":49,"tag":"PRAC"},{"start":100,"end":112,"tag":"SideEffects"},{"start":118,"end":127,"tag":"Lemtrada"},{"start":132,"end":150,"tag":"MultipleSclerosis"},{"start":171,"end":179,"tag":"Xeljanz"},{"start":188,"end":197,"tag":"patients"}],"urls":[{"start":228,"end":251,"url":"https://t.co/eF4Cbp0OUH","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-28-31-october-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":252,"end":275,"url":"https://t.co/dtSnP12Kz7","expanded_url":"https://twitter.com/EMA_News/status/1189919485236514816/photo/1","display_url":"pic.twitter.com/dtSnP12Kz7"}],"annotations":[{"start":20,"end":22,"probability":0.4364,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1189919459181510656"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":33,"quote_count":1},"created_at":"2019-10-31T08:00:51.000Z","author_id":"116716199","text":"Heads of Medicines Agencies of 28 countries joined the #ICMRA annual summit to reinforce global reliance &amp; collaboration in human #medicine #regulations. Read more about ICMRA‚Äôs efforts to maximize global regulatory impact &amp; protect #publichealth: \n\nüëâhttps://t.co/o9rhwoxcPu https://t.co/cXC9BzHih9","id":"1189814474309558272","conversation_id":"1189814474309558272","entities":{"mentions":{},"hashtags":[{"start":55,"end":61,"tag":"ICMRA"},{"start":134,"end":143,"tag":"medicine"},{"start":144,"end":156,"tag":"regulations"},{"start":241,"end":254,"tag":"publichealth"}],"urls":[{"start":259,"end":282,"url":"https://t.co/o9rhwoxcPu","expanded_url":"https://bit.ly/2C3MW61","display_url":"bit.ly/2C3MW61"},{"start":283,"end":306,"url":"https://t.co/cXC9BzHih9","expanded_url":"https://twitter.com/EMA_News/status/1189814474309558272/photo/1","display_url":"pic.twitter.com/cXC9BzHih9"}],"annotations":{}},"attachments":{"media_keys":["3_1189814465937780736"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":33,"quote_count":2},"created_at":"2019-10-30T08:47:42.000Z","author_id":"116716199","text":"Advanced therapy medicinal products (#ATMP) are highly personalized new treatments impacting health systems and regulation. International regulators focused on ATMPs and patient-centred #ClinicalTrials at the #ICMRA 2019 Summit.","id":"1189463879069454336","conversation_id":"1189463879069454336","entities":{"mentions":{},"hashtags":[{"start":37,"end":42,"tag":"ATMP"},{"start":186,"end":201,"tag":"ClinicalTrials"},{"start":209,"end":215,"tag":"ICMRA"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":25,"reply_count":0,"like_count":24,"quote_count":3},"created_at":"2019-10-29T10:38:48.000Z","author_id":"116716199","text":"The guide on #biosimilars for #HealthcareProfessionals was translated into 15 additional üá™üá∫ languages: Bulgarian, Czech, Danish, Greek, Estonian, Finnish, Croatian, Hungarian, Lithuanian, Latvian, Maltese, Romanian, Slovak, Slovenian and Swedish: https://t.co/OQIeHzbq5k https://t.co/3fPPS3jkOb","id":"1189129451449311233","conversation_id":"1189129451449311233","entities":{"mentions":{},"hashtags":[{"start":13,"end":25,"tag":"biosimilars"},{"start":30,"end":54,"tag":"HealthcareProfessionals"}],"urls":[{"start":247,"end":270,"url":"https://t.co/OQIeHzbq5k","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/overview/biosimilar-medicines-overview","display_url":"ema.europa.eu/en/human-regul‚Ä¶"},{"start":271,"end":294,"url":"https://t.co/3fPPS3jkOb","expanded_url":"https://twitter.com/EMA_News/status/1189129451449311233/photo/1","display_url":"pic.twitter.com/3fPPS3jkOb"}],"annotations":[{"start":116,"end":120,"probability":0.9053,"type":"Place","normalized_text":"Czech"},{"start":157,"end":164,"probability":0.7195,"type":"Place","normalized_text":"Croatian"},{"start":190,"end":196,"probability":0.5274,"type":"Place","normalized_text":"Latvian"},{"start":199,"end":205,"probability":0.4761,"type":"Place","normalized_text":"Maltese"},{"start":208,"end":215,"probability":0.9221,"type":"Place","normalized_text":"Romanian"},{"start":218,"end":223,"probability":0.775,"type":"Place","normalized_text":"Slovak"},{"start":226,"end":234,"probability":0.7381,"type":"Place","normalized_text":"Slovenian"}]},"attachments":{"media_keys":["3_1189129447569526784"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":2,"like_count":58,"quote_count":4},"created_at":"2019-10-29T08:35:30.000Z","author_id":"116716199","text":"Digitalized #healthcare, #bigdata &amp; real-world evidence #RWE: How to best address innovations into #RegulatoryScience? This is one of the key questions that will be discussed today during the International Coalition of Medicines Regulatory Authorities #ICMRA 2019 Summit in Rome.","id":"1189098419937337344","conversation_id":"1189098419937337344","entities":{"mentions":{},"hashtags":[{"start":12,"end":23,"tag":"healthcare"},{"start":25,"end":33,"tag":"bigdata"},{"start":60,"end":64,"tag":"RWE"},{"start":103,"end":121,"tag":"RegulatoryScience"},{"start":256,"end":262,"tag":"ICMRA"}],"urls":{},"annotations":[{"start":192,"end":238,"probability":0.759,"type":"Organization","normalized_text":"International Coalition of Medicines Regulatory"},{"start":274,"end":277,"probability":0.9544,"type":"Place","normalized_text":"Rome"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":25,"quote_count":2},"created_at":"2019-10-28T17:08:41.000Z","author_id":"116716199","text":"Heads of Medicines Agencies of 28 different countries around the world are gathered today to address emerging challenges of #innovation and #RegulatoryScience through a harmonized global approach: https://t.co/yzhwHE3y7y","id":"1188865179787776001","conversation_id":"1188865179787776001","entities":{"mentions":{},"hashtags":[{"start":124,"end":135,"tag":"innovation"},{"start":140,"end":158,"tag":"RegulatoryScience"}],"urls":[{"start":197,"end":220,"url":"https://t.co/yzhwHE3y7y","expanded_url":"http://www.icmra.info/drupal/en/home","display_url":"icmra.info/drupal/en/home","status":200,"unwound_url":"https://www.icmra.info/drupal/en/home"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":20,"quote_count":3},"created_at":"2019-10-28T13:28:44.000Z","author_id":"116716199","text":"The International Coalition of Medicines Regulatory Authorities (#ICMRA) annual summit starts today in Rome, Italy. A 3-day meeting to share experiences, lessons learnt &amp; strengthen reliance among regulators for better #medicines for human use. \nüëâhttps://t.co/yzhwHDLXg0 https://t.co/pKSdZynbyZ","id":"1188809828292087809","conversation_id":"1188809828292087809","entities":{"mentions":{},"hashtags":[{"start":65,"end":71,"tag":"ICMRA"},{"start":223,"end":233,"tag":"medicines"}],"urls":[{"start":251,"end":274,"url":"https://t.co/yzhwHDLXg0","expanded_url":"http://www.icmra.info/drupal/en/home","display_url":"icmra.info/drupal/en/home"},{"start":275,"end":298,"url":"https://t.co/pKSdZynbyZ","expanded_url":"https://twitter.com/EMA_News/status/1188809828292087809/photo/1","display_url":"pic.twitter.com/pKSdZynbyZ"}],"annotations":[{"start":4,"end":62,"probability":0.2508,"type":"Organization","normalized_text":"International Coalition of Medicines Regulatory Authorities"},{"start":103,"end":106,"probability":0.975,"type":"Place","normalized_text":"Rome"},{"start":109,"end":113,"probability":0.4508,"type":"Place","normalized_text":"Italy"}]},"attachments":{"media_keys":["3_1188809820410961920"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":1,"like_count":28,"quote_count":3},"created_at":"2019-10-18T13:02:29.000Z","author_id":"116716199","text":"Have you heard of Good Clinical Practice or simply GCP? It is an international ethical and scientific quality standard for designing, recording and reporting #ClinicalTrials that involve people. Check out this infographic: https://t.co/R3TzDJWSyu https://t.co/NqKgcemxCD","id":"1185179343984701442","conversation_id":"1185179343984701442","entities":{"mentions":{},"hashtags":[{"start":158,"end":173,"tag":"ClinicalTrials"}],"urls":[{"start":223,"end":246,"url":"https://t.co/R3TzDJWSyu","expanded_url":"https://www.ema.europa.eu/en/documents/leaflet/infographic-1000-gcp-inspections-requested-chmp_en.pdf","display_url":"ema.europa.eu/en/documents/l‚Ä¶"},{"start":247,"end":270,"url":"https://t.co/NqKgcemxCD","expanded_url":"https://twitter.com/EMA_News/status/1185179343984701442/photo/1","display_url":"pic.twitter.com/NqKgcemxCD"}],"annotations":[{"start":18,"end":39,"probability":0.3507,"type":"Other","normalized_text":"Good Clinical Practice"}]},"attachments":{"media_keys":["3_1185179337521324032"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":16,"quote_count":3},"created_at":"2019-10-18T12:00:00.000Z","author_id":"116716199","text":"EMA is working with regulatory authorities around the world to support @WHO and to advise on possible pathways for the development, evaluation and approval of #medicines and #vaccines to fight #Ebola. https://t.co/KGTJD1xmKx https://t.co/ulsWvlPJW3","id":"1185163618012352512","conversation_id":"1185163618012352512","entities":{"mentions":[{"start":71,"end":75,"username":"WHO","id":"14499829"}],"hashtags":[{"start":159,"end":169,"tag":"medicines"},{"start":174,"end":183,"tag":"vaccines"},{"start":193,"end":199,"tag":"Ebola"}],"urls":[{"start":201,"end":224,"url":"https://t.co/KGTJD1xmKx","expanded_url":"https://www.ema.europa.eu/en/news/first-vaccine-protect-against-ebola","display_url":"ema.europa.eu/en/news/first-‚Ä¶"},{"start":225,"end":248,"url":"https://t.co/ulsWvlPJW3","expanded_url":"https://twitter.com/EMA_News/status/1185163618012352512/photo/1","display_url":"pic.twitter.com/ulsWvlPJW3"}],"annotations":[{"start":0,"end":2,"probability":0.5747,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1185151286213332992"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":11,"quote_count":0},"created_at":"2019-10-18T11:35:00.000Z","author_id":"116716199","text":"Update on nitrosamine impurities for marketing authorisation holders who are currently reviewing their medicines for the possible presence of #nitrosamines and testing products at risk: https://t.co/GXBmi4hx42","id":"1185157325654380544","conversation_id":"1185157325654380544","entities":{"mentions":{},"hashtags":[{"start":142,"end":155,"tag":"nitrosamines"}],"urls":[{"start":186,"end":209,"url":"https://t.co/GXBmi4hx42","expanded_url":"https://www.ema.europa.eu/en/pharmaceutical-industry","display_url":"ema.europa.eu/en/pharmaceuti‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":2,"like_count":5,"quote_count":0},"created_at":"2019-10-18T11:15:00.000Z","author_id":"116716199","text":"First treatment for severe low blood sugar levels that can be administered without an injection to patients with #diabetes aged four years and older recommended for approval #CHMP: https://t.co/fLx8rHykqN","id":"1185152292523261953","conversation_id":"1185152292523261953","entities":{"mentions":{},"hashtags":[{"start":113,"end":122,"tag":"diabetes"},{"start":174,"end":179,"tag":"CHMP"}],"urls":[{"start":181,"end":204,"url":"https://t.co/fLx8rHykqN","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":1,"like_count":44,"quote_count":8},"created_at":"2019-10-18T11:07:05.000Z","author_id":"116716199","text":"Important step towards relieving the burden of the #Ebola virus! EMA‚Äôs human medicines committee (#CHMP) recommended granting conditional marketing authorisation for Ervebo, the 1st #vaccine to protect against Ebola. https://t.co/KGTJD1xmKx https://t.co/ukhE3q8E2c","id":"1185150302460231681","conversation_id":"1185150302460231681","entities":{"mentions":{},"hashtags":[{"start":51,"end":57,"tag":"Ebola"},{"start":98,"end":103,"tag":"CHMP"},{"start":182,"end":190,"tag":"vaccine"}],"urls":[{"start":217,"end":240,"url":"https://t.co/KGTJD1xmKx","expanded_url":"https://www.ema.europa.eu/en/news/first-vaccine-protect-against-ebola","display_url":"ema.europa.eu/en/news/first-‚Ä¶"},{"start":241,"end":264,"url":"https://t.co/ukhE3q8E2c","expanded_url":"https://twitter.com/EMA_News/status/1185150302460231681/photo/1","display_url":"pic.twitter.com/ukhE3q8E2c"}],"annotations":{}},"attachments":{"media_keys":["3_1185150296105902080"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":17,"quote_count":3},"created_at":"2019-10-18T10:51:58.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 7 #medicines for approval at its October 2019 meeting: https://t.co/fLx8rHykqN https://t.co/NGKEjMusHs","id":"1185146498977284096","conversation_id":"1185146498977284096","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":106,"end":129,"url":"https://t.co/fLx8rHykqN","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-october-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":130,"end":153,"url":"https://t.co/NGKEjMusHs","expanded_url":"https://twitter.com/EMA_News/status/1185146498977284096/photo/1","display_url":"pic.twitter.com/NGKEjMusHs"}],"annotations":[{"start":0,"end":2,"probability":0.4596,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1185146494581661697"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2019-10-17T09:11:49.000Z","author_id":"116716199","text":"EMA &amp; @EUnetHTA published the report of their July 2019 bilateral meeting. Topics discussed included recent experiences with exchanges on medicines, practices and experiences related to #patient involvement, and compliance with post-marketing activities: \nhttps://t.co/18oZtcR8XI https://t.co/NnWprwClBO","id":"1184758907274694656","conversation_id":"1184758907274694656","entities":{"mentions":[{"start":10,"end":19,"username":"EUnetHTA","id":"56493220"}],"hashtags":[{"start":190,"end":198,"tag":"patient"}],"urls":[{"start":260,"end":283,"url":"https://t.co/18oZtcR8XI","expanded_url":"https://www.ema.europa.eu/en/documents/minutes/minutes-european-medicines-agency/european-network-health-technology-assessment-meeting-july-2019_en.pdf","display_url":"ema.europa.eu/en/documents/m‚Ä¶"},{"start":284,"end":307,"url":"https://t.co/NnWprwClBO","expanded_url":"https://twitter.com/EMA_News/status/1184758907274694656/photo/1","display_url":"pic.twitter.com/NnWprwClBO"}],"annotations":{}},"attachments":{"media_keys":["3_1184758903692840960"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":0,"like_count":43,"quote_count":2},"created_at":"2019-10-16T12:03:51.000Z","author_id":"116716199","text":"How do EMA, @US_FDA and other regulators interact daily to protect #PublicHealth? This review shows, for the first time, how this collaboration takes place: https://t.co/vItn9S2gds https://t.co/d79hcley7o","id":"1184439811643498496","conversation_id":"1184439811643498496","entities":{"mentions":[{"start":12,"end":19,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":67,"end":80,"tag":"PublicHealth"}],"urls":[{"start":157,"end":180,"url":"https://t.co/vItn9S2gds","expanded_url":"https://ascpt.onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.1617","display_url":"ascpt.onlinelibrary.wiley.com/doi/epdf/10.10‚Ä¶"},{"start":181,"end":204,"url":"https://t.co/d79hcley7o","expanded_url":"https://twitter.com/EMA_News/status/1184439811643498496/photo/1","display_url":"pic.twitter.com/d79hcley7o"}],"annotations":{}},"attachments":{"media_keys":["3_1184439806371291138"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":20,"quote_count":2},"created_at":"2019-10-15T13:15:42.000Z","author_id":"116716199","text":"In 2019, 31 countries voluntarily provided information on sales or prescriptions of veterinary antibiotics, compared to 9 countries 10 years ago. #AMR #ESVAC #veterinary #antibiotics https://t.co/KIpT8D1YPu https://t.co/YaoGI3iCjJ","id":"1184095506517151744","conversation_id":"1184095506517151744","entities":{"mentions":{},"hashtags":[{"start":146,"end":150,"tag":"AMR"},{"start":151,"end":157,"tag":"ESVAC"},{"start":158,"end":169,"tag":"veterinary"},{"start":170,"end":182,"tag":"antibiotics"}],"urls":[{"start":183,"end":206,"url":"https://t.co/KIpT8D1YPu","expanded_url":"https://www.ema.europa.eu/en/news/european-countries-increase-commitment-responsible-antibiotic-use-animals","display_url":"ema.europa.eu/en/news/europe‚Ä¶"},{"start":207,"end":230,"url":"https://t.co/YaoGI3iCjJ","expanded_url":"https://twitter.com/EMA_News/status/1184095506517151744/photo/1","display_url":"pic.twitter.com/YaoGI3iCjJ"}],"annotations":{}},"attachments":{"media_keys":["3_1184095499458109440"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1184086747707256832"}],"possibly_sensitive":false,"lang":"und","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":8,"quote_count":1},"created_at":"2019-10-15T12:42:36.000Z","author_id":"116716199","text":"https://t.co/bYj6VbBEVs","id":"1184087174528094209","conversation_id":"1184086624621223942","entities":{"mentions":{},"hashtags":{},"urls":[{"start":0,"end":23,"url":"https://t.co/bYj6VbBEVs","expanded_url":"https://twitter.com/EMA_News/status/1184087174528094209/photo/1","display_url":"pic.twitter.com/bYj6VbBEVs"}],"annotations":{}},"attachments":{"media_keys":["3_1184087168232427521"]},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1184086624621223942"}],"possibly_sensitive":false,"lang":"und","public_metrics":{"retweet_count":6,"reply_count":1,"like_count":3,"quote_count":0},"created_at":"2019-10-15T12:40:54.000Z","author_id":"116716199","text":"https://t.co/kwCMAeBGQ8","id":"1184086747707256832","conversation_id":"1184086624621223942","entities":{"mentions":{},"hashtags":{},"urls":[{"start":0,"end":23,"url":"https://t.co/kwCMAeBGQ8","expanded_url":"https://twitter.com/EMA_News/status/1184086747707256832/photo/1","display_url":"pic.twitter.com/kwCMAeBGQ8"}],"annotations":{}},"attachments":{"media_keys":["3_1184086741269073920"]},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":1,"like_count":26,"quote_count":8},"created_at":"2019-10-15T12:40:25.000Z","author_id":"116716199","text":"EU guidance and national campaigns promoting prudent use of #antibiotics in animals to fight #AMR are showing results as new figures confirm: https://t.co/KIpT8D1YPu #ESVAC #veterinary \nhttps://t.co/hlxpHZe1IU https://t.co/XXK4MkmFJH","id":"1184086624621223942","conversation_id":"1184086624621223942","entities":{"mentions":{},"hashtags":[{"start":60,"end":72,"tag":"antibiotics"},{"start":93,"end":97,"tag":"AMR"},{"start":166,"end":172,"tag":"ESVAC"},{"start":173,"end":184,"tag":"veterinary"}],"urls":[{"start":142,"end":165,"url":"https://t.co/KIpT8D1YPu","expanded_url":"https://www.ema.europa.eu/en/news/european-countries-increase-commitment-responsible-antibiotic-use-animals","display_url":"ema.europa.eu/en/news/europe‚Ä¶"},{"start":186,"end":209,"url":"https://t.co/hlxpHZe1IU","expanded_url":"https://bit.ly/33vh8mo","display_url":"bit.ly/33vh8mo"},{"start":210,"end":233,"url":"https://t.co/XXK4MkmFJH","expanded_url":"https://twitter.com/EMA_News/status/1184086624621223942/photo/1","display_url":"pic.twitter.com/XXK4MkmFJH"}],"annotations":[{"start":0,"end":1,"probability":0.6412,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1184086618514378753"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":17,"quote_count":1},"created_at":"2019-10-15T12:18:56.000Z","author_id":"116716199","text":"#DYK that the responsible use of #antibiotics in animals lowers the risk of bacteria becoming resistant? The EMA #ESVAC report shows that European countries continue to reduce the use of antibiotics in animals. #AMR #veterinary https://t.co/KIpT8D1YPu https://t.co/vhyk5p92CR","id":"1184081217639141378","conversation_id":"1184081217639141378","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":33,"end":45,"tag":"antibiotics"},{"start":113,"end":119,"tag":"ESVAC"},{"start":211,"end":215,"tag":"AMR"},{"start":216,"end":227,"tag":"veterinary"}],"urls":[{"start":228,"end":251,"url":"https://t.co/KIpT8D1YPu","expanded_url":"https://www.ema.europa.eu/en/news/european-countries-increase-commitment-responsible-antibiotic-use-animals","display_url":"ema.europa.eu/en/news/europe‚Ä¶"},{"start":252,"end":275,"url":"https://t.co/vhyk5p92CR","expanded_url":"https://twitter.com/EMA_News/status/1184081217639141378/photo/1","display_url":"pic.twitter.com/vhyk5p92CR"}],"annotations":{}},"attachments":{"media_keys":["3_1184081211129565184"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":8,"quote_count":0},"created_at":"2019-10-14T15:56:19.000Z","author_id":"116716199","text":"What's on the agenda of the October meeting of EMA's human medicines committee? #CHMP https://t.co/4Zpe1sryNZ","id":"1183773536319692801","conversation_id":"1183773536319692801","entities":{"mentions":{},"hashtags":[{"start":80,"end":85,"tag":"CHMP"}],"urls":[{"start":86,"end":109,"url":"https://t.co/4Zpe1sryNZ","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-14-17-october-2019-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":[{"start":47,"end":49,"probability":0.3969,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":36,"quote_count":2},"created_at":"2019-10-14T12:12:34.000Z","author_id":"116716199","text":"We congratulate Pirkko Lepola who has been elected as the new chair of the European Network of #Paediatric Research at EMA (#EnprEMA) Coordinating Group. She will co-chair the group with Gunter Egger, Scientific Officer at EMA, for the next 3 years: https://t.co/ae12ti6HDy https://t.co/yl391Ci5Rk","id":"1183717227884929026","conversation_id":"1183717227884929026","entities":{"mentions":{},"hashtags":[{"start":95,"end":106,"tag":"Paediatric"},{"start":124,"end":132,"tag":"EnprEMA"}],"urls":[{"start":250,"end":273,"url":"https://t.co/ae12ti6HDy","expanded_url":"https://www.ema.europa.eu/en/news/european-network-paediatric-research-ema-elects-new-chair","display_url":"ema.europa.eu/en/news/europe‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/yl391Ci5Rk","expanded_url":"https://twitter.com/EMA_News/status/1183717227884929026/photo/1","display_url":"pic.twitter.com/yl391Ci5Rk"}],"annotations":[{"start":16,"end":28,"probability":0.8731,"type":"Person","normalized_text":"Pirkko Lepola"},{"start":187,"end":198,"probability":0.9419,"type":"Person","normalized_text":"Gunter Egger"}]},"attachments":{"media_keys":["3_1183717219332771840"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":12,"quote_count":2},"created_at":"2019-10-08T07:31:08.000Z","author_id":"116716199","text":"EMA‚Äôs #paediatric committee (#PDCO) seeks views of children &amp; young people with vitiligo (or their carers) on a potential new treatment. \n\n‚úèÔ∏èComplete the survey by 14 October: https://t.co/wnQAKaExwA \n\n ‚ÑπÔ∏èRead more: https://t.co/IDRMNUwJDx https://t.co/DdQ2gODhT3","id":"1181472077045489665","conversation_id":"1181472077045489665","entities":{"mentions":{},"hashtags":[{"start":6,"end":17,"tag":"paediatric"},{"start":29,"end":34,"tag":"PDCO"}],"urls":[{"start":180,"end":203,"url":"https://t.co/wnQAKaExwA","expanded_url":"https://bit.ly/35ev1qX","display_url":"bit.ly/35ev1qX"},{"start":220,"end":243,"url":"https://t.co/IDRMNUwJDx","expanded_url":"https://www.ema.europa.eu/en/patients-carers","display_url":"ema.europa.eu/en/patients-ca‚Ä¶"},{"start":244,"end":267,"url":"https://t.co/DdQ2gODhT3","expanded_url":"https://twitter.com/EMA_News/status/1181472077045489665/photo/1","display_url":"pic.twitter.com/DdQ2gODhT3"}],"annotations":{}},"attachments":{"media_keys":["3_1181472072335278080"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":1,"like_count":9,"quote_count":0},"created_at":"2019-10-04T12:44:24.000Z","author_id":"116716199","text":"See the highlights of the October meeting of our \nManagement Board: https://t.co/ccG3sF6EQE https://t.co/M9oWvD7rs3","id":"1180101361670742019","conversation_id":"1180101361670742019","entities":{"mentions":{},"hashtags":{},"urls":[{"start":68,"end":91,"url":"https://t.co/ccG3sF6EQE","expanded_url":"https://www.ema.europa.eu/en/news/ema-management-board-highlights-october-2019-meeting","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":92,"end":115,"url":"https://t.co/M9oWvD7rs3","expanded_url":"https://twitter.com/EMA_News/status/1180101361670742019/photo/1","display_url":"pic.twitter.com/M9oWvD7rs3"}],"annotations":[{"start":49,"end":65,"probability":0.5903,"type":"Organization","normalized_text":"Management Board"}]},"attachments":{"media_keys":["3_1180101354234273797"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":1,"like_count":13,"quote_count":0},"created_at":"2019-10-04T12:41:13.000Z","author_id":"116716199","text":"At its October meeting, our safety committee #PRAC recommended a 4-week limit for the use of high-strength #estradiol creams. Access the link to see the full infographic: https://t.co/IKKdvjNtLD #pharmacovigilance https://t.co/DuCUDxNDjX","id":"1180100559422066688","conversation_id":"1180100559422066688","entities":{"mentions":{},"hashtags":[{"start":45,"end":50,"tag":"PRAC"},{"start":107,"end":117,"tag":"estradiol"},{"start":195,"end":213,"tag":"pharmacovigilance"}],"urls":[{"start":171,"end":194,"url":"https://t.co/IKKdvjNtLD","expanded_url":"https://ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-30-september-3-october-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":214,"end":237,"url":"https://t.co/DuCUDxNDjX","expanded_url":"https://twitter.com/EMA_News/status/1180100559422066688/photo/1","display_url":"pic.twitter.com/DuCUDxNDjX"}],"annotations":{}},"attachments":{"media_keys":["3_1180100555018035205"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":51,"reply_count":3,"like_count":39,"quote_count":5},"created_at":"2019-09-26T10:08:03.000Z","author_id":"116716199","text":"EMA is requesting as a matter of precaution that marketing authorisation holders for human medicines containing chemically synthesised active substances review their medicines for the possible presence of #nitrosamines and test all products at risk. https://t.co/zLw66TOl6x https://t.co/uDfZrzLyiG","id":"1177162912693182465","conversation_id":"1177162912693182465","entities":{"mentions":{},"hashtags":[{"start":205,"end":218,"tag":"nitrosamines"}],"urls":[{"start":250,"end":273,"url":"https://t.co/zLw66TOl6x","expanded_url":"https://www.ema.europa.eu/en/news/ema-advises-companies-steps-take-avoid-nitrosamines-human-medicines","display_url":"ema.europa.eu/en/news/ema-ad‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/uDfZrzLyiG","expanded_url":"https://twitter.com/EMA_News/status/1177162912693182465/photo/1","display_url":"pic.twitter.com/uDfZrzLyiG"}],"annotations":{}},"attachments":{"media_keys":["3_1177162906930163712"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":1,"like_count":16,"quote_count":2},"created_at":"2019-09-25T16:11:16.000Z","author_id":"116716199","text":"EMA congratulates Prof. Ulrich J√§ger of @EHA_Hematology who has been elected as co-chair of our #HealthcareProfessionals‚Äô Working Party. He will co-chair the HCPWP meetings with Juan Garcia Burgos, EMA‚Äôs Head of Public Engagement, for the next 3 years: https://t.co/JVeJQ3gmnh https://t.co/wWJvKMSlJg","id":"1176891931424677888","conversation_id":"1176891931424677888","entities":{"mentions":[{"start":40,"end":55,"username":"EHA_Hematology","id":"279001852"}],"hashtags":[{"start":96,"end":120,"tag":"HealthcareProfessionals"}],"urls":[{"start":253,"end":276,"url":"https://t.co/JVeJQ3gmnh","expanded_url":"http://ema.europa.eu/en/news/working-parties-healthcare-professionals-patients-consumers-elect-new-co-chairs-0","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":277,"end":300,"url":"https://t.co/wWJvKMSlJg","expanded_url":"https://twitter.com/EMA_News/status/1176891931424677888/photo/1","display_url":"pic.twitter.com/wWJvKMSlJg"}],"annotations":[{"start":0,"end":2,"probability":0.6038,"type":"Person","normalized_text":"EMA"},{"start":18,"end":29,"probability":0.9718,"type":"Person","normalized_text":"Prof. Ulrich"},{"start":178,"end":195,"probability":0.9664,"type":"Person","normalized_text":"Juan Garcia Burgos"}]},"attachments":{"media_keys":["3_1176891924709543936"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":35,"quote_count":5},"created_at":"2019-09-25T16:08:00.000Z","author_id":"116716199","text":"EMA congratulates Kaisa Immonen of @eupatientsforum who has been re-elected as co-chair of our #Patients' and Consumers' Working Party. She will co-chair the PCWP meetings with Juan Garcia Burgos, EMA‚Äôs Head of Public Engagement, for the next 3 years. https://t.co/Fgf1Dkpc7s https://t.co/nlAR6YvxhI","id":"1176891109005508615","conversation_id":"1176891109005508615","entities":{"mentions":[{"start":35,"end":51,"username":"eupatientsforum","id":"545343465"}],"hashtags":[{"start":95,"end":104,"tag":"Patients"}],"urls":[{"start":252,"end":275,"url":"https://t.co/Fgf1Dkpc7s","expanded_url":"https://www.ema.europa.eu/en/news/working-parties-healthcare-professionals-patients-consumers-elect-new-co-chairs-0","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":276,"end":299,"url":"https://t.co/nlAR6YvxhI","expanded_url":"https://twitter.com/EMA_News/status/1176891109005508615/photo/1","display_url":"pic.twitter.com/nlAR6YvxhI"}],"annotations":[{"start":0,"end":2,"probability":0.4094,"type":"Person","normalized_text":"EMA"},{"start":18,"end":30,"probability":0.9107,"type":"Person","normalized_text":"Kaisa Immonen"},{"start":177,"end":194,"probability":0.9663,"type":"Person","normalized_text":"Juan Garcia Burgos"}]},"attachments":{"media_keys":["3_1176891102231703553"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2019-09-23T10:21:02.000Z","author_id":"116716199","text":"#DYK the new #veterinary legislation aims to better address #AntimicrobialResistance? See the role of EMA in the implementation of this important regulation: https://t.co/uoWpnyqBSw #AMR https://t.co/Ics4VhcvKe","id":"1176079016954081281","conversation_id":"1176079016954081281","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":13,"end":24,"tag":"veterinary"},{"start":60,"end":84,"tag":"AntimicrobialResistance"},{"start":182,"end":186,"tag":"AMR"}],"urls":[{"start":158,"end":181,"url":"https://t.co/uoWpnyqBSw","expanded_url":"https://www.ema.europa.eu/en/news/emas-work-new-veterinary-regulation-advances","display_url":"ema.europa.eu/en/news/emas-w‚Ä¶"},{"start":187,"end":210,"url":"https://t.co/Ics4VhcvKe","expanded_url":"https://twitter.com/EMA_News/status/1176079016954081281/photo/1","display_url":"pic.twitter.com/Ics4VhcvKe"}],"annotations":{}},"attachments":{"media_keys":["3_1176079009161068545"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":13,"quote_count":1},"created_at":"2019-09-20T10:20:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 7 #medicines for approval at its September 2019 meeting: https://t.co/vWHCQNF0Ca https://t.co/azwxCas5Vv","id":"1174991590970023936","conversation_id":"1174991590970023936","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":108,"end":131,"url":"https://t.co/vWHCQNF0Ca","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-september-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":132,"end":155,"url":"https://t.co/azwxCas5Vv","expanded_url":"https://twitter.com/EMA_News/status/1174991590970023936/photo/1","display_url":"pic.twitter.com/azwxCas5Vv"}],"annotations":[{"start":0,"end":2,"probability":0.4574,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1174990252303425538"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2019-09-16T08:40:00.000Z","author_id":"116716199","text":"Check out the agenda of this week‚Äôs meeting of the Committee for Human #Medicines (#CHMP): https://t.co/AYpyY8D9P1","id":"1173516873628966913","conversation_id":"1173516873628966913","entities":{"mentions":{},"hashtags":[{"start":71,"end":81,"tag":"Medicines"},{"start":83,"end":88,"tag":"CHMP"}],"urls":[{"start":91,"end":114,"url":"https://t.co/AYpyY8D9P1","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-16-19-september-2019-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":1,"like_count":30,"quote_count":9},"created_at":"2019-09-13T12:10:23.000Z","author_id":"116716199","text":"EMA will start a review of #ranitidine medicines after tests showed that some of these products contained an impurity: https://t.co/E9ogsvWylz","id":"1172482656350670851","conversation_id":"1172482656350670851","entities":{"mentions":{},"hashtags":[{"start":27,"end":38,"tag":"ranitidine"}],"urls":[{"start":119,"end":142,"url":"https://t.co/E9ogsvWylz","expanded_url":"https://www.ema.europa.eu/en/news/ema-review-ranitidine-medicines-following-detection-ndma","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":10,"quote_count":2},"created_at":"2019-09-13T12:08:48.000Z","author_id":"116716199","text":"EMA to provide guidance on avoiding #nitrosamines in human medicines: https://t.co/O5tARxUB1h https://t.co/MGeEIWwNQB","id":"1172482259343106048","conversation_id":"1172482259343106048","entities":{"mentions":{},"hashtags":[{"start":36,"end":49,"tag":"nitrosamines"}],"urls":[{"start":70,"end":93,"url":"https://t.co/O5tARxUB1h","expanded_url":"https://www.ema.europa.eu/en/news/ema-provide-guidance-avoiding-nitrosamines-human-medicines","display_url":"ema.europa.eu/en/news/ema-pr‚Ä¶"},{"start":94,"end":117,"url":"https://t.co/MGeEIWwNQB","expanded_url":"https://twitter.com/EMA_News/status/1172482259343106048/photo/1","display_url":"pic.twitter.com/MGeEIWwNQB"}],"annotations":{}},"attachments":{"media_keys":["3_1172482254804791296"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1172154017687973888"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":21,"quote_count":1},"created_at":"2019-09-12T14:25:25.000Z","author_id":"116716199","text":"Remember, as long as a vaccine remains on the EU market, EMA will permanently monitor, collect and analyse new information on the efficacy, quality and safety of a vaccine. #VaccinesWork #VaccinationSummit19 https://t.co/PrXIqHs4hY","id":"1172154249330995200","conversation_id":"1172122559367827456","entities":{"mentions":{},"hashtags":[{"start":173,"end":186,"tag":"VaccinesWork"},{"start":187,"end":207,"tag":"VaccinationSummit19"}],"urls":[{"start":208,"end":231,"url":"https://t.co/PrXIqHs4hY","expanded_url":"https://twitter.com/EMA_News/status/1172154249330995200/photo/1","display_url":"pic.twitter.com/PrXIqHs4hY"}],"annotations":{}},"attachments":{"media_keys":["3_1172154244931211265"]},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"replied_to","id":"1172122559367827456"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":16,"quote_count":0},"created_at":"2019-09-12T14:24:30.000Z","author_id":"116716199","text":"Even after a vaccine starts being used, EMA's experts continuously look into evidence and research results to make sure benefits are still higher than risks. #VaccinesWork #VaccinationSummit19 https://t.co/ZnW9eQVgw3","id":"1172154017687973888","conversation_id":"1172122559367827456","entities":{"mentions":{},"hashtags":[{"start":158,"end":171,"tag":"VaccinesWork"},{"start":172,"end":192,"tag":"VaccinationSummit19"}],"urls":[{"start":193,"end":216,"url":"https://t.co/ZnW9eQVgw3","expanded_url":"https://twitter.com/EMA_News/status/1172154017687973888/photo/1","display_url":"pic.twitter.com/ZnW9eQVgw3"}],"annotations":{}},"attachments":{"media_keys":["3_1172154012789026817"]},"in_reply_to_user_id":"116716199"},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1172118113174859776"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":54,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-09-12T12:41:01.000Z","author_id":"116716199","text":"RT @EU_Health: Our hashtag is being put to good use both online and offline today üòéüëå RT if you agree that #VaccinesWork #VaccinationSummit1‚Ä¶","id":"1172127975162167296","conversation_id":"1172127975162167296","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":106,"end":119,"tag":"VaccinesWork"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":2,"like_count":45,"quote_count":1},"created_at":"2019-09-12T12:19:29.000Z","author_id":"116716199","text":"#DidYouKnow that EMA looks into all available data before #vaccines are approved for use in the EU? Find out more about vaccines at #VaccinationSummit19: https://t.co/dOLcBJHae7\n#VaccinesWork https://t.co/hLDnedlNCq","id":"1172122559367827456","conversation_id":"1172122559367827456","entities":{"mentions":{},"hashtags":[{"start":0,"end":11,"tag":"DidYouKnow"},{"start":58,"end":67,"tag":"vaccines"},{"start":132,"end":152,"tag":"VaccinationSummit19"},{"start":178,"end":191,"tag":"VaccinesWork"}],"urls":[{"start":154,"end":177,"url":"https://t.co/dOLcBJHae7","expanded_url":"https://www.pscp.tv/w/1yNGapzqrojKj","display_url":"pscp.tv/w/1yNGapzqrojKj"},{"start":192,"end":215,"url":"https://t.co/hLDnedlNCq","expanded_url":"https://twitter.com/EMA_News/status/1172122559367827456/photo/1","display_url":"pic.twitter.com/hLDnedlNCq"}],"annotations":{}},"attachments":{"media_keys":["3_1172122552220737536"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1172048018389880833"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":46,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-09-12T09:31:43.000Z","author_id":"116716199","text":"RT @EU_Health: üî¥We are live from #VaccinationSummit19 #VaccinesWork https://t.co/qv0s4lcULg","id":"1172080338769784835","conversation_id":"1172080338769784835","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":33,"end":53,"tag":"VaccinationSummit19"},{"start":54,"end":67,"tag":"VaccinesWork"}],"urls":[{"start":68,"end":91,"url":"https://t.co/qv0s4lcULg","expanded_url":"https://www.pscp.tv/w/cEnp5TFkdktPVlJBWVJXUVh8MXlOR2FwenFyb2pLas1o8FR86bIMz39bSwtU5uVn44vhHNHpdtl8ur0NLgNH","display_url":"pscp.tv/w/cEnp5TFkdktP‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1171654195298131969"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":179,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-09-11T10:00:44.000Z","author_id":"116716199","text":"RT @EU_Health: #VaccinationSummit19 happens tomorrow in Brussels! üî¥You can follow via live stream too, all details available here ‚û°Ô∏è https:‚Ä¶","id":"1171725252931596289","conversation_id":"1171725252931596289","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":35,"tag":"VaccinationSummit19"}],"urls":{},"annotations":[{"start":56,"end":63,"probability":0.9861,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1171419345416794112"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-09-11T09:31:24.000Z","author_id":"116716199","text":"RT @EFA_Patients: On #AtopicEczemaDay we are looking #beneaththesurface and show what living with #eczema really means. Join us on Septembe‚Ä¶","id":"1171717868909748224","conversation_id":"1171717868909748224","entities":{"mentions":[{"start":3,"end":16,"username":"EFA_Patients","id":"1299643704"}],"hashtags":[{"start":21,"end":37,"tag":"AtopicEczemaDay"},{"start":53,"end":71,"tag":"beneaththesurface"},{"start":98,"end":105,"tag":"eczema"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1171324930287427584"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":188,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-09-10T07:49:30.000Z","author_id":"116716199","text":"RT @EU_Health: What are the benefits of vaccination? Are they safe? Are vaccine-preventable diseases increasing in the EU? These are some o‚Ä¶","id":"1171329837723738112","conversation_id":"1171329837723738112","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1170972092222844929"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":927,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-09-09T09:55:39.000Z","author_id":"116716199","text":"RT @EU_Health: #VaccinationSummit19 kicks off this Thursday in Brussels, the event is co-organised by the @EU_Commission and the @WHO¬†üî¥¬†You‚Ä¶","id":"1170999197048463366","conversation_id":"1170999197048463366","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":106,"end":120,"username":"EU_Commission","id":"157981564"},{"start":129,"end":133,"username":"WHO","id":"14499829"}],"hashtags":[{"start":15,"end":35,"tag":"VaccinationSummit19"}],"urls":{},"annotations":[{"start":63,"end":70,"probability":0.9882,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Media Studio","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":52,"reply_count":0,"like_count":58,"quote_count":2},"created_at":"2019-09-06T13:18:42.000Z","author_id":"116716199","text":"#VaccinesWork! There are just a few days until the #VaccinationSummit19 in Brussels, co-organised by the @EU_Commission and the @WHO. The event will be live streamed. The agenda and other details are available here https://t.co/AOsk12B4uG https://t.co/H9bOyysgQr","id":"1169963131453526016","conversation_id":"1169963131453526016","entities":{"mentions":[{"start":105,"end":119,"username":"EU_Commission","id":"157981564"},{"start":128,"end":132,"username":"WHO","id":"14499829"}],"hashtags":[{"start":0,"end":13,"tag":"VaccinesWork"},{"start":51,"end":71,"tag":"VaccinationSummit19"}],"urls":[{"start":215,"end":238,"url":"https://t.co/AOsk12B4uG","expanded_url":"http://europa.eu/!Ht49jh","display_url":"europa.eu/!Ht49jh"},{"start":239,"end":262,"url":"https://t.co/H9bOyysgQr","expanded_url":"https://twitter.com/EMA_News/status/1169963131453526016/video/1","display_url":"pic.twitter.com/H9bOyysgQr"}],"annotations":[{"start":75,"end":82,"probability":0.9723,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":["13_1161553418437222400"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":2,"quote_count":1},"created_at":"2019-09-06T10:26:42.000Z","author_id":"116716199","text":"At its September meeting, our safety committee started a review of data on skin cancer in patients using #Picato to treat #ActinicKeratosis. #PRAC #pharmacovigilance https://t.co/xXuPDs15zC https://t.co/g6EX1uedJl","id":"1169919849918795776","conversation_id":"1169919849918795776","entities":{"mentions":{},"hashtags":[{"start":105,"end":112,"tag":"Picato"},{"start":122,"end":139,"tag":"ActinicKeratosis"},{"start":141,"end":146,"tag":"PRAC"},{"start":147,"end":165,"tag":"pharmacovigilance"}],"urls":[{"start":166,"end":189,"url":"https://t.co/xXuPDs15zC","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-september-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":190,"end":213,"url":"https://t.co/g6EX1uedJl","expanded_url":"https://twitter.com/EMA_News/status/1169919849918795776/photo/1","display_url":"pic.twitter.com/g6EX1uedJl"}],"annotations":{}},"attachments":{"media_keys":["3_1169919844319408128"]}},{"source":"Twitter Web App","referenced_tweets":[{"type":"retweeted","id":"1168785418088792064"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-09-03T09:05:30.000Z","author_id":"116716199","text":"RT @relocatemaEN: Today is sustainable Tuesday. View photos of the green wall and the roof garden in the new EMA building. https://t.co/1Ks‚Ä¶","id":"1168812248346836992","conversation_id":"1168812248346836992","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":1,"like_count":24,"quote_count":1},"created_at":"2019-08-30T12:04:53.000Z","author_id":"116716199","text":".@ICH_news is organising a public meeting (31 Oct 2019, at the @US_FDA headquarters) to review the draft E8 Guideline ‚ÄòGeneral Considerations for #ClinicalTrials‚Äô. Those interested can attend in person or follow the event via webcast: https://t.co/NfJw1mkBJu https://t.co/AgPAEsQlVo","id":"1167407843311529988","conversation_id":"1167407843311529988","entities":{"mentions":[{"start":1,"end":10,"username":"ICH_news","id":"305434870"},{"start":63,"end":70,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":146,"end":161,"tag":"ClinicalTrials"}],"urls":[{"start":235,"end":258,"url":"https://t.co/NfJw1mkBJu","expanded_url":"https://www.ema.europa.eu/en/news/global-public-meeting-draft-ich-guideline-clinical-trials","display_url":"ema.europa.eu/en/news/global‚Ä¶"},{"start":259,"end":282,"url":"https://t.co/AgPAEsQlVo","expanded_url":"https://twitter.com/EMA_News/status/1167407843311529988/photo/1","display_url":"pic.twitter.com/AgPAEsQlVo"}],"annotations":{}},"attachments":{"media_keys":["3_1167407838542667781"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":41,"reply_count":2,"like_count":46,"quote_count":8},"created_at":"2019-08-26T11:34:33.000Z","author_id":"116716199","text":"How can we increase the use of #PatientRegistries in regulatory assessments of #medicines üíä? \nRead more in this article: \nüëâhttps://t.co/rPFHa826bf https://t.co/N03ghqWiXN","id":"1165950657653891072","conversation_id":"1165950657653891072","entities":{"mentions":{},"hashtags":[{"start":31,"end":49,"tag":"PatientRegistries"},{"start":79,"end":89,"tag":"medicines"}],"urls":[{"start":123,"end":146,"url":"https://t.co/rPFHa826bf","expanded_url":"https://link.springer.com/article/10.1007/s40264-019-00848-9","display_url":"link.springer.com/article/10.100‚Ä¶"},{"start":147,"end":170,"url":"https://t.co/N03ghqWiXN","expanded_url":"https://twitter.com/EMA_News/status/1165950657653891072/photo/1","display_url":"pic.twitter.com/N03ghqWiXN"}],"annotations":{}},"attachments":{"media_keys":["3_1165950652570374145"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":5,"quote_count":0},"created_at":"2019-08-19T14:14:45.000Z","author_id":"116716199","text":"We are looking for a Security Officer who will join the security team responsible for operations of physical security of EMA‚Äôs premises: https://t.co/UQzshElYlJ \n#JobsEMA #EUJobs https://t.co/GHTvBVim2f","id":"1163454259117117440","conversation_id":"1163454259117117440","entities":{"mentions":{},"hashtags":[{"start":162,"end":170,"tag":"JobsEMA"},{"start":171,"end":178,"tag":"EUJobs"}],"urls":[{"start":137,"end":160,"url":"https://t.co/UQzshElYlJ","expanded_url":"https://bit.ly/2NhdHuS","display_url":"bit.ly/2NhdHuS"},{"start":179,"end":202,"url":"https://t.co/GHTvBVim2f","expanded_url":"https://twitter.com/EMA_News/status/1163454259117117440/photo/1","display_url":"pic.twitter.com/GHTvBVim2f"}],"annotations":{}},"attachments":{"media_keys":["3_1163454247603789825"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":43,"reply_count":5,"like_count":73,"quote_count":6},"created_at":"2019-08-16T12:39:08.000Z","author_id":"116716199","text":"EMA and @US_FDA are aligned in &gt; 90% of marketing authorisation decisions for new #medicines üíä, as shown by joint analysis of 107 new medicine authorisations from 2014 to 2016: \nüëâhttps://t.co/PSAmNHCDAy https://t.co/XWCHJiy1Wy","id":"1162343030021664769","conversation_id":"1162343030021664769","entities":{"mentions":[{"start":8,"end":15,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":85,"end":95,"tag":"medicines"}],"urls":[{"start":182,"end":205,"url":"https://t.co/PSAmNHCDAy","expanded_url":"https://www.ema.europa.eu/en/news/emafda-analysis-shows-high-degree-alignment-marketing-application-decisions-between-eu-us","display_url":"ema.europa.eu/en/news/emafda‚Ä¶"},{"start":206,"end":229,"url":"https://t.co/XWCHJiy1Wy","expanded_url":"https://twitter.com/EMA_News/status/1162343030021664769/photo/1","display_url":"pic.twitter.com/XWCHJiy1Wy"}],"annotations":{}},"attachments":{"media_keys":["3_1162343025445625862"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":4,"quote_count":1},"created_at":"2019-08-12T13:47:03.000Z","author_id":"116716199","text":"Ready to apply? We are recruiting a Technical Solution Architect. You will be involved in the development, modification and integration of IT components and systems https://t.co/hPJupvCAOO\nMore info about #JobsEMA https://t.co/mZodptmu25 \n#EUJobs #ITJobs https://t.co/WTETRpNIR3","id":"1160910570238947329","conversation_id":"1160910570238947329","entities":{"mentions":{},"hashtags":[{"start":205,"end":213,"tag":"JobsEMA"},{"start":239,"end":246,"tag":"EUJobs"},{"start":247,"end":254,"tag":"ITJobs"}],"urls":[{"start":165,"end":188,"url":"https://t.co/hPJupvCAOO","expanded_url":"https://career5.successfactors.eu/career?career%5fns=job%5flisting&company=europeanmeP&navBarLevel=JOB%5fSEARCH&rcm%5fsite%5flocale=en%5fGB&career_job_req_id=1009&selected_lang=en_GB&jobAlertController_jobAlertId=&jobAlertController_jobAlertName=&_s.crb=hQCGWLkrM%2bNtwsX1RdFnEILkU70%3d","display_url":"career5.successfactors.eu/career?career%‚Ä¶"},{"start":214,"end":237,"url":"https://t.co/mZodptmu25","expanded_url":"https://www.ema.europa.eu/en/about-us/careers","display_url":"ema.europa.eu/en/about-us/ca‚Ä¶"},{"start":255,"end":278,"url":"https://t.co/WTETRpNIR3","expanded_url":"https://twitter.com/EMA_News/status/1160910570238947329/photo/1","display_url":"pic.twitter.com/WTETRpNIR3"}],"annotations":{}},"attachments":{"media_keys":["3_1160910564216004609"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"replied_to","id":"1159455410031681537"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-08-08T16:08:24.000Z","author_id":"116716199","text":"@scleroderma Many thanks for your question. The Committee seeks input from European patients, as this is a EU assessment","id":"1159496592686272512","conversation_id":"1159443792094814208","entities":{"mentions":[{"start":0,"end":12,"username":"scleroderma","id":"20174215"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"20174215"},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":2,"like_count":18,"quote_count":2},"created_at":"2019-08-08T12:38:36.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) seeks views of patients with #SystemicSclerosis associated with #InterstitialLungDisease (SSc-ILD) on a potential new treatment.\n‚úèÔ∏èComplete the survey by 26 August: https://t.co/BKvoYfIrCA\n#scleroderma\n‚ÑπÔ∏èMore info: https://t.co/IDRMNUwJDx https://t.co/v4Mk8JgkSb","id":"1159443792094814208","conversation_id":"1159443792094814208","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":69,"end":87,"tag":"SystemicSclerosis"},{"start":104,"end":128,"tag":"InterstitialLungDisease"},{"start":229,"end":241,"tag":"scleroderma"}],"urls":[{"start":205,"end":228,"url":"https://t.co/BKvoYfIrCA","expanded_url":"https://ec.europa.eu/eusurvey/runner/systemic_sclerosis_Consultation","display_url":"ec.europa.eu/eusurvey/runne‚Ä¶"},{"start":255,"end":278,"url":"https://t.co/IDRMNUwJDx","expanded_url":"https://www.ema.europa.eu/en/patients-carers","display_url":"ema.europa.eu/en/patients-ca‚Ä¶"},{"start":279,"end":302,"url":"https://t.co/v4Mk8JgkSb","expanded_url":"https://twitter.com/EMA_News/status/1159443792094814208/photo/1","display_url":"pic.twitter.com/v4Mk8JgkSb"}],"annotations":[{"start":0,"end":2,"probability":0.3981,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1159443785878839297"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":4,"quote_count":0},"created_at":"2019-08-05T11:27:50.000Z","author_id":"116716199","text":"We are recruiting a Master Data Manager. \nThe successful candidate will participate in the implementation of the ISO IDMP standards for the identification of medicinal products.\nüëâApply here: https://t.co/UxspDSHsOw\n#datamanagement #JobsEMA\n‚ÑπÔ∏èMore info: https://t.co/mZodptmu25 https://t.co/JPvZ7q8L3n","id":"1158338821320249344","conversation_id":"1158338821320249344","entities":{"mentions":{},"hashtags":[{"start":215,"end":230,"tag":"datamanagement"},{"start":231,"end":239,"tag":"JobsEMA"}],"urls":[{"start":191,"end":214,"url":"https://t.co/UxspDSHsOw","expanded_url":"https://career5.successfactors.eu/career?career%5fns=job%5flisting&company=europeanmeP&navBarLevel=JOB%5fSEARCH&rcm%5fsite%5flocale=en%5fGB&career_job_req_id=1007&selected_lang=en_GB&jobAlertController_jobAlertId=&jobAlertController_jobAlertName=&_s.crb=jpBKoexBXzGfgUkbJyHy3RoWv5I%3d","display_url":"career5.successfactors.eu/career?career%‚Ä¶"},{"start":253,"end":276,"url":"https://t.co/mZodptmu25","expanded_url":"https://www.ema.europa.eu/en/about-us/careers","display_url":"ema.europa.eu/en/about-us/ca‚Ä¶"},{"start":277,"end":300,"url":"https://t.co/JPvZ7q8L3n","expanded_url":"https://twitter.com/EMA_News/status/1158338821320249344/photo/1","display_url":"pic.twitter.com/JPvZ7q8L3n"}],"annotations":{}},"attachments":{"media_keys":["3_1158338812004720640"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":11,"quote_count":1},"created_at":"2019-08-02T14:19:54.000Z","author_id":"116716199","text":"We are recruiting a Head of Information Management Division, who will be responsible for technical leadership at #EMA, translating business needs into an IM strategy and roadmap. \nüëâApply by 28 August: https://t.co/Gj6afFBlBL \n#JobsEMA #ITjobs\nMore info: https://t.co/mZodptmu25 https://t.co/olQQPBRLA5","id":"1157294960288378885","conversation_id":"1157294960288378885","entities":{"mentions":{},"hashtags":[{"start":113,"end":117,"tag":"EMA"},{"start":226,"end":234,"tag":"JobsEMA"},{"start":235,"end":242,"tag":"ITjobs"}],"urls":[{"start":201,"end":224,"url":"https://t.co/Gj6afFBlBL","expanded_url":"https://career5.successfactors.eu/career?career%5fns=job%5flisting&company=europeanmeP&navBarLevel=JOB%5fSEARCH&rcm%5fsite%5flocale=en%5fGB&career_job_req_id=1008&selected_lang=en_GB&jobAlertController_jobAlertId=&jobAlertController_jobAlertName=&_s.crb=p3n%2bLzBkot6zy4EGCkt9UkIAKLc%3d","display_url":"career5.successfactors.eu/career?career%‚Ä¶"},{"start":254,"end":277,"url":"https://t.co/mZodptmu25","expanded_url":"https://www.ema.europa.eu/en/about-us/careers","display_url":"ema.europa.eu/en/about-us/ca‚Ä¶"},{"start":278,"end":301,"url":"https://t.co/olQQPBRLA5","expanded_url":"https://twitter.com/EMA_News/status/1157294960288378885/photo/1","display_url":"pic.twitter.com/olQQPBRLA5"}],"annotations":{}},"attachments":{"media_keys":["3_1157294951815876610"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":1,"like_count":7,"quote_count":1},"created_at":"2019-08-02T11:37:00.000Z","author_id":"116716199","text":"EMA‚Äôs paediatric committee (#PDCO) seeks contributions from young patients with X-linked #retinitis_pigmentosa on a potential new treatment. Survey open until 16 August: https://t.co/7OsWXI5PN2  \n#retinitis #XLRP #EMAPublicConsultation\nMore info: https://t.co/IDRMNUwJDx","id":"1157253963336617984","conversation_id":"1157253963336617984","entities":{"mentions":{},"hashtags":[{"start":28,"end":33,"tag":"PDCO"},{"start":89,"end":110,"tag":"retinitis_pigmentosa"},{"start":196,"end":206,"tag":"retinitis"},{"start":207,"end":212,"tag":"XLRP"},{"start":213,"end":235,"tag":"EMAPublicConsultation"}],"urls":[{"start":170,"end":193,"url":"https://t.co/7OsWXI5PN2","expanded_url":"https://ec.europa.eu/eusurvey/runner/Retinitis_Pigmentosa_Consultation_PDCO?startQuiz=true&surveylanguage=EN","display_url":"ec.europa.eu/eusurvey/runne‚Ä¶"},{"start":247,"end":270,"url":"https://t.co/IDRMNUwJDx","expanded_url":"https://www.ema.europa.eu/en/patients-carers","display_url":"ema.europa.eu/en/patients-ca‚Ä¶"}],"annotations":[{"start":80,"end":87,"probability":0.321,"type":"Organization","normalized_text":"X-linked"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":14,"quote_count":5},"created_at":"2019-08-01T12:03:21.000Z","author_id":"116716199","text":"EMA‚Äôs paediatric committee (#PDCO) wants to hear the views of young patients with X-linked #retinitis_pigmentosa, a rare #eyedisease, on a potential new gene therapy. Fill in the survey until 16 August: https://t.co/2ok3GIKtdL #retinitis #XLRP #EMAPublicConsultation https://t.co/oWewPP4tgh","id":"1156898206900506624","conversation_id":"1156898206900506624","entities":{"mentions":{},"hashtags":[{"start":28,"end":33,"tag":"PDCO"},{"start":91,"end":112,"tag":"retinitis_pigmentosa"},{"start":121,"end":132,"tag":"eyedisease"},{"start":227,"end":237,"tag":"retinitis"},{"start":238,"end":243,"tag":"XLRP"},{"start":244,"end":266,"tag":"EMAPublicConsultation"}],"urls":[{"start":203,"end":226,"url":"https://t.co/2ok3GIKtdL","expanded_url":"https://ec.europa.eu/eusurvey/runner/Retinitis_Pigmentosa_Consultation_PDCO","display_url":"ec.europa.eu/eusurvey/runne‚Ä¶"},{"start":267,"end":290,"url":"https://t.co/oWewPP4tgh","expanded_url":"https://twitter.com/EMA_News/status/1156898206900506624/photo/1","display_url":"pic.twitter.com/oWewPP4tgh"}],"annotations":{}},"attachments":{"media_keys":["3_1156898201967964160"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":0,"like_count":28,"quote_count":2},"created_at":"2019-07-31T12:24:42.000Z","author_id":"116716199","text":"How can regulators better guide medicine üíä developers in generating quality data for early access schemes like #Prime_EMA and Breakthrough Therapy? Find out in the report of an EMA-@US_FDA workshop held last year https://t.co/YUfqwLXxFD https://t.co/xwea5HMW4N","id":"1156541191154020352","conversation_id":"1156541191154020352","entities":{"mentions":[{"start":181,"end":188,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":111,"end":121,"tag":"Prime_EMA"}],"urls":[{"start":213,"end":236,"url":"https://t.co/YUfqwLXxFD","expanded_url":"https://www.ema.europa.eu/en/news/supporting-medicine-developers-generating-quality-data-packages-early-access-approaches-prime","display_url":"ema.europa.eu/en/news/suppor‚Ä¶"},{"start":237,"end":260,"url":"https://t.co/xwea5HMW4N","expanded_url":"https://twitter.com/EMA_News/status/1156541191154020352/photo/1","display_url":"pic.twitter.com/xwea5HMW4N"}],"annotations":{}},"attachments":{"media_keys":["3_1156541184640212994"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1154774537776619521"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-07-29T06:31:40.000Z","author_id":"116716199","text":"RT @relocatemaEN: We talked to two of the EMA-employees who relocated with the Agency to \nthe Netherlands. How are they doing and how are t‚Ä¶","id":"1155727574737260544","conversation_id":"1155727574737260544","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"}],"hashtags":{},"urls":{},"annotations":[{"start":42,"end":54,"probability":0.3238,"type":"Organization","normalized_text":"EMA-employees"},{"start":94,"end":104,"probability":0.9781,"type":"Place","normalized_text":"Netherlands"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":1,"like_count":42,"quote_count":8},"created_at":"2019-07-26T10:45:00.000Z","author_id":"116716199","text":"First ‚Äòhistology-independent‚Äô treatment for solid tumours with a specific gene mutation recommended for approval https://t.co/HUM1mYgzkM #CHMP","id":"1154704162447384576","conversation_id":"1154704162447384576","entities":{"mentions":{},"hashtags":[{"start":137,"end":142,"tag":"CHMP"}],"urls":[{"start":113,"end":136,"url":"https://t.co/HUM1mYgzkM","expanded_url":"https://www.ema.europa.eu/en/news/first-histology-independent-treatment-solid-tumours-specific-gene-mutation","display_url":"ema.europa.eu/en/news/first-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":19,"quote_count":2},"created_at":"2019-07-26T10:40:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 5 #medicines for approval at its July 2019 meeting: https://t.co/KZqessAmlB https://t.co/O5n6rEskv9","id":"1154702903614963712","conversation_id":"1154702903614963712","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":103,"end":126,"url":"https://t.co/KZqessAmlB","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":127,"end":150,"url":"https://t.co/O5n6rEskv9","expanded_url":"https://twitter.com/EMA_News/status/1154702903614963712/photo/1","display_url":"pic.twitter.com/O5n6rEskv9"}],"annotations":[{"start":0,"end":2,"probability":0.4573,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1154700635826245632"]}},{"source":"Twitter Web App","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":20,"quote_count":0},"created_at":"2019-07-25T12:57:20.000Z","author_id":"116716199","text":"EMA Executive Director welcomes Dr Kristina Garuolienƒó, Lithuanian Vice-Minister of Health to the Agency. Topics to be discussed include #availability of #medicines in the EU, #pharmaceutical research and development and #BigData https://t.co/mBzGHm7LOz","id":"1154375076059471873","conversation_id":"1154375076059471873","entities":{"mentions":{},"hashtags":[{"start":137,"end":150,"tag":"availability"},{"start":154,"end":164,"tag":"medicines"},{"start":176,"end":191,"tag":"pharmaceutical"},{"start":221,"end":229,"tag":"BigData"}],"urls":[{"start":230,"end":253,"url":"https://t.co/mBzGHm7LOz","expanded_url":"https://twitter.com/EMA_News/status/1154375076059471873/photo/1","display_url":"pic.twitter.com/mBzGHm7LOz"}],"annotations":[{"start":0,"end":21,"probability":0.4361,"type":"Organization","normalized_text":"EMA Executive Director"},{"start":32,"end":53,"probability":0.8879,"type":"Person","normalized_text":"Dr Kristina Garuolienƒó"}]},"attachments":{"media_keys":["3_1154375068719468544"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":14,"quote_count":0},"created_at":"2019-07-24T15:40:00.000Z","author_id":"116716199","text":"EMA‚Äôs paediatric committee (#PDCO) has elected Koenraad Norga from Belgium as its new chair for a three-year mandate starting in September: https://t.co/pSr4QIsHTi https://t.co/HwMcMDU8xU","id":"1154053625401892864","conversation_id":"1154053625401892864","entities":{"mentions":{},"hashtags":[{"start":28,"end":33,"tag":"PDCO"}],"urls":[{"start":140,"end":163,"url":"https://t.co/pSr4QIsHTi","expanded_url":"https://www.ema.europa.eu/en/news/paediatric-committee-elects-koenraad-norga-its-new-chair","display_url":"ema.europa.eu/en/news/paedia‚Ä¶"},{"start":164,"end":187,"url":"https://t.co/HwMcMDU8xU","expanded_url":"https://twitter.com/EMA_News/status/1154053625401892864/photo/1","display_url":"pic.twitter.com/HwMcMDU8xU"}],"annotations":[{"start":0,"end":2,"probability":0.4098,"type":"Organization","normalized_text":"EMA"},{"start":47,"end":60,"probability":0.8857,"type":"Person","normalized_text":"Koenraad Norga"},{"start":67,"end":73,"probability":0.9873,"type":"Place","normalized_text":"Belgium"}]},"attachments":{"media_keys":["3_1154051444003102723"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1,"reply_count":0,"like_count":6,"quote_count":0},"created_at":"2019-07-22T13:05:00.000Z","author_id":"116716199","text":"Check out the agenda of this week‚Äôs meeting of the Committee for Human #Medicines (#CHMP): https://t.co/Aw22aitKeq","id":"1153289843176198144","conversation_id":"1153289843176198144","entities":{"mentions":{},"hashtags":[{"start":71,"end":81,"tag":"Medicines"},{"start":83,"end":88,"tag":"CHMP"}],"urls":[{"start":91,"end":114,"url":"https://t.co/Aw22aitKeq","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-22-25-july-2019-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":1,"like_count":26,"quote_count":1},"created_at":"2019-07-17T14:07:42.000Z","author_id":"116716199","text":"EMA involves #patients, #consumers, #HealthcareProfessionals and #academics in its daily work. See the 2018 highlights of this valuable collaboration: \nüëâhttps://t.co/8df4NuEP55 https://t.co/JXDx8WKlHU","id":"1151493684145328129","conversation_id":"1151493684145328129","entities":{"mentions":{},"hashtags":[{"start":13,"end":22,"tag":"patients"},{"start":24,"end":34,"tag":"consumers"},{"start":36,"end":60,"tag":"HealthcareProfessionals"},{"start":65,"end":75,"tag":"academics"}],"urls":[{"start":153,"end":176,"url":"https://t.co/8df4NuEP55","expanded_url":"https://www.ema.europa.eu/en/documents/leaflet/public-engagement-highlights-2018_en.pdf","display_url":"ema.europa.eu/en/documents/l‚Ä¶"},{"start":177,"end":200,"url":"https://t.co/JXDx8WKlHU","expanded_url":"https://twitter.com/EMA_News/status/1151493684145328129/photo/1","display_url":"pic.twitter.com/JXDx8WKlHU"}],"annotations":{}},"attachments":{"media_keys":["3_1151493633176166400"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1151013370574909440"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-07-16T08:01:09.000Z","author_id":"116716199","text":"RT @WHO_Europe_VPI: European Region achieved record-high 91% coverage with 2nd dose of #measles vaccine in 2018, according to latest @WHO @‚Ä¶","id":"1151039051933376513","conversation_id":"1151039051933376513","entities":{"mentions":[{"start":3,"end":18,"username":"WHO_Europe_VPI","id":"561122363"},{"start":133,"end":137,"username":"WHO","id":"14499829"}],"hashtags":[{"start":87,"end":95,"tag":"measles"}],"urls":{},"annotations":[{"start":20,"end":34,"probability":0.7239,"type":"Organization","normalized_text":"European Region"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1150777729631031296"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-07-15T15:11:33.000Z","author_id":"116716199","text":"RT @WHO_Europe: Vaccination against #measles has increased amid ongoing measles outbreaks in Europe. An increasing number of parents are ch‚Ä¶","id":"1150784976587239424","conversation_id":"1150784976587239424","entities":{"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":36,"end":44,"tag":"measles"}],"urls":{},"annotations":[{"start":93,"end":98,"probability":0.9956,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":1,"like_count":32,"quote_count":4},"created_at":"2019-07-12T13:20:27.000Z","author_id":"116716199","text":"#DYK that the EU üá™üá∫ and the United States üá∫üá∏ have now fully implemented the mutual recognition agreement for inspections of manufacturing sites for certain human medicines in their respective territories?\nüëâ https://t.co/xAVM7uQBi2 https://t.co/GV4BgpwTQO","id":"1149669852975489027","conversation_id":"1149669852975489027","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"}],"urls":[{"start":207,"end":230,"url":"https://t.co/xAVM7uQBi2","expanded_url":"https://www.ema.europa.eu/en/news/eu-us-reach-milestone-mutual-recognition-inspections-medicines-manufacturers","display_url":"ema.europa.eu/en/news/eu-us-‚Ä¶"},{"start":231,"end":254,"url":"https://t.co/GV4BgpwTQO","expanded_url":"https://twitter.com/EMA_News/status/1149669852975489027/photo/1","display_url":"pic.twitter.com/GV4BgpwTQO"}],"annotations":[{"start":30,"end":42,"probability":0.776,"type":"Place","normalized_text":"United States"}]},"attachments":{"media_keys":["3_1149669441870934016"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":17,"quote_count":4},"created_at":"2019-07-12T10:37:27.000Z","author_id":"116716199","text":"What happened during the July meeting of EMA's #pharmacovigilance committee #PRAC? The PRAC started a review of the meningioma risk with #cyproterone and recommended new measures to avoid dosing errors with #methotrexate. #SafetyOfMedicines\nüëâhttps://t.co/CP0WxqvMkM https://t.co/okqZur3br5","id":"1149628833865146368","conversation_id":"1149628833865146368","entities":{"mentions":{},"hashtags":[{"start":47,"end":65,"tag":"pharmacovigilance"},{"start":76,"end":81,"tag":"PRAC"},{"start":137,"end":149,"tag":"cyproterone"},{"start":207,"end":220,"tag":"methotrexate"},{"start":222,"end":240,"tag":"SafetyOfMedicines"}],"urls":[{"start":242,"end":265,"url":"https://t.co/CP0WxqvMkM","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-july-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":266,"end":289,"url":"https://t.co/okqZur3br5","expanded_url":"https://twitter.com/EMA_News/status/1149628833865146368/photo/1","display_url":"pic.twitter.com/okqZur3br5"}],"annotations":{}},"attachments":{"media_keys":["3_1149628692378734599"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1149587938746888192"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-07-12T08:08:17.000Z","author_id":"116716199","text":"RT @V_Andriukaitis: We completed the Mutual Recognition Agreement on #pharmaceuticals with the US. This is the result of five years of clos‚Ä¶","id":"1149591294617874432","conversation_id":"1149591294617874432","entities":{"mentions":[{"start":3,"end":18,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":69,"end":85,"tag":"pharmaceuticals"}],"urls":{},"annotations":[{"start":95,"end":96,"probability":0.8016,"type":"Place","normalized_text":"US"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":0,"like_count":46,"quote_count":2},"created_at":"2019-07-08T13:49:05.000Z","author_id":"116716199","text":"The International Coalition of Medicines Regulatory Authorities (#ICMRA) has elected EMA‚Äôs Executive Director Guido Rasi as its new chair. Congratulations! \nüëâhttps://t.co/H0HtrPPI8y https://t.co/WpJ9jiwTLQ","id":"1148227506195107841","conversation_id":"1148227506195107841","entities":{"mentions":{},"hashtags":[{"start":65,"end":71,"tag":"ICMRA"}],"urls":[{"start":158,"end":181,"url":"https://t.co/H0HtrPPI8y","expanded_url":"https://www.ema.europa.eu/en/news/guido-rasi-elected-chair-international-coalition-medicines-regulatory-authorities-icmra","display_url":"ema.europa.eu/en/news/guido-‚Ä¶"},{"start":182,"end":205,"url":"https://t.co/WpJ9jiwTLQ","expanded_url":"https://twitter.com/EMA_News/status/1148227506195107841/photo/1","display_url":"pic.twitter.com/WpJ9jiwTLQ"}],"annotations":[{"start":4,"end":62,"probability":0.2146,"type":"Organization","normalized_text":"International Coalition of Medicines Regulatory Authorities"},{"start":110,"end":119,"probability":0.8682,"type":"Person","normalized_text":"Guido Rasi"}]},"attachments":{"media_keys":["3_1148227483021512704"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":41,"quote_count":10},"created_at":"2019-07-04T12:54:10.000Z","author_id":"116716199","text":"The EU üá™üá∫ network takes steps to improve reporting of and communication about medicines üíä shortages: \nüëâhttps://t.co/aOaXnNYej7 https://t.co/mAfdm33LMf","id":"1146764134387785728","conversation_id":"1146764134387785728","entities":{"mentions":{},"hashtags":{},"urls":[{"start":103,"end":126,"url":"https://t.co/aOaXnNYej7","expanded_url":"https://www.ema.europa.eu/en/news/medicine-shortages-eu-network-takes-steps-improve-reporting-communication","display_url":"ema.europa.eu/en/news/medici‚Ä¶"},{"start":127,"end":150,"url":"https://t.co/mAfdm33LMf","expanded_url":"https://twitter.com/EMA_News/status/1146764134387785728/photo/1","display_url":"pic.twitter.com/mAfdm33LMf"}],"annotations":[{"start":4,"end":10,"probability":0.5042,"type":"Organization","normalized_text":"EU üá™üá∫"}]},"attachments":{"media_keys":["3_1146764004976730113"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2019-07-03T15:06:16.000Z","author_id":"116716199","text":"How many recommendations for eligibility to EMA's PRIME scheme were granted in June? Follow #PRIME_EMA for the latest updates. \nüëâhttps://t.co/veBdR6jj8R https://t.co/BHemyWUH9T","id":"1146434993423622145","conversation_id":"1146434993423622145","entities":{"mentions":{},"hashtags":[{"start":92,"end":102,"tag":"PRIME_EMA"}],"urls":[{"start":129,"end":152,"url":"https://t.co/veBdR6jj8R","expanded_url":"https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-24-27-june-2019_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":153,"end":176,"url":"https://t.co/BHemyWUH9T","expanded_url":"https://twitter.com/EMA_News/status/1146434993423622145/photo/1","display_url":"pic.twitter.com/BHemyWUH9T"}],"annotations":[{"start":44,"end":46,"probability":0.4603,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1146434810744836097"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":14,"quote_count":1},"created_at":"2019-07-03T13:02:26.000Z","author_id":"116716199","text":"Academic sponsors or smaller companies often lack awareness or incentives to post clinical results. EMA is taking steps to ensure sponsors are aware of their obligations: https://t.co/C9EeuT2Ojl","id":"1146403828436258817","conversation_id":"1146403828436258817","entities":{"mentions":{},"hashtags":{},"urls":[{"start":171,"end":194,"url":"https://t.co/C9EeuT2Ojl","expanded_url":"https://www.ema.europa.eu/en/news/call-all-sponsors-publish-clinical-trial-results-eu-database","display_url":"ema.europa.eu/en/news/call-a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":45,"reply_count":0,"like_count":36,"quote_count":10},"created_at":"2019-07-03T12:22:28.000Z","author_id":"116716199","text":"There is still progress to be made when it comes to reporting of #ClinicalTrials results. We encourage all sponsors to take action: \nüëâhttps://t.co/C9EeuT2Ojl https://t.co/sODA6FfCLT","id":"1146393768528154625","conversation_id":"1146393768528154625","entities":{"mentions":{},"hashtags":[{"start":65,"end":80,"tag":"ClinicalTrials"}],"urls":[{"start":134,"end":157,"url":"https://t.co/C9EeuT2Ojl","expanded_url":"https://www.ema.europa.eu/en/news/call-all-sponsors-publish-clinical-trial-results-eu-database","display_url":"ema.europa.eu/en/news/call-a‚Ä¶"},{"start":158,"end":181,"url":"https://t.co/sODA6FfCLT","expanded_url":"https://twitter.com/EMA_News/status/1146393768528154625/photo/1","display_url":"pic.twitter.com/sODA6FfCLT"}],"annotations":{}},"attachments":{"media_keys":["3_1146392858594873345"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":88,"reply_count":4,"like_count":92,"quote_count":9},"created_at":"2019-07-03T12:11:39.000Z","author_id":"116716199","text":"In a letter published today, @EU_Commission, #EMA and the Heads of Medicines Agencies remind all sponsors of #ClinicalTrials conducted in the üá™üá∫ to make results of concluded trials publicly available in the EU Clinical Trials Database (#EudraCT).\nüëâhttps://t.co/C9EeuT2Ojl https://t.co/6VlpEQUSit","id":"1146391046877851648","conversation_id":"1146391046877851648","entities":{"mentions":[{"start":29,"end":43,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":45,"end":49,"tag":"EMA"},{"start":109,"end":124,"tag":"ClinicalTrials"},{"start":236,"end":244,"tag":"EudraCT"}],"urls":[{"start":248,"end":271,"url":"https://t.co/C9EeuT2Ojl","expanded_url":"https://www.ema.europa.eu/en/news/call-all-sponsors-publish-clinical-trial-results-eu-database","display_url":"ema.europa.eu/en/news/call-a‚Ä¶"},{"start":272,"end":295,"url":"https://t.co/6VlpEQUSit","expanded_url":"https://twitter.com/EMA_News/status/1146391046877851648/photo/1","display_url":"pic.twitter.com/6VlpEQUSit"}],"annotations":[{"start":58,"end":84,"probability":0.7173,"type":"Organization","normalized_text":"Heads of Medicines Agencies"},{"start":209,"end":235,"probability":0.6665,"type":"Other","normalized_text":"EU Clinical Trials Database"}]},"attachments":{"media_keys":["3_1146390883614507008"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":11,"quote_count":0},"created_at":"2019-06-28T10:45:00.000Z","author_id":"116716199","text":"New treatment for children with type 2 #diabetes recommended for approval https://t.co/tUdRHzipDK #CHMP","id":"1144557301984092161","conversation_id":"1144557301984092161","entities":{"mentions":{},"hashtags":[{"start":39,"end":48,"tag":"diabetes"},{"start":98,"end":103,"tag":"CHMP"}],"urls":[{"start":74,"end":97,"url":"https://t.co/tUdRHzipDK","expanded_url":"https://www.ema.europa.eu/en/news/new-treatment-children-type-2-diabetes","display_url":"ema.europa.eu/en/news/new-tr‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":20,"quote_count":0},"created_at":"2019-06-28T10:40:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 3 new #medicines for approval at its June 2019 meeting: https://t.co/qLvHMGEyRi https://t.co/hVWbqNf6hN","id":"1144556043852292097","conversation_id":"1144556043852292097","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":57,"end":67,"tag":"medicines"}],"urls":[{"start":107,"end":130,"url":"https://t.co/qLvHMGEyRi","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":131,"end":154,"url":"https://t.co/hVWbqNf6hN","expanded_url":"https://twitter.com/EMA_News/status/1144556043852292097/photo/1","display_url":"pic.twitter.com/hVWbqNf6hN"}],"annotations":[{"start":0,"end":2,"probability":0.4963,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1144554785384873984"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1144372681086787584"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-06-28T09:44:14.000Z","author_id":"116716199","text":"RT @FDA_Global: For day-to-day collaboration, the EMA has embedded its FDA liaison, Tania Teixeira, at FDA‚Äôs Headquarters in Silver Spring,‚Ä¶","id":"1144542008519905280","conversation_id":"1144542008519905280","entities":{"mentions":[{"start":3,"end":14,"username":"FDA_Global","id":"1143153214809923586"}],"hashtags":{},"urls":{},"annotations":[{"start":50,"end":52,"probability":0.6518,"type":"Organization","normalized_text":"EMA"},{"start":71,"end":73,"probability":0.7125,"type":"Organization","normalized_text":"FDA"},{"start":84,"end":97,"probability":0.9933,"type":"Person","normalized_text":"Tania Teixeira"},{"start":103,"end":105,"probability":0.9516,"type":"Organization","normalized_text":"FDA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1144372684740026368"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-06-28T09:43:31.000Z","author_id":"116716199","text":"RT @FDA_Global: Today‚Äôs #DIA2019 takeaway - while international collaboration can be a lot of work and requires selecting areas/projects th‚Ä¶","id":"1144541831054671873","conversation_id":"1144541831054671873","entities":{"mentions":[{"start":3,"end":14,"username":"FDA_Global","id":"1143153214809923586"}],"hashtags":[{"start":24,"end":32,"tag":"DIA2019"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":1,"like_count":3,"quote_count":0},"created_at":"2019-06-24T15:10:00.000Z","author_id":"116716199","text":"Check out the agenda of this week‚Äôs meeting of the Committee for Human #Medicines (#CHMP): https://t.co/gW6w8px8dz","id":"1143174440391467011","conversation_id":"1143174440391467011","entities":{"mentions":{},"hashtags":[{"start":71,"end":81,"tag":"Medicines"},{"start":83,"end":88,"tag":"CHMP"}],"urls":[{"start":91,"end":114,"url":"https://t.co/gW6w8px8dz","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-24-27-june-2019-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":0,"like_count":34,"quote_count":3},"created_at":"2019-06-24T11:46:01.000Z","author_id":"116716199","text":"Only one week left to share your ideas and suggestions with us on EMA's Regulatory Science Strategy to 2025. Your feedback is very important to help us ensure a thorough assessment of ground-breaking, more complex therapies. #RegScience2025 \nüëâhttps://t.co/xmCyJcI9ky https://t.co/3fAbVdSQ3b","id":"1143123105210130432","conversation_id":"1143123105210130432","entities":{"mentions":{},"hashtags":[{"start":225,"end":240,"tag":"RegScience2025"}],"urls":[{"start":243,"end":266,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":267,"end":290,"url":"https://t.co/3fAbVdSQ3b","expanded_url":"https://twitter.com/EMA_News/status/1143123105210130432/photo/1","display_url":"pic.twitter.com/3fAbVdSQ3b"}],"annotations":[{"start":66,"end":68,"probability":0.5162,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1143123024847233024"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1141254322275196928"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-06-20T07:44:58.000Z","author_id":"116716199","text":"RT @ECDC_EU: Infants and children are often believed to be the only age group affected by #measles, but the disease can be contracted at an‚Ä¶","id":"1141612893508706305","conversation_id":"1141612893508706305","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":90,"end":98,"tag":"measles"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1140945154280435712"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":69,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-06-19T07:42:01.000Z","author_id":"116716199","text":"RT @EU_Health: Are you a health professional communicating about #vaccination? \nHelp address misconceptions by following @ECDC_EU's tips:\n1‚Ä¶","id":"1141249763234451457","conversation_id":"1141249763234451457","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":121,"end":129,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":65,"end":77,"tag":"vaccination"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":35,"quote_count":2},"created_at":"2019-06-18T13:16:27.000Z","author_id":"116716199","text":"Today we are meeting EU healthcare payers in Diemen üá≥üá± to discuss evidence generation for #OrphanMedicines, unmet medical needs &amp; horizon scanning for #medicines. Our close collaboration is key for timely &amp; affordable access for #patients to new üíäüíä \nüëâhttps://t.co/c6tZFSAdTE https://t.co/1jzpWyLJYm","id":"1140971539430629376","conversation_id":"1140971539430629376","entities":{"mentions":{},"hashtags":[{"start":90,"end":106,"tag":"OrphanMedicines"},{"start":155,"end":165,"tag":"medicines"},{"start":237,"end":246,"tag":"patients"}],"urls":[{"start":259,"end":282,"url":"https://t.co/c6tZFSAdTE","expanded_url":"https://www.ema.europa.eu/en/events/european-medicines-agency-ema-european-union-eu-payer-community-meeting","display_url":"ema.europa.eu/en/events/euro‚Ä¶"},{"start":283,"end":306,"url":"https://t.co/1jzpWyLJYm","expanded_url":"https://twitter.com/EMA_News/status/1140971539430629376/photo/1","display_url":"pic.twitter.com/1jzpWyLJYm"}],"annotations":[{"start":21,"end":22,"probability":0.639,"type":"Organization","normalized_text":"EU"},{"start":45,"end":50,"probability":0.6347,"type":"Place","normalized_text":"Diemen"}]},"attachments":{"media_keys":["3_1140971513799221248"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":1,"quote_count":1},"created_at":"2019-06-17T14:51:52.000Z","author_id":"116716199","text":"What are the highlights of EMA‚Äôs Management Board meeting in June 2019? https://t.co/ltwPdAbYki","id":"1140633163628199938","conversation_id":"1140633163628199938","entities":{"mentions":{},"hashtags":{},"urls":[{"start":72,"end":95,"url":"https://t.co/ltwPdAbYki","expanded_url":"https://www.ema.europa.eu/en/news/highlights-management-board-meeting-june-2019","display_url":"ema.europa.eu/en/news/highli‚Ä¶"}],"annotations":[{"start":27,"end":29,"probability":0.6151,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":16,"quote_count":4},"created_at":"2019-06-17T08:12:47.000Z","author_id":"116716199","text":"What should regulators do to keep pace with scientific advances in medicine üíädevelopment? We want to hear your suggestions. #RegScience2025 \nüëâhttps://t.co/xmCyJcI9ky https://t.co/gK4nPYuBvz","id":"1140532729118900224","conversation_id":"1140532729118900224","entities":{"mentions":{},"hashtags":[{"start":124,"end":139,"tag":"RegScience2025"}],"urls":[{"start":142,"end":165,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":166,"end":189,"url":"https://t.co/gK4nPYuBvz","expanded_url":"https://twitter.com/EMA_News/status/1140532729118900224/video/1","display_url":"pic.twitter.com/gK4nPYuBvz"}],"annotations":{}},"attachments":{"media_keys":["7_1140532612232073218"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":18,"quote_count":2},"created_at":"2019-06-14T14:09:33.000Z","author_id":"116716199","text":"What happened during the June meeting of EMA's #pharmacovigilance committee #PRAC? The PRAC started a review of #leuprorelin medicines. #SafetyOfMedicines\nüëâhttps://t.co/gLd9looYjS https://t.co/sBQO7hPPkv","id":"1139535350991400960","conversation_id":"1139535350991400960","entities":{"mentions":{},"hashtags":[{"start":47,"end":65,"tag":"pharmacovigilance"},{"start":76,"end":81,"tag":"PRAC"},{"start":112,"end":124,"tag":"leuprorelin"},{"start":136,"end":154,"tag":"SafetyOfMedicines"}],"urls":[{"start":156,"end":179,"url":"https://t.co/gLd9looYjS","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-11-14-june-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":180,"end":203,"url":"https://t.co/sBQO7hPPkv","expanded_url":"https://twitter.com/EMA_News/status/1139535350991400960/photo/1","display_url":"pic.twitter.com/sBQO7hPPkv"}],"annotations":{}},"attachments":{"media_keys":["3_1139535262218883072"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":35,"quote_count":3},"created_at":"2019-06-12T10:23:20.000Z","author_id":"116716199","text":"How can the regulatory system better address the challenges faced by #patients due to scientific progress? Share your ideas üí°with us: \nüëâhttps://t.co/xmCyJcI9ky #RegScience2025 #healthcare https://t.co/6ol9e53ofx","id":"1138753644172578818","conversation_id":"1138753644172578818","entities":{"mentions":{},"hashtags":[{"start":69,"end":78,"tag":"patients"},{"start":160,"end":175,"tag":"RegScience2025"},{"start":176,"end":187,"tag":"healthcare"}],"urls":[{"start":136,"end":159,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":188,"end":211,"url":"https://t.co/6ol9e53ofx","expanded_url":"https://twitter.com/EMA_News/status/1138753644172578818/video/1","display_url":"pic.twitter.com/6ol9e53ofx"}],"annotations":{}},"attachments":{"media_keys":["7_1138753524790112256"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":1,"like_count":5,"quote_count":1},"created_at":"2019-06-11T14:45:00.000Z","author_id":"116716199","text":"What's on the agenda of our #pharmacovigilance committee (#PRAC) meeting in June? https://t.co/BeyzflxdmT","id":"1138457106313465856","conversation_id":"1138457106313465856","entities":{"mentions":{},"hashtags":[{"start":28,"end":46,"tag":"pharmacovigilance"},{"start":58,"end":63,"tag":"PRAC"}],"urls":[{"start":82,"end":105,"url":"https://t.co/BeyzflxdmT","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-11-14-june-2019_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":18,"quote_count":2},"created_at":"2019-06-11T12:30:00.000Z","author_id":"116716199","text":"Two additional countries to benefit from EU-US mutual recognition agreement for inspections: https://t.co/FPeFb7XNs3","id":"1138423133785006087","conversation_id":"1138423133785006087","entities":{"mentions":{},"hashtags":{},"urls":[{"start":93,"end":116,"url":"https://t.co/FPeFb7XNs3","expanded_url":"https://www.ema.europa.eu/en/news/two-additional-countries-benefit-eu-us-mutual-recognition-agreement-inspections-1","display_url":"ema.europa.eu/en/news/two-ad‚Ä¶"}],"annotations":[{"start":41,"end":45,"probability":0.4189,"type":"Organization","normalized_text":"EU-US"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":16,"quote_count":1},"created_at":"2019-06-06T14:45:00.000Z","author_id":"116716199","text":"Views and input from #GPs and #familydoctors will be more easily incorporated into the Agency‚Äôs activities. \nüëâhttps://t.co/uowNGaNRsh\n#familymedicine #generalpractice #primarycare https://t.co/RfaiLd4XZI","id":"1136645166931070976","conversation_id":"1136645166931070976","entities":{"mentions":{},"hashtags":[{"start":21,"end":25,"tag":"GPs"},{"start":30,"end":44,"tag":"familydoctors"},{"start":134,"end":149,"tag":"familymedicine"},{"start":150,"end":166,"tag":"generalpractice"},{"start":167,"end":179,"tag":"primarycare"}],"urls":[{"start":110,"end":133,"url":"https://t.co/uowNGaNRsh","expanded_url":"https://www.ema.europa.eu/en/news/strengthening-engagement-between-ema-general-practitioners","display_url":"ema.europa.eu/en/news/streng‚Ä¶"},{"start":180,"end":203,"url":"https://t.co/RfaiLd4XZI","expanded_url":"https://twitter.com/EMA_News/status/1136645166931070976/photo/1","display_url":"pic.twitter.com/RfaiLd4XZI"}],"annotations":{}},"attachments":{"media_keys":["3_1136634647453097985"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":1,"like_count":27,"quote_count":1},"created_at":"2019-06-06T14:10:00.000Z","author_id":"116716199","text":"EMA will gain a better understanding of how medicines üíä are being used in real life, for the benefit of #patients. \n#familymedicine #familydoctors #generalpractice #primarycare\nüëâhttps://t.co/uowNGaNRsh https://t.co/1hYCg7VN9k","id":"1136636358896836608","conversation_id":"1136636358896836608","entities":{"mentions":{},"hashtags":[{"start":104,"end":113,"tag":"patients"},{"start":116,"end":131,"tag":"familymedicine"},{"start":132,"end":146,"tag":"familydoctors"},{"start":147,"end":163,"tag":"generalpractice"},{"start":164,"end":176,"tag":"primarycare"}],"urls":[{"start":178,"end":201,"url":"https://t.co/uowNGaNRsh","expanded_url":"https://www.ema.europa.eu/en/news/strengthening-engagement-between-ema-general-practitioners","display_url":"ema.europa.eu/en/news/streng‚Ä¶"},{"start":202,"end":225,"url":"https://t.co/1hYCg7VN9k","expanded_url":"https://twitter.com/EMA_News/status/1136636358896836608/photo/1","display_url":"pic.twitter.com/1hYCg7VN9k"}],"annotations":{}},"attachments":{"media_keys":["3_1136632389449502724"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":2,"quote_count":2},"created_at":"2019-06-06T13:45:18.000Z","author_id":"116716199","text":"How many recommendations for eligibility to EMA's PRIME scheme were granted in May? Follow #PRIME_EMA for the latest updates. \nüëâhttps://t.co/NLY7DyJq5A https://t.co/fvgFWZuABd","id":"1136630145001959425","conversation_id":"1136630145001959425","entities":{"mentions":{},"hashtags":[{"start":91,"end":101,"tag":"PRIME_EMA"}],"urls":[{"start":128,"end":151,"url":"https://t.co/NLY7DyJq5A","expanded_url":"https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-27-29-may-2019_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":152,"end":175,"url":"https://t.co/fvgFWZuABd","expanded_url":"https://twitter.com/EMA_News/status/1136630145001959425/photo/1","display_url":"pic.twitter.com/fvgFWZuABd"}],"annotations":{}},"attachments":{"media_keys":["3_1136630102916325377"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":19,"quote_count":1},"created_at":"2019-06-06T12:54:17.000Z","author_id":"116716199","text":"Today we've signed üñäÔ∏è a joint statement with @UEMOPresidency, @WoncaEurope &amp; @PrimaryCare4um to strengthen our interaction with GPs and #familydoctors. Close collaboration helps us understand better the needs of #patients. #generalpractice #primarycare \nüëâhttps://t.co/uowNGaNRsh https://t.co/uIbHc4tapu","id":"1136617306539343873","conversation_id":"1136617306539343873","entities":{"mentions":[{"start":62,"end":74,"username":"WoncaEurope","id":"708589971079307266"},{"start":81,"end":96,"username":"PrimaryCare4um","id":"164835748"}],"hashtags":[{"start":140,"end":154,"tag":"familydoctors"},{"start":216,"end":225,"tag":"patients"},{"start":227,"end":243,"tag":"generalpractice"},{"start":244,"end":256,"tag":"primarycare"}],"urls":[{"start":259,"end":282,"url":"https://t.co/uowNGaNRsh","expanded_url":"https://www.ema.europa.eu/en/news/strengthening-engagement-between-ema-general-practitioners","display_url":"ema.europa.eu/en/news/streng‚Ä¶"},{"start":283,"end":306,"url":"https://t.co/uIbHc4tapu","expanded_url":"https://twitter.com/EMA_News/status/1136617306539343873/photo/1","display_url":"pic.twitter.com/uIbHc4tapu"}],"annotations":[{"start":129,"end":131,"probability":0.3768,"type":"Organization","normalized_text":"GPs"}]},"attachments":{"media_keys":["3_1136617118227718144"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2019-06-05T08:56:38.000Z","author_id":"116716199","text":"#DYK that EMA provides support to #SMEs to navigate the regulatory processes related to the development and the authorisation of #medicines?\n See the annual report 2018 for EMA's SME Office. #EMA4SME\nüëâhttps://t.co/0wgJ83nBiO https://t.co/bbr0SJDNwC","id":"1136195108934750208","conversation_id":"1136195108934750208","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":34,"end":39,"tag":"SMEs"},{"start":129,"end":139,"tag":"medicines"},{"start":191,"end":199,"tag":"EMA4SME"}],"urls":[{"start":201,"end":224,"url":"https://t.co/0wgJ83nBiO","expanded_url":"https://www.ema.europa.eu/en/documents/report/small-medium-sized-enterprise-sme-office-annual-report-2018_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":225,"end":248,"url":"https://t.co/bbr0SJDNwC","expanded_url":"https://twitter.com/EMA_News/status/1136195108934750208/photo/1","display_url":"pic.twitter.com/bbr0SJDNwC"}],"annotations":[{"start":10,"end":12,"probability":0.451,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1136194950838853632"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":26,"quote_count":2},"created_at":"2019-06-04T10:02:09.000Z","author_id":"116716199","text":"DYK that #EMA, the EU Member States and companies are responsible for detecting and managing safety signals? A safety signal is an information on a #SideEffect that may be caused by a üíä and requires further investigation. #AnnualReportEMA \nüëâhttps://t.co/2eyju4nZIe https://t.co/Sc5MOPxSau","id":"1135849212464246784","conversation_id":"1135849212464246784","entities":{"mentions":{},"hashtags":[{"start":9,"end":13,"tag":"EMA"},{"start":148,"end":159,"tag":"SideEffect"},{"start":222,"end":238,"tag":"AnnualReportEMA"}],"urls":[{"start":241,"end":264,"url":"https://t.co/2eyju4nZIe","expanded_url":"https://www.ema.europa.eu/en/documents/annual-report/2018-annual-report-european-medicines-agency_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"},{"start":265,"end":288,"url":"https://t.co/Sc5MOPxSau","expanded_url":"https://twitter.com/EMA_News/status/1135849212464246784/photo/1","display_url":"pic.twitter.com/Sc5MOPxSau"}],"annotations":[{"start":19,"end":34,"probability":0.6285,"type":"Organization","normalized_text":"EU Member States"}]},"attachments":{"media_keys":["3_1135849016338604033"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":50,"reply_count":1,"like_count":50,"quote_count":7},"created_at":"2019-06-03T13:20:22.000Z","author_id":"116716199","text":"EMA has released a draft guideline on the quality requirements for medical devices in human medicines that include a medical device, known as drug-device combinations, for a 3-month public consultation. \nüëâhttps://t.co/9Z9mh3cjSa https://t.co/doYXnu2bFl","id":"1135536707191881729","conversation_id":"1135536707191881729","entities":{"mentions":{},"hashtags":{},"urls":[{"start":205,"end":228,"url":"https://t.co/9Z9mh3cjSa","expanded_url":"https://www.ema.europa.eu/en/news/consultation-draft-guideline-quality-requirements-medical-devices-combination-products","display_url":"ema.europa.eu/en/news/consul‚Ä¶"},{"start":229,"end":252,"url":"https://t.co/doYXnu2bFl","expanded_url":"https://twitter.com/EMA_News/status/1135536707191881729/photo/1","display_url":"pic.twitter.com/doYXnu2bFl"}],"annotations":[{"start":0,"end":2,"probability":0.6698,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1135536651978125314"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":1,"like_count":31,"quote_count":1},"created_at":"2019-06-03T09:39:07.000Z","author_id":"116716199","text":"The EMA \"Regulatory Science to 2025\" strategy covers #medicines üíäfor both human and animal use üêÆüê∑üê∂. See what the strategy aims to achieve in #veterinary medicine: https://t.co/xmCyJcI9ky #RegScience2025 #AnimalHealth https://t.co/kTemFpd1FN","id":"1135481027160395777","conversation_id":"1135481027160395777","entities":{"mentions":{},"hashtags":[{"start":53,"end":63,"tag":"medicines"},{"start":141,"end":152,"tag":"veterinary"},{"start":187,"end":202,"tag":"RegScience2025"},{"start":203,"end":216,"tag":"AnimalHealth"}],"urls":[{"start":163,"end":186,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":217,"end":240,"url":"https://t.co/kTemFpd1FN","expanded_url":"https://twitter.com/EMA_News/status/1135481027160395777/photo/1","display_url":"pic.twitter.com/kTemFpd1FN"}],"annotations":{}},"attachments":{"media_keys":["3_1135480823543664640"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":8,"quote_count":2},"created_at":"2019-05-29T16:15:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 4 #medicines for approval at its May 2019 meeting: https://t.co/R5CACJltSE https://t.co/AHvM39hWAX","id":"1133768713411420160","conversation_id":"1133768713411420160","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":53,"end":63,"tag":"medicines"}],"urls":[{"start":102,"end":125,"url":"https://t.co/R5CACJltSE","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-27-29-may-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":126,"end":149,"url":"https://t.co/AHvM39hWAX","expanded_url":"https://twitter.com/EMA_News/status/1133768713411420160/photo/1","display_url":"pic.twitter.com/AHvM39hWAX"}],"annotations":[{"start":0,"end":2,"probability":0.4515,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1133766950377656320"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":2,"quote_count":1},"created_at":"2019-05-29T08:41:58.000Z","author_id":"116716199","text":"We are looking to recruit an experienced Head of Procurement and Purchase Standards Service. #JobsEMA\nThe successful candidate will lead all global procurement and contract management efforts within #EMA. \nInterested? Apply by 4 June 2019 23:59 CET \nüëâhttps://t.co/W0Z4Nv52Cs https://t.co/L5CvkdxZX0","id":"1133654705157156864","conversation_id":"1133654705157156864","entities":{"mentions":{},"hashtags":[{"start":93,"end":101,"tag":"JobsEMA"},{"start":199,"end":203,"tag":"EMA"}],"urls":[{"start":251,"end":274,"url":"https://t.co/W0Z4Nv52Cs","expanded_url":"https://career5.successfactors.eu/sfcareer/jobreqcareer?jobId=990&company=europeanmeP&username=","display_url":"career5.successfactors.eu/sfcareer/jobre‚Ä¶"},{"start":275,"end":298,"url":"https://t.co/L5CvkdxZX0","expanded_url":"https://twitter.com/EMA_News/status/1133654705157156864/photo/1","display_url":"pic.twitter.com/L5CvkdxZX0"}],"annotations":[{"start":41,"end":59,"probability":0.4705,"type":"Organization","normalized_text":"Head of Procurement"}]},"attachments":{"media_keys":["3_1133654531231895552"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1133380647265951744"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-28T14:40:17.000Z","author_id":"116716199","text":"RT @ECDC_VPD: \"4.5 million children and teenagers in üá™üá∫ below 20 years of age are unnecessarily at risk of #measles. Elimination can only b‚Ä¶","id":"1133382490377396226","conversation_id":"1133382490377396226","entities":{"mentions":[{"start":3,"end":12,"username":"ECDC_VPD","id":"186471638"}],"hashtags":[{"start":107,"end":115,"tag":"measles"}],"urls":{},"annotations":[{"start":53,"end":56,"probability":0.5991,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2019-05-28T12:35:31.000Z","author_id":"116716199","text":"#DYK that EMA provides scientific advice on any aspects of research and development related to the quality, safety or efficacy of #medicines for the use in animals? üê±üê∑üêÆ\n#AnnualReportEMA #Animalhealth \nüëâhttps://t.co/2eyju4nZIe https://t.co/fBcC8jZlGk","id":"1133351092144791553","conversation_id":"1133351092144791553","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":130,"end":140,"tag":"medicines"},{"start":169,"end":185,"tag":"AnnualReportEMA"},{"start":186,"end":199,"tag":"Animalhealth"}],"urls":[{"start":202,"end":225,"url":"https://t.co/2eyju4nZIe","expanded_url":"https://www.ema.europa.eu/en/documents/annual-report/2018-annual-report-european-medicines-agency_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"},{"start":226,"end":249,"url":"https://t.co/fBcC8jZlGk","expanded_url":"https://twitter.com/EMA_News/status/1133351092144791553/photo/1","display_url":"pic.twitter.com/fBcC8jZlGk"}],"annotations":{}},"attachments":{"media_keys":["3_1133349279362375680"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":6,"quote_count":1},"created_at":"2019-05-27T14:48:13.000Z","author_id":"116716199","text":"Check out the agenda of this week‚Äôs meeting of the Committee for Human #Medicines: \nüëâhttps://t.co/4GwwhtVPGv\n‚ùóÔ∏èThe #CHMP highlights will be published on Wednesday 29 May by 7pm CET.","id":"1133022097029115906","conversation_id":"1133022097029115906","entities":{"mentions":{},"hashtags":[{"start":71,"end":81,"tag":"Medicines"},{"start":115,"end":120,"tag":"CHMP"}],"urls":[{"start":85,"end":108,"url":"https://t.co/4GwwhtVPGv","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-27-29-may-2019-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":0,"like_count":36,"quote_count":1},"created_at":"2019-05-24T14:30:00.000Z","author_id":"116716199","text":"#AMR is a major threat to public health. To speed up the development of new medicines we are opening our forum for early dialogue to developers of new antimicrobials. Learn more: https://t.co/Th9rlzApCB https://t.co/9ZY1JBhgPL","id":"1131930351792795649","conversation_id":"1131930351792795649","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"AMR"}],"urls":[{"start":179,"end":202,"url":"https://t.co/Th9rlzApCB","expanded_url":"https://www.ema.europa.eu/en/news/ema-facilitates-early-engagement-medicine-developers-combat-antimicrobial-resistance","display_url":"ema.europa.eu/en/news/ema-fa‚Ä¶"},{"start":203,"end":226,"url":"https://t.co/9ZY1JBhgPL","expanded_url":"https://twitter.com/EMA_News/status/1131930351792795649/photo/1","display_url":"pic.twitter.com/9ZY1JBhgPL"}],"annotations":{}},"attachments":{"media_keys":["3_1131928647621840896"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":14,"quote_count":2},"created_at":"2019-05-24T08:30:00.000Z","author_id":"116716199","text":"In rare cases a medicine could be contaminated or counterfeited. Did you know that EMA coordinates the response with Member States and regulators across the globe to immediately tackle potential safety issues? #AnnualReportEMA https://t.co/2eyju4nZIe https://t.co/6f4QGBUGWX","id":"1131839753635192832","conversation_id":"1131839753635192832","entities":{"mentions":{},"hashtags":[{"start":210,"end":226,"tag":"AnnualReportEMA"}],"urls":[{"start":227,"end":250,"url":"https://t.co/2eyju4nZIe","expanded_url":"https://www.ema.europa.eu/en/documents/annual-report/2018-annual-report-european-medicines-agency_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"},{"start":251,"end":274,"url":"https://t.co/6f4QGBUGWX","expanded_url":"https://twitter.com/EMA_News/status/1131839753635192832/photo/1","display_url":"pic.twitter.com/6f4QGBUGWX"}],"annotations":[{"start":117,"end":129,"probability":0.4649,"type":"Organization","normalized_text":"Member States"}]},"attachments":{"media_keys":["3_1131837808153419779"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1130486562674888707"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-23T12:59:37.000Z","author_id":"116716199","text":"RT @EFSA_EU: Our food comes from our fields üöú and oceans üåä. Respecting natural habitats &amp; having a healthy environment result in a healthie‚Ä¶","id":"1131545217830653952","conversation_id":"1131545217830653952","entities":{"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":19,"quote_count":1},"created_at":"2019-05-22T13:06:09.000Z","author_id":"116716199","text":"We are looking for a Scientific Communication Officer with a strong scientific background and sound English writing skills: https://t.co/1pTcKiU3tz\n#JobsEMA https://t.co/4zIJ3T9v8a","id":"1131184473746354176","conversation_id":"1131184473746354176","entities":{"mentions":{},"hashtags":[{"start":148,"end":156,"tag":"JobsEMA"}],"urls":[{"start":124,"end":147,"url":"https://t.co/1pTcKiU3tz","expanded_url":"https://career5.successfactors.eu/sfcareer/jobreqcareer?jobId=987&company=europeanmeP&userna","display_url":"career5.successfactors.eu/sfcareer/jobre‚Ä¶"},{"start":157,"end":180,"url":"https://t.co/4zIJ3T9v8a","expanded_url":"https://twitter.com/EMA_News/status/1131184473746354176/photo/1","display_url":"pic.twitter.com/4zIJ3T9v8a"}],"annotations":{}},"attachments":{"media_keys":["3_1131184418842992640"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":18,"quote_count":4},"created_at":"2019-05-22T12:35:58.000Z","author_id":"116716199","text":"#DidYouKnow you can safely buy #medicines üíäonline? See how. #SafetyOfMedicines\nüëâhttps://t.co/7L9uHu1gvO https://t.co/lOvaBXOeF4","id":"1131176877689888768","conversation_id":"1131176877689888768","entities":{"mentions":{},"hashtags":[{"start":0,"end":11,"tag":"DidYouKnow"},{"start":31,"end":41,"tag":"medicines"},{"start":60,"end":78,"tag":"SafetyOfMedicines"}],"urls":[{"start":80,"end":103,"url":"https://t.co/7L9uHu1gvO","expanded_url":"https://www.ema.europa.eu/en/news/working-together-safe-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":104,"end":127,"url":"https://t.co/lOvaBXOeF4","expanded_url":"https://twitter.com/EMA_News/status/1131176877689888768/photo/1","display_url":"pic.twitter.com/lOvaBXOeF4"}],"annotations":{}},"attachments":{"media_keys":["3_1131176650606039041"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1131137478134587392"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-22T11:45:06.000Z","author_id":"116716199","text":"RT @EU_Health: How often do you see your general practitioner? üë©‚Äç‚öïÔ∏èüë®‚Äç‚öïÔ∏è\n\nNearly four in ten people (38%) in üá™üá∫ went to see their doctor onc‚Ä¶","id":"1131164078037176320","conversation_id":"1131164078037176320","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":[{"start":110,"end":113,"probability":0.7752,"type":"Place","normalized_text":"üá™üá∫"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":49,"reply_count":3,"like_count":62,"quote_count":9},"created_at":"2019-05-21T10:15:29.000Z","author_id":"116716199","text":"Always read the package leaflet before taking a #medicine üíä. EMA's decisions can lead to changes in this information. #SafetyOfMedicines\nüëâhttps://t.co/7L9uHu1gvO https://t.co/t7ztQPc97M","id":"1130779134479740930","conversation_id":"1130779134479740930","entities":{"mentions":{},"hashtags":[{"start":48,"end":57,"tag":"medicine"},{"start":118,"end":136,"tag":"SafetyOfMedicines"}],"urls":[{"start":138,"end":161,"url":"https://t.co/7L9uHu1gvO","expanded_url":"https://www.ema.europa.eu/en/news/working-together-safe-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":162,"end":185,"url":"https://t.co/t7ztQPc97M","expanded_url":"https://twitter.com/EMA_News/status/1130779134479740930/photo/1","display_url":"pic.twitter.com/t7ztQPc97M"}],"annotations":{}},"attachments":{"media_keys":["3_1130778817696600064"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":1,"like_count":36,"quote_count":3},"created_at":"2019-05-20T08:30:35.000Z","author_id":"116716199","text":"How can EMA's Regulatory Science Strategy shape the future of #academics in the #healthcare field? Share your thought with us: \nüëâhttps://t.co/xmCyJcI9ky \n#RegScience2025 #medicines üíä https://t.co/6qNSnq3Cgv","id":"1130390350621757440","conversation_id":"1130390350621757440","entities":{"mentions":{},"hashtags":[{"start":62,"end":72,"tag":"academics"},{"start":80,"end":91,"tag":"healthcare"},{"start":154,"end":169,"tag":"RegScience2025"},{"start":170,"end":180,"tag":"medicines"}],"urls":[{"start":129,"end":152,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":183,"end":206,"url":"https://t.co/6qNSnq3Cgv","expanded_url":"https://twitter.com/EMA_News/status/1130390350621757440/video/1","display_url":"pic.twitter.com/6qNSnq3Cgv"}],"annotations":{}},"attachments":{"media_keys":["7_1130389986883325952"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1129710897075752962"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-20T08:07:53.000Z","author_id":"116716199","text":"RT @EFSA_EU: Food safety authorities encourage alternatives to #AnimalTesting so that our animals are only used for research if it‚Äôs requir‚Ä¶","id":"1130384636624932881","conversation_id":"1130384636624932881","entities":{"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":[{"start":63,"end":77,"tag":"AnimalTesting"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":12,"quote_count":1},"created_at":"2019-05-17T10:46:58.000Z","author_id":"116716199","text":"What happened during the May meeting of EMA's #pharmacovigilance committee #PRAC? The PRAC started a review of #Xeljanz and concluded a referral procedure on #fenspiride medicines üíä #SafetyOfMedicines\nüëâhttps://t.co/S0lfeaKlOz https://t.co/G3wtZ5LVoP","id":"1129337509010452480","conversation_id":"1129337509010452480","entities":{"mentions":{},"hashtags":[{"start":46,"end":64,"tag":"pharmacovigilance"},{"start":75,"end":80,"tag":"PRAC"},{"start":111,"end":119,"tag":"Xeljanz"},{"start":158,"end":169,"tag":"fenspiride"},{"start":182,"end":200,"tag":"SafetyOfMedicines"}],"urls":[{"start":202,"end":225,"url":"https://t.co/S0lfeaKlOz","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-13-16-may-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":226,"end":249,"url":"https://t.co/G3wtZ5LVoP","expanded_url":"https://twitter.com/EMA_News/status/1129337509010452480/photo/1","display_url":"pic.twitter.com/G3wtZ5LVoP"}],"annotations":{}},"attachments":{"media_keys":["3_1129337440047652864"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1129007570872610816"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-16T12:59:05.000Z","author_id":"116716199","text":"RT @EU_Health: #DYK the 1‚É£st @EurobarometerEU on attitudes towards #vaccination shows that the vast majority of EU citizens believe vaccine‚Ä¶","id":"1129008367383531520","conversation_id":"1129008367383531520","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":29,"end":45,"username":"EurobarometerEU","id":"304876789"}],"hashtags":[{"start":15,"end":19,"tag":"DYK"},{"start":67,"end":79,"tag":"vaccination"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1128659027095846912"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-15T13:57:30.000Z","author_id":"116716199","text":"RT @EU_Health: Are our #communication tools sufficiently accessible, useful and relevant for those interested in  the üá™üá∫#health and #foodsa‚Ä¶","id":"1128660682856108032","conversation_id":"1128660682856108032","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":23,"end":37,"tag":"communication"},{"start":120,"end":127,"tag":"health"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":60,"reply_count":3,"like_count":63,"quote_count":11},"created_at":"2019-05-14T09:14:52.000Z","author_id":"116716199","text":"Have you experienced #SideEffects after taking medicines üíä? Don't hesitate to report them by using the website of your national authority. #SafetyOfMedicines \nüëâhttps://t.co/7L9uHu1gvO https://t.co/Rf177eYxyz","id":"1128227164908916738","conversation_id":"1128227164908916738","entities":{"mentions":{},"hashtags":[{"start":21,"end":33,"tag":"SideEffects"},{"start":139,"end":157,"tag":"SafetyOfMedicines"}],"urls":[{"start":160,"end":183,"url":"https://t.co/7L9uHu1gvO","expanded_url":"https://www.ema.europa.eu/en/news/working-together-safe-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":184,"end":207,"url":"https://t.co/Rf177eYxyz","expanded_url":"https://twitter.com/EMA_News/status/1128227164908916738/photo/1","display_url":"pic.twitter.com/Rf177eYxyz"}],"annotations":{}},"attachments":{"media_keys":["3_1128227069391974400"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":4,"quote_count":0},"created_at":"2019-05-14T07:46:07.000Z","author_id":"116716199","text":"What's on the agenda of our #pharmacovigilance committee's (#PRAC) meeting in May? https://t.co/6cbZaUQChe","id":"1128204829430616064","conversation_id":"1128204829430616064","entities":{"mentions":{},"hashtags":[{"start":28,"end":46,"tag":"pharmacovigilance"},{"start":60,"end":65,"tag":"PRAC"}],"urls":[{"start":83,"end":106,"url":"https://t.co/6cbZaUQChe","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-13-16-may-2019_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"quoted","id":"1127543948770037761"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":18,"quote_count":1},"created_at":"2019-05-13T12:32:40.000Z","author_id":"116716199","text":"We need to protect animal health, properly feed and care for them, to protect our own health too. Embracing a responsible use of #antimicrobials in animals in all #EU member states is an important measure to ensure the good health of animals. https://t.co/QFAgkJZPwc https://t.co/X0l5gv4qM2","id":"1127914555374489600","conversation_id":"1127914555374489600","entities":{"mentions":{},"hashtags":[{"start":129,"end":144,"tag":"antimicrobials"},{"start":163,"end":166,"tag":"EU"}],"urls":[{"start":243,"end":266,"url":"https://t.co/QFAgkJZPwc","expanded_url":"https://www.ema.europa.eu/en/veterinary-regulatory/overview/antimicrobial-resistance/european-surveillance-veterinary-antimicrobial-consumption-esvac","display_url":"ema.europa.eu/en/veterinary-‚Ä¶"},{"start":267,"end":290,"url":"https://t.co/X0l5gv4qM2","expanded_url":"https://twitter.com/EFSA_EU/status/1127543948770037761","display_url":"twitter.com/EFSA_EU/status‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1126761509369946112"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-10T08:26:49.000Z","author_id":"116716199","text":"RT @EU_Health: Just 3 days left to apply to our 2019 #EUHealthAward! \n\nWe are calling on cities, NGOs, &amp; schools to submit initiatives that‚Ä¶","id":"1126765523432140801","conversation_id":"1126765523432140801","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":53,"end":67,"tag":"EUHealthAward"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter for Android","referenced_tweets":[{"type":"retweeted","id":"1126151046097715200"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-09T07:25:08.000Z","author_id":"116716199","text":"RT @EFSA_EU: Do you want your Twitter account to look more #European tomorrow? Celebrate #EuropeDay with the #EUagencies and use our twibbo‚Ä¶","id":"1126387611243819008","conversation_id":"1126387611243819008","entities":{"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":[{"start":59,"end":68,"tag":"European"},{"start":89,"end":99,"tag":"EuropeDay"},{"start":109,"end":120,"tag":"EUagencies"}],"urls":{},"annotations":[{"start":30,"end":36,"probability":0.8386,"type":"Product","normalized_text":"Twitter"}]},"attachments":{"media_keys":{}}},{"source":"Twitter for Android","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":1,"like_count":53,"quote_count":4},"created_at":"2019-05-09T06:24:29.000Z","author_id":"116716199","text":"#EMA and its sister #EUagencies work across Europe to improve the lives of #EU citizens. Together, we celebrate #EuropeDay on 9 May! Find out more about our work: https://t.co/YRnGOjtnXc https://t.co/r6lkbI4tt2 https://t.co/8RcmgBOMhi","id":"1126372349740310528","conversation_id":"1126372349740310528","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":20,"end":31,"tag":"EUagencies"},{"start":75,"end":78,"tag":"EU"},{"start":112,"end":122,"tag":"EuropeDay"}],"urls":[{"start":163,"end":186,"url":"https://t.co/YRnGOjtnXc","expanded_url":"https://www.youtube.com/watch?v=DwPI_ullrWo","display_url":"youtube.com/watch?v=DwPI_u‚Ä¶"},{"start":211,"end":234,"url":"https://t.co/8RcmgBOMhi","expanded_url":"https://twitter.com/EMA_News/status/1126372349740310528/photo/1","display_url":"pic.twitter.com/8RcmgBOMhi"},{"start":187,"end":210,"url":"https://t.co/r6lkbI4tt2","expanded_url":"https://twitter.com/EU_CdT/status/1126118062338596865/photo/1","display_url":"pic.twitter.com/r6lkbI4tt2"}],"annotations":[{"start":44,"end":49,"probability":0.993,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["3_1126372347454341120","3_1126118019170746368"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1126131731495555074"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":1,"quote_count":0},"created_at":"2019-05-08T14:39:27.000Z","author_id":"116716199","text":"@BettinaRyll Thanks for getting in touch. We are aware of this problem and we are working to fix it.","id":"1126134521865355264","conversation_id":"1126131731495555074","entities":{"mentions":[{"start":0,"end":12,"username":"BettinaRyll","id":"810969654"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"810969654"},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1124273117218639872"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-08T13:50:41.000Z","author_id":"116716199","text":"RT @EU_Health: üíäWhich #medicines have been approved centrally by the @EU_Commission?\nThe newly refreshed \"Union Register\" offers you a simp‚Ä¶","id":"1126122252443975681","conversation_id":"1126122252443975681","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":69,"end":83,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":22,"end":32,"tag":"medicines"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"quoted","id":"1126065256793550848"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":30,"quote_count":1},"created_at":"2019-05-08T12:38:05.000Z","author_id":"116716199","text":"The Danish Medicines Agency has produced a useful explanatory video on #SafetyofMedicines. For those who don‚Äôt speak Danish, the English subtitle is available in the YouTube video:\nüëâhttps://t.co/KQWGAvgXPB https://t.co/zmpXP1kzWl","id":"1126103979522445314","conversation_id":"1126103979522445314","entities":{"mentions":{},"hashtags":[{"start":71,"end":89,"tag":"SafetyofMedicines"}],"urls":[{"start":182,"end":205,"url":"https://t.co/KQWGAvgXPB","expanded_url":"https://www.youtube.com/watch?v=Z7xmaVrRpXE&feature=youtu.be","display_url":"youtube.com/watch?v=Z7xmaV‚Ä¶"},{"start":206,"end":229,"url":"https://t.co/zmpXP1kzWl","expanded_url":"https://twitter.com/LMSTdk/status/1126065256793550848","display_url":"twitter.com/LMSTdk/status/‚Ä¶"}],"annotations":[{"start":4,"end":26,"probability":0.4151,"type":"Organization","normalized_text":"Danish Medicines Agency"},{"start":166,"end":172,"probability":0.4627,"type":"Product","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":3,"like_count":58,"quote_count":10},"created_at":"2019-05-08T07:36:56.000Z","author_id":"116716199","text":"#DYK that #patients and healthcare professionals are involved in the decision process when it comes to #SafetyOfMedicines?\nüëâhttps://t.co/7L9uHu1gvO https://t.co/qSlz9EApoM","id":"1126028194170249216","conversation_id":"1126028194170249216","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":10,"end":19,"tag":"patients"},{"start":103,"end":121,"tag":"SafetyOfMedicines"}],"urls":[{"start":124,"end":147,"url":"https://t.co/7L9uHu1gvO","expanded_url":"https://www.ema.europa.eu/en/news/working-together-safe-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":148,"end":171,"url":"https://t.co/qSlz9EApoM","expanded_url":"https://twitter.com/EMA_News/status/1126028194170249216/photo/1","display_url":"pic.twitter.com/qSlz9EApoM"}],"annotations":{}},"attachments":{"media_keys":["3_1126027827495735296"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1125346722476175360"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-07T15:39:14.000Z","author_id":"116716199","text":"RT @EFSA_EU: Do you want safe, traceable ingredients in your food? We all do. The EU system makes sure food is safe, backed by sound scienc‚Ä¶","id":"1125787179530313730","conversation_id":"1125787179530313730","entities":{"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":84,"reply_count":0,"like_count":110,"quote_count":15},"created_at":"2019-05-07T12:08:49.000Z","author_id":"116716199","text":"No üíä# is 100% safe. But #patients in Europe can rely on the unique EU network that ensures they have access to high-quality, effective and safe #medicines wherever they live. See how EMA keeps üíä safe.  #SafetyOfMedicines \nüëâhttps://t.co/7L9uHu1gvO https://t.co/rP8ce0GqHM","id":"1125734228405227520","conversation_id":"1125734228405227520","entities":{"mentions":{},"hashtags":[{"start":24,"end":33,"tag":"patients"},{"start":144,"end":154,"tag":"medicines"},{"start":202,"end":220,"tag":"SafetyOfMedicines"}],"urls":[{"start":223,"end":246,"url":"https://t.co/7L9uHu1gvO","expanded_url":"https://www.ema.europa.eu/en/news/working-together-safe-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":247,"end":270,"url":"https://t.co/rP8ce0GqHM","expanded_url":"https://twitter.com/EMA_News/status/1125734228405227520/video/1","display_url":"pic.twitter.com/rP8ce0GqHM"}],"annotations":[{"start":38,"end":43,"probability":0.9893,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["7_1125733677785341952"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":16,"quote_count":2},"created_at":"2019-05-07T07:11:00.000Z","author_id":"116716199","text":"How did EMA prepare for Brexit? Find out more from our Deputy Executive Director, No√´l Wathion, who led EMA‚Äôs operational and relocation preparedness activities for #Brexit. #AnnualReportEMA\nüëâhttps://t.co/FJoT1ZszvQ https://t.co/hrjDBBUfMN","id":"1125659278046564352","conversation_id":"1125659278046564352","entities":{"mentions":{},"hashtags":[{"start":165,"end":172,"tag":"Brexit"},{"start":174,"end":190,"tag":"AnnualReportEMA"}],"urls":[{"start":192,"end":215,"url":"https://t.co/FJoT1ZszvQ","expanded_url":"https://www.ema.europa.eu/en/news/ema-annual-report-2018-published","display_url":"ema.europa.eu/en/news/ema-an‚Ä¶"},{"start":216,"end":239,"url":"https://t.co/hrjDBBUfMN","expanded_url":"https://twitter.com/EMA_News/status/1125659278046564352/photo/1","display_url":"pic.twitter.com/hrjDBBUfMN"}],"annotations":[{"start":24,"end":29,"probability":0.5572,"type":"Other","normalized_text":"Brexit"},{"start":82,"end":93,"probability":0.7863,"type":"Person","normalized_text":"No√´l Wathion"},{"start":104,"end":106,"probability":0.5122,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1125367411883028480"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":61,"reply_count":0,"like_count":80,"quote_count":16},"created_at":"2019-05-06T11:34:37.000Z","author_id":"116716199","text":"#DYK the brightest medicine experts with diverse specialised knowledge in the world work to keep üíäüíä safe across the EU? #SafetyOfMedicines https://t.co/7L9uHu1gvO https://t.co/dpfJ3bECm8","id":"1125363232397512704","conversation_id":"1125363232397512704","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"DYK"},{"start":120,"end":138,"tag":"SafetyOfMedicines"}],"urls":[{"start":139,"end":162,"url":"https://t.co/7L9uHu1gvO","expanded_url":"https://www.ema.europa.eu/en/news/working-together-safe-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":163,"end":186,"url":"https://t.co/dpfJ3bECm8","expanded_url":"https://twitter.com/EMA_News/status/1125363232397512704/photo/1","display_url":"pic.twitter.com/dpfJ3bECm8"}],"annotations":{}},"attachments":{"media_keys":["3_1125362933691711489"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1125052535109120002"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":47,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-05-06T07:28:46.000Z","author_id":"116716199","text":"RT @EAAD_EU: 75% of the burden of bacteria resistant to #antibiotics in Europe is due to #healthcare associated infections. #InfectionPreve‚Ä¶","id":"1125301361833385984","conversation_id":"1125301361833385984","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"}],"hashtags":[{"start":56,"end":68,"tag":"antibiotics"},{"start":89,"end":100,"tag":"healthcare"}],"urls":{},"annotations":[{"start":72,"end":77,"probability":0.9966,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":1,"like_count":45,"quote_count":4},"created_at":"2019-05-03T14:59:35.000Z","author_id":"116716199","text":"What were EMA's key achievements in 2018? We have just published our 2018 Annual Report, which gives an overview of our activities during a challenging year. #AnnualReportEMA https://t.co/FJoT1ZszvQ https://t.co/gr0fYqUMpX","id":"1124327650053566465","conversation_id":"1124327650053566465","entities":{"mentions":{},"hashtags":[{"start":158,"end":174,"tag":"AnnualReportEMA"}],"urls":[{"start":175,"end":198,"url":"https://t.co/FJoT1ZszvQ","expanded_url":"https://www.ema.europa.eu/en/news/ema-annual-report-2018-published","display_url":"ema.europa.eu/en/news/ema-an‚Ä¶"},{"start":199,"end":222,"url":"https://t.co/gr0fYqUMpX","expanded_url":"https://twitter.com/EMA_News/status/1124327650053566465/photo/1","display_url":"pic.twitter.com/gr0fYqUMpX"}],"annotations":{}},"attachments":{"media_keys":["3_1124327584739860480"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1124239056928477184"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"created_at":"2019-05-03T12:17:27.000Z","author_id":"116716199","text":"@chrisOverflow @shiftms @TheLancet For further information, you may want to consult our public health communication on #Lemtrada published in April: https://t.co/XhfBCIFxbk","id":"1124286846408765440","conversation_id":"1124226846042853376","entities":{"mentions":[{"start":0,"end":14,"username":"ChrisOverflow","id":"1248926632297091074"},{"start":15,"end":23,"username":"shiftms","id":"14583151"},{"start":24,"end":34,"username":"TheLancet","id":"27013292"}],"hashtags":[{"start":119,"end":128,"tag":"Lemtrada"}],"urls":[{"start":149,"end":172,"url":"https://t.co/XhfBCIFxbk","expanded_url":"https://www.ema.europa.eu/en/news/use-multiple-sclerosis-medicine-lemtrada-restricted-while-ema-review-ongoing","display_url":"ema.europa.eu/en/news/use-mu‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"950088769"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":1,"like_count":13,"quote_count":3},"created_at":"2019-04-30T12:10:40.000Z","author_id":"116716199","text":"Two additional countries to benefit from the EU-US mutual recognition agreement for inspections: https://t.co/JLsJdSdoSZ","id":"1123197979295399936","conversation_id":"1123197979295399936","entities":{"mentions":{},"hashtags":{},"urls":[{"start":97,"end":120,"url":"https://t.co/JLsJdSdoSZ","expanded_url":"https://www.ema.europa.eu/en/news/two-additional-countries-benefit-eu-us-mutual-recognition-agreement-inspections-0","display_url":"ema.europa.eu/en/news/two-ad‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":8,"quote_count":0},"created_at":"2019-04-30T10:23:54.000Z","author_id":"116716199","text":"How many recommendations for eligibility to EMA's PRIME scheme were granted in April? Follow #PRIME_EMA for the latest updates. https://t.co/m3oKbp16oi https://t.co/gBZpDnwbNo","id":"1123171110755930112","conversation_id":"1123171110755930112","entities":{"mentions":{},"hashtags":[{"start":93,"end":103,"tag":"PRIME_EMA"}],"urls":[{"start":128,"end":151,"url":"https://t.co/m3oKbp16oi","expanded_url":"https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-23-26-april-2019_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":152,"end":175,"url":"https://t.co/gBZpDnwbNo","expanded_url":"https://twitter.com/EMA_News/status/1123171110755930112/photo/1","display_url":"pic.twitter.com/gBZpDnwbNo"}],"annotations":[{"start":44,"end":46,"probability":0.4909,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1123171008435884033"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"quoted","id":"1120978657806290945"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":16,"quote_count":0},"created_at":"2019-04-30T09:28:38.000Z","author_id":"116716199","text":"Safe and nutritious food protects #PublicHealth. See how the EU food safety system - through the work of @EFSA_EU, other EU agencies, the @EU_Commission and EU Member States - enhances the lives of citizens.  #EUandMyFood https://t.co/oohQhLZUrJ","id":"1123157202011873281","conversation_id":"1123157202011873281","entities":{"mentions":[{"start":105,"end":113,"username":"EFSA_EU","id":"84582815"},{"start":138,"end":152,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":34,"end":47,"tag":"PublicHealth"},{"start":209,"end":221,"tag":"EUandMyFood"}],"urls":[{"start":222,"end":245,"url":"https://t.co/oohQhLZUrJ","expanded_url":"https://twitter.com/EFSA_EU/status/1120978657806290945","display_url":"twitter.com/EFSA_EU/status‚Ä¶"}],"annotations":[{"start":61,"end":62,"probability":0.5383,"type":"Organization","normalized_text":"EU"},{"start":157,"end":172,"probability":0.4308,"type":"Organization","normalized_text":"EU Member States"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1122415151616069632"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":63,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-29T07:25:14.000Z","author_id":"116716199","text":"RT @EU_Health: How much #vaccine confidence do we have? What about our #doctors? How is the delivery of #vaccination services in the #EU or‚Ä¶","id":"1122763756981956609","conversation_id":"1122763756981956609","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":24,"end":32,"tag":"vaccine"},{"start":71,"end":79,"tag":"doctors"},{"start":104,"end":116,"tag":"vaccination"},{"start":133,"end":136,"tag":"EU"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":12,"quote_count":1},"created_at":"2019-04-26T15:41:00.000Z","author_id":"116716199","text":"#CHMP recommends granting a marketing authorisation for a new long-lasting implant to treat opioid dependence: https://t.co/m8GGIDpK38","id":"1121801357265182721","conversation_id":"1121801357265182721","entities":{"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"CHMP"}],"urls":[{"start":111,"end":134,"url":"https://t.co/m8GGIDpK38","expanded_url":"https://www.ema.europa.eu/en/news/new-long-lasting-implant-treat-opioid-dependence","display_url":"ema.europa.eu/en/news/new-lo‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":18,"quote_count":3},"created_at":"2019-04-26T15:30:14.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee (#CHMP) recommends 13 #medicines for approval at its April 2019 meeting: https://t.co/4jW4cVNWto https://t.co/kmZbJh1OZj","id":"1121798647283249152","conversation_id":"1121798647283249152","entities":{"mentions":{},"hashtags":[{"start":33,"end":38,"tag":"CHMP"},{"start":54,"end":64,"tag":"medicines"}],"urls":[{"start":105,"end":128,"url":"https://t.co/4jW4cVNWto","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-23-26-april-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":129,"end":152,"url":"https://t.co/kmZbJh1OZj","expanded_url":"https://twitter.com/EMA_News/status/1121798647283249152/photo/1","display_url":"pic.twitter.com/kmZbJh1OZj"}],"annotations":[{"start":0,"end":2,"probability":0.4519,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1121798593273221121"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1121745743528677376"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":42,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-26T12:14:34.000Z","author_id":"116716199","text":"RT @EU_Health: On European Immunization Week, check the new Eurobarometer on Europeans' attitudes towards vaccination! https://t.co/zoeIiIk‚Ä¶","id":"1121749406712250368","conversation_id":"1121749406712250368","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":[{"start":18,"end":43,"probability":0.5297,"type":"Other","normalized_text":"European Immunization Week"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1121728565861597184"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-26T11:50:03.000Z","author_id":"116716199","text":"RT @jyrkikatainen: It's good news that around half of EU citizens were vaccinated in the last 5 years. However, the Eurobarometer reinforce‚Ä¶","id":"1121743239277699074","conversation_id":"1121743239277699074","entities":{"mentions":[{"start":3,"end":17,"username":"jyrkikatainen","id":"23746425"}],"hashtags":{},"urls":{},"annotations":[{"start":54,"end":55,"probability":0.5131,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1121730424525545473"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-26T11:24:53.000Z","author_id":"116716199","text":"RT @EU_Health: This 1‚É£st @EurobarometerEU on attitudes towards vaccination shows that the vast majority of EU citizens believe vaccination‚Ä¶","id":"1121736904536358912","conversation_id":"1121736904536358912","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":25,"end":41,"username":"EurobarometerEU","id":"304876789"}],"hashtags":{},"urls":{},"annotations":[{"start":107,"end":108,"probability":0.4337,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":10,"quote_count":1},"created_at":"2019-04-26T09:49:08.000Z","author_id":"116716199","text":"How can our #RegScience2025 strategy enable and leverage research and innovation in regulatory science? #Goal5  \nüëâhttps://t.co/xmCyJcI9ky https://t.co/6unSLoAsFW","id":"1121712809157513216","conversation_id":"1121712809157513216","entities":{"mentions":{},"hashtags":[{"start":12,"end":27,"tag":"RegScience2025"},{"start":104,"end":110,"tag":"Goal5"}],"urls":[{"start":114,"end":137,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":138,"end":161,"url":"https://t.co/6unSLoAsFW","expanded_url":"https://twitter.com/EMA_News/status/1121712809157513216/photo/1","display_url":"pic.twitter.com/6unSLoAsFW"}],"annotations":{}},"attachments":{"media_keys":["3_1121712530970357760"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1121700442608553985"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":41,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-26T09:29:52.000Z","author_id":"116716199","text":"RT @EU_Health: #Vaccination is one of the greatest successes of public #health of our time. Over the past 60 years, it has saved more child‚Ä¶","id":"1121707957853544449","conversation_id":"1121707957853544449","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":27,"tag":"Vaccination"},{"start":71,"end":78,"tag":"health"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1121325499882647552"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-26T07:43:07.000Z","author_id":"116716199","text":"RT @ECDC_VPD: Unvaccinated young children are disproportionately affected by #measles and run the highest risk of serious complications.  h‚Ä¶","id":"1121681094187683841","conversation_id":"1121681094187683841","entities":{"mentions":[{"start":3,"end":12,"username":"ECDC_VPD","id":"186471638"}],"hashtags":[{"start":77,"end":85,"tag":"measles"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1121352968035536897"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":239,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-26T07:28:53.000Z","author_id":"116716199","text":"RT @WHO: It's World Immunization Week!\n\nVaccines are one of our best investments for a healthier world. As vaccine coverage has increased,‚Ä¶","id":"1121677513195835392","conversation_id":"1121677513195835392","entities":{"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":54,"reply_count":1,"like_count":75,"quote_count":4},"created_at":"2019-04-25T12:15:11.000Z","author_id":"116716199","text":"Let‚Äôs listen to our ‚ÄúVaccines heroes‚Äù: paediatricians &amp; nurses who, after treating thousands of patients, feel comfortable to recommend immunisation; scientists who spend thousands of hours developing and testing vaccines; or patients. #VaccinesWork\nüëâhttps://t.co/A2D0fv9F9W https://t.co/hWm94Ekn4N","id":"1121387176321855489","conversation_id":"1121387176321855489","entities":{"mentions":{},"hashtags":[{"start":240,"end":253,"tag":"VaccinesWork"}],"urls":[{"start":255,"end":278,"url":"https://t.co/A2D0fv9F9W","expanded_url":"https://www.ema.europa.eu/en/news/european-immunization-week-2019-statement-executive-director-guido-rasi","display_url":"ema.europa.eu/en/news/europe‚Ä¶"},{"start":279,"end":302,"url":"https://t.co/hWm94Ekn4N","expanded_url":"https://twitter.com/EMA_News/status/1121387176321855489/video/1","display_url":"pic.twitter.com/hWm94Ekn4N"}],"annotations":{}},"attachments":{"media_keys":["7_1121386583716958208"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1120970423754272768"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-25T11:51:06.000Z","author_id":"116716199","text":"RT @WEBRADR: .@WEBRADR publication in #DrugSafety - Establishing a Framework for the Use of Social Media in Pharmacovigilance in Europe #ph‚Ä¶","id":"1121381114592006145","conversation_id":"1121381114592006145","entities":{"mentions":[{"start":3,"end":11,"username":"WEBRADR","id":"2797520425"},{"start":14,"end":22,"username":"WEBRADR","id":"2797520425"}],"hashtags":[{"start":38,"end":49,"tag":"DrugSafety"}],"urls":{},"annotations":[{"start":129,"end":134,"probability":0.9821,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1120960569152958464"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":127,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-25T08:14:58.000Z","author_id":"116716199","text":"RT @EU_Health: It's the European Immunization Week! DYK vaccination saves between 1 and 3 million lives worldwide every year? \n\n#EU actions‚Ä¶","id":"1121326721804976129","conversation_id":"1121326721804976129","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":128,"end":131,"tag":"EU"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":61,"reply_count":1,"like_count":76,"quote_count":4},"created_at":"2019-04-25T07:36:32.000Z","author_id":"116716199","text":"EMA supports European Immunization Week. In a statement published today, our Exec Director, Guido Rasi, explains why it's important to listen to ‚ÄúVaccine heroes‚Äù and reminds us to base our decisions on science-based facts about immunisation. \nhttps://t.co/A2D0fv9F9W #VaccinesWork https://t.co/4bmWF2ZL3H","id":"1121317050507563008","conversation_id":"1121317050507563008","entities":{"mentions":{},"hashtags":[{"start":267,"end":280,"tag":"VaccinesWork"}],"urls":[{"start":243,"end":266,"url":"https://t.co/A2D0fv9F9W","expanded_url":"https://www.ema.europa.eu/en/news/european-immunization-week-2019-statement-executive-director-guido-rasi","display_url":"ema.europa.eu/en/news/europe‚Ä¶"},{"start":281,"end":304,"url":"https://t.co/4bmWF2ZL3H","expanded_url":"https://twitter.com/EMA_News/status/1121317050507563008/photo/1","display_url":"pic.twitter.com/4bmWF2ZL3H"}],"annotations":[{"start":0,"end":2,"probability":0.484,"type":"Organization","normalized_text":"EMA"},{"start":13,"end":38,"probability":0.3284,"type":"Other","normalized_text":"European Immunization Week"},{"start":92,"end":101,"probability":0.9635,"type":"Person","normalized_text":"Guido Rasi"}]},"attachments":{"media_keys":["3_1121316879904202752"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":7,"quote_count":1},"created_at":"2019-04-23T14:33:21.000Z","author_id":"116716199","text":"Check out the agenda of this week‚Äôs meeting of the Committee for Human #Medicines (#CHMP): https://t.co/m9SZoXBvmp","id":"1120697171450503173","conversation_id":"1120697171450503173","entities":{"mentions":{},"hashtags":[{"start":71,"end":81,"tag":"Medicines"},{"start":83,"end":88,"tag":"CHMP"}],"urls":[{"start":91,"end":114,"url":"https://t.co/m9SZoXBvmp","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-23-26-april-2019-meeting_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":16,"quote_count":5},"created_at":"2019-04-12T10:26:16.000Z","author_id":"116716199","text":"Our safety committee #PRAC starts a review of risks with high-strength #estradiol-containing creams and restricts the use of the #MultipleSclerosis medicine #Lemtrada as a precautionary measure during the assessment of the risks with this treatment: https://t.co/EkwaV9x5d5","id":"1116648722514026497","conversation_id":"1116648722514026497","entities":{"mentions":{},"hashtags":[{"start":21,"end":26,"tag":"PRAC"},{"start":71,"end":81,"tag":"estradiol"},{"start":129,"end":147,"tag":"MultipleSclerosis"},{"start":157,"end":166,"tag":"Lemtrada"}],"urls":[{"start":250,"end":273,"url":"https://t.co/EkwaV9x5d5","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":22,"quote_count":3},"created_at":"2019-04-11T10:32:09.000Z","author_id":"116716199","text":"What is the role of regulatory agencies in establishing the added therapeutic benefit of innovative treatments? Find out in this @NatRevDrugDisc article: https://t.co/OQ54HYfmk2 #medicines https://t.co/YBOOlxZkyo","id":"1116287816076603392","conversation_id":"1116287816076603392","entities":{"mentions":[{"start":129,"end":144,"username":"NatRevDrugDisc","id":"36066745"}],"hashtags":[{"start":178,"end":188,"tag":"medicines"}],"urls":[{"start":154,"end":177,"url":"https://t.co/OQ54HYfmk2","expanded_url":"https://www.ema.europa.eu/en/news/role-regulators-establishing-added-benefit-novel-therapies","display_url":"ema.europa.eu/en/news/role-r‚Ä¶"},{"start":189,"end":212,"url":"https://t.co/YBOOlxZkyo","expanded_url":"https://twitter.com/EMA_News/status/1116287816076603392/photo/1","display_url":"pic.twitter.com/YBOOlxZkyo"}],"annotations":{}},"attachments":{"media_keys":["3_1116287797705490432"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":11,"quote_count":1},"created_at":"2019-04-08T15:39:04.000Z","author_id":"116716199","text":"What is on the agenda of our safety committee's meeting in April? https://t.co/aCU2wRYOwG #PRAC #pharmacovigilance","id":"1115277890147561473","conversation_id":"1115277890147561473","entities":{"mentions":{},"hashtags":[{"start":90,"end":95,"tag":"PRAC"},{"start":96,"end":114,"tag":"pharmacovigilance"}],"urls":[{"start":66,"end":89,"url":"https://t.co/aCU2wRYOwG","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-8-11-april-2019_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1114879246449692672"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":134,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-08T08:37:54.000Z","author_id":"116716199","text":"RT @EU_Health: Antimicrobial resistance is one of the greatest public #health threats of our time. Use #antibiotics prudently, only when pr‚Ä¶","id":"1115171898827182080","conversation_id":"1115171898827182080","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":70,"end":77,"tag":"health"},{"start":103,"end":115,"tag":"antibiotics"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":0,"like_count":31,"quote_count":4},"created_at":"2019-04-05T07:00:00.000Z","author_id":"116716199","text":"With its \"Regulatory Science to 2025\" strategy, #EMA aims to address emerging health threats and therapeutic challenges. You can share your thoughts on proposed actions. #RegScience2025 https://t.co/xmCyJcI9ky https://t.co/8CZA7aKPh7","id":"1114060100476514309","conversation_id":"1114060100476514309","entities":{"mentions":{},"hashtags":[{"start":48,"end":52,"tag":"EMA"},{"start":170,"end":185,"tag":"RegScience2025"}],"urls":[{"start":186,"end":209,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":210,"end":233,"url":"https://t.co/8CZA7aKPh7","expanded_url":"https://twitter.com/EMA_News/status/1114060100476514309/photo/1","display_url":"pic.twitter.com/8CZA7aKPh7"}],"annotations":{}},"attachments":{"media_keys":["3_1113806552169963520"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1113749130659160064"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":138,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-04T11:36:15.000Z","author_id":"116716199","text":"RT @EU_Commission: There is an increasing risk of the UK leaving the EU without a #Brexit deal\nWe #Prepare4Brexit on public health, in part‚Ä¶","id":"1113767232264441861","conversation_id":"1113767232264441861","entities":{"mentions":[{"start":3,"end":17,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":82,"end":89,"tag":"Brexit"},{"start":98,"end":113,"tag":"Prepare4Brexit"}],"urls":{},"annotations":[{"start":54,"end":55,"probability":0.9,"type":"Place","normalized_text":"UK"},{"start":69,"end":70,"probability":0.3932,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1113753603544690688"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-04T10:46:37.000Z","author_id":"116716199","text":"RT @EU_Health: Check @EMA_News Q&amp;A on #medicines and #Brexit preparedness üëâhttps://t.co/tqqqqxAmAm https://t.co/V95sqxtaBd","id":"1113754742633717760","conversation_id":"1113754742633717760","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":21,"end":30,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":42,"end":52,"tag":"medicines"},{"start":57,"end":64,"tag":"Brexit"}],"urls":[{"start":79,"end":102,"url":"https://t.co/tqqqqxAmAm","expanded_url":"https://www.ema.europa.eu/en/documents/other/european-authorities-working-avoid-shortages-medicines-due-brexit-questions-answers_en.pdf","display_url":"ema.europa.eu/en/documents/o‚Ä¶"},{"start":103,"end":126,"url":"https://t.co/V95sqxtaBd","expanded_url":"https://twitter.com/EU_Health/status/1113753603544690688/photo/1","display_url":"pic.twitter.com/V95sqxtaBd"}],"annotations":{}},"attachments":{"media_keys":["3_1113753444144308224"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1113752498567880704"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-04T10:45:31.000Z","author_id":"116716199","text":"RT @EU_Health: VP @jyrkikatainen #Patients in the #EU should not worry about finding the #medicines they need. Our rules provide for approp‚Ä¶","id":"1113754464073277440","conversation_id":"1113754464073277440","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":18,"end":32,"username":"jyrkikatainen","id":"23746425"}],"hashtags":[{"start":33,"end":42,"tag":"Patients"},{"start":50,"end":53,"tag":"EU"},{"start":89,"end":99,"tag":"medicines"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1113752282468900865"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-04T10:45:16.000Z","author_id":"116716199","text":"RT @EU_Health: VP @jyrkikatainen: We have been  working very hard over the last two years together with @EMA_News and national authorities‚Ä¶","id":"1113754400022061056","conversation_id":"1113754400022061056","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":18,"end":32,"username":"jyrkikatainen","id":"23746425"},{"start":104,"end":113,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1113744368748384256"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-04-04T10:29:05.000Z","author_id":"116716199","text":"RT @Food_EU: Vice-President @jyrkikatainen is in the press room today to present the EU‚Äôs Brexit Preparedness measures in the area of #Heal‚Ä¶","id":"1113750330150404097","conversation_id":"1113750330150404097","entities":{"mentions":[{"start":3,"end":11,"username":"Food_EU","id":"2874880006"},{"start":28,"end":42,"username":"jyrkikatainen","id":"23746425"}],"hashtags":{},"urls":{},"annotations":[{"start":85,"end":86,"probability":0.6555,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2019-04-04T10:02:48.000Z","author_id":"116716199","text":"How many recommendations for eligibility to EMA's PRIME scheme were granted in March? Follow #PRIME_EMA for the latest updates. https://t.co/XsFsG3gxeu. https://t.co/GST95Hq2fc","id":"1113743712268562432","conversation_id":"1113743712268562432","entities":{"mentions":{},"hashtags":[{"start":93,"end":103,"tag":"PRIME_EMA"}],"urls":[{"start":128,"end":151,"url":"https://t.co/XsFsG3gxeu","expanded_url":"https://www.ema.europa.eu/en/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-25-28-march-2019_en.pdf","display_url":"ema.europa.eu/en/documents/r‚Ä¶"},{"start":153,"end":176,"url":"https://t.co/GST95Hq2fc","expanded_url":"https://twitter.com/EMA_News/status/1113743712268562432/photo/1","display_url":"pic.twitter.com/GST95Hq2fc"}],"annotations":[{"start":44,"end":46,"probability":0.4756,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1113743583520206849"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":1,"like_count":28,"quote_count":5},"created_at":"2019-04-04T07:00:00.000Z","author_id":"116716199","text":"#EMA has updated its relocation tracking tool, which provides an overview of the main milestones and deliverables for the Agency‚Äôs move to Amsterdam: https://t.co/R8GllwEWVk https://t.co/mit0a5HXJP","id":"1113697711650422786","conversation_id":"1113697711650422786","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"}],"urls":[{"start":150,"end":173,"url":"https://t.co/R8GllwEWVk","expanded_url":"https://www.ema.europa.eu/en/documents/other/ema-tracking-tool-relocation-amsterdam-main-milestones_en.pdf","display_url":"ema.europa.eu/en/documents/o‚Ä¶"},{"start":174,"end":197,"url":"https://t.co/mit0a5HXJP","expanded_url":"https://twitter.com/EMA_News/status/1113697711650422786/photo/1","display_url":"pic.twitter.com/mit0a5HXJP"}],"annotations":[{"start":139,"end":147,"probability":0.9896,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1113467561285386240"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":0,"like_count":24,"quote_count":2},"created_at":"2019-03-29T11:54:42.000Z","author_id":"116716199","text":"New gene therapy to treat rare inherited blood condition https://t.co/7puRpMz7BJ #CHMP","id":"1111597548899389441","conversation_id":"1111597548899389441","entities":{"mentions":{},"hashtags":[{"start":81,"end":86,"tag":"CHMP"}],"urls":[{"start":57,"end":80,"url":"https://t.co/7puRpMz7BJ","expanded_url":"https://www.ema.europa.eu/en/news/new-gene-therapy-treat-rare-inherited-blood-condition","display_url":"ema.europa.eu/en/news/new-ge‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":12,"quote_count":0},"created_at":"2019-03-29T11:49:02.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee recommends 1 #medicine for approval at its March 2019 meeting https://t.co/lLCQjAWUlY #CHMP https://t.co/Upx8sfJmWa","id":"1111596123318308864","conversation_id":"1111596123318308864","entities":{"mentions":{},"hashtags":[{"start":45,"end":54,"tag":"medicine"},{"start":118,"end":123,"tag":"CHMP"}],"urls":[{"start":94,"end":117,"url":"https://t.co/lLCQjAWUlY","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-march-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":124,"end":147,"url":"https://t.co/Upx8sfJmWa","expanded_url":"https://twitter.com/EMA_News/status/1111596123318308864/photo/1","display_url":"pic.twitter.com/Upx8sfJmWa"}],"annotations":[{"start":0,"end":2,"probability":0.561,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1111596082822348800"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":31,"quote_count":1},"created_at":"2019-03-28T13:52:22.000Z","author_id":"116716199","text":"EMA‚Äôs #RegScience2025 strategy aims to protect #PublicHealth by ensuring that regulators can keep pace with scientific advances related to medicines üíä. Patients, healthcare professionals, academics, you can get involved by sharing your comments: https://t.co/xmCyJcI9ky #Goal3 https://t.co/eLTIJC6Dq6","id":"1111264772979343360","conversation_id":"1111264772979343360","entities":{"mentions":{},"hashtags":[{"start":6,"end":21,"tag":"RegScience2025"},{"start":47,"end":60,"tag":"PublicHealth"},{"start":270,"end":276,"tag":"Goal3"}],"urls":[{"start":246,"end":269,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":277,"end":300,"url":"https://t.co/eLTIJC6Dq6","expanded_url":"https://twitter.com/EMA_News/status/1111264772979343360/photo/1","display_url":"pic.twitter.com/eLTIJC6Dq6"}],"annotations":{}},"attachments":{"media_keys":["3_1111261722009051137"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":18,"quote_count":0},"created_at":"2019-03-28T10:32:55.000Z","author_id":"116716199","text":"#EMA works closely with the network of Official Medicines Control Laboratories #OMCL as part of the Agency‚Äôs sampling and testing programme for #medicines üíä in the EU üá™üá∫. See how OMCL protects public health: https://t.co/48vdxxYUrw  https://t.co/9ftCgLFK2S https://t.co/b4IiOMfKfE","id":"1111214578879393792","conversation_id":"1111214578879393792","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":79,"end":84,"tag":"OMCL"},{"start":144,"end":154,"tag":"medicines"}],"urls":[{"start":208,"end":231,"url":"https://t.co/48vdxxYUrw","expanded_url":"https://bit.ly/2HL8hWO","display_url":"bit.ly/2HL8hWO"},{"start":233,"end":256,"url":"https://t.co/9ftCgLFK2S","expanded_url":"https://bit.ly/2uFU4Ch","display_url":"bit.ly/2uFU4Ch"},{"start":257,"end":280,"url":"https://t.co/b4IiOMfKfE","expanded_url":"https://twitter.com/EMA_News/status/1111214578879393792/photo/1","display_url":"pic.twitter.com/b4IiOMfKfE"}],"annotations":[{"start":39,"end":77,"probability":0.6037,"type":"Organization","normalized_text":"Official Medicines Control Laboratories"}]},"attachments":{"media_keys":["3_1111214473640071169"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2019-03-28T09:41:11.000Z","author_id":"116716199","text":"#EMA and @EDQM_news have reviewed EMA‚Äôs sampling and testing programme for #medicines üíä authorised for the EU üá™üá∫. See the findings here: https://t.co/QpEYQCISxn https://t.co/3BUywqs3Nk","id":"1111201557134143488","conversation_id":"1111201557134143488","entities":{"mentions":[{"start":9,"end":19,"username":"edqm_news","id":"2242197968"}],"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":75,"end":85,"tag":"medicines"}],"urls":[{"start":137,"end":160,"url":"https://t.co/QpEYQCISxn","expanded_url":"https://www.ema.europa.eu/en/news/20-years-sampling-testing-programme-medicines-authorised-eu","display_url":"ema.europa.eu/en/news/20-yea‚Ä¶"},{"start":161,"end":184,"url":"https://t.co/3BUywqs3Nk","expanded_url":"https://twitter.com/EMA_News/status/1111201557134143488/photo/1","display_url":"pic.twitter.com/3BUywqs3Nk"}],"annotations":{}},"attachments":{"media_keys":["3_1111201528927473664"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":20,"quote_count":2},"created_at":"2019-03-27T14:55:03.000Z","author_id":"116716199","text":"According to our latest report üìÉ, EMA‚Äôs new EudraVigilance system improved reporting of #SideEffects: https://t.co/OOudKyR6AQ https://t.co/NbYSfElKCc","id":"1110918156749553671","conversation_id":"1110918156749553671","entities":{"mentions":{},"hashtags":[{"start":88,"end":100,"tag":"SideEffects"}],"urls":[{"start":102,"end":125,"url":"https://t.co/OOudKyR6AQ","expanded_url":"https://www.ema.europa.eu/en/news/new-eudravigilance-system-improves-reporting-side-effects-detection-safety-signals","display_url":"ema.europa.eu/en/news/new-eu‚Ä¶"},{"start":126,"end":149,"url":"https://t.co/NbYSfElKCc","expanded_url":"https://twitter.com/EMA_News/status/1110918156749553671/photo/1","display_url":"pic.twitter.com/NbYSfElKCc"}],"annotations":[{"start":35,"end":37,"probability":0.4401,"type":"Organization","normalized_text":"EMA"},{"start":45,"end":58,"probability":0.4209,"type":"Organization","normalized_text":"EudraVigilance"}]},"attachments":{"media_keys":["3_1110917916608864256"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":51,"reply_count":0,"like_count":39,"quote_count":5},"created_at":"2019-03-26T12:00:44.000Z","author_id":"116716199","text":"We have published a Q&amp;A document for patients, healthcare professionals, farmers, pet owners and the general public on the preparatory work that EU authorities are doing to prevent #medicine shortages due to the UK‚Äôs withdrawal from the EU. #Brexit https://t.co/bRrPChv8pr https://t.co/NbN75dZGKE","id":"1110511901182701568","conversation_id":"1110511901182701568","entities":{"mentions":{},"hashtags":[{"start":185,"end":194,"tag":"medicine"},{"start":245,"end":252,"tag":"Brexit"}],"urls":[{"start":253,"end":276,"url":"https://t.co/bRrPChv8pr","expanded_url":"https://www.ema.europa.eu/en/news/questions-answers-eu-actions-prevent-medicine-shortages-due-brexit","display_url":"ema.europa.eu/en/news/questi‚Ä¶"},{"start":277,"end":300,"url":"https://t.co/NbN75dZGKE","expanded_url":"https://twitter.com/EMA_News/status/1110511901182701568/photo/1","display_url":"pic.twitter.com/NbN75dZGKE"}],"annotations":[{"start":145,"end":146,"probability":0.6529,"type":"Organization","normalized_text":"EU"},{"start":212,"end":213,"probability":0.9802,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":["3_1110509947257843712"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":7,"quote_count":1},"created_at":"2019-03-25T12:58:52.000Z","author_id":"116716199","text":"What is on the agenda of EMA‚Äôs human #medicines committee (#CHMP) in March? Find out more: https://t.co/j9UkAMtZ60","id":"1110164143187873793","conversation_id":"1110164143187873793","entities":{"mentions":{},"hashtags":[{"start":37,"end":47,"tag":"medicines"},{"start":59,"end":64,"tag":"CHMP"}],"urls":[{"start":91,"end":114,"url":"https://t.co/j9UkAMtZ60","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-agenda-25-28-march-2019_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":21,"quote_count":3},"created_at":"2019-03-22T13:46:43.000Z","author_id":"116716199","text":"At its first meeting in Amsterdam, EMA‚Äôs Management Board re-elected Christa Wirthumer-Hoche as chair and heard updates on #Brexit, medicines üíä for children and the Clinical Trials Information System. https://t.co/hmuMCkTqnQ https://t.co/68gqDPU2oe","id":"1109089020959698944","conversation_id":"1109089020959698944","entities":{"mentions":{},"hashtags":[{"start":123,"end":130,"tag":"Brexit"}],"urls":[{"start":201,"end":224,"url":"https://t.co/hmuMCkTqnQ","expanded_url":"https://www.ema.europa.eu/en/news/ema-management-board-highlights-march-2019-meeting","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":225,"end":248,"url":"https://t.co/68gqDPU2oe","expanded_url":"https://twitter.com/EMA_News/status/1109089020959698944/photo/1","display_url":"pic.twitter.com/68gqDPU2oe"}],"annotations":[{"start":24,"end":32,"probability":0.9982,"type":"Place","normalized_text":"Amsterdam"},{"start":35,"end":37,"probability":0.5888,"type":"Place","normalized_text":"EMA"},{"start":69,"end":85,"probability":0.8048,"type":"Person","normalized_text":"Christa Wirthumer"}]},"attachments":{"media_keys":["3_1109088949199351810"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":48,"reply_count":1,"like_count":62,"quote_count":7},"created_at":"2019-03-21T16:06:19.000Z","author_id":"116716199","text":"#FakeMedicines are a serious threat to public health, but new rules to enhance patients' safety are being applied as part of the Falsified Medicines Directive: https://t.co/HOHtFNmfFp\n@V_Andriukaitis @EC_AVService @EU_Health https://t.co/s9f9wgxHnN","id":"1108761767424024577","conversation_id":"1108761767424024577","entities":{"mentions":[{"start":184,"end":199,"username":"V_Andriukaitis","id":"575269517"},{"start":200,"end":213,"username":"EC_AVService","id":"56392389"},{"start":214,"end":224,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":0,"end":14,"tag":"FakeMedicines"}],"urls":[{"start":160,"end":183,"url":"https://t.co/HOHtFNmfFp","expanded_url":"https://www.ema.europa.eu/en/news/new-safety-features-medicines-sold-eu","display_url":"ema.europa.eu/en/news/new-sa‚Ä¶"},{"start":225,"end":248,"url":"https://t.co/s9f9wgxHnN","expanded_url":"https://twitter.com/EMA_News/status/1108761767424024577/video/1","display_url":"pic.twitter.com/s9f9wgxHnN"}],"annotations":[{"start":129,"end":157,"probability":0.693,"type":"Organization","normalized_text":"Falsified Medicines Directive"}]},"attachments":{"media_keys":["7_1108761468357480448"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1108721542647738370"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-03-21T13:58:36.000Z","author_id":"116716199","text":"RT @EU_Health: #EUHaveYourSay  What should be the key principles for electronic product information  (package leaflet 4 patients &amp; product‚Ä¶","id":"1108729623565733891","conversation_id":"1108729623565733891","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":29,"tag":"EUHaveYourSay"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":3,"like_count":30,"quote_count":8},"created_at":"2019-03-21T08:34:27.000Z","author_id":"116716199","text":"Christa Wirthumer-Hoche has just been re-elected as chair of EMA‚Äôs Management Board. Congratulations! https://t.co/SHLE9zV7Mu","id":"1108648050157932544","conversation_id":"1108648050157932544","entities":{"mentions":{},"hashtags":{},"urls":[{"start":102,"end":125,"url":"https://t.co/SHLE9zV7Mu","expanded_url":"https://twitter.com/EMA_News/status/1108648050157932544/photo/1","display_url":"pic.twitter.com/SHLE9zV7Mu"}],"annotations":[{"start":0,"end":22,"probability":0.6254,"type":"Person","normalized_text":"Christa Wirthumer-Hoche"}]},"attachments":{"media_keys":["3_1108647627569201153"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":9,"quote_count":1},"created_at":"2019-03-20T15:00:38.000Z","author_id":"116716199","text":"See what's on the agenda for our Management Board meeting on Thursday: https://t.co/buz3XZVma8","id":"1108382850276048897","conversation_id":"1108382850276048897","entities":{"mentions":{},"hashtags":{},"urls":[{"start":71,"end":94,"url":"https://t.co/buz3XZVma8","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-103rd-meeting-management-board_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":6,"quote_count":1},"created_at":"2019-03-20T14:17:18.000Z","author_id":"116716199","text":"Send us your feedback on our \"Regulatory Science to 2025\" strategy #RegScience2025. #Goal2 is about improving the scientific quality of #medicines evaluation: https://t.co/i2qJkW5Mcr https://t.co/F4Ash93uCX","id":"1108371944389439488","conversation_id":"1108371944389439488","entities":{"mentions":{},"hashtags":[{"start":67,"end":82,"tag":"RegScience2025"},{"start":84,"end":90,"tag":"Goal2"},{"start":136,"end":146,"tag":"medicines"}],"urls":[{"start":159,"end":182,"url":"https://t.co/i2qJkW5Mcr","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025#public-consultation-section","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":183,"end":206,"url":"https://t.co/F4Ash93uCX","expanded_url":"https://twitter.com/EMA_News/status/1108371944389439488/photo/1","display_url":"pic.twitter.com/F4Ash93uCX"}],"annotations":{}},"attachments":{"media_keys":["3_1108371860293586944"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":10,"quote_count":0},"created_at":"2019-03-20T13:20:44.000Z","author_id":"116716199","text":"EMA is advising healthcare professionals and #patients not to exceed the recommended dose of #Xeljanz (tofacitinib) when treating #RheumatoidArthritis. \nhttps://t.co/QLMVtqvrRK","id":"1108357708833542146","conversation_id":"1108357708833542146","entities":{"mentions":{},"hashtags":[{"start":45,"end":54,"tag":"patients"},{"start":93,"end":101,"tag":"Xeljanz"},{"start":130,"end":150,"tag":"RheumatoidArthritis"}],"urls":[{"start":153,"end":176,"url":"https://t.co/QLMVtqvrRK","expanded_url":"https://www.ema.europa.eu/en/news/increased-risk-blood-clots-lungs-death-higher-dose-xeljanz-tofacitinib-rheumatoid-arthritis","display_url":"ema.europa.eu/en/news/increa‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.5831,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":1,"like_count":24,"quote_count":2},"created_at":"2019-03-19T15:45:03.000Z","author_id":"116716199","text":"What are the 5 goals of EMA's Regulatory Science to 2025 strategy? A series of infocards to be published this week will explain each objective. Share your thoughts on the strategy. #RegScience2025 https://t.co/xmCyJcI9ky https://t.co/eCHGxZcnx5","id":"1108031639970594816","conversation_id":"1108031639970594816","entities":{"mentions":{},"hashtags":[{"start":181,"end":196,"tag":"RegScience2025"}],"urls":[{"start":197,"end":220,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":221,"end":244,"url":"https://t.co/eCHGxZcnx5","expanded_url":"https://twitter.com/EMA_News/status/1108031639970594816/photo/1","display_url":"pic.twitter.com/eCHGxZcnx5"}],"annotations":[{"start":24,"end":47,"probability":0.3259,"type":"Organization","normalized_text":"EMA's Regulatory Science"}]},"attachments":{"media_keys":["3_1108030983843037186"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":39,"quote_count":0},"created_at":"2019-03-19T12:54:21.000Z","author_id":"116716199","text":"Today we welcome Commissioner @V_Andriukaitis and Minister Bruins to our new Amsterdam home üá≥üá±. We are grateful for the Commissioner‚Äôs support and for the close and fruitful collaboration with the Dutch government. https://t.co/Ha5mYS085F","id":"1107988681497997312","conversation_id":"1107988681497997312","entities":{"mentions":[{"start":30,"end":45,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":{},"urls":[{"start":215,"end":238,"url":"https://t.co/Ha5mYS085F","expanded_url":"https://twitter.com/EMA_News/status/1107988681497997312/photo/1","display_url":"pic.twitter.com/Ha5mYS085F"}],"annotations":[{"start":50,"end":64,"probability":0.5914,"type":"Organization","normalized_text":"Minister Bruins"},{"start":77,"end":85,"probability":0.912,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1107988152994721793"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":33,"reply_count":3,"like_count":87,"quote_count":3},"created_at":"2019-03-19T10:52:28.000Z","author_id":"116716199","text":"Today EU Commissioner @V_Andriukaitis came to see personally how #EMA is settling in Amsterdam. He stressed that EMA is playing a key role in ensuring timely access to and safety of #medicines in Europe. https://t.co/lRI2vQfUtj","id":"1107958009333014528","conversation_id":"1107958009333014528","entities":{"mentions":[{"start":22,"end":37,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":65,"end":69,"tag":"EMA"},{"start":182,"end":192,"tag":"medicines"}],"urls":[{"start":204,"end":227,"url":"https://t.co/lRI2vQfUtj","expanded_url":"https://twitter.com/EMA_News/status/1107958009333014528/photo/1","display_url":"pic.twitter.com/lRI2vQfUtj"}],"annotations":[{"start":85,"end":93,"probability":0.9917,"type":"Place","normalized_text":"Amsterdam"},{"start":196,"end":201,"probability":0.9949,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["3_1107957156769349633"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":56,"reply_count":0,"like_count":50,"quote_count":6},"created_at":"2019-03-18T14:11:47.000Z","author_id":"116716199","text":"#EMA &amp; the EU medicines network are working on a plan to ensure that regulators can keep pace with scientific advances related to üíä.\n\"Regulatory Science to 2025\" strategy (#RegScience2025) is published for public consultation. Share your comments: https://t.co/xmCyJcI9ky https://t.co/zZ7lqzsgBx","id":"1107645779735400449","conversation_id":"1107645779735400449","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":176,"end":191,"tag":"RegScience2025"}],"urls":[{"start":252,"end":275,"url":"https://t.co/xmCyJcI9ky","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/regulatory-science-2025","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":276,"end":299,"url":"https://t.co/zZ7lqzsgBx","expanded_url":"https://twitter.com/EMA_News/status/1107645779735400449/photo/1","display_url":"pic.twitter.com/zZ7lqzsgBx"}],"annotations":[{"start":11,"end":30,"probability":0.3652,"type":"Organization","normalized_text":"EU medicines network"}]},"attachments":{"media_keys":["3_1107645749129551872"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":12,"quote_count":1},"created_at":"2019-03-15T16:10:49.000Z","author_id":"116716199","text":"EMA's safety committee (#PRAC) started a new review on screening patients before treatment with fluorouracil, capecitabine, tegafur and flucytosine to decrease the risk of side effects: https://t.co/OQR1XYtgb7 #EMA","id":"1106588570649853953","conversation_id":"1106588570649853953","entities":{"mentions":{},"hashtags":[{"start":24,"end":29,"tag":"PRAC"},{"start":210,"end":214,"tag":"EMA"}],"urls":[{"start":186,"end":209,"url":"https://t.co/OQR1XYtgb7","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-12-15-march-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":996,"reply_count":234,"like_count":2513,"quote_count":398},"created_at":"2019-03-15T10:00:17.000Z","author_id":"116716199","text":"Today we are saying ‚Äòhallo‚Äô to our new home. Thank you, #Amsterdam and the Netherlands, for the warm welcome! https://t.co/hiU4KWxtVc","id":"1106495322128334849","conversation_id":"1106495322128334849","entities":{"mentions":{},"hashtags":[{"start":56,"end":66,"tag":"Amsterdam"}],"urls":[{"start":110,"end":133,"url":"https://t.co/hiU4KWxtVc","expanded_url":"https://twitter.com/EMA_News/status/1106495322128334849/photo/1","display_url":"pic.twitter.com/hiU4KWxtVc"}],"annotations":[{"start":75,"end":85,"probability":0.977,"type":"Place","normalized_text":"Netherlands"}]},"attachments":{"media_keys":["3_1106495148861607938"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1106453727567712257"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-03-15T08:37:37.000Z","author_id":"116716199","text":"RT @ECDC_EU: What is the #EU doing to address #PublicHealth issues in Europe such as #AntibioticResistance and #vaccination? \n\nWatch live a‚Ä¶","id":"1106474521970778112","conversation_id":"1106474521970778112","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":25,"end":28,"tag":"EU"},{"start":46,"end":59,"tag":"PublicHealth"},{"start":85,"end":106,"tag":"AntibioticResistance"},{"start":111,"end":123,"tag":"vaccination"}],"urls":{},"annotations":[{"start":70,"end":75,"probability":0.989,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":1,"like_count":6,"quote_count":1},"created_at":"2019-03-12T17:16:43.000Z","author_id":"116716199","text":"What is on the agenda of the EMA‚Äôs safety committee meeting (#PRAC) in March? Find out more: https://t.co/cM1Fg38fsy","id":"1105517993939865601","conversation_id":"1105517993939865601","entities":{"mentions":{},"hashtags":[{"start":61,"end":66,"tag":"PRAC"}],"urls":[{"start":93,"end":116,"url":"https://t.co/cM1Fg38fsy","expanded_url":"https://www.ema.europa.eu/en/documents/agenda/agenda-prac-draft-agenda-meeting-12-15-march-2019_en.pdf","display_url":"ema.europa.eu/en/documents/a‚Ä¶"}],"annotations":[{"start":29,"end":31,"probability":0.5433,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":1,"like_count":40,"quote_count":2},"created_at":"2019-03-12T15:23:54.000Z","author_id":"116716199","text":"Check out our booklet describing the journey of a #medicine üíä for human use authorised through #EMA, from the laboratory üë©‚Äçüî¨to #patients: https://t.co/RmuMvpPqUG https://t.co/y5NWS1hgQe","id":"1105489598908633088","conversation_id":"1105489598908633088","entities":{"mentions":{},"hashtags":[{"start":50,"end":59,"tag":"medicine"},{"start":95,"end":99,"tag":"EMA"},{"start":127,"end":136,"tag":"patients"}],"urls":[{"start":138,"end":161,"url":"https://t.co/RmuMvpPqUG","expanded_url":"https://www.ema.europa.eu/en/documents/other/laboratory-patient-journey-centrally-authorised-medicine_en.pdf","display_url":"ema.europa.eu/en/documents/o‚Ä¶"},{"start":162,"end":185,"url":"https://t.co/y5NWS1hgQe","expanded_url":"https://twitter.com/EMA_News/status/1105489598908633088/photo/1","display_url":"pic.twitter.com/y5NWS1hgQe"}],"annotations":{}},"attachments":{"media_keys":["3_1105489468516167680"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1105469588362444800"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2019-03-12T14:56:01.000Z","author_id":"116716199","text":"@MinVWS @relocatemaNL Thank you for your warm welcome!","id":"1105482582261665792","conversation_id":"1105469588362444800","entities":{"mentions":[{"start":0,"end":7,"username":"MinVWS","id":"15581273"},{"start":8,"end":21,"username":"relocatemaNL","id":"1005062303052632066"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"15581273"},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1105116931168841729"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":8,"quote_count":0},"created_at":"2019-03-11T15:31:57.000Z","author_id":"116716199","text":"@MedicijnNL Thank you for your warm welcome! We look forward to continuing working together in Amsterdam.","id":"1105129238716444672","conversation_id":"1105116931168841729","entities":{"mentions":[{"start":0,"end":11,"username":"MedicijnNL","id":"883813550"}],"hashtags":{},"urls":{},"annotations":[{"start":95,"end":103,"probability":0.9966,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"883813550"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":173,"reply_count":15,"like_count":307,"quote_count":23},"created_at":"2019-03-11T14:14:06.000Z","author_id":"116716199","text":"As of today, #EMA is operating from Amsterdam. Our staff will gradually move throughout this week into the Spark building in Amsterdam Sloterdijk. https://t.co/SkKUTwkdc9 https://t.co/79UEtWbExG","id":"1105109649186062337","conversation_id":"1105109649186062337","entities":{"mentions":{},"hashtags":[{"start":13,"end":17,"tag":"EMA"}],"urls":[{"start":147,"end":170,"url":"https://t.co/SkKUTwkdc9","expanded_url":"https://www.ema.europa.eu/en/news/ema-now-operating-amsterdam","display_url":"ema.europa.eu/en/news/ema-no‚Ä¶"},{"start":171,"end":194,"url":"https://t.co/79UEtWbExG","expanded_url":"https://twitter.com/EMA_News/status/1105109649186062337/photo/1","display_url":"pic.twitter.com/79UEtWbExG"}],"annotations":[{"start":36,"end":44,"probability":0.988,"type":"Place","normalized_text":"Amsterdam"},{"start":125,"end":133,"probability":0.9763,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1105109550577971200"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1105080141548568576"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-03-11T12:18:39.000Z","author_id":"116716199","text":"RT @EU_Health: How to make sure #pharmaceuticals for human &amp; veterinary use don't harm the environment &amp; don't contribute to #antimicrobial‚Ä¶","id":"1105080593254092800","conversation_id":"1105080593254092800","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":32,"end":48,"tag":"pharmaceuticals"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1102617602675875842"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-03-04T17:33:43.000Z","author_id":"116716199","text":"@E_Jeannot Thanks for getting in touch. This document is available only in English.","id":"1102623167657463811","conversation_id":"1102579160197795841","entities":{"mentions":[{"start":0,"end":10,"username":"E_Jeannot","id":"526289972"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"526289972"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":105,"reply_count":2,"like_count":113,"quote_count":11},"created_at":"2019-03-04T14:38:51.000Z","author_id":"116716199","text":"We have published a booklet describing the journey of a #medicine for human use authorised through #EMA, from initial research to discussions on #patient access to medicines across the EU: https://t.co/RmuMvpPqUG https://t.co/7F5lM61K8q","id":"1102579160197795841","conversation_id":"1102579160197795841","entities":{"mentions":{},"hashtags":[{"start":56,"end":65,"tag":"medicine"},{"start":99,"end":103,"tag":"EMA"},{"start":145,"end":153,"tag":"patient"}],"urls":[{"start":189,"end":212,"url":"https://t.co/RmuMvpPqUG","expanded_url":"https://www.ema.europa.eu/en/documents/other/laboratory-patient-journey-centrally-authorised-medicine_en.pdf","display_url":"ema.europa.eu/en/documents/o‚Ä¶"},{"start":213,"end":236,"url":"https://t.co/7F5lM61K8q","expanded_url":"https://twitter.com/EMA_News/status/1102579160197795841/photo/1","display_url":"pic.twitter.com/7F5lM61K8q"}],"annotations":{}},"attachments":{"media_keys":["3_1102579094024269824"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1102480698307420161"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":46,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-03-04T09:23:25.000Z","author_id":"116716199","text":"RT @EU_Health: The #EU #Coalition for #Vaccination holds its first meeting today in #Brussels from 10:00 CET, in the presence of our Direct‚Ä¶","id":"1102499781346295810","conversation_id":"1102499781346295810","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":19,"end":22,"tag":"EU"},{"start":23,"end":33,"tag":"Coalition"},{"start":38,"end":50,"tag":"Vaccination"},{"start":84,"end":93,"tag":"Brussels"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1101517870465536002"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"created_at":"2019-03-01T17:17:28.000Z","author_id":"116716199","text":"@seidenschwang Dear Ralf, currently there is an open call for IT Information Security Experts. Closing date is 26/03/2023. You can apply using this link: https://t.co/vJQkO1rXo3","id":"1101531915860000768","conversation_id":"1101490431681019909","entities":{"mentions":{},"hashtags":{},"urls":[{"start":154,"end":177,"url":"https://t.co/vJQkO1rXo3","expanded_url":"https://career5.successfactors.eu/sfcareer/jobreqcareer?jobId=744&company=europeanmeP&username","display_url":"career5.successfactors.eu/sfcareer/jobre‚Ä¶"}],"annotations":[{"start":20,"end":23,"probability":0.8624,"type":"Person","normalized_text":"Ralf"},{"start":62,"end":92,"probability":0.3974,"type":"Organization","normalized_text":"IT Information Security Experts"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1075767460584771584"},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1101508206919147521"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":5,"quote_count":0},"created_at":"2019-03-01T16:00:40.000Z","author_id":"116716199","text":"@seidenschwang Thank you for getting in touch. All new roles within #EMA will be published on our Jobs@EMA portal: https://t.co/IKg5tNj4RJ","id":"1101512586619703297","conversation_id":"1101490431681019909","entities":{"mentions":{},"hashtags":[{"start":68,"end":72,"tag":"EMA"}],"urls":[{"start":115,"end":138,"url":"https://t.co/IKg5tNj4RJ","expanded_url":"https://career5.successfactors.eu/career?company=europeanmeP&career_ns=job_listing_summary&navBarLevel=JOB_SEARCH&_s.crb=P%2fZUhTpi%2fw0tWPSPUvDhhM%2ft8%2bo%3d","display_url":"career5.successfactors.eu/career?company‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"1075767460584771584"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2649,"reply_count":518,"like_count":3235,"quote_count":1269},"created_at":"2019-03-01T14:32:38.000Z","author_id":"116716199","text":"Today we are closing our London offices after almost a quarter of a century. Thank you, London for being such a gracious host! https://t.co/R8LXjfzvp3 https://t.co/8abqMcbROJ","id":"1101490431681019909","conversation_id":"1101490431681019909","entities":{"mentions":{},"hashtags":{},"urls":[{"start":127,"end":150,"url":"https://t.co/R8LXjfzvp3","expanded_url":"https://www.ema.europa.eu/en/about-us/history-ema/ema-london-1995-2019","display_url":"ema.europa.eu/en/about-us/hi‚Ä¶"},{"start":151,"end":174,"url":"https://t.co/8abqMcbROJ","expanded_url":"https://twitter.com/EMA_News/status/1101490431681019909/video/1","display_url":"pic.twitter.com/8abqMcbROJ"}],"annotations":[{"start":25,"end":30,"probability":0.8991,"type":"Place","normalized_text":"London"},{"start":88,"end":93,"probability":0.9599,"type":"Place","normalized_text":"London"}]},"attachments":{"media_keys":["7_1101487915035705344"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2019-03-01T14:04:00.000Z","author_id":"116716199","text":"Extension of indication for a new add-on treatment for patients with severe #asthma: https://t.co/HO3RLCvcfb #CHMP","id":"1101483226617528320","conversation_id":"1101483226617528320","entities":{"mentions":{},"hashtags":[{"start":76,"end":83,"tag":"asthma"},{"start":109,"end":114,"tag":"CHMP"}],"urls":[{"start":85,"end":108,"url":"https://t.co/HO3RLCvcfb","expanded_url":"https://www.ema.europa.eu/en/news/new-add-treatment-patients-severe-asthma","display_url":"ema.europa.eu/en/news/new-ad‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":5,"quote_count":1},"created_at":"2019-03-01T13:45:01.000Z","author_id":"116716199","text":"Positive opinion for a new add-on treatment to #insulin for certain patients with type 1 #diabetes: https://t.co/4sS2ySsaH8 #CHMP #mellitus","id":"1101478449036869632","conversation_id":"1101478449036869632","entities":{"mentions":{},"hashtags":[{"start":47,"end":55,"tag":"insulin"},{"start":89,"end":98,"tag":"diabetes"},{"start":124,"end":129,"tag":"CHMP"},{"start":130,"end":139,"tag":"mellitus"}],"urls":[{"start":100,"end":123,"url":"https://t.co/4sS2ySsaH8","expanded_url":"https://www.ema.europa.eu/en/news/new-add-treatment-insulin-treatment-certain-patients-type-1-diabetes","display_url":"ema.europa.eu/en/news/new-ad‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":2,"like_count":7,"quote_count":1},"created_at":"2019-03-01T13:30:00.000Z","author_id":"116716199","text":"EMA recommended granting a conditional marketing authorisation for the first treatment for a rare disease characterised by high levels of #triglycerides in blood: https://t.co/8DqmtHo7qk #CHMP","id":"1101474671243886597","conversation_id":"1101474671243886597","entities":{"mentions":{},"hashtags":[{"start":138,"end":152,"tag":"triglycerides"},{"start":187,"end":192,"tag":"CHMP"}],"urls":[{"start":163,"end":186,"url":"https://t.co/8DqmtHo7qk","expanded_url":"https://www.ema.europa.eu/en/news/first-treatment-rare-disease-characterised-high-levels-triglycerides-blood","display_url":"ema.europa.eu/en/news/first-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":7,"quote_count":2},"created_at":"2019-03-01T13:15:00.000Z","author_id":"116716199","text":"EMA recommended granting a conditional marketing authorisation for the first antidote for reversal of anticoagulation with factor Xa inhibitors #apixaban and #rivaroxaban: https://t.co/YhlOa1USf2 #CHMP","id":"1101470895405715456","conversation_id":"1101470895405715456","entities":{"mentions":{},"hashtags":[{"start":144,"end":153,"tag":"apixaban"},{"start":158,"end":170,"tag":"rivaroxaban"},{"start":196,"end":201,"tag":"CHMP"}],"urls":[{"start":172,"end":195,"url":"https://t.co/YhlOa1USf2","expanded_url":"https://www.ema.europa.eu/en/news/first-antidote-reversal-anticoagulation-factor-xa-inhibitors-apixaban-rivaroxaban","display_url":"ema.europa.eu/en/news/first-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":8,"quote_count":0},"created_at":"2019-03-01T13:10:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee recommended the authorisation of a new treatment for #phenylketonuria, a rare inherited metabolic disease: https://t.co/iszqrenBwJ #CHMP","id":"1101469637043257350","conversation_id":"1101469637043257350","entities":{"mentions":{},"hashtags":[{"start":85,"end":101,"tag":"phenylketonuria"},{"start":163,"end":168,"tag":"CHMP"}],"urls":[{"start":139,"end":162,"url":"https://t.co/iszqrenBwJ","expanded_url":"https://www.ema.europa.eu/en/news/chmp-recommends-authorisation-new-treatment-phenylketonuria-rare-inherited-metabolic-disease","display_url":"ema.europa.eu/en/news/chmp-r‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.4636,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":1,"like_count":15,"quote_count":0},"created_at":"2019-03-01T12:50:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee recommends 8 #medicines for approval at its February 2019 meeting https://t.co/VCEdeqiAar #CHMP https://t.co/0Z1cCNfkng","id":"1101464603614158848","conversation_id":"1101464603614158848","entities":{"mentions":{},"hashtags":[{"start":45,"end":55,"tag":"medicines"},{"start":122,"end":127,"tag":"CHMP"}],"urls":[{"start":98,"end":121,"url":"https://t.co/VCEdeqiAar","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-25-28-february-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":128,"end":151,"url":"https://t.co/0Z1cCNfkng","expanded_url":"https://twitter.com/EMA_News/status/1101464603614158848/photo/1","display_url":"pic.twitter.com/0Z1cCNfkng"}],"annotations":[{"start":0,"end":2,"probability":0.5738,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1101463417293029378"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1101126596763766784"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-03-01T09:08:38.000Z","author_id":"116716199","text":"RT @EU_Health: ‚úÖ24 networks\n‚úÖ&gt;900 highly-specialised healthcare units...\n‚úÖ...from over 300 hospitals...\n‚úÖ...in 26 üá™üá∫ countries\n\nThese are t‚Ä¶","id":"1101408897372471296","conversation_id":"1101408897372471296","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":0,"like_count":30,"quote_count":9},"created_at":"2019-02-28T13:30:00.000Z","author_id":"116716199","text":"We have published today our first guidance on new rules for certain #MedicalDevices: https://t.co/Q7PssNRn8M\n#EMA https://t.co/KUM284w3wl","id":"1101112282615111680","conversation_id":"1101112282615111680","entities":{"mentions":{},"hashtags":[{"start":68,"end":83,"tag":"MedicalDevices"},{"start":109,"end":113,"tag":"EMA"}],"urls":[{"start":85,"end":108,"url":"https://t.co/Q7PssNRn8M","expanded_url":"https://www.ema.europa.eu/en/news/first-guidance-new-rules-certain-medical-devices","display_url":"ema.europa.eu/en/news/first-‚Ä¶"},{"start":114,"end":137,"url":"https://t.co/KUM284w3wl","expanded_url":"https://twitter.com/EMA_News/status/1101112282615111680/photo/1","display_url":"pic.twitter.com/KUM284w3wl"}],"annotations":{}},"attachments":{"media_keys":["3_1101100848837476359"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":45,"reply_count":4,"like_count":141,"quote_count":10},"created_at":"2019-02-28T12:09:53.000Z","author_id":"116716199","text":"#EMA supports #RareDiseaseDay every day! Our Committee for Orphan Medicinal Products is the only committee fully dedicated to medicines for rare diseases. #ShowYourRare https://t.co/uNumz8tDDX https://t.co/heMlVfyYnm","id":"1101092120595759104","conversation_id":"1101092120595759104","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":14,"end":29,"tag":"RareDiseaseDay"},{"start":155,"end":168,"tag":"ShowYourRare"}],"urls":[{"start":169,"end":192,"url":"https://t.co/uNumz8tDDX","expanded_url":"https://www.ema.europa.eu/en/committees/committee-orphan-medicinal-products-comp","display_url":"ema.europa.eu/en/committees/‚Ä¶"},{"start":193,"end":216,"url":"https://t.co/heMlVfyYnm","expanded_url":"https://twitter.com/EMA_News/status/1101092120595759104/photo/1","display_url":"pic.twitter.com/heMlVfyYnm"}],"annotations":[{"start":59,"end":83,"probability":0.5859,"type":"Organization","normalized_text":"Orphan Medicinal Products"}]},"attachments":{"media_keys":["3_1101092005969563649"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1101021934677037056"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":854,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-28T09:03:17.000Z","author_id":"116716199","text":"RT @rarediseaseday: Today is #RareDiseaseDay 2019! Events are taking place in 90+ countries around the world to raise awareness of the impa‚Ä¶","id":"1101045163118510080","conversation_id":"1101045163118510080","entities":{"mentions":[{"start":3,"end":18,"username":"rarediseaseday","id":"19982434"}],"hashtags":[{"start":29,"end":44,"tag":"RareDiseaseDay"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1100336018052575237"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-26T10:32:36.000Z","author_id":"116716199","text":"RT @EAAD_EU: Dominique Monnet, ECDC Head of ARHAI, coordination amongst #EU agencies, @EFSA_EU, @ECDC_EU @EMA_News and analyses of surveill‚Ä¶","id":"1100342863169245186","conversation_id":"1100342863169245186","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"},{"start":86,"end":94,"username":"EFSA_EU","id":"84582815"},{"start":96,"end":104,"username":"ECDC_EU","id":"204752573"},{"start":105,"end":114,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":72,"end":75,"tag":"EU"}],"urls":{},"annotations":[{"start":13,"end":28,"probability":0.9842,"type":"Person","normalized_text":"Dominique Monnet"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":12,"quote_count":5},"created_at":"2019-02-25T16:46:55.000Z","author_id":"116716199","text":"Check out the agenda of this week‚Äôs meeting of the Committee for Human #Medicines (#CHMP): https://t.co/3V1eOGk7Yw This is the last meeting in London. As of March, all meetings will take place in Amsterdam. #EMA","id":"1100074674871042050","conversation_id":"1100074674871042050","entities":{"mentions":{},"hashtags":[{"start":71,"end":81,"tag":"Medicines"},{"start":83,"end":88,"tag":"CHMP"},{"start":207,"end":211,"tag":"EMA"}],"urls":[{"start":91,"end":114,"url":"https://t.co/3V1eOGk7Yw","expanded_url":"https://bit.ly/2TlODGe","display_url":"bit.ly/2TlODGe"}],"annotations":[{"start":143,"end":148,"probability":0.9975,"type":"Place","normalized_text":"London"},{"start":196,"end":204,"probability":0.9974,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1099980140463968257"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-25T11:10:06.000Z","author_id":"116716199","text":"RT @ECDC_EU: Extended deadline: Take part in the #ECDCAntibioticSurvey by 1 March 2019 to help us gain an understanding of European #health‚Ä¶","id":"1099989913934721025","conversation_id":"1099989913934721025","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":49,"end":70,"tag":"ECDCAntibioticSurvey"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1098892686013153280"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-22T13:48:19.000Z","author_id":"116716199","text":"RT @rarediseaseday: The Committee for Orphan Medicinal Products, the only committee fully dedicated to recommending the designation of orph‚Ä¶","id":"1098942566689591296","conversation_id":"1098942566689591296","entities":{"mentions":[{"start":3,"end":18,"username":"rarediseaseday","id":"19982434"}],"hashtags":{},"urls":{},"annotations":[{"start":38,"end":62,"probability":0.432,"type":"Organization","normalized_text":"Orphan Medicinal Products"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":11,"quote_count":2},"created_at":"2019-02-21T11:49:58.000Z","author_id":"116716199","text":"EU and Switzerland to improve information-sharing on good manufacturing practice through the use of the #EudraGMDP database: https://t.co/0bfzKOvdok #EMA #Swissmedic","id":"1098550392894439424","conversation_id":"1098550392894439424","entities":{"mentions":{},"hashtags":[{"start":104,"end":114,"tag":"EudraGMDP"},{"start":149,"end":153,"tag":"EMA"},{"start":154,"end":165,"tag":"Swissmedic"}],"urls":[{"start":125,"end":148,"url":"https://t.co/0bfzKOvdok","expanded_url":"https://www.ema.europa.eu/en/news/eu-switzerland-improve-information-sharing-good-manufacturing-practice-through-use-eudragmdp","display_url":"ema.europa.eu/en/news/eu-swi‚Ä¶"}],"annotations":[{"start":0,"end":1,"probability":0.686,"type":"Organization","normalized_text":"EU"},{"start":7,"end":17,"probability":0.9668,"type":"Place","normalized_text":"Switzerland"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":14,"quote_count":1},"created_at":"2019-02-15T14:00:39.000Z","author_id":"116716199","text":"At its monthly meeting, EMA's safety committee (#PRAC) recommended the precautionary suspension of #fenspiride #medicines due to a potential risk of heart rhythm problems: https://t.co/mByXYhvllb","id":"1096408955738308609","conversation_id":"1096408955738308609","entities":{"mentions":{},"hashtags":[{"start":48,"end":53,"tag":"PRAC"},{"start":99,"end":110,"tag":"fenspiride"},{"start":111,"end":121,"tag":"medicines"}],"urls":[{"start":172,"end":195,"url":"https://t.co/mByXYhvllb","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-11-14-february-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-11-14-february-2019"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":48,"reply_count":1,"like_count":35,"quote_count":8},"created_at":"2019-02-15T12:06:48.000Z","author_id":"116716199","text":"What is the role of #BigData for the evaluation and supervision of #medicines in the EU? Read the summary report from the #HMA - #EMA joint task force and join the discussion by providing your feedback on the recommendations: https://t.co/4dxc5xY3C2 https://t.co/RN9Fj3P7S1","id":"1096380300706369537","conversation_id":"1096380300706369537","entities":{"mentions":{},"hashtags":[{"start":20,"end":28,"tag":"BigData"},{"start":67,"end":77,"tag":"medicines"},{"start":122,"end":126,"tag":"HMA"},{"start":129,"end":133,"tag":"EMA"}],"urls":[{"start":226,"end":249,"url":"https://t.co/4dxc5xY3C2","expanded_url":"https://www.ema.europa.eu/en/news/role-big-data-evaluation-supervision-medicines-eu","display_url":"ema.europa.eu/en/news/role-b‚Ä¶"},{"start":250,"end":273,"url":"https://t.co/RN9Fj3P7S1","expanded_url":"https://twitter.com/EMA_News/status/1096380300706369537/photo/1","display_url":"pic.twitter.com/RN9Fj3P7S1"}],"annotations":{}},"attachments":{"media_keys":["3_1096380160151117824"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1096023396188606464"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-15T10:44:36.000Z","author_id":"116716199","text":"RT @OIEAnimalHealth: OIE Press Release: The Third Annual Report on Antimicrobial Agents Intended for Use in Animals is now available online‚Ä¶","id":"1096359616223555585","conversation_id":"1096359616223555585","entities":{"mentions":[{"start":3,"end":19,"username":"OIEAnimalHealth","id":"2826426188"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1095202283762139136"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-14T09:32:44.000Z","author_id":"116716199","text":"RT @EU_opendata: Calling all data geeks and data journalists! Use #opendata from the EU institutions, agencies and bodies to tackle the cha‚Ä¶","id":"1095979143626440704","conversation_id":"1095979143626440704","entities":{"mentions":[{"start":3,"end":15,"username":"EU_opendata","id":"115660120"}],"hashtags":[{"start":66,"end":75,"tag":"opendata"}],"urls":{},"annotations":[{"start":85,"end":86,"probability":0.6347,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1095323538226118658"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-12T18:52:50.000Z","author_id":"116716199","text":"RT @ECDC_HIVAIDS: Are you a doctor, nurse, pharmacist, hospital manager, clinical scientist, physiotherapist, nursing assistant, dental/pha‚Ä¶","id":"1095395320538779650","conversation_id":"1095395320538779650","entities":{"mentions":[{"start":3,"end":16,"username":"ECDC_HIVAIDS","id":"2182569746"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1095335052047597569"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-12T16:26:09.000Z","author_id":"116716199","text":"RT @BUrl_EFSA: In the margins of the #EUAgencies meeting taking place in Brussels, very fruitful exchange with the executive directors of @‚Ä¶","id":"1095358405106196480","conversation_id":"1095358405106196480","entities":{"mentions":[{"start":3,"end":13,"username":"BUrl_EFSA","id":"915409662"}],"hashtags":[{"start":37,"end":48,"tag":"EUAgencies"}],"urls":{},"annotations":[{"start":73,"end":80,"probability":0.9944,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1093863472834768899"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":35,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-12T13:38:50.000Z","author_id":"116716199","text":"RT @V_Andriukaitis: #patients need to be 100% sure that medicines they take are sure. Doctors &amp; pharmacists must be able to be 100% sure wh‚Ä¶","id":"1095316298337275910","conversation_id":"1095316298337275910","entities":{"mentions":[{"start":3,"end":18,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":20,"end":29,"tag":"patients"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1093536150600511488"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-12T10:11:41.000Z","author_id":"116716199","text":"RT @eurordis: The EURORDIS Black Pearl Awards Ceremony takes place on 12 February. Tune in live on the night to watch the 2019 recipients r‚Ä¶","id":"1095264170730246145","conversation_id":"1095264170730246145","entities":{"mentions":[{"start":3,"end":12,"username":"eurordis","id":"26993786"}],"hashtags":{},"urls":{},"annotations":[{"start":18,"end":53,"probability":0.4947,"type":"Other","normalized_text":"EURORDIS Black Pearl Awards Ceremony"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":10,"quote_count":2},"created_at":"2019-02-11T17:10:33.000Z","author_id":"116716199","text":"Two additional countries to benefit from the EU-US mutual recognition agreement for inspections: https://t.co/ytK8VLas6X @US_FDA","id":"1095007191025754112","conversation_id":"1095007191025754112","entities":{"mentions":[{"start":121,"end":128,"username":"US_FDA","id":"208120290"}],"hashtags":{},"urls":[{"start":97,"end":120,"url":"https://t.co/ytK8VLas6X","expanded_url":"https://www.ema.europa.eu/en/news/two-additional-countries-benefit-eu-us-mutual-recognition-agreement-inspections","display_url":"ema.europa.eu/en/news/two-ad‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2019-02-11T15:21:57.000Z","author_id":"116716199","text":"#EMA has launched a secure online platform for submitting and managing parallel distribution notifications through the recently implemented #IRIS Regulatory &amp; Scientific Information Management Platform: https://t.co/6cVGIqfq3j","id":"1094979863075872768","conversation_id":"1094979863075872768","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":140,"end":145,"tag":"IRIS"}],"urls":[{"start":207,"end":230,"url":"https://t.co/6cVGIqfq3j","expanded_url":"https://www.ema.europa.eu/en/news/new-online-platform-parallel-distribution","display_url":"ema.europa.eu/en/news/new-on‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/new-online-platform-parallel-distribution"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1093541369258364928"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":167,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-11T10:18:49.000Z","author_id":"116716199","text":"RT @rarediseaseday: Out now - New official #RareDiseaseDay 2019 video! Watch and share Filip and Alina's story. Filip is from Romania and l‚Ä¶","id":"1094903574377779205","conversation_id":"1094903574377779205","entities":{"mentions":[{"start":3,"end":18,"username":"rarediseaseday","id":"19982434"}],"hashtags":[{"start":43,"end":58,"tag":"RareDiseaseDay"}],"urls":{},"annotations":[{"start":87,"end":91,"probability":0.8632,"type":"Person","normalized_text":"Filip"},{"start":97,"end":101,"probability":0.9442,"type":"Person","normalized_text":"Alina"},{"start":112,"end":116,"probability":0.7174,"type":"Person","normalized_text":"Filip"},{"start":126,"end":132,"probability":0.9358,"type":"Place","normalized_text":"Romania"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1093868576270884865"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-08T14:01:11.000Z","author_id":"116716199","text":"RT @EU_Health: 400 #fakemeds notifications (2013- 2017) received from national authorities. \n\nHundreds of illegal websites shut down every‚Ä¶","id":"1093872374133321728","conversation_id":"1093872374133321728","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":19,"end":28,"tag":"fakemeds"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":92,"reply_count":3,"like_count":94,"quote_count":11},"created_at":"2019-02-08T11:59:58.000Z","author_id":"116716199","text":"New safety features for #medicines sold in the EU: a unique identifier and an anti-tampering device on medicines packaging to help protect EU citizens against the threat of #FalsifiedMedicines: https://t.co/HOHtFNmfFp #PatientSafety https://t.co/mEufeswUnl","id":"1093841869006614528","conversation_id":"1093841869006614528","entities":{"mentions":{},"hashtags":[{"start":24,"end":34,"tag":"medicines"},{"start":173,"end":192,"tag":"FalsifiedMedicines"},{"start":218,"end":232,"tag":"PatientSafety"}],"urls":[{"start":194,"end":217,"url":"https://t.co/HOHtFNmfFp","expanded_url":"https://www.ema.europa.eu/en/news/new-safety-features-medicines-sold-eu","display_url":"ema.europa.eu/en/news/new-sa‚Ä¶"},{"start":233,"end":256,"url":"https://t.co/mEufeswUnl","expanded_url":"https://twitter.com/EMA_News/status/1093841869006614528/photo/1","display_url":"pic.twitter.com/mEufeswUnl"}],"annotations":[{"start":139,"end":140,"probability":0.5632,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1093841781144371200"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2019-02-08T11:29:14.000Z","author_id":"116716199","text":"How to better address shortages or problems with the availability of #medicines in Europe? Read more in our report from a stakeholder meeting organised by #EMA and #HMA on this topic: https://t.co/Zk5RjSla1w https://t.co/T7WyrW55Rl","id":"1093834131702771712","conversation_id":"1093834131702771712","entities":{"mentions":{},"hashtags":[{"start":69,"end":79,"tag":"medicines"},{"start":155,"end":159,"tag":"EMA"},{"start":164,"end":168,"tag":"HMA"}],"urls":[{"start":184,"end":207,"url":"https://t.co/Zk5RjSla1w","expanded_url":"https://www.ema.europa.eu/en/events/multi-stakeholder-workshop-heads-medicines-agencies-european-medicine-agency-task-force-availability","display_url":"ema.europa.eu/en/events/mult‚Ä¶"},{"start":208,"end":231,"url":"https://t.co/T7WyrW55Rl","expanded_url":"https://twitter.com/EMA_News/status/1093834131702771712/photo/1","display_url":"pic.twitter.com/T7WyrW55Rl"}],"annotations":[{"start":83,"end":88,"probability":0.9914,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["3_1093834065298575366"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1093465795315798018"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":226,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-07T15:35:25.000Z","author_id":"116716199","text":"RT @EU_opendata: Here we come for 2019! For this year's #EUdatathon, use #opendata to compete with your #app for one of the 3 challenges! ‚Äî‚Ä¶","id":"1093533699252150272","conversation_id":"1093533699252150272","entities":{"mentions":[{"start":3,"end":15,"username":"EU_opendata","id":"115660120"}],"hashtags":[{"start":56,"end":67,"tag":"EUdatathon"},{"start":73,"end":82,"tag":"opendata"},{"start":104,"end":108,"tag":"app"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1093486054038999040"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1226,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-07T14:20:27.000Z","author_id":"116716199","text":"RT @WHO: #Measles is one of the most contagious diseases on the planet.\nWhen people are unvaccinated, it can very quickly spread https://t.‚Ä¶","id":"1093514833369157632","conversation_id":"1093514833369157632","entities":{"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":[{"start":9,"end":17,"tag":"Measles"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":1,"like_count":13,"quote_count":2},"created_at":"2019-02-06T15:53:01.000Z","author_id":"116716199","text":"In January, EMA reviewed 7 recommendations for eligibility to #PRIME: 1 was granted and 6 were denied. See more here: https://t.co/WTOLUCnQ8l https://t.co/kVAOLuZmCt","id":"1093175741141995520","conversation_id":"1093175741141995520","entities":{"mentions":{},"hashtags":[{"start":62,"end":68,"tag":"PRIME"}],"urls":[{"start":118,"end":141,"url":"https://t.co/WTOLUCnQ8l","expanded_url":"https://www.ema.europa.eu/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-28-31-january-2019_en.pdf","display_url":"ema.europa.eu/documents/repo‚Ä¶"},{"start":142,"end":165,"url":"https://t.co/kVAOLuZmCt","expanded_url":"https://twitter.com/EMA_News/status/1093175741141995520/photo/1","display_url":"pic.twitter.com/kVAOLuZmCt"}],"annotations":[{"start":12,"end":14,"probability":0.4346,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1093175437520445440"]}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1091669058037047298"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":152,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-02-02T12:32:12.000Z","author_id":"116716199","text":"RT @EU_Health: Trust in #vaccines is essential for maintaining high coverage rates, but our new study shows #vaccineconfidence is declining‚Ä¶","id":"1091675653265596416","conversation_id":"1091675653265596416","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":24,"end":33,"tag":"vaccines"},{"start":108,"end":126,"tag":"vaccineconfidence"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":9,"quote_count":3},"created_at":"2019-02-01T13:22:00.000Z","author_id":"116716199","text":"First oral add-on treatment for patients with type 1 #diabetes recommended for approval #medicines #CHMP https://t.co/t1Bl7YBJmN","id":"1091325796290043904","conversation_id":"1091325796290043904","entities":{"mentions":{},"hashtags":[{"start":53,"end":62,"tag":"diabetes"},{"start":88,"end":98,"tag":"medicines"},{"start":99,"end":104,"tag":"CHMP"}],"urls":[{"start":105,"end":128,"url":"https://t.co/t1Bl7YBJmN","expanded_url":"https://www.ema.europa.eu/en/news/first-oral-add-treatment-insulin-treatment-certain-patients-type-1-diabetes","display_url":"ema.europa.eu/en/news/first-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":9,"quote_count":1},"created_at":"2019-02-01T13:09:51.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee recommends 6 #medicines for approval at its January 2019 meeting https://t.co/tbTjgH8u8w #CHMP https://t.co/9nrb2BxBMd","id":"1091322738692800512","conversation_id":"1091322738692800512","entities":{"mentions":{},"hashtags":[{"start":45,"end":55,"tag":"medicines"},{"start":121,"end":126,"tag":"CHMP"}],"urls":[{"start":97,"end":120,"url":"https://t.co/tbTjgH8u8w","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-28-31-january-2019","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":127,"end":150,"url":"https://t.co/9nrb2BxBMd","expanded_url":"https://twitter.com/EMA_News/status/1091322738692800512/photo/1","display_url":"pic.twitter.com/9nrb2BxBMd"}],"annotations":[{"start":0,"end":2,"probability":0.5647,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1091322673374867457"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":45,"reply_count":1,"like_count":36,"quote_count":10},"created_at":"2019-02-01T11:37:44.000Z","author_id":"116716199","text":"EMA and the European Commission have published updated guidance to help pharmaceutical companies prepare for Brexit: https://t.co/eT5xYFkiZk https://t.co/tVY6BzhCeC","id":"1091299555679891456","conversation_id":"1091299555679891456","entities":{"mentions":{},"hashtags":{},"urls":[{"start":117,"end":140,"url":"https://t.co/eT5xYFkiZk","expanded_url":"http://bit.ly/2D53a1C","display_url":"bit.ly/2D53a1C"},{"start":141,"end":164,"url":"https://t.co/tVY6BzhCeC","expanded_url":"https://twitter.com/EMA_News/status/1091299555679891456/photo/1","display_url":"pic.twitter.com/tVY6BzhCeC"}],"annotations":[{"start":0,"end":2,"probability":0.4755,"type":"Organization","normalized_text":"EMA"},{"start":12,"end":30,"probability":0.5078,"type":"Organization","normalized_text":"European Commission"},{"start":109,"end":114,"probability":0.5555,"type":"Other","normalized_text":"Brexit"}]},"attachments":{"media_keys":["3_1091299091789828096"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":0,"like_count":17,"quote_count":11},"created_at":"2019-01-31T11:44:02.000Z","author_id":"116716199","text":"Send your comments until 31 July 2019 on key principles for the development of electronic product information (ePI) for human medicines in the EU: https://t.co/RRJdchN3XJ https://t.co/K7vLt3TGRU","id":"1090938753198292992","conversation_id":"1090938753198292992","entities":{"mentions":{},"hashtags":{},"urls":[{"start":147,"end":170,"url":"https://t.co/RRJdchN3XJ","expanded_url":"https://bit.ly/2RWcXid","display_url":"bit.ly/2RWcXid"},{"start":171,"end":194,"url":"https://t.co/K7vLt3TGRU","expanded_url":"https://twitter.com/EMA_News/status/1090938753198292992/photo/1","display_url":"pic.twitter.com/K7vLt3TGRU"}],"annotations":{}},"attachments":{"media_keys":["3_1090936745259134979"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":1,"like_count":11,"quote_count":0},"created_at":"2019-01-28T15:40:00.000Z","author_id":"116716199","text":"See what's on the agenda of the January meeting of EMA‚Äôs human #medicines committee: https://t.co/QlHKo3ejrh #CHMP","id":"1089910973694119937","conversation_id":"1089910973694119937","entities":{"mentions":{},"hashtags":[{"start":63,"end":73,"tag":"medicines"},{"start":109,"end":114,"tag":"CHMP"}],"urls":[{"start":85,"end":108,"url":"https://t.co/QlHKo3ejrh","expanded_url":"https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-28-31-january-2019_en.pdf","display_url":"ema.europa.eu/documents/agen‚Ä¶"}],"annotations":[{"start":51,"end":53,"probability":0.3904,"type":"Other","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7148,"reply_count":1052,"like_count":7461,"quote_count":2958},"created_at":"2019-01-25T17:01:15.000Z","author_id":"116716199","text":"Today, EMA staff lowered the 28 EU flags and symbolically said goodbye to their London offices. Guido Rasi expressed his thanks to the UK for its contribution to the work of the Agency and for having been a gracious host of EMA since 1995. https://t.co/KpsBvaXt42","id":"1088844259934064640","conversation_id":"1088844259934064640","entities":{"mentions":{},"hashtags":{},"urls":[{"start":240,"end":263,"url":"https://t.co/KpsBvaXt42","expanded_url":"https://twitter.com/EMA_News/status/1088844259934064640/photo/1","display_url":"pic.twitter.com/KpsBvaXt42"}],"annotations":[{"start":7,"end":9,"probability":0.6869,"type":"Organization","normalized_text":"EMA"},{"start":80,"end":85,"probability":0.8025,"type":"Place","normalized_text":"London"},{"start":96,"end":105,"probability":0.9888,"type":"Person","normalized_text":"Guido Rasi"},{"start":135,"end":136,"probability":0.6657,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":["3_1088842127637917696"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":57,"reply_count":0,"like_count":61,"quote_count":5},"created_at":"2019-01-24T15:12:46.000Z","author_id":"116716199","text":"#EMA has updated its relocation tracking tool, which provides an overview of the main milestones and deliverables for the Agency‚Äôs move to Amsterdam: https://t.co/R8GllwWxMS https://t.co/8G1OBj6rUs","id":"1088454570878021632","conversation_id":"1088454570878021632","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"}],"urls":[{"start":150,"end":173,"url":"https://t.co/R8GllwWxMS","expanded_url":"https://www.ema.europa.eu/en/documents/other/ema-tracking-tool-relocation-amsterdam-main-milestones_en.pdf","display_url":"ema.europa.eu/en/documents/o‚Ä¶"},{"start":174,"end":197,"url":"https://t.co/8G1OBj6rUs","expanded_url":"https://twitter.com/EMA_News/status/1088454570878021632/photo/1","display_url":"pic.twitter.com/8G1OBj6rUs"}],"annotations":[{"start":139,"end":147,"probability":0.9896,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1088454514506514432"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":21,"quote_count":1},"created_at":"2019-01-24T10:30:05.000Z","author_id":"116716199","text":"What is the European regulatory experience with advanced therapy medicinal products? Find out in this article: https://t.co/51SbpWmAUK #ATMPs https://t.co/UZ2Gv5ARtz","id":"1088383430772047872","conversation_id":"1088383430772047872","entities":{"mentions":{},"hashtags":[{"start":135,"end":141,"tag":"ATMPs"}],"urls":[{"start":111,"end":134,"url":"https://t.co/51SbpWmAUK","expanded_url":"https://www.nature.com/articles/nrd.2018.200#f1","display_url":"nature.com/articles/nrd.2‚Ä¶"},{"start":142,"end":165,"url":"https://t.co/UZ2Gv5ARtz","expanded_url":"https://twitter.com/EMA_News/status/1088383430772047872/photo/1","display_url":"pic.twitter.com/UZ2Gv5ARtz"}],"annotations":{}},"attachments":{"media_keys":["3_1088383388799639568"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":3,"like_count":35,"quote_count":7},"created_at":"2019-01-23T14:34:54.000Z","author_id":"116716199","text":"The countdown is running for EMA‚Äôs move to Amsterdam. EMA‚Äôs #Brexit preparedness business continuity plan entered into its 4th phase on 1 January 2019. See our relocation updates: https://t.co/j3lyNx3169 https://t.co/zZQM3OyIiG","id":"1088082651439919104","conversation_id":"1088082651439919104","entities":{"mentions":{},"hashtags":[{"start":60,"end":67,"tag":"Brexit"}],"urls":[{"start":180,"end":203,"url":"https://t.co/j3lyNx3169","expanded_url":"https://www.ema.europa.eu/en/news/ema-relocation-updates","display_url":"ema.europa.eu/en/news/ema-re‚Ä¶"},{"start":204,"end":227,"url":"https://t.co/zZQM3OyIiG","expanded_url":"https://twitter.com/EMA_News/status/1088082651439919104/photo/1","display_url":"pic.twitter.com/zZQM3OyIiG"}],"annotations":[{"start":29,"end":31,"probability":0.5022,"type":"Organization","normalized_text":"EMA"},{"start":43,"end":51,"probability":0.9565,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1088082613422751745"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":0,"like_count":26,"quote_count":5},"created_at":"2019-01-23T13:56:37.000Z","author_id":"116716199","text":"No new #patients should start treatment with #Lartruvo after study shows cancer medicine does not prolong life: https://t.co/cM7hP65gDj","id":"1088073017954107392","conversation_id":"1088073017954107392","entities":{"mentions":{},"hashtags":[{"start":7,"end":16,"tag":"patients"},{"start":45,"end":54,"tag":"Lartruvo"}],"urls":[{"start":112,"end":135,"url":"https://t.co/cM7hP65gDj","expanded_url":"https://www.ema.europa.eu/en/news/no-new-patients-should-start-treatment-lartruvo-after-study-shows-cancer-medicine-does-not-prolong","display_url":"ema.europa.eu/en/news/no-new‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1087691665790386176"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":42,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-01-23T09:34:10.000Z","author_id":"116716199","text":"RT @EU_Health: Falsified #medicines can be ineffective, harmful or even deadly and are a serious threat to public #health. \n\nRead our repor‚Ä¶","id":"1088006971813441537","conversation_id":"1088006971813441537","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":25,"end":35,"tag":"medicines"},{"start":114,"end":121,"tag":"health"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":0,"like_count":25,"quote_count":5},"created_at":"2019-01-21T13:39:32.000Z","author_id":"116716199","text":"Executive Director Guido Rasi on EMA Regulatory Science to 2025. What are your thoughts on this strategy? You can comment via the online questionnaire. https://t.co/KQDSN3Qtq4 #RegScience2025 https://t.co/fq4FOdWVEQ","id":"1087343943979814912","conversation_id":"1087343943979814912","entities":{"mentions":{},"hashtags":[{"start":176,"end":191,"tag":"RegScience2025"}],"urls":[{"start":152,"end":175,"url":"https://t.co/KQDSN3Qtq4","expanded_url":"http://bit.ly/2Luj4E8","display_url":"bit.ly/2Luj4E8"},{"start":192,"end":215,"url":"https://t.co/fq4FOdWVEQ","expanded_url":"https://twitter.com/EMA_News/status/1087343943979814912/video/1","display_url":"pic.twitter.com/fq4FOdWVEQ"}],"annotations":[{"start":19,"end":28,"probability":0.5416,"type":"Person","normalized_text":"Guido Rasi"},{"start":33,"end":54,"probability":0.7502,"type":"Organization","normalized_text":"EMA Regulatory Science"}]},"attachments":{"media_keys":["7_1087343666501435392"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1087036161422323712"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":0,"quote_count":0},"created_at":"2019-01-21T11:09:19.000Z","author_id":"116716199","text":"@astvansh Thanks for getting in touch. To send us your request, please fill in this form: https://t.co/oYxXr8dsVh\nWe will get back to you as soon as possible.","id":"1087306139153371136","conversation_id":"1087036161422323712","entities":{"mentions":[{"start":0,"end":9,"username":"astvansh","id":"34275335"}],"hashtags":{},"urls":[{"start":90,"end":113,"url":"https://t.co/oYxXr8dsVh","expanded_url":"https://www.ema.europa.eu/en/about-us/contact/send-question-european-medicines-agency","display_url":"ema.europa.eu/en/about-us/co‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"34275335"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":55,"reply_count":0,"like_count":48,"quote_count":3},"created_at":"2019-01-14T12:33:15.000Z","author_id":"116716199","text":"In the fight against #AMR, it is vital to develop new #medicines against multi-drug resistant bacteria. See EMA‚Äôs revised guidance published for a 6-month #PublicConsultation and join the discussion by sharing your thoughts: https://t.co/TMq3SnKyW4 https://t.co/3XX2KG8EsH","id":"1084790548521775104","conversation_id":"1084790548521775104","entities":{"mentions":{},"hashtags":[{"start":21,"end":25,"tag":"AMR"},{"start":54,"end":64,"tag":"medicines"},{"start":155,"end":174,"tag":"PublicConsultation"}],"urls":[{"start":225,"end":248,"url":"https://t.co/TMq3SnKyW4","expanded_url":"https://www.ema.europa.eu/en/news/revised-guideline-aims-strengthen-global-approach-development-new-antibacterial-medicines","display_url":"ema.europa.eu/en/news/revise‚Ä¶"},{"start":249,"end":272,"url":"https://t.co/3XX2KG8EsH","expanded_url":"https://twitter.com/EMA_News/status/1084790548521775104/photo/1","display_url":"pic.twitter.com/3XX2KG8EsH"}],"annotations":{}},"attachments":{"media_keys":["3_1084790507602104320"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1083029667538448387"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":47,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-01-10T13:20:57.000Z","author_id":"116716199","text":"RT @DutchMFA: Welcome @EMA_News! #KingdomNL welcomes the European Medicines Agency in Amsterdam in their new temporary premises. Successful‚Ä¶","id":"1083352999634919424","conversation_id":"1083352999634919424","entities":{"mentions":[{"start":3,"end":12,"username":"DutchMFA","id":"98853413"},{"start":22,"end":31,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":33,"end":43,"tag":"KingdomNL"}],"urls":{},"annotations":[{"start":57,"end":81,"probability":0.4263,"type":"Organization","normalized_text":"European Medicines Agency"},{"start":86,"end":94,"probability":0.9944,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1082635215003111424"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":69,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2019-01-08T13:53:19.000Z","author_id":"116716199","text":"RT @Food_EU: New #EU rules on #veterinary medicines &amp; medicated #feed published in Official Journal üá™üá∫on 7 January 2019 üëâhttps://t.co/jq7n5‚Ä¶","id":"1082636368835170306","conversation_id":"1082636368835170306","entities":{"mentions":[{"start":3,"end":11,"username":"Food_EU","id":"2874880006"}],"hashtags":[{"start":17,"end":20,"tag":"EU"},{"start":30,"end":41,"tag":"veterinary"},{"start":68,"end":73,"tag":"feed"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":19,"quote_count":1},"created_at":"2019-01-07T10:35:00.000Z","author_id":"116716199","text":"EMA recommended 10 #veterinary #medicines for marketing authorisation in 2018. Don‚Äôt miss our annual Veterinary medicines highlights here: https://t.co/TR7vn9GeBg https://t.co/7vdUkWDyJx","id":"1082224072724021248","conversation_id":"1082224072724021248","entities":{"mentions":{},"hashtags":[{"start":19,"end":30,"tag":"veterinary"},{"start":31,"end":41,"tag":"medicines"}],"urls":[{"start":139,"end":162,"url":"https://t.co/TR7vn9GeBg","expanded_url":"https://www.ema.europa.eu/documents/report/veterinary-medicines-highlights-2018_en.pdf","display_url":"ema.europa.eu/documents/repo‚Ä¶"},{"start":163,"end":186,"url":"https://t.co/7vdUkWDyJx","expanded_url":"https://twitter.com/EMA_News/status/1082224072724021248/photo/1","display_url":"pic.twitter.com/7vdUkWDyJx"}],"annotations":{}},"attachments":{"media_keys":["3_1082222482038374400"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":73,"reply_count":2,"like_count":74,"quote_count":8},"created_at":"2019-01-04T13:36:00.000Z","author_id":"116716199","text":"In 2018, EMA recommended 84 #medicines for marketing authorisation and issued significant new safety advice ‚Äì Check out our Human medicines highlights 2018 infographic: https://t.co/8TP8QT73x8 https://t.co/ZCbVCWEHik","id":"1081182459180527617","conversation_id":"1081182459180527617","entities":{"mentions":{},"hashtags":[{"start":28,"end":38,"tag":"medicines"}],"urls":[{"start":169,"end":192,"url":"https://t.co/8TP8QT73x8","expanded_url":"https://www.ema.europa.eu/documents/report/human-medicines-highlights-2018_en.pdf","display_url":"ema.europa.eu/documents/repo‚Ä¶"},{"start":193,"end":216,"url":"https://t.co/ZCbVCWEHik","expanded_url":"https://twitter.com/EMA_News/status/1081182459180527617/photo/1","display_url":"pic.twitter.com/ZCbVCWEHik"}],"annotations":{}},"attachments":{"media_keys":["3_1081181706365874178"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":13,"quote_count":2},"created_at":"2018-12-20T11:10:20.000Z","author_id":"116716199","text":"EMA wants to hear from people who suffer from hair loss to understand their views and perspectives on a treatment for #alopecia areata. Take the survey: https://t.co/3pxwKQ2Jfo #EMAPublicConsultation https://t.co/43h4XOxKS6","id":"1075709985764581376","conversation_id":"1075709985764581376","entities":{"mentions":{},"hashtags":[{"start":118,"end":127,"tag":"alopecia"},{"start":177,"end":199,"tag":"EMAPublicConsultation"}],"urls":[{"start":153,"end":176,"url":"https://t.co/3pxwKQ2Jfo","expanded_url":"https://bit.ly/2CoPcG1","display_url":"bit.ly/2CoPcG1"},{"start":200,"end":223,"url":"https://t.co/43h4XOxKS6","expanded_url":"https://twitter.com/EMA_News/status/1075709985764581376/photo/1","display_url":"pic.twitter.com/43h4XOxKS6"}],"annotations":[{"start":0,"end":2,"probability":0.3426,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1075709936750026752"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":25,"reply_count":0,"like_count":30,"quote_count":5},"created_at":"2018-12-19T15:12:07.000Z","author_id":"116716199","text":"Watch our new video on the ‚ÄòRegulatory Science to 2025‚Äô strategy featuring Anthony Humphreys, head of EMA‚Äôs Scientific Committees Regulatory Science Strategy division. Send your comments on the strategy via the online questionnaire. #RegScience2025 https://t.co/0l6poTRoud https://t.co/UMzQAsSVo5","id":"1075408443186561031","conversation_id":"1075408443186561031","entities":{"mentions":{},"hashtags":[{"start":233,"end":248,"tag":"RegScience2025"}],"urls":[{"start":249,"end":272,"url":"https://t.co/0l6poTRoud","expanded_url":"https://bit.ly/2Luj4E8","display_url":"bit.ly/2Luj4E8"},{"start":273,"end":296,"url":"https://t.co/UMzQAsSVo5","expanded_url":"https://twitter.com/EMA_News/status/1075408443186561031/video/1","display_url":"pic.twitter.com/UMzQAsSVo5"}],"annotations":[{"start":28,"end":45,"probability":0.4524,"type":"Organization","normalized_text":"Regulatory Science"},{"start":75,"end":91,"probability":0.9969,"type":"Person","normalized_text":"Anthony Humphreys"}]},"attachments":{"media_keys":["7_1075408089828995072"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":50,"reply_count":0,"like_count":45,"quote_count":9},"created_at":"2018-12-19T11:55:31.000Z","author_id":"116716199","text":"EMA has published its draft ‚ÄòRegulatory Science to 2025‚Äô strategy for a six-month public consultation. Join the discussion by sending your comments via the online questionnaire. #RegScience2025 https://t.co/ovOSZoVoBs https://t.co/0l6poTRoud https://t.co/XOyuBnbWNk","id":"1075358965830172672","conversation_id":"1075358965830172672","entities":{"mentions":{},"hashtags":[{"start":178,"end":193,"tag":"RegScience2025"}],"urls":[{"start":194,"end":217,"url":"https://t.co/ovOSZoVoBs","expanded_url":"https://bit.ly/2S4Fzlu","display_url":"bit.ly/2S4Fzlu"},{"start":218,"end":241,"url":"https://t.co/0l6poTRoud","expanded_url":"https://bit.ly/2Luj4E8","display_url":"bit.ly/2Luj4E8"},{"start":242,"end":265,"url":"https://t.co/XOyuBnbWNk","expanded_url":"https://twitter.com/EMA_News/status/1075358965830172672/photo/1","display_url":"pic.twitter.com/XOyuBnbWNk"}],"annotations":[{"start":0,"end":2,"probability":0.578,"type":"Organization","normalized_text":"EMA"},{"start":29,"end":46,"probability":0.5439,"type":"Organization","normalized_text":"Regulatory Science"}]},"attachments":{"media_keys":["3_1075358888059383808"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":18,"quote_count":4},"created_at":"2018-12-17T11:18:23.000Z","author_id":"116716199","text":"#EMA has updated its relocation tracking tool, which provides an overview of the main milestones and deliverables for the Agency‚Äôs move to Amsterdam: https://t.co/Hr2szNvJBm https://t.co/KPhltG2nE7","id":"1074624847030947845","conversation_id":"1074624847030947845","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"}],"urls":[{"start":150,"end":173,"url":"https://t.co/Hr2szNvJBm","expanded_url":"https://www.ema.europa.eu/documents/other/ema-tracking-tool-relocation-amsterdam-main-milestones_en.pdf","display_url":"ema.europa.eu/documents/othe‚Ä¶"},{"start":174,"end":197,"url":"https://t.co/KPhltG2nE7","expanded_url":"https://twitter.com/EMA_News/status/1074624847030947845/photo/1","display_url":"pic.twitter.com/KPhltG2nE7"}],"annotations":[{"start":139,"end":147,"probability":0.9896,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1074624765401464832"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":5,"quote_count":2},"created_at":"2018-12-14T13:00:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee recommends 7 #medicines for approval at its December 2018 meeting https://t.co/eGAyZE81RU #CHMP https://t.co/0oofJFa5Th","id":"1073563254981648387","conversation_id":"1073563254981648387","entities":{"mentions":{},"hashtags":[{"start":45,"end":55,"tag":"medicines"},{"start":122,"end":127,"tag":"CHMP"}],"urls":[{"start":98,"end":121,"url":"https://t.co/eGAyZE81RU","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-december-2018","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":128,"end":151,"url":"https://t.co/0oofJFa5Th","expanded_url":"https://twitter.com/EMA_News/status/1073563254981648387/photo/1","display_url":"pic.twitter.com/0oofJFa5Th"}],"annotations":[{"start":0,"end":2,"probability":0.5609,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1073561591684231169"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":1,"like_count":6,"quote_count":0},"created_at":"2018-12-14T11:58:34.000Z","author_id":"116716199","text":"What are the highlights of the December 2018 meeting of EMA's Management Board? https://t.co/5aWdBkjcPI https://t.co/Ecxdn13MVC","id":"1073547794173095936","conversation_id":"1073547794173095936","entities":{"mentions":{},"hashtags":{},"urls":[{"start":80,"end":103,"url":"https://t.co/5aWdBkjcPI","expanded_url":"https://www.ema.europa.eu/en/news/ema-management-board-highlights-december-2018-meeting","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"},{"start":104,"end":127,"url":"https://t.co/Ecxdn13MVC","expanded_url":"https://twitter.com/EMA_News/status/1073547794173095936/photo/1","display_url":"pic.twitter.com/Ecxdn13MVC"}],"annotations":[{"start":56,"end":58,"probability":0.3669,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1073547662530674689"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1073155663591825409"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-12-14T10:33:31.000Z","author_id":"116716199","text":"RT @eurordis: Do you or someone you know live with a #raredisease? Have you captured a special moment in their life in a photo? Enter your‚Ä¶","id":"1073526391801610241","conversation_id":"1073526391801610241","entities":{"mentions":[{"start":3,"end":12,"username":"eurordis","id":"26993786"}],"hashtags":[{"start":53,"end":65,"tag":"raredisease"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1073511664576839680"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":94,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-12-14T09:39:52.000Z","author_id":"116716199","text":"RT @EU_Health: #Antibiotics are ineffective against viruses, cold or flu. Their misuse puts us all at risk. \n\nNew #Eurobarometer on #antibi‚Ä¶","id":"1073512891733733376","conversation_id":"1073512891733733376","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":15,"end":27,"tag":"Antibiotics"},{"start":114,"end":128,"tag":"Eurobarometer"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"quoted","id":"1073150319469694977"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":16,"quote_count":1},"created_at":"2018-12-13T15:56:27.000Z","author_id":"116716199","text":"EMA welcomes the adoption of the new #dataprotection rules for EU institutions (#EUI) that entered into force on 11 December 2018. Regulation (EU) 2018/1725, known as the 'EU DPR', brings data protection rules for #EUI in line with standards imposed by #GDPR. https://t.co/4Y8JG3HJRp","id":"1073245271352639489","conversation_id":"1073245271352639489","entities":{"mentions":{},"hashtags":[{"start":37,"end":52,"tag":"dataprotection"},{"start":80,"end":84,"tag":"EUI"},{"start":214,"end":218,"tag":"EUI"},{"start":253,"end":258,"tag":"GDPR"}],"urls":[{"start":260,"end":283,"url":"https://t.co/4Y8JG3HJRp","expanded_url":"https://twitter.com/EU_EDPS/status/1073150319469694977","display_url":"twitter.com/EU_EDPS/status‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.5203,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":0,"like_count":12,"quote_count":1},"created_at":"2018-12-13T09:38:00.000Z","author_id":"116716199","text":"We would like to hear from #patients who take #rituximab for rheumatoid arthritis, Granulomatosis with polyangiitis or microscopic polyangiitis: What do you think about the educational materials available for this medicine?Take this survey by 22 Jan 2019: https://t.co/kwEHINjdBa https://t.co/GHtf8NjDzL","id":"1073150031492837376","conversation_id":"1073150031492837376","entities":{"mentions":{},"hashtags":[{"start":27,"end":36,"tag":"patients"},{"start":46,"end":56,"tag":"rituximab"}],"urls":[{"start":256,"end":279,"url":"https://t.co/kwEHINjdBa","expanded_url":"https://ec.europa.eu/eusurvey/runner/MabThera_rituximab","display_url":"ec.europa.eu/eusurvey/runne‚Ä¶"},{"start":280,"end":303,"url":"https://t.co/GHtf8NjDzL","expanded_url":"https://twitter.com/EMA_News/status/1073150031492837376/photo/1","display_url":"pic.twitter.com/GHtf8NjDzL"}],"annotations":{}},"attachments":{"media_keys":["16_1072888348761616389"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1072436315789119490"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-12-11T11:13:47.000Z","author_id":"116716199","text":"RT @EU_Health: What is the impact of EU rules on #medicines for #children &amp; #raredisease? \n\nReply to our #publicconsultation by 4 January 2‚Ä¶","id":"1072449362196865030","conversation_id":"1072449362196865030","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":49,"end":59,"tag":"medicines"},{"start":64,"end":73,"tag":"children"},{"start":80,"end":92,"tag":"raredisease"},{"start":109,"end":128,"tag":"publicconsultation"}],"urls":{},"annotations":[{"start":37,"end":38,"probability":0.4503,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":9,"quote_count":0},"created_at":"2018-12-10T14:52:00.000Z","author_id":"116716199","text":"See what's on the agenda of the December meeting of EMA‚Äôs human #medicines committee: https://t.co/FfHnIsbm1M #CHMP","id":"1072141888617107456","conversation_id":"1072141888617107456","entities":{"mentions":{},"hashtags":[{"start":64,"end":74,"tag":"medicines"},{"start":110,"end":115,"tag":"CHMP"}],"urls":[{"start":86,"end":109,"url":"https://t.co/FfHnIsbm1M","expanded_url":"https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-10-13-december-2018_en.pdf","display_url":"ema.europa.eu/documents/agen‚Ä¶"}],"annotations":[{"start":52,"end":54,"probability":0.4037,"type":"Other","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1071081322884538368"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-12-10T09:42:16.000Z","author_id":"116716199","text":"RT @ECDC_VPD: In a Council Recommendation adopted by EU health ministers today, @ECDC_EU has been called on to implement a number of key ac‚Ä¶","id":"1072063943219253248","conversation_id":"1072063943219253248","entities":{"mentions":[{"start":3,"end":12,"username":"ECDC_VPD","id":"186471638"},{"start":80,"end":88,"username":"ECDC_EU","id":"204752573"}],"hashtags":{},"urls":{},"annotations":[{"start":53,"end":54,"probability":0.9238,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1071051751111970816"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-12-07T15:25:11.000Z","author_id":"116716199","text":"RT @EMCDDA: Today, we are stepping up our cooperation with the European Medicines Agency  @EMA_News with the signature of an updated workin‚Ä¶","id":"1071063077230137345","conversation_id":"1071063077230137345","entities":{"mentions":[{"start":3,"end":10,"username":"EMCDDA","id":"50638521"},{"start":90,"end":99,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":[{"start":63,"end":87,"probability":0.5178,"type":"Organization","normalized_text":"European Medicines Agency"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":2,"like_count":30,"quote_count":4},"created_at":"2018-12-07T14:25:42.000Z","author_id":"116716199","text":"#EMA and @EUnetHTA continue their collaboration at a meeting on 7 Dec. Parallel scientific advice, #PatientRegistries, lessons from medicine assessments, guideline development and evidence for #OrphanMedicines are some of the topics being discussed: https://t.co/CPD8feAJSl https://t.co/d45XtR3MNl","id":"1071048107188719616","conversation_id":"1071048107188719616","entities":{"mentions":[{"start":9,"end":18,"username":"EUnetHTA","id":"56493220"}],"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":99,"end":117,"tag":"PatientRegistries"},{"start":193,"end":209,"tag":"OrphanMedicines"}],"urls":[{"start":250,"end":273,"url":"https://t.co/CPD8feAJSl","expanded_url":"https://www.ema.europa.eu/en/events/16th-joint-european-medicines-agencyeuropean-network-health-technology-assessment-dialogue-meeting","display_url":"ema.europa.eu/en/events/16th‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/d45XtR3MNl","expanded_url":"https://twitter.com/EMA_News/status/1071048107188719616/photo/1","display_url":"pic.twitter.com/d45XtR3MNl"}],"annotations":{}},"attachments":{"media_keys":["3_1071042605641859072"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1071002172693848064"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":123,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-12-07T12:29:42.000Z","author_id":"116716199","text":"RT @EU_Health: .@V_Andriukaitis: \"As a doctor I can honestly say that #vaccination is truly one of the greatest successes of public health‚Ä¶","id":"1071018912920293379","conversation_id":"1071018912920293379","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":16,"end":31,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":70,"end":82,"tag":"vaccination"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":1,"like_count":11,"quote_count":1},"created_at":"2018-12-06T15:05:46.000Z","author_id":"116716199","text":"Watch now our workshop on regulatory science for veterinary medicines: #RegScience2025 https://t.co/h8cgvmqzmg https://t.co/61Rzg6RkHZ","id":"1070695801452748811","conversation_id":"1070695801452748811","entities":{"mentions":{},"hashtags":[{"start":71,"end":86,"tag":"RegScience2025"}],"urls":[{"start":87,"end":110,"url":"https://t.co/h8cgvmqzmg","expanded_url":"https://bit.ly/2Egmj12","display_url":"bit.ly/2Egmj12"},{"start":111,"end":134,"url":"https://t.co/61Rzg6RkHZ","expanded_url":"https://twitter.com/EMA_News/status/1070695801452748811/video/1","display_url":"pic.twitter.com/61Rzg6RkHZ"}],"annotations":{}},"attachments":{"media_keys":["7_1070694536773582848"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":2,"quote_count":0},"created_at":"2018-12-06T09:43:53.000Z","author_id":"116716199","text":"Follow today the live broadcast of EMA's workshop on advancing regulatory science to 2025 for #veterinary #medicines. It will start at 14:00, UK time. #RegScience2025 https://t.co/AuGcXzqzZ9 https://t.co/77FqM08qGo","id":"1070614799715893248","conversation_id":"1070614799715893248","entities":{"mentions":{},"hashtags":[{"start":94,"end":105,"tag":"veterinary"},{"start":106,"end":116,"tag":"medicines"},{"start":151,"end":166,"tag":"RegScience2025"}],"urls":[{"start":167,"end":190,"url":"https://t.co/AuGcXzqzZ9","expanded_url":"https://www.ema.europa.eu/en/events/multi-stakeholder-workshop-launch-consultation-european-medicines-agency-ema-veterinary-regulatory","display_url":"ema.europa.eu/en/events/mult‚Ä¶"},{"start":191,"end":214,"url":"https://t.co/77FqM08qGo","expanded_url":"https://twitter.com/EMA_News/status/1070614799715893248/photo/1","display_url":"pic.twitter.com/77FqM08qGo"}],"annotations":[{"start":35,"end":37,"probability":0.3392,"type":"Organization","normalized_text":"EMA"},{"start":142,"end":143,"probability":0.9371,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":["3_1070614678148145153"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1070585736955609088"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"created_at":"2018-12-06T09:29:20.000Z","author_id":"116716199","text":"@LaSuze7 Thank you for getting in touch. The live broadcast will start at 14h00, UK time.","id":"1070611138012999681","conversation_id":"1070585736955609088","entities":{"mentions":[{"start":0,"end":8,"username":"LaSuze7","id":"2202837937"}],"hashtags":{},"urls":{},"annotations":[{"start":74,"end":78,"probability":0.7066,"type":"Place","normalized_text":"14h00"},{"start":81,"end":82,"probability":0.7043,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"2202837937"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":11,"quote_count":1},"created_at":"2018-12-05T11:28:21.000Z","author_id":"116716199","text":"As EMA is currently assessing the development plan for a potential new treatment for #AADC, we would like to hear the views of parents and #patients confronted with this condition. Share your thoughts in this short survey. Deadline: 7 December 2018. https://t.co/vUeqsPPhsi https://t.co/5i4HWGvX5b","id":"1070278701592526848","conversation_id":"1070278701592526848","entities":{"mentions":{},"hashtags":[{"start":85,"end":90,"tag":"AADC"},{"start":139,"end":148,"tag":"patients"}],"urls":[{"start":250,"end":273,"url":"https://t.co/vUeqsPPhsi","expanded_url":"https://ec.europa.eu/eusurvey/runner/AADC","display_url":"ec.europa.eu/eusurvey/runne‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/5i4HWGvX5b","expanded_url":"https://twitter.com/EMA_News/status/1070278701592526848/photo/1","display_url":"pic.twitter.com/5i4HWGvX5b"}],"annotations":[{"start":3,"end":5,"probability":0.3609,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["16_1070278619728134145"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":1,"like_count":15,"quote_count":1},"created_at":"2018-11-30T15:04:22.000Z","author_id":"116716199","text":"Data from patient registries to replace #ClinicalTrials in previously untreated #haemophilia patients. #PatientRegistries \nhttps://t.co/FFMOu6N8xF https://t.co/uQk6NjtTJ4","id":"1068521121509568513","conversation_id":"1068521121509568513","entities":{"mentions":{},"hashtags":[{"start":40,"end":55,"tag":"ClinicalTrials"},{"start":80,"end":92,"tag":"haemophilia"},{"start":103,"end":121,"tag":"PatientRegistries"}],"urls":[{"start":123,"end":146,"url":"https://t.co/FFMOu6N8xF","expanded_url":"https://www.ema.europa.eu/en/news/data-patient-registries-replace-clinical-trials-previously-untreated-haemophilia-patients","display_url":"ema.europa.eu/en/news/data-p‚Ä¶"},{"start":147,"end":170,"url":"https://t.co/uQk6NjtTJ4","expanded_url":"https://twitter.com/EMA_News/status/1068521121509568513/photo/1","display_url":"pic.twitter.com/uQk6NjtTJ4"}],"annotations":{}},"attachments":{"media_keys":["3_1068521084096368642"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":17,"quote_count":2},"created_at":"2018-11-30T13:18:24.000Z","author_id":"116716199","text":"What are the potential effects of #medicines on the #environment? EMA's revised guideline is looking into this. Share your thoughts on this document by participating in our #PublicConsultation. #EMAPublicConsultation https://t.co/414JKeVIir https://t.co/NsTgOU6zwZ","id":"1068494455932690434","conversation_id":"1068494455932690434","entities":{"mentions":{},"hashtags":[{"start":34,"end":44,"tag":"medicines"},{"start":52,"end":64,"tag":"environment"},{"start":173,"end":192,"tag":"PublicConsultation"},{"start":194,"end":216,"tag":"EMAPublicConsultation"}],"urls":[{"start":217,"end":240,"url":"https://t.co/414JKeVIir","expanded_url":"https://www.ema.europa.eu/en/news/revised-guideline-assess-risk-human-medicines-environment","display_url":"ema.europa.eu/en/news/revise‚Ä¶"},{"start":241,"end":264,"url":"https://t.co/NsTgOU6zwZ","expanded_url":"https://twitter.com/EMA_News/status/1068494455932690434/photo/1","display_url":"pic.twitter.com/NsTgOU6zwZ"}],"annotations":{}},"attachments":{"media_keys":["3_1068494377553747968"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":1,"like_count":5,"quote_count":1},"created_at":"2018-11-29T14:54:16.000Z","author_id":"116716199","text":"What do regulators need to do to ensure that innovation delivers great solutions for the health of #animals? #EMA  will host a workshop to gather views of veterinarians, academia, trade associations, regulators on this topic. https://t.co/gnlCFUhSse #RegScience2025 https://t.co/p1vA709Jhr","id":"1068156194408271872","conversation_id":"1068156194408271872","entities":{"mentions":{},"hashtags":[{"start":99,"end":107,"tag":"animals"},{"start":109,"end":113,"tag":"EMA"},{"start":250,"end":265,"tag":"RegScience2025"}],"urls":[{"start":226,"end":249,"url":"https://t.co/gnlCFUhSse","expanded_url":"https://www.ema.europa.eu/en/news/workshop-advancing-regulatory-science-2025-veterinary-medicines","display_url":"ema.europa.eu/en/news/worksh‚Ä¶"},{"start":266,"end":289,"url":"https://t.co/p1vA709Jhr","expanded_url":"https://twitter.com/EMA_News/status/1068156194408271872/photo/1","display_url":"pic.twitter.com/p1vA709Jhr"}],"annotations":{}},"attachments":{"media_keys":["3_1068155825246605313"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":1,"like_count":18,"quote_count":1},"created_at":"2018-11-29T12:00:22.000Z","author_id":"116716199","text":"Five additional Member States now included in the EU-US mutual recognition agreement for #medicines #inspections: https://t.co/XEMFMXKD6c","id":"1068112431434661889","conversation_id":"1068112431434661889","entities":{"mentions":{},"hashtags":[{"start":89,"end":99,"tag":"medicines"},{"start":100,"end":112,"tag":"inspections"}],"urls":[{"start":114,"end":137,"url":"https://t.co/XEMFMXKD6c","expanded_url":"https://www.ema.europa.eu/en/news/five-additional-countries-benefit-eu-us-mutual-recognition-agreement-inspections","display_url":"ema.europa.eu/en/news/five-a‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/five-additional-countries-benefit-eu-us-mutual-recognition-agreement-inspections"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1067717055770701824"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-28T16:55:47.000Z","author_id":"116716199","text":"RT @EUnetHTA: Patient group consultation on medicinal product for relapsed or refractory Acute Myeloid Leukaemia (AML) now open - closing J‚Ä¶","id":"1067824384814039042","conversation_id":"1067824384814039042","entities":{"mentions":[{"start":3,"end":12,"username":"EUnetHTA","id":"56493220"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1067757478732095488"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":2,"quote_count":1},"created_at":"2018-11-28T13:57:52.000Z","author_id":"116716199","text":"@MAbutuc Yes, ePI will support patients with visual impairments and citizens with low literacy levels. https://t.co/zFkOo5aZ89 #ePI4Medicines","id":"1067779611256385536","conversation_id":"1067757478732095488","entities":{"mentions":[{"start":0,"end":8,"username":"MAbutuc","id":"781199327779819520"}],"hashtags":[{"start":127,"end":141,"tag":"ePI4Medicines"}],"urls":[{"start":103,"end":126,"url":"https://t.co/zFkOo5aZ89","expanded_url":"https://www.ema.europa.eu/en/news/towards-electronic-product-information-eu-medicines","display_url":"ema.europa.eu/en/news/toward‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"781199327779819520"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":5,"quote_count":1},"created_at":"2018-11-28T11:49:36.000Z","author_id":"116716199","text":"To optimise the video quality of the live broadcast of EMA‚Äôs workshop on electronic product information, we recommend clicking on the ‚ÄòHD‚Äô symbol in the video window, then selecting the '720p' option. #ePI4medicines https://t.co/ueTozZXBRx","id":"1067747333381783553","conversation_id":"1067747333381783553","entities":{"mentions":{},"hashtags":[{"start":201,"end":215,"tag":"ePI4medicines"}],"urls":[{"start":216,"end":239,"url":"https://t.co/ueTozZXBRx","expanded_url":"https://www.ema.europa.eu/en/events/european-medicines-agency-ema-heads-medicines-agencies-hma-european-commission-ec-workshop","display_url":"ema.europa.eu/en/events/euro‚Ä¶"}],"annotations":[{"start":55,"end":57,"probability":0.3315,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":3,"quote_count":2},"created_at":"2018-11-28T11:35:00.000Z","author_id":"116716199","text":"If you experience difficulties viewing the broadcast of our workshop on electronic product information, please try connecting using this link: https://t.co/rx1ixgcLEG #ePI4Medicines. https://t.co/SSGfmK6Z20","id":"1067743658097733632","conversation_id":"1067743658097733632","entities":{"mentions":{},"hashtags":[{"start":167,"end":181,"tag":"ePI4Medicines"}],"urls":[{"start":143,"end":166,"url":"https://t.co/rx1ixgcLEG","expanded_url":"https://www.ustream.tv/channel/european-medicines-agency","display_url":"ustream.tv/channel/europe‚Ä¶"},{"start":183,"end":206,"url":"https://t.co/SSGfmK6Z20","expanded_url":"https://twitter.com/EMA_News/status/1067743658097733632/photo/1","display_url":"pic.twitter.com/SSGfmK6Z20"}],"annotations":{}},"attachments":{"media_keys":["3_1067743589499834369"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":11,"quote_count":6},"created_at":"2018-11-28T09:05:00.000Z","author_id":"116716199","text":"Watch now the live broadcast of our workshop on electronic product information. Participants interested in tweeting about this event are invited to use the hashtag #ePI4Medicines. https://t.co/ueToA0fcJ5 https://t.co/sBKHjuzWWr","id":"1067705908845719552","conversation_id":"1067705908845719552","entities":{"mentions":{},"hashtags":[{"start":164,"end":178,"tag":"ePI4Medicines"}],"urls":[{"start":180,"end":203,"url":"https://t.co/ueToA0fcJ5","expanded_url":"https://www.ema.europa.eu/en/events/european-medicines-agency-ema-heads-medicines-agencies-hma-european-commission-ec-workshop","display_url":"ema.europa.eu/en/events/euro‚Ä¶"},{"start":204,"end":227,"url":"https://t.co/sBKHjuzWWr","expanded_url":"https://twitter.com/EMA_News/status/1067705908845719552/photo/1","display_url":"pic.twitter.com/sBKHjuzWWr"}],"annotations":{}},"attachments":{"media_keys":["3_1067474337878482946"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1067420189074038784"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-27T14:24:52.000Z","author_id":"116716199","text":"RT @EUnetHTA: Minute of July 5, 2018 EMA/EUnetHTA meeting now available https://t.co/CDoxsn7rpP @EMA_News https://t.co/i29acFcWvS","id":"1067424019677396993","conversation_id":"1067424019677396993","entities":{"mentions":[{"start":3,"end":12,"username":"EUnetHTA","id":"56493220"},{"start":96,"end":105,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":[{"start":72,"end":95,"url":"https://t.co/CDoxsn7rpP","expanded_url":"https://goo.gl/y1FTQc","display_url":"goo.gl/y1FTQc"},{"start":106,"end":129,"url":"https://t.co/i29acFcWvS","expanded_url":"https://twitter.com/EUnetHTA/status/1067420189074038784/photo/1","display_url":"pic.twitter.com/i29acFcWvS"}],"annotations":{}},"attachments":{"media_keys":["3_1067419766250450945"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1067098593692135425"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":88,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-27T11:09:33.000Z","author_id":"116716199","text":"RT @Food_EU: Major step forward in the fight against #antimicrobialresistance: @EUCouncil today adopted #veterinary medicines &amp; medicated #‚Ä¶","id":"1067374863676071937","conversation_id":"1067374863676071937","entities":{"mentions":[{"start":3,"end":11,"username":"Food_EU","id":"2874880006"},{"start":79,"end":89,"username":"EUCouncil","id":"206717989"}],"hashtags":[{"start":53,"end":77,"tag":"antimicrobialresistance"},{"start":104,"end":115,"tag":"veterinary"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1065588216290557952"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":141,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-22T15:05:52.000Z","author_id":"116716199","text":"RT @EU_Health: State of #Health in the #EU: more protection and prevention needed for longer and healthier lives - new Health a Glance repo‚Ä¶","id":"1065622395325685760","conversation_id":"1065622395325685760","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":24,"end":31,"tag":"Health"},{"start":39,"end":42,"tag":"EU"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1065520023526096896"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-22T10:34:14.000Z","author_id":"116716199","text":"RT @UMCGlobalSafety: Make sure the medicine is right for your patient ‚Äì be it parent, baby or child! Reporting side effects helps the safe‚Ä¶","id":"1065554037431549953","conversation_id":"1065554037431549953","entities":{"mentions":[{"start":3,"end":19,"username":"UMCGlobalSafety","id":"3173443348"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":18,"reply_count":0,"like_count":23,"quote_count":8},"created_at":"2018-11-21T13:06:38.000Z","author_id":"116716199","text":"What are the opportunities, needs &amp; concerns regarding the use of electronic product information in the #EU? This to be discussed with stakeholders during a workshop organised by EMA, the Heads of #Medicines Agencies &amp; the @EU_Commission: https://t.co/zFkOo5aZ89\n#ePI4Medicines https://t.co/nYWGAlXcGI","id":"1065230003103776768","conversation_id":"1065230003103776768","entities":{"mentions":[{"start":231,"end":245,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":108,"end":111,"tag":"EU"},{"start":201,"end":211,"tag":"Medicines"},{"start":271,"end":285,"tag":"ePI4Medicines"}],"urls":[{"start":247,"end":270,"url":"https://t.co/zFkOo5aZ89","expanded_url":"https://www.ema.europa.eu/en/news/towards-electronic-product-information-eu-medicines","display_url":"ema.europa.eu/en/news/toward‚Ä¶"},{"start":286,"end":309,"url":"https://t.co/nYWGAlXcGI","expanded_url":"https://twitter.com/EMA_News/status/1065230003103776768/photo/1","display_url":"pic.twitter.com/nYWGAlXcGI"}],"annotations":{}},"attachments":{"media_keys":["3_1065225635482750986"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":20,"quote_count":1},"created_at":"2018-11-20T17:34:26.000Z","author_id":"116716199","text":"EMA and @US_FDA are organising a workshop on 26 November on how to support medicine developers in generating quality and manufacturing data for programmes like #PRIME in the EU and Breakthrough Therapies in the US. You will be able to watch it live: https://t.co/Lfx1M91Ls4 https://t.co/E518fgF0M3","id":"1064935007628730369","conversation_id":"1064935007628730369","entities":{"mentions":[{"start":8,"end":15,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":160,"end":166,"tag":"PRIME"}],"urls":[{"start":250,"end":273,"url":"https://t.co/Lfx1M91Ls4","expanded_url":"https://www.ema.europa.eu/en/news/workshop-how-better-support-medicine-developers-generation-preparation-quality-data-packages-prime","display_url":"ema.europa.eu/en/news/worksh‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/E518fgF0M3","expanded_url":"https://twitter.com/EMA_News/status/1064935007628730369/photo/1","display_url":"pic.twitter.com/E518fgF0M3"}],"annotations":[{"start":174,"end":175,"probability":0.4248,"type":"Place","normalized_text":"EU"},{"start":211,"end":212,"probability":0.6918,"type":"Place","normalized_text":"US"}]},"attachments":{"media_keys":["3_1064934943531417606"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":95,"reply_count":0,"like_count":107,"quote_count":10},"created_at":"2018-11-20T12:33:59.000Z","author_id":"116716199","text":"It‚Äôs #medsafetyweek this week! Our video explains how #SideEffects should be reported and what EMA does to monitor medicines to protect public health in Europe. https://t.co/KNLEjUnIBC","id":"1064859398751875072","conversation_id":"1064859398751875072","entities":{"mentions":{},"hashtags":[{"start":5,"end":19,"tag":"medsafetyweek"},{"start":54,"end":66,"tag":"SideEffects"}],"urls":[{"start":161,"end":184,"url":"https://t.co/KNLEjUnIBC","expanded_url":"https://twitter.com/EMA_News/status/1064859398751875072/video/1","display_url":"pic.twitter.com/KNLEjUnIBC"}],"annotations":[{"start":95,"end":97,"probability":0.4746,"type":"Organization","normalized_text":"EMA"},{"start":153,"end":158,"probability":0.9965,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["7_1064859129695617024"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1064825269553373184"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-20T11:54:24.000Z","author_id":"116716199","text":"RT @UMCGlobalSafety: Pregnant or thinking about having a baby? Speak to your doctor about taking #medicines and tell them about any #sideef‚Ä¶","id":"1064849436990468096","conversation_id":"1064849436990468096","entities":{"mentions":[{"start":3,"end":19,"username":"UMCGlobalSafety","id":"3173443348"}],"hashtags":[{"start":97,"end":107,"tag":"medicines"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1064466937764343808"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":35,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-19T11:56:48.000Z","author_id":"116716199","text":"RT @UMCGlobalSafety: Welcome to #MedSafetyWeek! Join our campaign to encourage safe use of medicines in children and pregnancy. Learn more‚Ä¶","id":"1064487654677495809","conversation_id":"1064487654677495809","entities":{"mentions":[{"start":3,"end":19,"username":"UMCGlobalSafety","id":"3173443348"}],"hashtags":[{"start":32,"end":46,"tag":"MedSafetyWeek"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":[{"type":"retweeted","id":"1064258237984374785"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-19T09:29:08.000Z","author_id":"116716199","text":"RT @UMCGlobalSafety: We've taken part in World #Antibiotic Awareness Week this week, with our comic campaign #AnnieMacAMR! Learn more about‚Ä¶","id":"1064450493097943040","conversation_id":"1064450493097943040","entities":{"mentions":[{"start":3,"end":19,"username":"UMCGlobalSafety","id":"3173443348"}],"hashtags":[{"start":47,"end":58,"tag":"Antibiotic"},{"start":109,"end":121,"tag":"AnnieMacAMR"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":21,"quote_count":1},"created_at":"2018-11-16T13:30:00.000Z","author_id":"116716199","text":"International collaboration - #CHMP recommends first oral-only treatment for #sleepingsickness https://t.co/7hngxhoF3L This is the 10th positive opinion on a #medicine for use outside the #EU","id":"1063423943862824961","conversation_id":"1063423943862824961","entities":{"mentions":{},"hashtags":[{"start":30,"end":35,"tag":"CHMP"},{"start":77,"end":94,"tag":"sleepingsickness"},{"start":158,"end":167,"tag":"medicine"},{"start":188,"end":191,"tag":"EU"}],"urls":[{"start":95,"end":118,"url":"https://t.co/7hngxhoF3L","expanded_url":"https://www.ema.europa.eu/en/news/chmp-recommends-first-oral-only-treatment-sleeping-sickness","display_url":"ema.europa.eu/en/news/chmp-r‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":6,"quote_count":1},"created_at":"2018-11-16T13:10:00.000Z","author_id":"116716199","text":"EMA‚Äôs human medicines committee recommends 4 #medicines for approval at its November 2018 meeting https://t.co/d7bElZrOiy #CHMP https://t.co/rYztsyKtaz","id":"1063418910643343360","conversation_id":"1063418910643343360","entities":{"mentions":{},"hashtags":[{"start":45,"end":55,"tag":"medicines"},{"start":122,"end":127,"tag":"CHMP"}],"urls":[{"start":98,"end":121,"url":"https://t.co/d7bElZrOiy","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-november-2018","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":128,"end":151,"url":"https://t.co/rYztsyKtaz","expanded_url":"https://twitter.com/EMA_News/status/1063418910643343360/photo/1","display_url":"pic.twitter.com/rYztsyKtaz"}],"annotations":[{"start":0,"end":2,"probability":0.5565,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1063416463036506112"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1063325938006585344"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":28,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-16T09:26:55.000Z","author_id":"116716199","text":"RT @UMCGlobalSafety: It‚Äôs #MedSafetyWeek next week! 32 medicines regulators around the globe join forces, to encourage reporting side effec‚Ä¶","id":"1063362771679625217","conversation_id":"1063362771679625217","entities":{"mentions":[{"start":3,"end":19,"username":"UMCGlobalSafety","id":"3173443348"}],"hashtags":[{"start":26,"end":40,"tag":"MedSafetyWeek"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":6,"quote_count":0},"created_at":"2018-11-15T15:45:09.000Z","author_id":"116716199","text":"EMA report: there was a downward trend in sales (mg/CPU) of #fluoroquinolones, 3rd- and 4th-generation cephalosporins and polymyxins used in animals between 2011 and 2016: https://t.co/0icVENarBo #AMR #EAAD https://t.co/Yjghqbt8LM","id":"1063095566970875904","conversation_id":"1063095566970875904","entities":{"mentions":{},"hashtags":[{"start":60,"end":77,"tag":"fluoroquinolones"},{"start":196,"end":200,"tag":"AMR"},{"start":201,"end":206,"tag":"EAAD"}],"urls":[{"start":172,"end":195,"url":"https://t.co/0icVENarBo","expanded_url":"https://www.ema.europa.eu/en/news/sales-antibiotics-use-food-producing-animals-drop-across-eu","display_url":"ema.europa.eu/en/news/sales-‚Ä¶"},{"start":207,"end":230,"url":"https://t.co/Yjghqbt8LM","expanded_url":"https://twitter.com/EMA_News/status/1063095566970875904/photo/1","display_url":"pic.twitter.com/Yjghqbt8LM"}],"annotations":{}},"attachments":{"media_keys":["3_1063095535043858434"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"quoted","id":"1062993769522454528"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":18,"quote_count":1},"created_at":"2018-11-15T13:22:40.000Z","author_id":"116716199","text":"EMA supports the efforts to create a sustainable network in the EU that can run #ClinicalStudies for new #antibiotics rapidly and efficiently. Marco Cavaleri, our Head of the Anti-infectives and Vaccines service, will represent EMA at #KickingoffECRAID. #KeepAntibioticsWorking https://t.co/vXTemENYez","id":"1063059712520962055","conversation_id":"1063059712520962055","entities":{"mentions":{},"hashtags":[{"start":80,"end":96,"tag":"ClinicalStudies"},{"start":105,"end":117,"tag":"antibiotics"},{"start":235,"end":252,"tag":"KickingoffECRAID"},{"start":254,"end":277,"tag":"KeepAntibioticsWorking"}],"urls":[{"start":278,"end":301,"url":"https://t.co/vXTemENYez","expanded_url":"https://twitter.com/PREPARE_EUROPE/status/1062993769522454528","display_url":"twitter.com/PREPARE_EUROPE‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.5907,"type":"Organization","normalized_text":"EMA"},{"start":64,"end":65,"probability":0.4924,"type":"Place","normalized_text":"EU"},{"start":143,"end":156,"probability":0.9407,"type":"Person","normalized_text":"Marco Cavaleri"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1063030198185144320"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-15T11:44:58.000Z","author_id":"116716199","text":"RT @V_Andriukaitis: Only 38% Europeans aware that no #antibiotics are allowed to be used for stimulating growth in animals. We need to shed‚Ä¶","id":"1063035123229167616","conversation_id":"1063035123229167616","entities":{"mentions":[{"start":3,"end":18,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":53,"end":65,"tag":"antibiotics"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1063034778562281473"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-15T11:44:11.000Z","author_id":"116716199","text":"RT @ECDC_EU: Tweet this to join our #TwitterStorm at 15:00 CET, 15 Nov: #Antibiotic resistance is one of the most urgent global health thre‚Ä¶","id":"1063034926960914432","conversation_id":"1063034926960914432","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":36,"end":49,"tag":"TwitterStorm"},{"start":72,"end":83,"tag":"Antibiotic"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":13,"quote_count":1},"created_at":"2018-11-15T10:46:10.000Z","author_id":"116716199","text":"EU guidance and national campaigns promoting prudent use of #antibiotics in animals to fight #AntimicrobialResistance are having a positive effect: https://t.co/0icVENarBo #KeepAntibioticsWorking #AMR #EAAD https://t.co/UAEWNiIcw8","id":"1063020324994891776","conversation_id":"1063020324994891776","entities":{"mentions":{},"hashtags":[{"start":60,"end":72,"tag":"antibiotics"},{"start":93,"end":117,"tag":"AntimicrobialResistance"},{"start":172,"end":195,"tag":"KeepAntibioticsWorking"},{"start":196,"end":200,"tag":"AMR"},{"start":201,"end":206,"tag":"EAAD"}],"urls":[{"start":148,"end":171,"url":"https://t.co/0icVENarBo","expanded_url":"https://www.ema.europa.eu/en/news/sales-antibiotics-use-food-producing-animals-drop-across-eu","display_url":"ema.europa.eu/en/news/sales-‚Ä¶"},{"start":207,"end":230,"url":"https://t.co/UAEWNiIcw8","expanded_url":"https://twitter.com/EMA_News/status/1063020324994891776/photo/1","display_url":"pic.twitter.com/UAEWNiIcw8"}],"annotations":[{"start":0,"end":1,"probability":0.6008,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":["3_1063020061584171008"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1063017516140847104"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":99,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-15T10:44:01.000Z","author_id":"116716199","text":"RT @EAAD_EU: #Antibiotics are commonly used in #hospitals and long-term care facilities for treatment or prevention of #infections. Some of‚Ä¶","id":"1063019786320236544","conversation_id":"1063019786320236544","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"}],"hashtags":[{"start":13,"end":25,"tag":"Antibiotics"},{"start":47,"end":57,"tag":"hospitals"},{"start":119,"end":130,"tag":"infections"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1063014207489138688"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-15T10:25:33.000Z","author_id":"116716199","text":"RT @EU_Health: #EAAD Andrea #Ammon @ECDC_EU: Unnecessary use of #antibiotics drives #antimicrobialresistance \n\nFollow the event live: https‚Ä¶","id":"1063015140164075520","conversation_id":"1063015140164075520","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":35,"end":43,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":15,"end":20,"tag":"EAAD"},{"start":28,"end":34,"tag":"Ammon"},{"start":64,"end":76,"tag":"antibiotics"},{"start":84,"end":108,"tag":"antimicrobialresistance"}],"urls":{},"annotations":[{"start":21,"end":26,"probability":0.9133,"type":"Person","normalized_text":"Andrea"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1063011224558821376"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":69,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-15T10:11:59.000Z","author_id":"116716199","text":"RT @ECDC_EU: For invasive bacteria, #antibiotic treatment is often the only option to prevent fatal outcome. In many countries resistance t‚Ä¶","id":"1063011723915997184","conversation_id":"1063011723915997184","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":36,"end":47,"tag":"antibiotic"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"quoted","id":"1062979767140581378"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":2,"quote_count":0},"created_at":"2018-11-15T09:31:43.000Z","author_id":"116716199","text":"Follow the live broadcast. https://t.co/JX4upmuEeH","id":"1063001590062350336","conversation_id":"1063001590062350336","entities":{"mentions":{},"hashtags":{},"urls":[{"start":27,"end":50,"url":"https://t.co/JX4upmuEeH","expanded_url":"https://twitter.com/EAAD_EU/status/1062979767140581378","display_url":"twitter.com/EAAD_EU/status‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1062990675820589056"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":78,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-15T09:26:39.000Z","author_id":"116716199","text":"RT @EU_Health: 20% of  those who used antibiotics took them for #flu or cold.\n\n7% took them without a medical prescription.\n\nNew #Eurobarom‚Ä¶","id":"1063000315769831424","conversation_id":"1063000315769831424","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":64,"end":68,"tag":"flu"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":11,"quote_count":3},"created_at":"2018-11-14T16:16:39.000Z","author_id":"116716199","text":"SMEs and academics, have your say! We published for #PublicConsultation a guideline on quality, non-clinical and clinical aspects of medicines containing genetically modified cells, including #CARTcell and stem cell products. #EMAPublicConsultation \nhttps://t.co/LQYmBItFyr https://t.co/2vuklesPAJ","id":"1062741107212197890","conversation_id":"1062741107212197890","entities":{"mentions":{},"hashtags":[{"start":52,"end":71,"tag":"PublicConsultation"},{"start":192,"end":201,"tag":"CARTcell"},{"start":226,"end":248,"tag":"EMAPublicConsultation"}],"urls":[{"start":250,"end":273,"url":"https://t.co/LQYmBItFyr","expanded_url":"https://www.ema.europa.eu/documents/scientific-guideline/draft-guideline-quality-non-clinical-clinical-aspects-medicinal-products-containing-genetically_en.pdf","display_url":"ema.europa.eu/documents/scie‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/2vuklesPAJ","expanded_url":"https://twitter.com/EMA_News/status/1062741107212197890/photo/1","display_url":"pic.twitter.com/2vuklesPAJ"}],"annotations":{}},"attachments":{"media_keys":["3_1062741038962540544"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":42,"reply_count":0,"like_count":30,"quote_count":3},"created_at":"2018-11-14T14:45:03.000Z","author_id":"116716199","text":"EMA gives guidance on safety monitoring of #medicines used in children: https://t.co/RyxRQatnhV #SideEffects #Pharmacovigilance https://t.co/9oKMcZjjpc","id":"1062718056370135040","conversation_id":"1062718056370135040","entities":{"mentions":{},"hashtags":[{"start":43,"end":53,"tag":"medicines"},{"start":96,"end":108,"tag":"SideEffects"},{"start":109,"end":127,"tag":"Pharmacovigilance"}],"urls":[{"start":72,"end":95,"url":"https://t.co/RyxRQatnhV","expanded_url":"https://www.ema.europa.eu/en/news/ema-gives-guidance-safety-monitoring-medicines-used-children","display_url":"ema.europa.eu/en/news/ema-gi‚Ä¶"},{"start":128,"end":151,"url":"https://t.co/9oKMcZjjpc","expanded_url":"https://twitter.com/EMA_News/status/1062718056370135040/photo/1","display_url":"pic.twitter.com/9oKMcZjjpc"}],"annotations":[{"start":0,"end":2,"probability":0.4141,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1062717925742673920"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1062644159268446208"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":126,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-14T09:56:34.000Z","author_id":"116716199","text":"RT @WHO: #AntimicrobialResistance is a threat we must all work to fight. \n\nPreventing the spread of infection can be simple:\nüîπPractice good‚Ä¶","id":"1062645455501312000","conversation_id":"1062645455501312000","entities":{"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":[{"start":9,"end":33,"tag":"AntimicrobialResistance"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1061925978807721985"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":270,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-13T18:15:40.000Z","author_id":"116716199","text":"RT @WHO: Overuse and misuse of antibiotics are the leading causes of antimicrobial resistance. Without effective #antibioticsüíä and other an‚Ä¶","id":"1062408670057844738","conversation_id":"1062408670057844738","entities":{"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":[{"start":113,"end":125,"tag":"antibiotics"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":0,"like_count":12,"quote_count":0},"created_at":"2018-11-13T16:33:53.000Z","author_id":"116716199","text":"What are EMA‚Äôs plans for #Brexit to ensure focus on #medicines evaluation and supervision? Read more in our latest report from industry stakeholder workshop: https://t.co/IGC1HtLDA1","id":"1062383055581655041","conversation_id":"1062383055581655041","entities":{"mentions":{},"hashtags":[{"start":25,"end":32,"tag":"Brexit"},{"start":52,"end":62,"tag":"medicines"}],"urls":[{"start":158,"end":181,"url":"https://t.co/IGC1HtLDA1","expanded_url":"https://www.ema.europa.eu/en/news/emas-brexit-plans-ensure-agencys-focus-medicines-evaluation-supervision","display_url":"ema.europa.eu/en/news/emas-b‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1062328394505953280"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":80,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-13T14:10:56.000Z","author_id":"116716199","text":"RT @WHO_Europe: Every infection prevented is an antibiotic treatment avoided. \n\nReducing the need for antibiotics helps reduce the spread o‚Ä¶","id":"1062347082776956929","conversation_id":"1062347082776956929","entities":{"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1061806584773439489"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3228,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-13T10:19:26.000Z","author_id":"116716199","text":"RT @WHO: This week is World Antibiotic Awareness Week!\n\nThe rise of #AntibioticResistance is a global threat. \nIt can affect anyone,\nof any‚Ä¶","id":"1062288821914689537","conversation_id":"1062288821914689537","entities":{"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":[{"start":68,"end":89,"tag":"AntibioticResistance"}],"urls":{},"annotations":[{"start":22,"end":52,"probability":0.6304,"type":"Other","normalized_text":"World Antibiotic Awareness Week"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1062020856703041536"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":51,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-12T16:52:43.000Z","author_id":"116716199","text":"RT @EU_Health: How can we stop the growing threat of #antimicrobialresistance to #KeepAntibioticsWorking? \n\nNew Eurobarometer data &amp; info o‚Ä¶","id":"1062025408202371073","conversation_id":"1062025408202371073","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":53,"end":77,"tag":"antimicrobialresistance"},{"start":81,"end":104,"tag":"KeepAntibioticsWorking"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1061982144854192129"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":125,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-12T14:03:23.000Z","author_id":"116716199","text":"RT @EAAD_EU: This week is #WAAW18, and the week of the 11th European Antibiotic Awareness Day (#EAAD)! \n\nMark the occasion by telling us wh‚Ä¶","id":"1061982794396655617","conversation_id":"1061982794396655617","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"}],"hashtags":[{"start":26,"end":33,"tag":"WAAW18"},{"start":95,"end":100,"tag":"EAAD"}],"urls":{},"annotations":[{"start":55,"end":92,"probability":0.8133,"type":"Other","normalized_text":"11th European Antibiotic Awareness Day"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":11,"quote_count":0},"created_at":"2018-11-12T13:27:00.000Z","author_id":"116716199","text":"See what's on the agenda of the November meeting of our human #medicines committee: https://t.co/tHcmKTlcuJ #CHMP","id":"1061973637421387782","conversation_id":"1061973637421387782","entities":{"mentions":{},"hashtags":[{"start":62,"end":72,"tag":"medicines"},{"start":108,"end":113,"tag":"CHMP"}],"urls":[{"start":84,"end":107,"url":"https://t.co/tHcmKTlcuJ","expanded_url":"https://www.ema.europa.eu/documents/agenda/agenda-chmp-agenda-12-15-november-2018-meeting_en.pdf","display_url":"ema.europa.eu/documents/agen‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1061321841086812166"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":1,"quote_count":0},"created_at":"2018-11-12T09:54:09.000Z","author_id":"116716199","text":"@BettinaRyll Thank you for getting in touch. The page is available here: https://t.co/tlAoklpuFB","id":"1061920070815899648","conversation_id":"1061321841086812166","entities":{"mentions":[{"start":0,"end":12,"username":"BettinaRyll","id":"810969654"}],"hashtags":{},"urls":[{"start":73,"end":96,"url":"https://t.co/tlAoklpuFB","expanded_url":"https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/medicines-under-additional-monitoring","display_url":"ema.europa.eu/en/human-regul‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"810969654"},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":7,"quote_count":3},"created_at":"2018-11-09T07:49:00.000Z","author_id":"116716199","text":"Follow the live broadcast of EMA's workshop on availability of medicines, today from 8:00 (UK time): https://t.co/vALUCJz7MZ https://t.co/Gq7ZHHPIkV","id":"1060801413218029569","conversation_id":"1060801413218029569","entities":{"mentions":{},"hashtags":{},"urls":[{"start":101,"end":124,"url":"https://t.co/vALUCJz7MZ","expanded_url":"https://www.ema.europa.eu/en/news/working-stakeholders-improve-availability-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":125,"end":148,"url":"https://t.co/Gq7ZHHPIkV","expanded_url":"https://twitter.com/EMA_News/status/1060801413218029569/photo/1","display_url":"pic.twitter.com/Gq7ZHHPIkV"}],"annotations":[{"start":91,"end":92,"probability":0.7879,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":["16_1060590338795061248"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1060177175729573888"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":144,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-07T15:19:08.000Z","author_id":"116716199","text":"RT @WHO: In 2017, over 116 million children received basic vaccines.\nBut, globally, 1 in 10 children still misses out. \nNew report ‚û° https:‚Ä¶","id":"1060189919342145537","conversation_id":"1060189919342145537","entities":{"mentions":[{"start":3,"end":7,"username":"WHO","id":"14499829"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1059745585622933504"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":173,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-06T14:10:54.000Z","author_id":"116716199","text":"RT @EAAD_EU: #AntibioticResistance is an increasing threat to human health. Everyone is responsible for addressing this issue: patients, he‚Ä¶","id":"1059810360520335360","conversation_id":"1059810360520335360","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"}],"hashtags":[{"start":13,"end":34,"tag":"AntibioticResistance"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1059721498510983169"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":123,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-11-06T09:47:15.000Z","author_id":"116716199","text":"RT @EAAD_EU: Each year, 33000 people die from an infection due to bacteria resistant to #antibiotics in the EU/EEA. See the latest @ECDC_EU‚Ä¶","id":"1059744008816209920","conversation_id":"1059744008816209920","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"},{"start":131,"end":139,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":88,"end":100,"tag":"antibiotics"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":30,"reply_count":0,"like_count":26,"quote_count":5},"created_at":"2018-10-31T15:45:00.000Z","author_id":"116716199","text":"Availability of medicines: A workshop on 8-9 November held at #EMA will gather stakeholders' perspectives on how to better address potential problems with the supply of #medicines and how to avoid shortages. You will be able to watch it live: https://t.co/vALUCJz7MZ https://t.co/bPaR978sI6","id":"1057659712991305730","conversation_id":"1057659712991305730","entities":{"mentions":{},"hashtags":[{"start":62,"end":66,"tag":"EMA"},{"start":169,"end":179,"tag":"medicines"}],"urls":[{"start":243,"end":266,"url":"https://t.co/vALUCJz7MZ","expanded_url":"https://www.ema.europa.eu/en/news/working-stakeholders-improve-availability-medicines-eu","display_url":"ema.europa.eu/en/news/workin‚Ä¶"},{"start":267,"end":290,"url":"https://t.co/bPaR978sI6","expanded_url":"https://twitter.com/EMA_News/status/1057659712991305730/photo/1","display_url":"pic.twitter.com/bPaR978sI6"}],"annotations":{}},"attachments":{"media_keys":["3_1057658062562082823"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1057597441011343360"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-31T12:22:53.000Z","author_id":"116716199","text":"RT @EFSA_EU: Let's reduce, replace &amp; re-think the use of antimicrobials in animals! Today at #ConfAMR2018 our experts Ernesto Liebana Criad‚Ä¶","id":"1057608847563649025","conversation_id":"1057608847563649025","entities":{"mentions":[{"start":3,"end":11,"username":"EFSA_EU","id":"84582815"}],"hashtags":[{"start":97,"end":109,"tag":"ConfAMR2018"}],"urls":{},"annotations":[{"start":118,"end":132,"probability":0.6118,"type":"Person","normalized_text":"Ernesto Liebana"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1057181870365073409"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-30T11:51:02.000Z","author_id":"116716199","text":"RT @OIEAnimalHealth: Listen to today‚Äôs speakers at the 2nd #OIE Global Conference on #AntiMicrobialResistance, #ConfAMR2018, using this liv‚Ä¶","id":"1057238445704273920","conversation_id":"1057238445704273920","entities":{"mentions":[{"start":3,"end":19,"username":"OIEAnimalHealth","id":"2826426188"}],"hashtags":[{"start":59,"end":63,"tag":"OIE"},{"start":85,"end":109,"tag":"AntiMicrobialResistance"},{"start":111,"end":123,"tag":"ConfAMR2018"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1055410902223253506"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-25T13:25:56.000Z","author_id":"116716199","text":"RT @relocatemaEN: Throwback Thursday: the core of the new EMA building picking up speed. @RijksvastgoedNL @EMA_News @AmsterdamNL @Iamsterda‚Ä¶","id":"1055450387447271426","conversation_id":"1055450387447271426","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"},{"start":89,"end":105,"username":"RijksvastgoedNL","id":"109229083"},{"start":106,"end":115,"username":"EMA_News","id":"116716199"},{"start":116,"end":128,"username":"AmsterdamNL","id":"31100650"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1055412928097239041"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-25T10:57:59.000Z","author_id":"116716199","text":"RT @EP_Environment: #AntimicrobialResistance - legislation to curb the use of veterinary antimicrobials adopted, reports by @GrosseteteF an‚Ä¶","id":"1055413153440456706","conversation_id":"1055413153440456706","entities":{"mentions":[{"start":3,"end":18,"username":"EP_Environment","id":"951333319"},{"start":124,"end":136,"username":"GrosseteteF","id":"472043689"}],"hashtags":[{"start":20,"end":44,"tag":"AntimicrobialResistance"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1055407344639754240"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-25T10:42:15.000Z","author_id":"116716199","text":"RT @Food_EU: A victory for public #health &amp; #foodsafety - #EPlenary adopts @GrosseteteF report on our #veterinary #medicines proposal aimed‚Ä¶","id":"1055409197762953217","conversation_id":"1055409197762953217","entities":{"mentions":[{"start":3,"end":11,"username":"Food_EU","id":"2874880006"},{"start":79,"end":91,"username":"GrosseteteF","id":"472043689"}],"hashtags":[{"start":34,"end":41,"tag":"health"},{"start":48,"end":59,"tag":"foodsafety"},{"start":62,"end":71,"tag":"EPlenary"},{"start":106,"end":117,"tag":"veterinary"},{"start":118,"end":128,"tag":"medicines"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":2,"quote_count":0},"created_at":"2018-10-25T08:34:00.000Z","author_id":"116716199","text":"During its October 2018 meeting, EMA's Committee for Human #Medicines (#CHMP) reviewed 6 recommendations for eligibility to #PRIME. See how many were granted: https://t.co/Imd8r89zEj https://t.co/bK925NUS6D","id":"1055376920072863744","conversation_id":"1055376920072863744","entities":{"mentions":{},"hashtags":[{"start":59,"end":69,"tag":"Medicines"},{"start":71,"end":76,"tag":"CHMP"},{"start":124,"end":130,"tag":"PRIME"}],"urls":[{"start":159,"end":182,"url":"https://t.co/Imd8r89zEj","expanded_url":"https://www.ema.europa.eu/documents/report/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-15-18-october-2018_en.pdf","display_url":"ema.europa.eu/documents/repo‚Ä¶"},{"start":183,"end":206,"url":"https://t.co/bK925NUS6D","expanded_url":"https://twitter.com/EMA_News/status/1055376920072863744/photo/1","display_url":"pic.twitter.com/bK925NUS6D"}],"annotations":{}},"attachments":{"media_keys":["3_1055115344858308613"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":6,"quote_count":0},"created_at":"2018-10-24T14:05:15.000Z","author_id":"116716199","text":"Follow the afternoon session of our workshop on regulatory science. #RegScience2025 \nhttps://t.co/GEBw3vjHtr https://t.co/Ld8Pmk7GSu","id":"1055097894280351746","conversation_id":"1055097894280351746","entities":{"mentions":{},"hashtags":[{"start":68,"end":83,"tag":"RegScience2025"}],"urls":[{"start":85,"end":108,"url":"https://t.co/GEBw3vjHtr","expanded_url":"https://www.ema.europa.eu/en/events/multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science","display_url":"ema.europa.eu/en/events/mult‚Ä¶"},{"start":109,"end":132,"url":"https://t.co/Ld8Pmk7GSu","expanded_url":"https://twitter.com/EMA_News/status/1055097894280351746/video/1","display_url":"pic.twitter.com/Ld8Pmk7GSu"}],"annotations":{}},"attachments":{"media_keys":["7_1055097685911498752"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":23,"quote_count":3},"created_at":"2018-10-24T12:35:52.000Z","author_id":"116716199","text":"See a statement of Guido Rasi, our Executive Director, from today‚Äôs workshop on regulatory science. #RegScience2025 https://t.co/GEBw3vjHtr https://t.co/31ZEqG0ZKb","id":"1055075402065031174","conversation_id":"1055075402065031174","entities":{"mentions":{},"hashtags":[{"start":100,"end":115,"tag":"RegScience2025"}],"urls":[{"start":116,"end":139,"url":"https://t.co/GEBw3vjHtr","expanded_url":"https://www.ema.europa.eu/en/events/multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science","display_url":"ema.europa.eu/en/events/mult‚Ä¶"},{"start":140,"end":163,"url":"https://t.co/31ZEqG0ZKb","expanded_url":"https://twitter.com/EMA_News/status/1055075402065031174/photo/1","display_url":"pic.twitter.com/31ZEqG0ZKb"}],"annotations":[{"start":19,"end":28,"probability":0.9602,"type":"Person","normalized_text":"Guido Rasi"}]},"attachments":{"media_keys":["3_1055074795103158273"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":17,"quote_count":4},"created_at":"2018-10-24T09:38:16.000Z","author_id":"116716199","text":"What are the challenges that #EMA and EU Medicines Network will face in the future given the fast pace of innovation in the #pharmaceutical arena? Follow the live broadcast of our regulatory science workshop today. #RegScience2025 \nhttps://t.co/GEBw3vjHtr","id":"1055030705946877952","conversation_id":"1055030705946877952","entities":{"mentions":{},"hashtags":[{"start":29,"end":33,"tag":"EMA"},{"start":124,"end":139,"tag":"pharmaceutical"},{"start":215,"end":230,"tag":"RegScience2025"}],"urls":[{"start":232,"end":255,"url":"https://t.co/GEBw3vjHtr","expanded_url":"https://www.ema.europa.eu/en/events/multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science","display_url":"ema.europa.eu/en/events/mult‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/events/multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science"}],"annotations":[{"start":38,"end":57,"probability":0.9375,"type":"Organization","normalized_text":"EU Medicines Network"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":4,"quote_count":0},"created_at":"2018-10-24T08:48:24.000Z","author_id":"116716199","text":"Follow the live broadcast of our regulatory science workshop today. Those interested in commenting on Twitter, please use the #RegScience2025 hashtag. https://t.co/GEBw3vjHtr","id":"1055018156325068801","conversation_id":"1055018156325068801","entities":{"mentions":{},"hashtags":[{"start":126,"end":141,"tag":"RegScience2025"}],"urls":[{"start":151,"end":174,"url":"https://t.co/GEBw3vjHtr","expanded_url":"https://www.ema.europa.eu/en/events/multistakeholder-workshop-launch-consultation-european-medicines-agency-ema-human-regulatory-science","display_url":"ema.europa.eu/en/events/mult‚Ä¶"}],"annotations":[{"start":102,"end":108,"probability":0.6279,"type":"Product","normalized_text":"Twitter"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1054729633948753922"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":61,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-23T14:18:07.000Z","author_id":"116716199","text":"RT @V_Andriukaitis: Tomorrow is #WorldPolioDay üíß\nThanks to #vaccines we often forget the awful consequences of #polio &amp; #vaccine confidence‚Ä¶","id":"1054738743230431232","conversation_id":"1054738743230431232","entities":{"mentions":[{"start":3,"end":18,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":32,"end":46,"tag":"WorldPolioDay"},{"start":59,"end":68,"tag":"vaccines"},{"start":111,"end":117,"tag":"polio"},{"start":124,"end":132,"tag":"vaccine"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":30,"quote_count":3},"created_at":"2018-10-23T12:59:06.000Z","author_id":"116716199","text":"Tomorrow, EMA will host a workshop on shaping regulatory science to 2025 to ensure that innovation delivers great solutions for #PublicHealth. Watch the live broadcast here from 08h30: https://t.co/o6C8Z0JBdG. Engage in conversation by using #RegScience2025. https://t.co/RdwXwl7Ymp","id":"1054718860241330178","conversation_id":"1054718860241330178","entities":{"mentions":{},"hashtags":[{"start":128,"end":141,"tag":"PublicHealth"},{"start":242,"end":257,"tag":"RegScience2025"}],"urls":[{"start":185,"end":208,"url":"https://t.co/o6C8Z0JBdG","expanded_url":"https://bit.ly/2yUsYbZ","display_url":"bit.ly/2yUsYbZ"},{"start":259,"end":282,"url":"https://t.co/RdwXwl7Ymp","expanded_url":"https://twitter.com/EMA_News/status/1054718860241330178/photo/1","display_url":"pic.twitter.com/RdwXwl7Ymp"}],"annotations":[{"start":10,"end":12,"probability":0.5647,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1054718713499402240"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1040201052576993281"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":53,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-23T10:39:54.000Z","author_id":"116716199","text":"RT @EAAD_EU: 18 November is European Antibiotic Awareness Day (#EAAD)! Check out our multilingual website for the latest news, updates, res‚Ä¶","id":"1054683827585642496","conversation_id":"1054683827585642496","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"}],"hashtags":[{"start":63,"end":68,"tag":"EAAD"}],"urls":{},"annotations":[{"start":28,"end":60,"probability":0.603,"type":"Other","normalized_text":"European Antibiotic Awareness Day"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":12,"quote_count":1},"created_at":"2018-10-19T12:47:11.000Z","author_id":"116716199","text":"First treatment for rare inherited muscle disorders was recommended for approval: https://t.co/Lf3Z6WW6Vj #CHMP","id":"1053266310157791232","conversation_id":"1053266310157791232","entities":{"mentions":{},"hashtags":[{"start":106,"end":111,"tag":"CHMP"}],"urls":[{"start":82,"end":105,"url":"https://t.co/Lf3Z6WW6Vj","expanded_url":"https://www.ema.europa.eu/en/news/first-treatment-rare-inherited-muscle-contraction-disorders","display_url":"ema.europa.eu/en/news/first-‚Ä¶","status":200,"unwound_url":"https://www.ema.europa.eu/en/news/first-treatment-rare-inherited-muscle-contraction-disorders"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":17,"quote_count":0},"created_at":"2018-10-19T12:22:21.000Z","author_id":"116716199","text":"EMA recommends for approval the first monoclonal antibody for #HereditaryAngioedema: https://t.co/GOQv8jfVq9 #CHMP","id":"1053260060745519104","conversation_id":"1053260060745519104","entities":{"mentions":{},"hashtags":[{"start":62,"end":83,"tag":"HereditaryAngioedema"},{"start":109,"end":114,"tag":"CHMP"}],"urls":[{"start":85,"end":108,"url":"https://t.co/GOQv8jfVq9","expanded_url":"https://www.ema.europa.eu/en/news/new-medicine-hereditary-angioedema-rare-disease-causing-swelling-beneath-skin","display_url":"ema.europa.eu/en/news/new-me‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.3814,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":23,"reply_count":0,"like_count":36,"quote_count":3},"created_at":"2018-10-19T11:59:00.000Z","author_id":"116716199","text":"EMA recommends for approval the first #vaccine in the EU for the prevention of #dengue: https://t.co/Zg04twI8Mk #CHMP","id":"1053254183506399232","conversation_id":"1053254183506399232","entities":{"mentions":{},"hashtags":[{"start":38,"end":46,"tag":"vaccine"},{"start":79,"end":86,"tag":"dengue"},{"start":112,"end":117,"tag":"CHMP"}],"urls":[{"start":88,"end":111,"url":"https://t.co/Zg04twI8Mk","expanded_url":"https://www.ema.europa.eu/en/news/first-vaccine-prevention-dengue","display_url":"ema.europa.eu/en/news/first-‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.5448,"type":"Organization","normalized_text":"EMA"},{"start":54,"end":55,"probability":0.3809,"type":"Place","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":4,"quote_count":1},"created_at":"2018-10-19T11:37:29.000Z","author_id":"116716199","text":"Our Committee for Human Medicines recommends 6 #medicines for approval at its October 2018 meeting: https://t.co/deAeUGV8LO #CHMP https://t.co/rLsBM98dbj","id":"1053248766935998465","conversation_id":"1053248766935998465","entities":{"mentions":{},"hashtags":[{"start":47,"end":57,"tag":"medicines"},{"start":124,"end":129,"tag":"CHMP"}],"urls":[{"start":100,"end":123,"url":"https://t.co/deAeUGV8LO","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"},{"start":130,"end":153,"url":"https://t.co/rLsBM98dbj","expanded_url":"https://twitter.com/EMA_News/status/1053248766935998465/photo/1","display_url":"pic.twitter.com/rLsBM98dbj"}],"annotations":{}},"attachments":{"media_keys":["3_1053248555908038656"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1052939711587786757"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-19T08:43:14.000Z","author_id":"116716199","text":"RT @relocatemaEN: In Brussels the European Union has reached an agreement to legislate on  the relocation of the European Medicines Agency‚Ä¶","id":"1053204915538067458","conversation_id":"1053204915538067458","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"}],"hashtags":{},"urls":{},"annotations":[{"start":21,"end":28,"probability":0.8959,"type":"Place","normalized_text":"Brussels"},{"start":34,"end":47,"probability":0.5944,"type":"Organization","normalized_text":"European Union"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1052956700133744640"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-18T17:01:56.000Z","author_id":"116716199","text":"RT @EU_Health: What is the impact of EU rules on #medicines for #children &amp; #raredisease? \n\nReply to our #publicconsultation by 4 January 2‚Ä¶","id":"1052968032950243328","conversation_id":"1052968032950243328","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":49,"end":59,"tag":"medicines"},{"start":64,"end":73,"tag":"children"},{"start":80,"end":92,"tag":"raredisease"},{"start":109,"end":128,"tag":"publicconsultation"}],"urls":{},"annotations":[{"start":37,"end":38,"probability":0.4503,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":0,"like_count":30,"quote_count":1},"created_at":"2018-10-17T14:14:22.000Z","author_id":"116716199","text":"What do regulators need to do to ensure that innovation delivers great solutions for #PublicHealth? #EMA and the EU medicines network are working on a new plan to keep on top of developments: https://t.co/LrzG570j1S #RegScience2025 https://t.co/59POkLzUDu","id":"1052563475199873024","conversation_id":"1052563475199873024","entities":{"mentions":{},"hashtags":[{"start":85,"end":98,"tag":"PublicHealth"},{"start":100,"end":104,"tag":"EMA"},{"start":216,"end":231,"tag":"RegScience2025"}],"urls":[{"start":192,"end":215,"url":"https://t.co/LrzG570j1S","expanded_url":"https://www.ema.europa.eu/en/news/shaping-regulatory-science-2025","display_url":"ema.europa.eu/en/news/shapin‚Ä¶"},{"start":232,"end":255,"url":"https://t.co/59POkLzUDu","expanded_url":"https://twitter.com/EMA_News/status/1052563475199873024/photo/1","display_url":"pic.twitter.com/59POkLzUDu"}],"annotations":[{"start":113,"end":132,"probability":0.359,"type":"Organization","normalized_text":"EU medicines network"}]},"attachments":{"media_keys":["3_1052563080905990144"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1052484748420018177"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-17T09:20:11.000Z","author_id":"116716199","text":"RT @V_Andriukaitis: I practice what I preach: #flu #vaccination done ‚úÖ with participation of some colleagues this year üíâ \nüë©üèª‚Äç‚öïÔ∏èüë®üèæ‚Äç‚öïÔ∏èI encou‚Ä¶","id":"1052489442160795649","conversation_id":"1052489442160795649","entities":{"mentions":[{"start":3,"end":18,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":46,"end":50,"tag":"flu"},{"start":51,"end":63,"tag":"vaccination"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":22,"quote_count":3},"created_at":"2018-10-15T13:52:08.000Z","author_id":"116716199","text":"Do you know that the overall sales of #veterinary #antibiotics across Europe have decreased by more than 20% between 2011 and 2016? Read more in the latest EMA report: https://t.co/0icVENarBo #AMR #AntimicrobialResistance https://t.co/M5zZt6tmco","id":"1051833104166469632","conversation_id":"1051833104166469632","entities":{"mentions":{},"hashtags":[{"start":38,"end":49,"tag":"veterinary"},{"start":50,"end":62,"tag":"antibiotics"},{"start":192,"end":196,"tag":"AMR"},{"start":197,"end":221,"tag":"AntimicrobialResistance"}],"urls":[{"start":168,"end":191,"url":"https://t.co/0icVENarBo","expanded_url":"https://www.ema.europa.eu/en/news/sales-antibiotics-use-food-producing-animals-drop-across-eu","display_url":"ema.europa.eu/en/news/sales-‚Ä¶"},{"start":222,"end":245,"url":"https://t.co/M5zZt6tmco","expanded_url":"https://twitter.com/EMA_News/status/1051833104166469632/photo/1","display_url":"pic.twitter.com/M5zZt6tmco"}],"annotations":[{"start":70,"end":75,"probability":0.9711,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["3_1051833044980719616"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2018-10-15T11:22:40.000Z","author_id":"116716199","text":"EU authorities take further action in the ongoing review of sartan medicines: https://t.co/1BPliQ9TJr #Valsartan","id":"1051795490013138944","conversation_id":"1051795490013138944","entities":{"mentions":{},"hashtags":[{"start":102,"end":112,"tag":"Valsartan"}],"urls":[{"start":78,"end":101,"url":"https://t.co/1BPliQ9TJr","expanded_url":"https://www.ema.europa.eu/en/news/eu-authorities-take-further-action-ongoing-review-sartans-zheijiang-huahai-placed-under-increased","display_url":"ema.europa.eu/en/news/eu-aut‚Ä¶"}],"annotations":[{"start":0,"end":1,"probability":0.7618,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1049986623952293888"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-10T11:49:48.000Z","author_id":"116716199","text":"RT @ECDC_EU: Today, the Heads of #EUagencies met under ECDC chairmanship for the first time. ECDC took over the chairmanship from @Frontex‚Ä¶","id":"1049990378412228608","conversation_id":"1049990378412228608","entities":{"mentions":[{"start":3,"end":11,"username":"ECDC_EU","id":"204752573"},{"start":130,"end":138,"username":"Frontex","id":"3305994758"}],"hashtags":[{"start":33,"end":44,"tag":"EUagencies"}],"urls":{},"annotations":[{"start":55,"end":71,"probability":0.5102,"type":"Person","normalized_text":"ECDC chairmanship"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":31,"reply_count":0,"like_count":23,"quote_count":6},"created_at":"2018-10-09T16:03:33.000Z","author_id":"116716199","text":"EMA‚Äôs #Brexit preparedness business continuity plan entered into its third phase on 1 October 2018. See our implementation plan: https://t.co/309m6bYgB3 https://t.co/gYTXSRy8rQ","id":"1049691848820891651","conversation_id":"1049691848820891651","entities":{"mentions":{},"hashtags":[{"start":6,"end":13,"tag":"Brexit"}],"urls":[{"start":129,"end":152,"url":"https://t.co/309m6bYgB3","expanded_url":"https://www.ema.europa.eu/en/news/update-emas-brexit-preparedness","display_url":"ema.europa.eu/en/news/update‚Ä¶"},{"start":153,"end":176,"url":"https://t.co/gYTXSRy8rQ","expanded_url":"https://twitter.com/EMA_News/status/1049691848820891651/photo/1","display_url":"pic.twitter.com/gYTXSRy8rQ"}],"annotations":[{"start":0,"end":2,"probability":0.4425,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1049691734899417089"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1049301453406457863"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":0,"quote_count":0},"created_at":"2018-10-08T15:54:51.000Z","author_id":"116716199","text":"@kirstinemoll The 'Medicines' search on the top menu is replacing ‚ÄòFind medicine‚Äô from the old website, as shown in the attached image. You can also find useful information on what we publish on medicines and when: https://t.co/QJbuWGeG7a https://t.co/VXLpvX3yGf","id":"1049327269192380418","conversation_id":"1049301453406457863","entities":{"mentions":[{"start":0,"end":13,"username":"kirstinemoll","id":"852754297"}],"hashtags":{},"urls":[{"start":215,"end":238,"url":"https://t.co/QJbuWGeG7a","expanded_url":"https://www.ema.europa.eu/en/about-us/how-we-work/what-we-publish-medicines-when","display_url":"ema.europa.eu/en/about-us/ho‚Ä¶"},{"start":239,"end":262,"url":"https://t.co/VXLpvX3yGf","expanded_url":"https://twitter.com/EMA_News/status/1049327269192380418/photo/1","display_url":"pic.twitter.com/VXLpvX3yGf"}],"annotations":{}},"attachments":{"media_keys":["3_1049327190440075264"]},"in_reply_to_user_id":"852754297"},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1049188061152731136"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"created_at":"2018-10-08T12:20:01.000Z","author_id":"116716199","text":"@Alea_Sara @NoInvisibles @redaccionmedica Thanks for getting in touch. Please ask us your questions via this form (https://t.co/oYxXr8dsVh) and we will get back to you as soon as possible.","id":"1049273205565919232","conversation_id":"1049185933512327173","entities":{"mentions":[{"start":0,"end":10,"username":"Alea_Sara","id":"986764440"},{"start":11,"end":24,"username":"NoInvisibles","id":"1389099654"},{"start":25,"end":41,"username":"redaccionmedica","id":"229001251"}],"hashtags":{},"urls":[{"start":115,"end":138,"url":"https://t.co/oYxXr8dsVh","expanded_url":"https://www.ema.europa.eu/en/about-us/contact/send-question-european-medicines-agency","display_url":"ema.europa.eu/en/about-us/co‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"986764440"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":51,"reply_count":1,"like_count":35,"quote_count":5},"created_at":"2018-10-05T14:07:12.000Z","author_id":"116716199","text":"EMA's #Pharmacovigilance Committee recommends restrictions on use of #fluoroquinolone and #quinolone antibiotics and confirms precautionary advice on #HIV medicine: https://t.co/2k0NmzzYNv","id":"1048213016586702848","conversation_id":"1048213016586702848","entities":{"mentions":{},"hashtags":[{"start":6,"end":24,"tag":"Pharmacovigilance"},{"start":69,"end":85,"tag":"fluoroquinolone"},{"start":90,"end":100,"tag":"quinolone"},{"start":150,"end":154,"tag":"HIV"}],"urls":[{"start":165,"end":188,"url":"https://t.co/2k0NmzzYNv","expanded_url":"https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-1-4-october-2018","display_url":"ema.europa.eu/en/news/meetin‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":6,"quote_count":3},"created_at":"2018-10-05T10:40:19.000Z","author_id":"116716199","text":"See the highlights of our 4 October Management Board meeting: https://t.co/XBzKltwU7g","id":"1048160950635913219","conversation_id":"1048160950635913219","entities":{"mentions":{},"hashtags":{},"urls":[{"start":62,"end":85,"url":"https://t.co/XBzKltwU7g","expanded_url":"https://www.ema.europa.eu/en/news/ema-management-board-highlights-october-2018-meeting","display_url":"ema.europa.eu/en/news/ema-ma‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":7,"quote_count":1},"created_at":"2018-10-04T09:44:12.000Z","author_id":"116716199","text":"What's on the agenda of #EMA's Management Board meeting today? https://t.co/4UQ3uN1ar6 https://t.co/yno8gzkabZ","id":"1047784443149279233","conversation_id":"1047784443149279233","entities":{"mentions":{},"hashtags":[{"start":24,"end":28,"tag":"EMA"}],"urls":[{"start":63,"end":86,"url":"https://t.co/4UQ3uN1ar6","expanded_url":"https://www.ema.europa.eu/events/management-board-meeting-4-october-2018","display_url":"ema.europa.eu/events/managem‚Ä¶"},{"start":87,"end":110,"url":"https://t.co/yno8gzkabZ","expanded_url":"https://twitter.com/EMA_News/status/1047784443149279233/photo/1","display_url":"pic.twitter.com/yno8gzkabZ"}],"annotations":{}},"attachments":{"media_keys":["3_1047784327231287296"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":74,"reply_count":1,"like_count":66,"quote_count":8},"created_at":"2018-10-02T11:19:14.000Z","author_id":"116716199","text":"#EMA and @EU_Health have published today a joint action plan to support the development of #medicines for children in Europe: https://t.co/2YyfLoOgSn https://t.co/NNkfMve3fK","id":"1047083581686853634","conversation_id":"1047083581686853634","entities":{"mentions":[{"start":9,"end":19,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":91,"end":101,"tag":"medicines"}],"urls":[{"start":126,"end":149,"url":"https://t.co/2YyfLoOgSn","expanded_url":"https://www.ema.europa.eu/en/news/boosting-development-medicines-children","display_url":"ema.europa.eu/en/news/boosti‚Ä¶"},{"start":150,"end":173,"url":"https://t.co/NNkfMve3fK","expanded_url":"https://twitter.com/EMA_News/status/1047083581686853634/photo/1","display_url":"pic.twitter.com/NNkfMve3fK"}],"annotations":[{"start":118,"end":123,"probability":0.9942,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["3_1047083130803380225"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":13,"quote_count":0},"created_at":"2018-10-02T09:42:27.000Z","author_id":"116716199","text":"During its September 2018 meeting, EMA's Committee for Medicinal Products for Human Use reviewed 4 recommendations for eligibility to #PRIME. See how many were granted: https://t.co/gHlgNYIbzO #CHMP https://t.co/W3EbmXX22A","id":"1047059225552281602","conversation_id":"1047059225552281602","entities":{"mentions":{},"hashtags":[{"start":134,"end":140,"tag":"PRIME"},{"start":193,"end":198,"tag":"CHMP"}],"urls":[{"start":169,"end":192,"url":"https://t.co/gHlgNYIbzO","expanded_url":"https://www.ema.europa.eu/documents/chmp-annex/recommendations-eligibility-prime-scheme-adopted-chmp-meeting-17-20-september-2018_en.pdf","display_url":"ema.europa.eu/documents/chmp‚Ä¶"},{"start":199,"end":222,"url":"https://t.co/W3EbmXX22A","expanded_url":"https://twitter.com/EMA_News/status/1047059225552281602/photo/1","display_url":"pic.twitter.com/W3EbmXX22A"}],"annotations":{}},"attachments":{"media_keys":["3_1047059133860597760"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1047018895142457346"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":39,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-02T08:22:03.000Z","author_id":"116716199","text":"RT @EU_opendata: Tune in at 9:30 CET by #livestream for the speeches, presentations and all the action of #EUdatathon2018 final event! http‚Ä¶","id":"1047038990489178112","conversation_id":"1047038990489178112","entities":{"mentions":[{"start":3,"end":15,"username":"EU_opendata","id":"115660120"}],"hashtags":[{"start":40,"end":51,"tag":"livestream"},{"start":106,"end":121,"tag":"EUdatathon2018"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1046468924546711552"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-10-01T10:54:11.000Z","author_id":"116716199","text":"@HedleyHarrison Thank you for getting in touch. Could you please send your questions via our AskEMA form? We will get back to you as soon as possible. https://t.co/oYxXr8dsVh","id":"1046714889434214400","conversation_id":"1044221969678430208","entities":{"mentions":[{"start":0,"end":15,"username":"HedleyHarrison","id":"549504886"}],"hashtags":{},"urls":[{"start":151,"end":174,"url":"https://t.co/oYxXr8dsVh","expanded_url":"https://www.ema.europa.eu/en/about-us/contact/send-question-european-medicines-agency","display_url":"ema.europa.eu/en/about-us/co‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"549504886"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2018-09-28T16:50:21.000Z","author_id":"116716199","text":"EU inspection finds Zhejiang Huahai site non-compliant for the manufacture of #valsartan: https://t.co/8shHm0DAzo","id":"1045717356771766272","conversation_id":"1045717356771766272","entities":{"mentions":{},"hashtags":[{"start":78,"end":88,"tag":"valsartan"}],"urls":[{"start":90,"end":113,"url":"https://t.co/8shHm0DAzo","expanded_url":"https://www.ema.europa.eu/en/news/eu-inspection-finds-zhejiang-huahai-site-non-compliant-manufacture-valsartan","display_url":"ema.europa.eu/en/news/eu-ins‚Ä¶"}],"annotations":[{"start":20,"end":34,"probability":0.4617,"type":"Place","normalized_text":"Zhejiang Huahai"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":41,"reply_count":0,"like_count":50,"quote_count":5},"created_at":"2018-09-28T09:57:01.000Z","author_id":"116716199","text":"What does it take to use #RealWorldData at its full potential in the development and utilisation of #medicines? Our Executive Director and Senior Medical Officer call for action in a new paper: https://t.co/v8shAVELkQ","id":"1045613340314210304","conversation_id":"1045613340314210304","entities":{"mentions":{},"hashtags":[{"start":25,"end":39,"tag":"RealWorldData"},{"start":100,"end":110,"tag":"medicines"}],"urls":[{"start":194,"end":217,"url":"https://t.co/v8shAVELkQ","expanded_url":"https://www.ema.europa.eu/en/news/harnessing-potential-real-world-data-through-learning-healthcare-system","display_url":"ema.europa.eu/en/news/harnes‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1045354403098759174"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":2,"quote_count":0},"created_at":"2018-09-27T17:05:58.000Z","author_id":"116716199","text":"@NarcolepsyUK @bmj_latest We have re-launched our website today and it seems we have some issues with broken links. We apologize for that. The response is available here: https://t.co/WAL7e0nuxd","id":"1045358902148255745","conversation_id":"1044963840000225280","entities":{"mentions":[{"start":0,"end":13,"username":"NarcolepsyUK","id":"189931440"},{"start":14,"end":25,"username":"bmj_latest","id":"16949344"}],"hashtags":{},"urls":[{"start":171,"end":194,"url":"https://t.co/WAL7e0nuxd","expanded_url":"https://www.ema.europa.eu/en/news-events/publications/open-letters","display_url":"ema.europa.eu/en/news-events‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"189931440"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":2,"like_count":44,"quote_count":5},"created_at":"2018-09-27T08:54:51.000Z","author_id":"116716199","text":"The new version of our corporate website is now available: https://t.co/UyGIp25bt7 https://t.co/dQHibw0Tqx","id":"1045235306214162433","conversation_id":"1045235306214162433","entities":{"mentions":{},"hashtags":{},"urls":[{"start":59,"end":82,"url":"https://t.co/UyGIp25bt7","expanded_url":"https://www.ema.europa.eu/en","display_url":"ema.europa.eu/en"},{"start":83,"end":106,"url":"https://t.co/dQHibw0Tqx","expanded_url":"https://twitter.com/EMA_News/status/1045235306214162433/photo/1","display_url":"pic.twitter.com/dQHibw0Tqx"}],"annotations":{}},"attachments":{"media_keys":["3_1045235211326361600"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1044999656638492672"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1,"reply_count":1,"like_count":2,"quote_count":0},"created_at":"2018-09-26T17:48:43.000Z","author_id":"116716199","text":"@RxRegA Thank you for your message. We are switching over to a new version of our corporate website. It will be available again shortly.","id":"1045007272110428161","conversation_id":"1044999656638492672","entities":{"mentions":[{"start":0,"end":7,"username":"RxRegA","id":"2426498719"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"2426498719"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":2,"like_count":5,"quote_count":2},"created_at":"2018-09-26T14:56:08.000Z","author_id":"116716199","text":"See our response to the recent BMJ article on the #Pandemrix vaccine: https://t.co/x9BUPw13RP @bmj_latest","id":"1044963840000225280","conversation_id":"1044963840000225280","entities":{"mentions":[{"start":94,"end":105,"username":"bmj_latest","id":"16949344"}],"hashtags":[{"start":50,"end":60,"tag":"Pandemrix"}],"urls":[{"start":70,"end":93,"url":"https://t.co/x9BUPw13RP","expanded_url":"http://www.ema.europa.eu/docs/en_GB/document_library/Other/2018/09/WC500255857.pdf","display_url":"ema.europa.eu/docs/en_GB/doc‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1044498733398978560"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":93,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-25T14:42:13.000Z","author_id":"116716199","text":"RT @EU_opendata: Less than ONE week to go for #EUdatathon2018! If you can make it to Brussels, come and join us! Meet the movers and shaker‚Ä¶","id":"1044597951354548225","conversation_id":"1044597951354548225","entities":{"mentions":[{"start":3,"end":15,"username":"EU_opendata","id":"115660120"}],"hashtags":[{"start":46,"end":61,"tag":"EUdatathon2018"}],"urls":{},"annotations":[{"start":85,"end":92,"probability":0.9662,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":17,"reply_count":0,"like_count":45,"quote_count":10},"created_at":"2018-09-25T13:38:55.000Z","author_id":"116716199","text":"See the agenda of the #patients', consumers' and #HealthcareProfessionals' working parties meeting taking place today and tomorrow at EMA. Updates on Good #Pharmacovigilance Practices and digital media in the healthcare context are among the topics: https://t.co/SgBt6auuhM https://t.co/U4TU3owH41","id":"1044582019492065280","conversation_id":"1044582019492065280","entities":{"mentions":{},"hashtags":[{"start":22,"end":31,"tag":"patients"},{"start":49,"end":73,"tag":"HealthcareProfessionals"},{"start":155,"end":173,"tag":"Pharmacovigilance"}],"urls":[{"start":250,"end":273,"url":"https://t.co/SgBt6auuhM","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2018/09/event_detail_001734.jsp&mid=WC0b01ac058004d5c3","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":274,"end":297,"url":"https://t.co/U4TU3owH41","expanded_url":"https://twitter.com/EMA_News/status/1044582019492065280/photo/1","display_url":"pic.twitter.com/U4TU3owH41"}],"annotations":{}},"attachments":{"media_keys":["3_1044581972134178828"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":55,"reply_count":6,"like_count":38,"quote_count":9},"created_at":"2018-09-24T13:48:12.000Z","author_id":"116716199","text":"EMA has revised the number of centrally authorised #medicines at risk of #Brexit-related supply shortages. The focus is now on 39 centrally authorised medicines, down from 108: https://t.co/ZAEliiJnZ7","id":"1044221969678430208","conversation_id":"1044221969678430208","entities":{"mentions":{},"hashtags":[{"start":51,"end":61,"tag":"medicines"},{"start":73,"end":80,"tag":"Brexit"}],"urls":[{"start":177,"end":200,"url":"https://t.co/ZAEliiJnZ7","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003030.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":[{"start":0,"end":2,"probability":0.6216,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":1,"like_count":39,"quote_count":2},"created_at":"2018-09-24T08:57:59.000Z","author_id":"116716199","text":"We will launch a new version of our corporate website (https://t.co/h6nXXGjvkL) on 27 September 2018: https://t.co/GBAiSUU7v9 https://t.co/9jxioid9NQ","id":"1044148931628859393","conversation_id":"1044148931628859393","entities":{"mentions":{},"hashtags":{},"urls":[{"start":55,"end":78,"url":"https://t.co/h6nXXGjvkL","expanded_url":"http://www.ema.europa.eu","display_url":"ema.europa.eu"},{"start":102,"end":125,"url":"https://t.co/GBAiSUU7v9","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003028.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":126,"end":149,"url":"https://t.co/9jxioid9NQ","expanded_url":"https://twitter.com/EMA_News/status/1044148931628859393/photo/1","display_url":"pic.twitter.com/9jxioid9NQ"}],"annotations":{}},"attachments":{"media_keys":["3_1044148762946490368"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":17,"quote_count":1},"created_at":"2018-09-21T15:39:27.000Z","author_id":"116716199","text":"EMA's  Committee for Medicinal Products for Human Use (#CHMP) recommends 13 #medicines for approval at its September 2018 meeting: https://t.co/yeI7JtO9W1 https://t.co/hnpnSktN0Q","id":"1043162800439406592","conversation_id":"1043162800439406592","entities":{"mentions":{},"hashtags":[{"start":55,"end":60,"tag":"CHMP"},{"start":76,"end":86,"tag":"medicines"}],"urls":[{"start":131,"end":154,"url":"https://t.co/yeI7JtO9W1","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003019.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":155,"end":178,"url":"https://t.co/hnpnSktN0Q","expanded_url":"https://twitter.com/EMA_News/status/1043162800439406592/photo/1","display_url":"pic.twitter.com/hnpnSktN0Q"}],"annotations":{}},"attachments":{"media_keys":["3_1043162585976201222"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":1,"like_count":7,"quote_count":3},"created_at":"2018-09-21T15:07:50.000Z","author_id":"116716199","text":"Update on #valsartan: EMA's review of impurities was extended to other sartan medicines: https://t.co/cXKcZeh010","id":"1043154843651723264","conversation_id":"1043154843651723264","entities":{"mentions":{},"hashtags":[{"start":10,"end":20,"tag":"valsartan"}],"urls":[{"start":89,"end":112,"url":"https://t.co/cXKcZeh010","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003023.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":10,"reply_count":0,"like_count":18,"quote_count":1},"created_at":"2018-09-21T14:56:05.000Z","author_id":"116716199","text":"Luxturna, a new #GeneTherapy for rare inherited disorder causing vision loss was recommended for approval: https://t.co/tZWijwbFXr #CHMP","id":"1043151887690805249","conversation_id":"1043151887690805249","entities":{"mentions":{},"hashtags":[{"start":16,"end":28,"tag":"GeneTherapy"},{"start":131,"end":136,"tag":"CHMP"}],"urls":[{"start":107,"end":130,"url":"https://t.co/tZWijwbFXr","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003025.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":13,"quote_count":2},"created_at":"2018-09-21T13:01:04.000Z","author_id":"116716199","text":"New #medicine for the prevention of #migraine recommended for approval: https://t.co/aWXjNGdIcm #CHMP","id":"1043122942085877762","conversation_id":"1043122942085877762","entities":{"mentions":{},"hashtags":[{"start":4,"end":13,"tag":"medicine"},{"start":36,"end":45,"tag":"migraine"},{"start":96,"end":101,"tag":"CHMP"}],"urls":[{"start":72,"end":95,"url":"https://t.co/aWXjNGdIcm","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003024.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":1,"like_count":4,"quote_count":0},"created_at":"2018-09-21T12:36:00.000Z","author_id":"116716199","text":"Vabomere, a combination of an #antibiotic and new beta-lactamase inhibitor was recommended for approval: https://t.co/vOLlXDDIno #antimicrobialresistance","id":"1043116635471663108","conversation_id":"1043116635471663108","entities":{"mentions":{},"hashtags":[{"start":30,"end":41,"tag":"antibiotic"},{"start":129,"end":153,"tag":"antimicrobialresistance"}],"urls":[{"start":105,"end":128,"url":"https://t.co/vOLlXDDIno","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003026.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":11,"quote_count":1},"created_at":"2018-09-21T10:06:24.000Z","author_id":"116716199","text":"Portugal to also benefit from EU-US mutual recognition agreement for inspections of manufacturing sites for human #medicines: https://t.co/lF5BI7wXsw","id":"1043078985490554880","conversation_id":"1043078985490554880","entities":{"mentions":{},"hashtags":[{"start":114,"end":124,"tag":"medicines"}],"urls":[{"start":126,"end":149,"url":"https://t.co/lF5BI7wXsw","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003022.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":[{"start":0,"end":7,"probability":0.9498,"type":"Place","normalized_text":"Portugal"},{"start":30,"end":34,"probability":0.7129,"type":"Organization","normalized_text":"EU-US"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"fr","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":7,"quote_count":1},"created_at":"2018-09-19T13:00:01.000Z","author_id":"116716199","text":"Qu'est-ce qu'un #biosimilaire? Comment EMA s‚Äôassure-t-elle que ces m√©dicaments biologiques sont s√ªrs et efficaces que tout autre m√©dicament? Regardez notre vid√©o et consultez le guide sur les biosimilaires pour les professionnels de sant√©: https://t.co/DABf6JDIKQ https://t.co/xCnwfqauKY","id":"1042397901526388737","conversation_id":"1042397901526388737","entities":{"mentions":{},"hashtags":[{"start":16,"end":29,"tag":"biosimilaire"}],"urls":[{"start":240,"end":263,"url":"https://t.co/DABf6JDIKQ","expanded_url":"https://www.youtube.com/watch?v=70sVGNVG7Jk&index=5&list=PL7K5dNgKnawb3IQri7lIr5wbaWxP71jQJ","display_url":"youtube.com/watch?v=70sVGN‚Ä¶"},{"start":264,"end":287,"url":"https://t.co/xCnwfqauKY","expanded_url":"https://twitter.com/EMA_News/status/1042397901526388737/photo/1","display_url":"pic.twitter.com/xCnwfqauKY"}],"annotations":{}},"attachments":{"media_keys":["3_1042340063051476992"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":1,"like_count":26,"quote_count":3},"created_at":"2018-09-19T09:50:36.000Z","author_id":"116716199","text":"#EMA ‚Äôs Committee for Medicinal Products for Human Use (#CHMP) elects new chair: Harald Enzmann to begin 3-year mandate from 15 October 2018: https://t.co/0ThVbDC0ah https://t.co/BS5UfvzDH8","id":"1042350235543121925","conversation_id":"1042350235543121925","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":56,"end":61,"tag":"CHMP"}],"urls":[{"start":142,"end":165,"url":"https://t.co/0ThVbDC0ah","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003020.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":166,"end":189,"url":"https://t.co/BS5UfvzDH8","expanded_url":"https://twitter.com/EMA_News/status/1042350235543121925/photo/1","display_url":"pic.twitter.com/BS5UfvzDH8"}],"annotations":[{"start":81,"end":94,"probability":0.9423,"type":"Person","normalized_text":"Harald Enzmann"}]},"attachments":{"media_keys":["3_1042350209320341504"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1042347594406608896"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":32,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-19T09:42:20.000Z","author_id":"116716199","text":"RT @EU_Health: Committed to improving the lives of #patients with #rarediseases: we have reached a total of 2000 designations of orphan med‚Ä¶","id":"1042348155604557824","conversation_id":"1042348155604557824","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":51,"end":60,"tag":"patients"},{"start":66,"end":79,"tag":"rarediseases"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1042012418912800768"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-18T13:42:57.000Z","author_id":"116716199","text":"RT @relocatemaEN: Around 03.00 am the highest point of the core of the new EMA building was reached. We talked to a foreman, construction s‚Ä¶","id":"1042046319345459201","conversation_id":"1042046319345459201","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"}],"hashtags":{},"urls":{},"annotations":[{"start":75,"end":77,"probability":0.4844,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":10,"quote_count":0},"created_at":"2018-09-17T14:30:00.000Z","author_id":"116716199","text":"See what's on the agenda of the September meeting of our Committee for medicinal products for human use: https://t.co/CLlLyaiAt9 #CHMP #medicines","id":"1041695771161026560","conversation_id":"1041695771161026560","entities":{"mentions":{},"hashtags":[{"start":129,"end":134,"tag":"CHMP"},{"start":135,"end":145,"tag":"medicines"}],"urls":[{"start":105,"end":128,"url":"https://t.co/CLlLyaiAt9","expanded_url":"https://bit.ly/2xj0VmK","display_url":"bit.ly/2xj0VmK"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1035452855312891904"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-14T13:44:27.000Z","author_id":"116716199","text":"RT @relocatemaEN: A glimpse into the work platform on the inside of the core of the new EMA building. @ZuidasAmsterdam @AmsterdamNL @EMA_Ne‚Ä¶","id":"1040597146033119237","conversation_id":"1040597146033119237","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"},{"start":102,"end":118,"username":"ZuidasAmsterdam","id":"193616695"},{"start":119,"end":131,"username":"AmsterdamNL","id":"31100650"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":88,"reply_count":1,"like_count":85,"quote_count":8},"created_at":"2018-09-14T09:46:51.000Z","author_id":"116716199","text":"EMA and the @EU_Commission have published the #biosimilar guide for #HealthcareProfessionals in eight EU languages. Find them here: https://t.co/nxOQZYHxpX https://t.co/3br4YBPQpi","id":"1040537351150284800","conversation_id":"1040537351150284800","entities":{"mentions":[{"start":12,"end":26,"username":"EU_Commission","id":"157981564"}],"hashtags":[{"start":46,"end":57,"tag":"biosimilar"},{"start":68,"end":92,"tag":"HealthcareProfessionals"}],"urls":[{"start":132,"end":155,"url":"https://t.co/nxOQZYHxpX","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003016.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":156,"end":179,"url":"https://t.co/3br4YBPQpi","expanded_url":"https://twitter.com/EMA_News/status/1040537351150284800/photo/1","display_url":"pic.twitter.com/3br4YBPQpi"}],"annotations":{}},"attachments":{"media_keys":["3_1040536721472073728"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":1,"like_count":15,"quote_count":0},"created_at":"2018-09-14T08:24:00.000Z","author_id":"116716199","text":"EMA's Committee for Orphan Medicinal Products (#COMP) has elected Dr Violeta Stoyanova-Beninska as its new chair for a three-year mandate: https://t.co/i3rUgH8CSF https://t.co/NgvH2zKoLv","id":"1040516500833153024","conversation_id":"1040516500833153024","entities":{"mentions":{},"hashtags":[{"start":47,"end":52,"tag":"COMP"}],"urls":[{"start":139,"end":162,"url":"https://t.co/i3rUgH8CSF","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003017.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":163,"end":186,"url":"https://t.co/NgvH2zKoLv","expanded_url":"https://twitter.com/EMA_News/status/1040516500833153024/photo/1","display_url":"pic.twitter.com/NgvH2zKoLv"}],"annotations":[{"start":20,"end":44,"probability":0.305,"type":"Organization","normalized_text":"Orphan Medicinal Products"},{"start":66,"end":85,"probability":0.7154,"type":"Person","normalized_text":"Dr Violeta Stoyanova"}]},"attachments":{"media_keys":["3_1040254884241653760"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1040209565143449600"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-13T15:12:53.000Z","author_id":"116716199","text":"RT @EFA_Patients: Can you imagine people staring at you all the time because you look different? This is what people with #AtopicEczema som‚Ä¶","id":"1040257010539941888","conversation_id":"1040257010539941888","entities":{"mentions":[{"start":3,"end":16,"username":"EFA_Patients","id":"1299643704"}],"hashtags":[{"start":122,"end":135,"tag":"AtopicEczema"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":83,"reply_count":0,"like_count":87,"quote_count":6},"created_at":"2018-09-13T10:34:11.000Z","author_id":"116716199","text":"What is a #biosimilar? How does #EMA ensure that these #BiologicalMedicines are as safe and effective as any other medicine? Watch our new video available in 8 EU languages: \nhttps://t.co/nxOQZYHxpX https://t.co/fZoqC3f46O","id":"1040186873719783424","conversation_id":"1040186873719783424","entities":{"mentions":{},"hashtags":[{"start":10,"end":21,"tag":"biosimilar"},{"start":32,"end":36,"tag":"EMA"},{"start":55,"end":75,"tag":"BiologicalMedicines"}],"urls":[{"start":175,"end":198,"url":"https://t.co/nxOQZYHxpX","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003016.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":199,"end":222,"url":"https://t.co/fZoqC3f46O","expanded_url":"https://twitter.com/EMA_News/status/1040186873719783424/photo/1","display_url":"pic.twitter.com/fZoqC3f46O"}],"annotations":{}},"attachments":{"media_keys":["3_1040186625731579905"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1040176054407708673"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-13T10:00:49.000Z","author_id":"116716199","text":"RT @relocatemaEN: Something to be proud of: building the core of the new EMA building in a few weeks. Work in progress. @EMA_News @Amsterda‚Ä¶","id":"1040178478577070080","conversation_id":"1040178478577070080","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"},{"start":120,"end":129,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":12,"quote_count":4},"created_at":"2018-09-13T09:18:33.000Z","author_id":"116716199","text":"See our latest update on EMA's review of #valsartan medicines: https://t.co/cF7jY8SPTD","id":"1040167841427873793","conversation_id":"1040167841427873793","entities":{"mentions":{},"hashtags":[{"start":41,"end":51,"tag":"valsartan"}],"urls":[{"start":63,"end":86,"url":"https://t.co/cF7jY8SPTD","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/09/news_detail_003015.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":[{"start":25,"end":27,"probability":0.3491,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1040124231311405056"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":47,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-13T08:24:55.000Z","author_id":"116716199","text":"RT @V_Andriukaitis: Important to keep #AMR #antimicrobialresistance high on the agenda. It is a real #health threat globally. \nüî¥Discussion‚Ä¶","id":"1040154343385825280","conversation_id":"1040154343385825280","entities":{"mentions":[{"start":3,"end":18,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":38,"end":42,"tag":"AMR"},{"start":43,"end":67,"tag":"antimicrobialresistance"},{"start":101,"end":108,"tag":"health"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2018-09-12T08:51:11.000Z","author_id":"116716199","text":"We are experiencing issues with our external internet provider, therefore EMA services are not available for external users at this moment. IT colleagues are working to fix the problem as quickly as possible.","id":"1039798567274274816","conversation_id":"1039798567274274816","entities":{"mentions":{},"hashtags":{},"urls":{},"annotations":[{"start":74,"end":76,"probability":0.5029,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":0,"like_count":29,"quote_count":1},"created_at":"2018-09-12T08:30:00.000Z","author_id":"116716199","text":"How many European electronic #healthcare databases are readily available to be used in medicine regulation? Read more in a new BMJ article. https://t.co/wpTxI4cD6P @bmj_latest https://t.co/pXhImnJefO","id":"1039793235881803776","conversation_id":"1039793235881803776","entities":{"mentions":[{"start":164,"end":175,"username":"bmj_latest","id":"16949344"}],"hashtags":[{"start":29,"end":40,"tag":"healthcare"}],"urls":[{"start":140,"end":163,"url":"https://t.co/wpTxI4cD6P","expanded_url":"https://bmjopen.bmj.com/content/8/9/e023090.full","display_url":"bmjopen.bmj.com/content/8/9/e0‚Ä¶"},{"start":176,"end":199,"url":"https://t.co/pXhImnJefO","expanded_url":"https://twitter.com/EMA_News/status/1039793235881803776/photo/1","display_url":"pic.twitter.com/pXhImnJefO"}],"annotations":{}},"attachments":{"media_keys":["3_1039552194503221248"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1039291239043137536"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-11T08:36:07.000Z","author_id":"116716199","text":"RT @TGAgovau: This week at #ICMRA Summit 2018, international medicines regulator leaders talk biosimilars and regenerative medicine. @US_FD‚Ä¶","id":"1039432386264657921","conversation_id":"1039432386264657921","entities":{"mentions":[{"start":3,"end":12,"username":"TGAgovau","id":"3800463014"}],"hashtags":[{"start":27,"end":33,"tag":"ICMRA"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1039082600160219136"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-09-10T14:53:11.000Z","author_id":"116716199","text":"RT @EU2018AT: üá¶üáπüá™üá∫ What‚Äòs on the #eu2018at agenda for the informal meeting of the EU #health ministers in #Vienna? Have a look üëá\n#epsco #di‚Ä¶","id":"1039164890924101632","conversation_id":"1039164890924101632","entities":{"mentions":[{"start":3,"end":12,"username":"eu2018at","id":"1101202211277815808"}],"hashtags":[{"start":33,"end":42,"tag":"eu2018at"},{"start":85,"end":92,"tag":"health"},{"start":106,"end":113,"tag":"Vienna"},{"start":129,"end":135,"tag":"epsco"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":5,"reply_count":0,"like_count":10,"quote_count":3},"created_at":"2018-09-07T12:48:00.000Z","author_id":"116716199","text":"EMA's #Pharmacovigilance Committee elects Dr Martin Huber from Germany as new vice-chair: https://t.co/bVPAVriGfz #PRAC","id":"1038046223620435969","conversation_id":"1038046223620435969","entities":{"mentions":{},"hashtags":[{"start":6,"end":24,"tag":"Pharmacovigilance"},{"start":114,"end":119,"tag":"PRAC"}],"urls":[{"start":90,"end":113,"url":"https://t.co/bVPAVriGfz","expanded_url":"https://bit.ly/2CvXVIN","display_url":"bit.ly/2CvXVIN"}],"annotations":[{"start":42,"end":56,"probability":0.8078,"type":"Person","normalized_text":"Dr Martin Huber"},{"start":63,"end":69,"probability":0.9949,"type":"Place","normalized_text":"Germany"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":11,"quote_count":1},"created_at":"2018-09-03T16:07:00.000Z","author_id":"116716199","text":"See what's on the agenda of the #Pharmacovigilance Risk Assessment Committee meeting in September: https://t.co/Ix8Qe32zcF #PRAC","id":"1036646752319938562","conversation_id":"1036646752319938562","entities":{"mentions":{},"hashtags":[{"start":32,"end":50,"tag":"Pharmacovigilance"},{"start":123,"end":128,"tag":"PRAC"}],"urls":[{"start":99,"end":122,"url":"https://t.co/Ix8Qe32zcF","expanded_url":"https://bit.ly/2wEQ2LB","display_url":"bit.ly/2wEQ2LB"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":77,"reply_count":2,"like_count":72,"quote_count":3},"created_at":"2018-09-03T09:10:00.000Z","author_id":"116716199","text":"What is #EMA doing to support the development of #medicines for patients with #rarediseases? See how #orphan medicine designation works: https://t.co/UacwF56DZb https://t.co/3DoucmfzBZ","id":"1036541810590580736","conversation_id":"1036541810590580736","entities":{"mentions":{},"hashtags":[{"start":8,"end":12,"tag":"EMA"},{"start":49,"end":59,"tag":"medicines"},{"start":78,"end":91,"tag":"rarediseases"},{"start":101,"end":108,"tag":"orphan"}],"urls":[{"start":137,"end":160,"url":"https://t.co/UacwF56DZb","expanded_url":"https://bit.ly/2CQZZ9q","display_url":"bit.ly/2CQZZ9q"},{"start":161,"end":184,"url":"https://t.co/3DoucmfzBZ","expanded_url":"https://twitter.com/EMA_News/status/1036541810590580736/photo/1","display_url":"pic.twitter.com/3DoucmfzBZ"}],"annotations":{}},"attachments":{"media_keys":["3_1036540373794004992"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":0,"like_count":19,"quote_count":5},"created_at":"2018-08-31T11:35:00.000Z","author_id":"116716199","text":"#EMA has updated its relocation tracking tool, including a new work stream on removal and logistics. The tool provides an overview of the main milestones and deliverables for the Agency‚Äôs move to Amsterdam https://t.co/pVvEK9ikaO https://t.co/9el4IzqxXk","id":"1035491137455251456","conversation_id":"1035491137455251456","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"}],"urls":[{"start":206,"end":229,"url":"https://t.co/pVvEK9ikaO","expanded_url":"https://bit.ly/2oONC8q","display_url":"bit.ly/2oONC8q"},{"start":230,"end":253,"url":"https://t.co/9el4IzqxXk","expanded_url":"https://twitter.com/EMA_News/status/1035491137455251456/photo/1","display_url":"pic.twitter.com/9el4IzqxXk"}],"annotations":[{"start":196,"end":204,"probability":0.9803,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1035489174428807169"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":21,"quote_count":4},"created_at":"2018-08-29T13:00:00.000Z","author_id":"116716199","text":"Towards improving the availability of #medicines - Task force set up by EU regulators publishes its work programme 2019/20 and prepares a multi-stakeholder workshop https://t.co/F43WnsSnIL","id":"1034787754335457280","conversation_id":"1034787754335457280","entities":{"mentions":{},"hashtags":[{"start":38,"end":48,"tag":"medicines"}],"urls":[{"start":165,"end":188,"url":"https://t.co/F43WnsSnIL","expanded_url":"https://bit.ly/2LB6wZY","display_url":"bit.ly/2LB6wZY"}],"annotations":[{"start":72,"end":73,"probability":0.9026,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":108,"reply_count":1,"like_count":109,"quote_count":8},"created_at":"2018-08-28T16:05:00.000Z","author_id":"116716199","text":"Children and babies react differently to #medicines. See how EMA supports the development of medicines tailored for children‚Äôs specific therapeutic needs: https://t.co/q4pMU4RXKM https://t.co/jHxdqcGuKO","id":"1034471923873447937","conversation_id":"1034471923873447937","entities":{"mentions":{},"hashtags":[{"start":41,"end":51,"tag":"medicines"}],"urls":[{"start":155,"end":178,"url":"https://t.co/q4pMU4RXKM","expanded_url":"https://bit.ly/2JbhsfA","display_url":"bit.ly/2JbhsfA"},{"start":179,"end":202,"url":"https://t.co/jHxdqcGuKO","expanded_url":"https://twitter.com/EMA_News/status/1034471923873447937/photo/1","display_url":"pic.twitter.com/jHxdqcGuKO"}],"annotations":[{"start":61,"end":63,"probability":0.4098,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1034470051729035264"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":56,"reply_count":0,"like_count":42,"quote_count":8},"created_at":"2018-08-23T12:28:53.000Z","author_id":"116716199","text":"Read the Brexit-related guidance for companies prepared by #EMA and the European Commission: https://t.co/jwy0svo1qf #Brexit @EU_Health https://t.co/rpyjkMJfrR","id":"1032605594572734464","conversation_id":"1032605594572734464","entities":{"mentions":[{"start":125,"end":135,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":59,"end":63,"tag":"EMA"},{"start":117,"end":124,"tag":"Brexit"}],"urls":[{"start":93,"end":116,"url":"https://t.co/jwy0svo1qf","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/about_us/general/general_content_001891.jsp&mid=WC0b01ac0580cb2e5b","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":136,"end":159,"url":"https://t.co/rpyjkMJfrR","expanded_url":"https://twitter.com/EMA_News/status/1032605594572734464/photo/1","display_url":"pic.twitter.com/rpyjkMJfrR"}],"annotations":[{"start":72,"end":90,"probability":0.5596,"type":"Organization","normalized_text":"European Commission"}]},"attachments":{"media_keys":["3_1032605503401197570"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":58,"reply_count":0,"like_count":62,"quote_count":6},"created_at":"2018-08-22T14:17:31.000Z","author_id":"116716199","text":"Watch this video to find out how #EMA monitors medicines once they are on the market: https://t.co/oSvgc6Z32j https://t.co/L8j3IfGyR3","id":"1032270545331601409","conversation_id":"1032270545331601409","entities":{"mentions":{},"hashtags":[{"start":33,"end":37,"tag":"EMA"}],"urls":[{"start":86,"end":109,"url":"https://t.co/oSvgc6Z32j","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/08/news_detail_003010.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":110,"end":133,"url":"https://t.co/L8j3IfGyR3","expanded_url":"https://twitter.com/EMA_News/status/1032270545331601409/video/1","display_url":"pic.twitter.com/L8j3IfGyR3"}],"annotations":{}},"attachments":{"media_keys":["7_1032269899673096194"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1031454303481999362"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":257,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-08-22T09:42:45.000Z","author_id":"116716199","text":"RT @WHO_Europe: More than 41,000 children and adults in the European Region have been infected with #measles in the first 6 months of 2018.‚Ä¶","id":"1032201397901684737","conversation_id":"1032201397901684737","entities":{"mentions":[{"start":3,"end":14,"username":"WHO_Europe","id":"125403342"}],"hashtags":[{"start":100,"end":108,"tag":"measles"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":40,"reply_count":1,"like_count":31,"quote_count":4},"created_at":"2018-08-20T14:15:00.000Z","author_id":"116716199","text":"Update on #valsartan review - The company Zhejiang Tianyu is no longer authorised to manufacture valsartan active substance for EU #medicines due to presence of NDMA https://t.co/Ulo7ISlGG5","id":"1031545137351065602","conversation_id":"1031545137351065602","entities":{"mentions":{},"hashtags":[{"start":10,"end":20,"tag":"valsartan"},{"start":131,"end":141,"tag":"medicines"}],"urls":[{"start":166,"end":189,"url":"https://t.co/Ulo7ISlGG5","expanded_url":"https://bit.ly/2ORbVxN","display_url":"bit.ly/2ORbVxN"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":136,"reply_count":2,"like_count":177,"quote_count":28},"created_at":"2018-08-15T14:16:54.000Z","author_id":"116716199","text":"Our video explains what it takes to develop a #medicine and to get it authorised: https://t.co/3ATGWRqO4g https://t.co/Oqj5fepdub","id":"1029733675079028736","conversation_id":"1029733675079028736","entities":{"mentions":{},"hashtags":[{"start":46,"end":55,"tag":"medicine"}],"urls":[{"start":82,"end":105,"url":"https://t.co/3ATGWRqO4g","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/08/news_detail_003005.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"},{"start":106,"end":129,"url":"https://t.co/Oqj5fepdub","expanded_url":"https://twitter.com/EMA_News/status/1029733675079028736/video/1","display_url":"pic.twitter.com/Oqj5fepdub"}],"annotations":{}},"attachments":{"media_keys":["7_1029733134462603264"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":27,"reply_count":1,"like_count":36,"quote_count":5},"created_at":"2018-08-15T11:33:14.000Z","author_id":"116716199","text":"See how the construction of EMA's new building in Amsterdam is progressing: https://t.co/fdXoWLKvzq @relocatemaEN https://t.co/Gq7lPtUmvB","id":"1029692489521942528","conversation_id":"1029692489521942528","entities":{"mentions":[{"start":100,"end":113,"username":"relocatemaEN","id":"1005070894602039296"}],"hashtags":{},"urls":[{"start":76,"end":99,"url":"https://t.co/fdXoWLKvzq","expanded_url":"https://english.relocatema.nl/new-and-temporary-premises/photos-new-building/6-august-2018","display_url":"english.relocatema.nl/new-and-tempor‚Ä¶"},{"start":114,"end":137,"url":"https://t.co/Gq7lPtUmvB","expanded_url":"https://twitter.com/EMA_News/status/1029692489521942528/photo/1","display_url":"pic.twitter.com/Gq7lPtUmvB"}],"annotations":[{"start":28,"end":30,"probability":0.2644,"type":"Place","normalized_text":"EMA"},{"start":50,"end":58,"probability":0.9964,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":["3_1029692438452097026"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1029677153582030849"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":8,"quote_count":0},"created_at":"2018-08-15T11:20:56.000Z","author_id":"116716199","text":"@pro_patient @eupatientsforum @healthparl We are grateful to #patient representatives who work with #EMA to make information on medicines more understandable.","id":"1029689393748078592","conversation_id":"1029677153582030849","entities":{"mentions":[{"start":0,"end":12,"username":"pro_patient","id":"912332762752962561"},{"start":13,"end":29,"username":"eupatientsforum","id":"545343465"},{"start":30,"end":41,"username":"healthparl","id":"2816655812"}],"hashtags":[{"start":61,"end":69,"tag":"patient"},{"start":100,"end":104,"tag":"EMA"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"912332762752962561"},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1029015335830093825"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-08-14T08:39:20.000Z","author_id":"116716199","text":"RT @relocatemaEN: The concrete casting for the core of the new EMA building starts today.\nThis 'sliding process' continues 24 hours a day a‚Ä¶","id":"1029286334945533952","conversation_id":"1029286334945533952","entities":{"mentions":[{"start":3,"end":16,"username":"relocatemaEN","id":"1005070894602039296"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":18,"quote_count":2},"created_at":"2018-08-14T07:05:00.000Z","author_id":"116716199","text":"Reporting #SideEffects is crucial to protect animal and human #health. Check EMA's bulletin on the #veterinary #pharmacovigilance activities: https://t.co/yLOIM5yR4Y https://t.co/P96owHZmY3","id":"1029262596275240963","conversation_id":"1029262596275240963","entities":{"mentions":{},"hashtags":[{"start":10,"end":22,"tag":"SideEffects"},{"start":62,"end":69,"tag":"health"},{"start":99,"end":110,"tag":"veterinary"},{"start":111,"end":129,"tag":"pharmacovigilance"}],"urls":[{"start":142,"end":165,"url":"https://t.co/yLOIM5yR4Y","expanded_url":"http://bit.ly/2wcOK9R","display_url":"bit.ly/2wcOK9R"},{"start":166,"end":189,"url":"https://t.co/P96owHZmY3","expanded_url":"https://twitter.com/EMA_News/status/1029262596275240963/photo/1","display_url":"pic.twitter.com/P96owHZmY3"}],"annotations":{}},"attachments":{"media_keys":["3_1029046228682768385"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":13,"quote_count":4},"created_at":"2018-08-10T14:18:49.000Z","author_id":"116716199","text":"Update on the review of #valsartan medicines due to detection of NDMA: https://t.co/1ZvyrSMUTj","id":"1027922219245162496","conversation_id":"1027922219245162496","entities":{"mentions":{},"hashtags":[{"start":24,"end":34,"tag":"valsartan"}],"urls":[{"start":71,"end":94,"url":"https://t.co/1ZvyrSMUTj","expanded_url":"http://bit.ly/2M51mdL","display_url":"bit.ly/2M51mdL"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":43,"reply_count":0,"like_count":40,"quote_count":5},"created_at":"2018-08-08T15:10:02.000Z","author_id":"116716199","text":"Find out what #EMA is in a nutshell and how it protects #patients across the EU: https://t.co/o6fnFBr4Pe https://t.co/Aw6DYDG2vo","id":"1027210332723441666","conversation_id":"1027210332723441666","entities":{"mentions":{},"hashtags":[{"start":14,"end":18,"tag":"EMA"},{"start":56,"end":65,"tag":"patients"}],"urls":[{"start":81,"end":104,"url":"https://t.co/o6fnFBr4Pe","expanded_url":"http://bit.ly/2AT3lwD","display_url":"bit.ly/2AT3lwD"},{"start":105,"end":128,"url":"https://t.co/Aw6DYDG2vo","expanded_url":"https://twitter.com/EMA_News/status/1027210332723441666/video/1","display_url":"pic.twitter.com/Aw6DYDG2vo"}],"annotations":{}},"attachments":{"media_keys":["7_1027209752810532864"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":21,"reply_count":0,"like_count":16,"quote_count":1},"created_at":"2018-08-03T08:21:18.000Z","author_id":"116716199","text":"During its July 2018 meeting, EMA's Committee for Medicinal Products for Human Use reviewed 5 recommendations for eligibility to #PRIME: 2 were granted and 3 were denied. #CHMP https://t.co/uhThMcM4Dt https://t.co/3FKYYa8rjY","id":"1025295533705973760","conversation_id":"1025295533705973760","entities":{"mentions":{},"hashtags":[{"start":129,"end":135,"tag":"PRIME"},{"start":171,"end":176,"tag":"CHMP"}],"urls":[{"start":177,"end":200,"url":"https://t.co/uhThMcM4Dt","expanded_url":"http://bit.ly/2LVSLcm","display_url":"bit.ly/2LVSLcm"},{"start":201,"end":224,"url":"https://t.co/3FKYYa8rjY","expanded_url":"https://twitter.com/EMA_News/status/1025295533705973760/photo/1","display_url":"pic.twitter.com/3FKYYa8rjY"}],"annotations":[{"start":30,"end":32,"probability":0.4498,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":["3_1025295270693797888"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":1,"like_count":16,"quote_count":2},"created_at":"2018-08-02T11:30:00.000Z","author_id":"116716199","text":"We have just published an update on the review of recalled #valsartan medicines, including a preliminary assessment of possible risk to patients: https://t.co/HJzFLCphGu","id":"1024980631535722497","conversation_id":"1024980631535722497","entities":{"mentions":{},"hashtags":[{"start":59,"end":69,"tag":"valsartan"}],"urls":[{"start":146,"end":169,"url":"https://t.co/HJzFLCphGu","expanded_url":"https://bit.ly/2vsy5yx","display_url":"bit.ly/2vsy5yx"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":75,"reply_count":3,"like_count":46,"quote_count":18},"created_at":"2018-08-01T14:02:51.000Z","author_id":"116716199","text":"Starting in October, #EMA will further temporarily scale back and suspend activities to safeguard core business while preparing for the physical move to Amsterdam in March 2019: https://t.co/8iNE9HakJ8 #Brexit","id":"1024656709682429953","conversation_id":"1024656709682429953","entities":{"mentions":{},"hashtags":[{"start":21,"end":25,"tag":"EMA"},{"start":202,"end":209,"tag":"Brexit"}],"urls":[{"start":178,"end":201,"url":"https://t.co/8iNE9HakJ8","expanded_url":"http://bit.ly/2vmHR52","display_url":"bit.ly/2vmHR52"}],"annotations":[{"start":153,"end":161,"probability":0.9747,"type":"Place","normalized_text":"Amsterdam"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":101,"reply_count":1,"like_count":81,"quote_count":5},"created_at":"2018-08-01T10:31:53.000Z","author_id":"116716199","text":"The European Network of Centres for #Pharmacoepidemiology &amp; #Pharmacovigilance (ENCePP) has updated its Guide on Methodological Standards in Pharmacoepidemiology with new guidance on studying the use and effects of #medicines in real-life studies: https://t.co/O8G1R5Tjth https://t.co/zCKqGTgzeu","id":"1024603620279558144","conversation_id":"1024603620279558144","entities":{"mentions":{},"hashtags":[{"start":36,"end":57,"tag":"Pharmacoepidemiology"},{"start":64,"end":82,"tag":"Pharmacovigilance"},{"start":219,"end":229,"tag":"medicines"}],"urls":[{"start":252,"end":275,"url":"https://t.co/O8G1R5Tjth","expanded_url":"http://bit.ly/29G7THk","display_url":"bit.ly/29G7THk"},{"start":276,"end":299,"url":"https://t.co/zCKqGTgzeu","expanded_url":"https://twitter.com/EMA_News/status/1024603620279558144/photo/1","display_url":"pic.twitter.com/zCKqGTgzeu"}],"annotations":{}},"attachments":{"media_keys":["3_1024603586121093120"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":19,"quote_count":0},"created_at":"2018-07-30T08:00:00.000Z","author_id":"116716199","text":"Contribute to improving the benefit and risk assessment of #vaccines. Take part in a public consultation launched by @ECDC_EU by sharing your comments until 3 August 2018, 17:30 (Stockholm time): https://t.co/qJP6RZVFiP","id":"1023840619456851968","conversation_id":"1023840619456851968","entities":{"mentions":[{"start":117,"end":125,"username":"ECDC_EU","id":"204752573"}],"hashtags":[{"start":59,"end":68,"tag":"vaccines"}],"urls":[{"start":196,"end":219,"url":"https://t.co/qJP6RZVFiP","expanded_url":"http://bit.ly/2JYGiQl","display_url":"bit.ly/2JYGiQl"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":16,"quote_count":1},"created_at":"2018-07-28T09:00:01.000Z","author_id":"116716199","text":"Today is #WorldHepatitisDay. EMA supports the fight against this disease by facilitating #patients' access to medicines. #Hepatitis https://t.co/dkYPNH2bRA","id":"1023130946638295040","conversation_id":"1023130946638295040","entities":{"mentions":{},"hashtags":[{"start":9,"end":27,"tag":"WorldHepatitisDay"},{"start":89,"end":98,"tag":"patients"},{"start":121,"end":131,"tag":"Hepatitis"}],"urls":[{"start":132,"end":155,"url":"https://t.co/dkYPNH2bRA","expanded_url":"https://twitter.com/EMA_News/status/1023130946638295040/photo/1","display_url":"pic.twitter.com/dkYPNH2bRA"}],"annotations":{}},"attachments":{"media_keys":["3_1022881531772198917"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1022832988147666945"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":1,"like_count":0,"quote_count":0},"created_at":"2018-07-27T15:33:25.000Z","author_id":"116716199","text":"@rpg7twit Thanks for your question. The maximum is 67 days.","id":"1022867560390451201","conversation_id":"1022832988147666945","entities":{"mentions":[{"start":0,"end":9,"username":"rpg7twit","id":"15577562"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"15577562"},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":26,"reply_count":0,"like_count":20,"quote_count":4},"created_at":"2018-07-27T12:40:00.000Z","author_id":"116716199","text":"#CHMP recommends 16 #medicines for approval at its July 2018 meeting: https://t.co/2SfIGJJK1l https://t.co/ogk52XaF5k","id":"1022823919797977088","conversation_id":"1022823919797977088","entities":{"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"CHMP"},{"start":20,"end":30,"tag":"medicines"}],"urls":[{"start":70,"end":93,"url":"https://t.co/2SfIGJJK1l","expanded_url":"https://bit.ly/2LtRZUH","display_url":"bit.ly/2LtRZUH"},{"start":94,"end":117,"url":"https://t.co/ogk52XaF5k","expanded_url":"https://twitter.com/EMA_News/status/1022823919797977088/photo/1","display_url":"pic.twitter.com/ogk52XaF5k"}],"annotations":{}},"attachments":{"media_keys":["3_1022821517015633920"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":7,"quote_count":0},"created_at":"2018-07-27T12:35:00.000Z","author_id":"116716199","text":"New #medicine for hereditary rare disease recommended for approval: https://t.co/iz5yswmzzz #CHMP","id":"1022822662043627521","conversation_id":"1022822662043627521","entities":{"mentions":{},"hashtags":[{"start":4,"end":13,"tag":"medicine"},{"start":92,"end":97,"tag":"CHMP"}],"urls":[{"start":68,"end":91,"url":"https://t.co/iz5yswmzzz","expanded_url":"https://bit.ly/2LHiHZ5","display_url":"bit.ly/2LHiHZ5"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":6,"reply_count":0,"like_count":4,"quote_count":0},"created_at":"2018-07-27T12:30:00.000Z","author_id":"116716199","text":"Two new #paediatric-use marketing authorisations recommended by #CHMP https://t.co/RP7fWwmVmK","id":"1022821403261689857","conversation_id":"1022821403261689857","entities":{"mentions":{},"hashtags":[{"start":8,"end":19,"tag":"paediatric"},{"start":64,"end":69,"tag":"CHMP"}],"urls":[{"start":70,"end":93,"url":"https://t.co/RP7fWwmVmK","expanded_url":"https://bit.ly/2mLHgWN","display_url":"bit.ly/2mLHgWN"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1021385997706244097"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":22,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-24T12:58:25.000Z","author_id":"116716199","text":"RT @POST_UK: The Government has launched a new Antimicrobial Resistance \ncompetition that will award ¬£10 million over the coming years. Wit‚Ä¶","id":"1021741391628652544","conversation_id":"1021741391628652544","entities":{"mentions":[{"start":3,"end":11,"username":"POST_UK","id":"22506791"}],"hashtags":{},"urls":{},"annotations":[{"start":13,"end":26,"probability":0.6729,"type":"Organization","normalized_text":"The Government"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":7,"quote_count":1},"created_at":"2018-07-23T13:01:00.000Z","author_id":"116716199","text":"Check out the agenda of the July meeting of our Committee for medicinal products for human use: https://t.co/xDVer6lFSM #CHMP #medicines","id":"1021379654123261954","conversation_id":"1021379654123261954","entities":{"mentions":{},"hashtags":[{"start":120,"end":125,"tag":"CHMP"},{"start":126,"end":136,"tag":"medicines"}],"urls":[{"start":96,"end":119,"url":"https://t.co/xDVer6lFSM","expanded_url":"https://bit.ly/2uIrd0x","display_url":"bit.ly/2uIrd0x"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1019964763231674374"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":41,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-19T15:22:22.000Z","author_id":"116716199","text":"RT @EU_Health: What is the progress of countries in implementing the global action plan on #antimicrobial resistance? \n\nGlobal tripartite d‚Ä¶","id":"1019965677787144192","conversation_id":"1019965677787144192","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":[{"start":91,"end":105,"tag":"antimicrobial"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":0,"like_count":17,"quote_count":1},"created_at":"2018-07-18T11:16:47.000Z","author_id":"116716199","text":"Read the results of our 2017 stakeholder survey on our communication activities to the public. #EMA https://t.co/bp9cbpaxIQ https://t.co/NhHT2zFpUj","id":"1019541487804141568","conversation_id":"1019541487804141568","entities":{"mentions":{},"hashtags":[{"start":95,"end":99,"tag":"EMA"}],"urls":[{"start":100,"end":123,"url":"https://t.co/bp9cbpaxIQ","expanded_url":"http://bit.ly/2JxOois","display_url":"bit.ly/2JxOois"},{"start":124,"end":147,"url":"https://t.co/NhHT2zFpUj","expanded_url":"https://twitter.com/EMA_News/status/1019541487804141568/photo/1","display_url":"pic.twitter.com/NhHT2zFpUj"}],"annotations":{}},"attachments":{"media_keys":["3_1019541465297506304"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1019501174154768386"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":0,"quote_count":0},"created_at":"2018-07-18T10:08:40.000Z","author_id":"116716199","text":"@SoniSaFr Thank you for the message. We do not have a liaison office in Japan.","id":"1019524346702913536","conversation_id":"1019500874278821888","entities":{"mentions":[{"start":0,"end":9,"username":"SoniSaFr","id":"475308529"}],"hashtags":{},"urls":{},"annotations":[{"start":72,"end":76,"probability":0.9873,"type":"Place","normalized_text":"Japan"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"475308529"},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1019415253099032577"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-18T10:07:26.000Z","author_id":"116716199","text":"@bingar21 Thank you for your message. The review is ongoing. We will update the public as soon as more information becomes available. Contact us directly if you have any further questions: https://t.co/rMxJXL615X","id":"1019524033564602369","conversation_id":"1019242369194037248","entities":{"mentions":[{"start":0,"end":9,"username":"bingar21","id":"50271949"}],"hashtags":{},"urls":[{"start":189,"end":212,"url":"https://t.co/rMxJXL615X","expanded_url":"http://bit.ly/X4lXwT","display_url":"bit.ly/X4lXwT"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"50271949"},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1019339204592111627"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":1,"quote_count":0},"created_at":"2018-07-18T10:03:10.000Z","author_id":"116716199","text":"@italianbeard There is no immediate risk. It is still too early to provide information on the longer-term risk NDMA may have posed for patients. EMA has made this aspect of the review a priority. Please contact @Aifa_ufficiale  for the list of recalled products.","id":"1019522962632921088","conversation_id":"1019339204592111627","entities":{"mentions":[{"start":0,"end":13,"username":"italianbeard","id":"2337582771"},{"start":211,"end":226,"username":"Aifa_ufficiale","id":"441940097"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"2337582771"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":35,"reply_count":0,"like_count":29,"quote_count":0},"created_at":"2018-07-17T15:28:12.000Z","author_id":"116716199","text":"We have just published an update on the review of #valsartan medicines following the detection of an impurity in the active substance: https://t.co/7cMYiIPqJT","id":"1019242369194037248","conversation_id":"1019242369194037248","entities":{"mentions":{},"hashtags":[{"start":50,"end":60,"tag":"valsartan"}],"urls":[{"start":135,"end":158,"url":"https://t.co/7cMYiIPqJT","expanded_url":"http://bit.ly/2usKvqs","display_url":"bit.ly/2usKvqs"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":37,"reply_count":0,"like_count":40,"quote_count":1},"created_at":"2018-07-17T12:58:52.000Z","author_id":"116716199","text":"EMA's 1st report on its policy on the publication of #ClinicalData provides information on the total number of documents published, the amount of commercially confidential information redacted and the anonymisation techniques used: https://t.co/CtaEFoQ7Rg","id":"1019204790570639362","conversation_id":"1019204790570639362","entities":{"mentions":{},"hashtags":[{"start":53,"end":66,"tag":"ClinicalData"}],"urls":[{"start":232,"end":255,"url":"https://t.co/CtaEFoQ7Rg","expanded_url":"http://bit.ly/2JvEzBw","display_url":"bit.ly/2JvEzBw"}],"annotations":[{"start":0,"end":2,"probability":0.3947,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":16,"quote_count":0},"created_at":"2018-07-16T12:19:14.000Z","author_id":"116716199","text":"See how the #EUAgencies contribute to the lives of everyone in Europe in this new clip from the EU Agencies Network: https://t.co/JKaMT6pkTd https://t.co/54HuiYoiJe","id":"1018832426443902977","conversation_id":"1018832426443902977","entities":{"mentions":{},"hashtags":[{"start":12,"end":23,"tag":"EUAgencies"}],"urls":[{"start":117,"end":140,"url":"https://t.co/JKaMT6pkTd","expanded_url":"https://www.youtube.com/watch?v=DwPI_ullrWo&feature=youtu.be","display_url":"youtube.com/watch?v=DwPI_u‚Ä¶"},{"start":141,"end":164,"url":"https://t.co/54HuiYoiJe","expanded_url":"https://twitter.com/EMA_News/status/1018832426443902977/photo/1","display_url":"pic.twitter.com/54HuiYoiJe"}],"annotations":[{"start":63,"end":68,"probability":0.9953,"type":"Place","normalized_text":"Europe"},{"start":96,"end":114,"probability":0.9245,"type":"Organization","normalized_text":"EU Agencies Network"}]},"attachments":{"media_keys":["3_1018832413001166849"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":5,"quote_count":2},"created_at":"2018-07-13T12:35:11.000Z","author_id":"116716199","text":"EMA's #Pharmacovigilance Committee recommends restricting the use of prostate cancer medicine #Xofigo: https://t.co/1VGUIFPGco #PRAC","id":"1017749278700331010","conversation_id":"1017749278700331010","entities":{"mentions":{},"hashtags":[{"start":6,"end":24,"tag":"Pharmacovigilance"},{"start":94,"end":101,"tag":"Xofigo"},{"start":127,"end":132,"tag":"PRAC"}],"urls":[{"start":103,"end":126,"url":"https://t.co/1VGUIFPGco","expanded_url":"http://bit.ly/2uixVd9","display_url":"bit.ly/2uixVd9"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1016672706522222592"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-12T09:21:57.000Z","author_id":"116716199","text":"@TranspariMED @ancelsantos Thank you for the message. We have seen your request and we are looking into it.","id":"1017338260782309376","conversation_id":"1016672706522222592","entities":{"mentions":[{"start":0,"end":13,"username":"TranspariMED","id":"837335683215798272"},{"start":14,"end":26,"username":"ancelsantos","id":"1408190809"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"837335683215798272"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":0,"like_count":53,"quote_count":7},"created_at":"2018-07-11T16:31:06.000Z","author_id":"116716199","text":"EMA‚Äôs #Pharmacovigilance and Risk Assessment Committee (#PRAC) elects new Chair: Sabine Straus from the Netherlands to begin three-year mandate from 3 September 2018. https://t.co/3bSFY6Cybs https://t.co/97ZCoGI2TC","id":"1017083872226500608","conversation_id":"1017083872226500608","entities":{"mentions":{},"hashtags":[{"start":6,"end":24,"tag":"Pharmacovigilance"},{"start":56,"end":61,"tag":"PRAC"}],"urls":[{"start":167,"end":190,"url":"https://t.co/3bSFY6Cybs","expanded_url":"http://bit.ly/2up5pWr","display_url":"bit.ly/2up5pWr"},{"start":191,"end":214,"url":"https://t.co/97ZCoGI2TC","expanded_url":"https://twitter.com/EMA_News/status/1017083872226500608/photo/1","display_url":"pic.twitter.com/97ZCoGI2TC"}],"annotations":[{"start":81,"end":93,"probability":0.9662,"type":"Person","normalized_text":"Sabine Straus"},{"start":104,"end":114,"probability":0.9347,"type":"Place","normalized_text":"Netherlands"}]},"attachments":{"media_keys":["3_1017083538703872003"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":1,"like_count":13,"quote_count":4},"created_at":"2018-07-10T16:28:36.000Z","author_id":"116716199","text":"#EMA identifies gaps in industry preparedness for #Brexit, following a recent survey: https://t.co/g06USSWZwR","id":"1016720856750411776","conversation_id":"1016720856750411776","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":50,"end":57,"tag":"Brexit"}],"urls":[{"start":86,"end":109,"url":"https://t.co/g06USSWZwR","expanded_url":"http://bit.ly/2u6YPVm","display_url":"bit.ly/2u6YPVm"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1016350561673842688"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-09T16:33:10.000Z","author_id":"116716199","text":"RT @EU_Health: Today, over 300 policy makers, healthcare providers &amp; patient representatives discussed about the future cooperation on Heal‚Ä¶","id":"1016359617423728641","conversation_id":"1016359617423728641","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1016306941021360128"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-09T13:29:43.000Z","author_id":"116716199","text":"RT @EU_Health: \"This is an area where the added value of Europe is huge: Europe cares  for patients and for people and we try to improve th‚Ä¶","id":"1016313450702794753","conversation_id":"1016313450702794753","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":[{"start":57,"end":62,"probability":0.9952,"type":"Place","normalized_text":"Europe"},{"start":73,"end":78,"probability":0.9817,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1016298485870682113"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":4,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-09T12:32:31.000Z","author_id":"116716199","text":"RT @EU_Health: Jane Moseley @EMA_News: Do we get the data that we need? Does data meets the needs of #HTA regulators? https://t.co/i61avrb3‚Ä¶","id":"1016299055666925568","conversation_id":"1016299055666925568","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"},{"start":28,"end":37,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":101,"end":105,"tag":"HTA"}],"urls":{},"annotations":[{"start":15,"end":26,"probability":0.9719,"type":"Person","normalized_text":"Jane Moseley"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":44,"reply_count":0,"like_count":47,"quote_count":3},"created_at":"2018-07-09T09:00:00.000Z","author_id":"116716199","text":"A safety signal is information on a new or known #SideEffect that may be caused by a #medicine and requires further investigation. Check out the key figures on #pharmacovigilance in 2017: https://t.co/Ah40V9scoS #AnnualReportEMA https://t.co/DcUjMSJ2yL","id":"1016245573962223622","conversation_id":"1016245573962223622","entities":{"mentions":{},"hashtags":[{"start":49,"end":60,"tag":"SideEffect"},{"start":85,"end":94,"tag":"medicine"},{"start":160,"end":178,"tag":"pharmacovigilance"},{"start":212,"end":228,"tag":"AnnualReportEMA"}],"urls":[{"start":188,"end":211,"url":"https://t.co/Ah40V9scoS","expanded_url":"https://bit.ly/2rl0X9M","display_url":"bit.ly/2rl0X9M"},{"start":229,"end":252,"url":"https://t.co/DcUjMSJ2yL","expanded_url":"https://twitter.com/EMA_News/status/1016245573962223622/photo/1","display_url":"pic.twitter.com/DcUjMSJ2yL"}],"annotations":{}},"attachments":{"media_keys":["3_1015220918430429184"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":51,"reply_count":0,"like_count":54,"quote_count":5},"created_at":"2018-07-06T13:20:54.000Z","author_id":"116716199","text":"What are EMA's tools to support the development of new and innovative #medicines? Check out our new infosheet: https://t.co/V9cMaDHid7 https://t.co/NVJmGTIAMB","id":"1015224068994424832","conversation_id":"1015224068994424832","entities":{"mentions":{},"hashtags":[{"start":70,"end":80,"tag":"medicines"}],"urls":[{"start":111,"end":134,"url":"https://t.co/V9cMaDHid7","expanded_url":"http://bit.ly/2IWjzUt","display_url":"bit.ly/2IWjzUt"},{"start":135,"end":158,"url":"https://t.co/NVJmGTIAMB","expanded_url":"https://twitter.com/EMA_News/status/1015224068994424832/photo/1","display_url":"pic.twitter.com/NVJmGTIAMB"}],"annotations":{}},"attachments":{"media_keys":["3_1015224010345467904"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":36,"reply_count":4,"like_count":31,"quote_count":10},"created_at":"2018-07-05T17:04:29.000Z","author_id":"116716199","text":"EMA is reviewing medicines containing the active substance valsartan that is supplied by Zhejiang Huahai Pharmaceuticals, a company in Linhai, China: https://t.co/d1sV4cj6Gp","id":"1014917948174209025","conversation_id":"1014917948174209025","entities":{"mentions":{},"hashtags":{},"urls":[{"start":150,"end":173,"url":"https://t.co/d1sV4cj6Gp","expanded_url":"http://bit.ly/2zdVgSm","display_url":"bit.ly/2zdVgSm"}],"annotations":[{"start":0,"end":2,"probability":0.6056,"type":"Organization","normalized_text":"EMA"},{"start":89,"end":119,"probability":0.7839,"type":"Organization","normalized_text":"Zhejiang Huahai Pharmaceuticals"},{"start":135,"end":147,"probability":0.6439,"type":"Place","normalized_text":"Linhai, China"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":43,"quote_count":4},"created_at":"2018-07-05T12:56:25.000Z","author_id":"116716199","text":"#EMA and @EUnetHTA continue their collaboration at a meeting on 5 July. Topics covered include #ATMPs, labelling, #OrphanMedicines and #patient registries: https://t.co/tPInUr51Mq https://t.co/NLAZ2QqdCJ","id":"1014855517087371264","conversation_id":"1014855517087371264","entities":{"mentions":[{"start":9,"end":18,"username":"EUnetHTA","id":"56493220"}],"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":95,"end":101,"tag":"ATMPs"},{"start":114,"end":130,"tag":"OrphanMedicines"},{"start":135,"end":143,"tag":"patient"}],"urls":[{"start":156,"end":179,"url":"https://t.co/tPInUr51Mq","expanded_url":"http://bit.ly/2KRgDKB","display_url":"bit.ly/2KRgDKB"},{"start":180,"end":203,"url":"https://t.co/NLAZ2QqdCJ","expanded_url":"https://twitter.com/EMA_News/status/1014855517087371264/photo/1","display_url":"pic.twitter.com/NLAZ2QqdCJ"}],"annotations":{}},"attachments":{"media_keys":["3_1014855398845710336"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":16,"reply_count":0,"like_count":16,"quote_count":0},"created_at":"2018-07-05T07:00:00.000Z","author_id":"116716199","text":"During its June 2018 meeting, #EMA reviewed 4 recommendations for eligibility to #PRIME: 3 were granted and 1 was denied. See more: https://t.co/ApOdKX60qj https://t.co/5OPs2rRlKD","id":"1014765823745904640","conversation_id":"1014765823745904640","entities":{"mentions":{},"hashtags":[{"start":30,"end":34,"tag":"EMA"},{"start":81,"end":87,"tag":"PRIME"}],"urls":[{"start":132,"end":155,"url":"https://t.co/ApOdKX60qj","expanded_url":"http://bit.ly/2u5m0hT","display_url":"bit.ly/2u5m0hT"},{"start":156,"end":179,"url":"https://t.co/5OPs2rRlKD","expanded_url":"https://twitter.com/EMA_News/status/1014765823745904640/photo/1","display_url":"pic.twitter.com/5OPs2rRlKD"}],"annotations":{}},"attachments":{"media_keys":["3_1014499183687028742"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":19,"reply_count":2,"like_count":23,"quote_count":2},"created_at":"2018-07-04T13:30:00.000Z","author_id":"116716199","text":"Transparency is at the core of EMA‚Äôs activities ‚Äì Check out the figures on requests and access to documents by citizens in 2017: https://t.co/Ah40V9aBxk #AnnualReportEMA https://t.co/TNLSQRBOK3","id":"1014501584749891585","conversation_id":"1014501584749891585","entities":{"mentions":{},"hashtags":[{"start":153,"end":169,"tag":"AnnualReportEMA"}],"urls":[{"start":129,"end":152,"url":"https://t.co/Ah40V9aBxk","expanded_url":"https://bit.ly/2rl0X9M","display_url":"bit.ly/2rl0X9M"},{"start":170,"end":193,"url":"https://t.co/TNLSQRBOK3","expanded_url":"https://twitter.com/EMA_News/status/1014501584749891585/photo/1","display_url":"pic.twitter.com/TNLSQRBOK3"}],"annotations":{}},"attachments":{"media_keys":["3_1014498860432084992"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1012629022684205057"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-07-03T16:31:16.000Z","author_id":"116716199","text":"RT @eurofound: Have you heard that .@EU_opendata is organising the 2nd edition of the #EUDatathon2018? Participants are invited to develop‚Ä¶","id":"1014184811475488771","conversation_id":"1014184811475488771","entities":{"mentions":[{"start":3,"end":13,"username":"eurofound","id":"74109828"},{"start":36,"end":48,"username":"EU_opendata","id":"115660120"}],"hashtags":[{"start":86,"end":101,"tag":"EUDatathon2018"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":15,"quote_count":2},"created_at":"2018-06-29T12:10:00.000Z","author_id":"116716199","text":"#CHMP recommends 9 #medicines for approval at its June 2018 meeting https://t.co/sgBxpTXzo2 https://t.co/z0ulI2IPJw","id":"1012669512242597888","conversation_id":"1012669512242597888","entities":{"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"CHMP"},{"start":19,"end":29,"tag":"medicines"}],"urls":[{"start":68,"end":91,"url":"https://t.co/sgBxpTXzo2","expanded_url":"https://bit.ly/2Ky9Rwj","display_url":"bit.ly/2Ky9Rwj"},{"start":92,"end":115,"url":"https://t.co/z0ulI2IPJw","expanded_url":"https://twitter.com/EMA_News/status/1012669512242597888/photo/1","display_url":"pic.twitter.com/z0ulI2IPJw"}],"annotations":{}},"attachments":{"media_keys":["3_1012667628115169281"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":63,"reply_count":0,"like_count":59,"quote_count":17},"created_at":"2018-06-29T12:05:01.000Z","author_id":"116716199","text":"First two #CARTcell #medicines recommended for approval in the European Union https://t.co/QwCo5T4hhn #CHMP","id":"1012668256660828160","conversation_id":"1012668256660828160","entities":{"mentions":{},"hashtags":[{"start":10,"end":19,"tag":"CARTcell"},{"start":20,"end":30,"tag":"medicines"},{"start":102,"end":107,"tag":"CHMP"}],"urls":[{"start":78,"end":101,"url":"https://t.co/QwCo5T4hhn","expanded_url":"https://bit.ly/2KvReJm","display_url":"bit.ly/2KvReJm"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":48,"reply_count":1,"like_count":59,"quote_count":7},"created_at":"2018-06-28T13:02:28.000Z","author_id":"116716199","text":"Colleagues from the #pharmacovigilance department have published an article in the BMJ discussing the limited relevance of EU-funded initiatives linked to #RealWorldEvidence for regulatory decision-making: https://t.co/7cV7keeqaB #RWE @bmj_latest https://t.co/lIIfyYWabM","id":"1012320328108986370","conversation_id":"1012320328108986370","entities":{"mentions":[{"start":235,"end":246,"username":"bmj_latest","id":"16949344"}],"hashtags":[{"start":20,"end":38,"tag":"pharmacovigilance"},{"start":155,"end":173,"tag":"RealWorldEvidence"},{"start":230,"end":234,"tag":"RWE"}],"urls":[{"start":206,"end":229,"url":"https://t.co/7cV7keeqaB","expanded_url":"http://bit.ly/2lGjGuf","display_url":"bit.ly/2lGjGuf"},{"start":247,"end":270,"url":"https://t.co/lIIfyYWabM","expanded_url":"https://twitter.com/EMA_News/status/1012320328108986370/photo/1","display_url":"pic.twitter.com/lIIfyYWabM"}],"annotations":[{"start":123,"end":131,"probability":0.5797,"type":"Organization","normalized_text":"EU-funded"}]},"attachments":{"media_keys":["3_1012314408289210368"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":41,"reply_count":0,"like_count":33,"quote_count":4},"created_at":"2018-06-27T11:14:00.000Z","author_id":"116716199","text":"#EMA carried out a total of 925 activities involving #patients and 445 activities involving #HealthcareProfessionals during 2017. Read more in our latest Stakeholder Engagement report: https://t.co/g6x8v4koFs https://t.co/0Voic7XJLP","id":"1011930641607340032","conversation_id":"1011930641607340032","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":53,"end":62,"tag":"patients"},{"start":92,"end":116,"tag":"HealthcareProfessionals"}],"urls":[{"start":185,"end":208,"url":"https://t.co/g6x8v4koFs","expanded_url":"http://bit.ly/2IvNnaf","display_url":"bit.ly/2IvNnaf"},{"start":209,"end":232,"url":"https://t.co/0Voic7XJLP","expanded_url":"https://twitter.com/EMA_News/status/1011930641607340032/photo/1","display_url":"pic.twitter.com/0Voic7XJLP"}],"annotations":{}},"attachments":{"media_keys":["3_1011930356742852608"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1011593243505709057"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-06-26T13:44:39.000Z","author_id":"116716199","text":"RT @DKMA_dk: It is official. Our Medical Chief, @NikolaiBrun is the new chair of #HMA/@EMA_News joint Task Force on Big Data. The overarchi‚Ä¶","id":"1011606167473270789","conversation_id":"1011606167473270789","entities":{"mentions":[{"start":3,"end":11,"username":"DKMA_dk","id":"826788051175211010"},{"start":48,"end":60,"username":"NikolaiBrun","id":"875273882298724352"},{"start":86,"end":95,"username":"EMA_News","id":"116716199"}],"hashtags":[{"start":81,"end":85,"tag":"HMA"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1011538330054520832"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":35,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-06-26T13:21:36.000Z","author_id":"116716199","text":"RT @EU_Health: Adopted: updated list of communicable diseases to be monitored through the EU‚Äôs epidemiological surveillance network.  \n\nOn‚Ä¶","id":"1011600364704026625","conversation_id":"1011600364704026625","entities":{"mentions":[{"start":3,"end":13,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":{},"annotations":[{"start":90,"end":91,"probability":0.5597,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":2,"reply_count":0,"like_count":6,"quote_count":2},"created_at":"2018-06-25T13:35:00.000Z","author_id":"116716199","text":"Check out the agenda of the June meeting of our Committee for medicinal products for human use: https://t.co/4wjY1XSueQ #CHMP #medicines","id":"1011241349801078787","conversation_id":"1011241349801078787","entities":{"mentions":{},"hashtags":[{"start":120,"end":125,"tag":"CHMP"},{"start":126,"end":136,"tag":"medicines"}],"urls":[{"start":96,"end":119,"url":"https://t.co/4wjY1XSueQ","expanded_url":"https://bit.ly/2IpoUDt","display_url":"bit.ly/2IpoUDt"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":20,"reply_count":0,"like_count":14,"quote_count":2},"created_at":"2018-06-25T08:00:00.000Z","author_id":"116716199","text":"Do you represent patients' associations or clinicians? This call for expressions of interest might be for you: https://t.co/rIiQq2g35I https://t.co/UqJVpZhEhD","id":"1011157045037420544","conversation_id":"1011157045037420544","entities":{"mentions":{},"hashtags":{},"urls":[{"start":111,"end":134,"url":"https://t.co/rIiQq2g35I","expanded_url":"http://bit.ly/2K0ysKV","display_url":"bit.ly/2K0ysKV"},{"start":135,"end":158,"url":"https://t.co/UqJVpZhEhD","expanded_url":"https://twitter.com/EMA_News/status/1011157045037420544/photo/1","display_url":"pic.twitter.com/UqJVpZhEhD"}],"annotations":{}},"attachments":{"media_keys":["3_1010150932250800128"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":34,"reply_count":0,"like_count":35,"quote_count":3},"created_at":"2018-06-22T13:11:21.000Z","author_id":"116716199","text":"What were the topics discussed by the @EU_Commission, #EMA, and @US_FDA during their meeting in Brussels? The focus was on the EU-US Mutual Recognition Agreement on pharmaceutical inspections, #AdvancedTherapies, generic #medicines and #RealWorldEvidence: https://t.co/zzNG7MFuqc","id":"1010148234910629888","conversation_id":"1010148234910629888","entities":{"mentions":[{"start":38,"end":52,"username":"EU_Commission","id":"157981564"},{"start":64,"end":71,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":54,"end":58,"tag":"EMA"},{"start":193,"end":211,"tag":"AdvancedTherapies"},{"start":221,"end":231,"tag":"medicines"},{"start":236,"end":254,"tag":"RealWorldEvidence"}],"urls":[{"start":256,"end":279,"url":"https://t.co/zzNG7MFuqc","expanded_url":"http://bit.ly/2IkAcJ0","display_url":"bit.ly/2IkAcJ0"}],"annotations":[{"start":96,"end":103,"probability":0.9903,"type":"Place","normalized_text":"Brussels"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":8,"quote_count":2},"created_at":"2018-06-22T11:40:28.000Z","author_id":"116716199","text":"EMA recommends for marketing authorisation the first stem cell-based #veterinary medicine, meant for horses with joint inflammation: https://t.co/KLIsuIDPDw #StemCells","id":"1010125364633522182","conversation_id":"1010125364633522182","entities":{"mentions":{},"hashtags":[{"start":69,"end":80,"tag":"veterinary"},{"start":157,"end":167,"tag":"StemCells"}],"urls":[{"start":133,"end":156,"url":"https://t.co/KLIsuIDPDw","expanded_url":"http://bit.ly/2IfBEMX","display_url":"bit.ly/2IfBEMX"}],"annotations":[{"start":0,"end":2,"probability":0.5482,"type":"Organization","normalized_text":"EMA"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1009484999429623809"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":8,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-06-21T12:32:29.000Z","author_id":"116716199","text":"RT @EP_Environment: Superbugs: MEPs advocate further measures to curb use of antimicrobials https://t.co/BhS9rKIWON #OneHealth","id":"1009776066255380480","conversation_id":"1009776066255380480","entities":{"mentions":[{"start":3,"end":18,"username":"EP_Environment","id":"951333319"}],"hashtags":[{"start":116,"end":126,"tag":"OneHealth"}],"urls":[{"start":92,"end":115,"url":"https://t.co/BhS9rKIWON","expanded_url":"http://www.europarl.europa.eu/news/en/press-room/20180620IPR06249/superbugs-meps-advocate-further-measures-to-curb-use-of-antimicrobials","display_url":"europarl.europa.eu/news/en/press-‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":3,"reply_count":0,"like_count":6,"quote_count":1},"created_at":"2018-06-21T09:01:49.000Z","author_id":"116716199","text":"Follow the live broadcast of our joint workshop with @US_FDA and PMDA on the development of #antibiotics for children: https://t.co/f1tmiXF2Bw https://t.co/U2ip9bg7e6","id":"1009723049577467904","conversation_id":"1009723049577467904","entities":{"mentions":[{"start":53,"end":60,"username":"US_FDA","id":"208120290"}],"hashtags":[{"start":92,"end":104,"tag":"antibiotics"}],"urls":[{"start":119,"end":142,"url":"https://t.co/f1tmiXF2Bw","expanded_url":"http://bit.ly/2K52vAa","display_url":"bit.ly/2K52vAa"},{"start":143,"end":166,"url":"https://t.co/U2ip9bg7e6","expanded_url":"https://twitter.com/EMA_News/status/1009723049577467904/photo/1","display_url":"pic.twitter.com/U2ip9bg7e6"}],"annotations":{}},"attachments":{"media_keys":["16_1009722422428405761"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1009563123257245696"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-06-21T08:33:31.000Z","author_id":"116716199","text":"@scuttlebuttlodg Please access this link, https://t.co/pJSTrDwxxJ, and go to the 'Public hearing' tab. You can consult the recording of the hearing, all written interventions, and the summary report.","id":"1009715929914200064","conversation_id":"1006942637490888705","entities":{"mentions":[{"start":0,"end":16,"username":"scuttlebuttlodg","id":"104657439"}],"hashtags":{},"urls":[{"start":42,"end":65,"url":"https://t.co/pJSTrDwxxJ","expanded_url":"http://bit.ly/2JTby85","display_url":"bit.ly/2JTby85"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"104657439"},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":38,"reply_count":1,"like_count":22,"quote_count":5},"created_at":"2018-06-19T15:15:00.000Z","author_id":"116716199","text":"Updated guidance for pharmaceutical companies to prepare for UK‚Äôs withdrawal from EU published: https://t.co/0Pe3BBhMZr","id":"1009092188964130818","conversation_id":"1009092188964130818","entities":{"mentions":{},"hashtags":{},"urls":[{"start":96,"end":119,"url":"https://t.co/0Pe3BBhMZr","expanded_url":"https://bit.ly/2tf1uLs","display_url":"bit.ly/2tf1uLs"}],"annotations":[{"start":61,"end":62,"probability":0.9327,"type":"Place","normalized_text":"UK"},{"start":82,"end":83,"probability":0.3723,"type":"Organization","normalized_text":"EU"}]},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1008977881345810432"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":12,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-06-19T10:15:37.000Z","author_id":"116716199","text":"RT @EAAD_EU: With our Technical Advisory Committee. EU/EEA countries, @EU_Health @whoeurope, @EUjamrai, @EMA_News &amp; professional partners a‚Ä¶","id":"1009016848090914817","conversation_id":"1009016848090914817","entities":{"mentions":[{"start":3,"end":11,"username":"EAAD_EU","id":"1725283578"},{"start":70,"end":80,"username":"EU_Health","id":"606325697"},{"start":81,"end":91,"username":"WHOEUROPE","id":"259766445"},{"start":93,"end":102,"username":"EUjamrai","id":"925330504630591488"},{"start":104,"end":113,"username":"EMA_News","id":"116716199"}],"hashtags":{},"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"retweeted","id":"1008688382145331201"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":49,"reply_count":0,"like_count":0,"quote_count":0},"created_at":"2018-06-18T15:00:38.000Z","author_id":"116716199","text":"RT @V_Andriukaitis: Oh well yes, I intend to tweet on as many positive articles on vaccines as possible. \nConsider this a #booster #vaccina‚Ä¶","id":"1008726183893139459","conversation_id":"1008726183893139459","entities":{"mentions":[{"start":3,"end":18,"username":"V_Andriukaitis","id":"575269517"}],"hashtags":[{"start":122,"end":130,"tag":"booster"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1007603220200460288"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":1,"reply_count":1,"like_count":4,"quote_count":1},"created_at":"2018-06-15T16:05:17.000Z","author_id":"116716199","text":"@TranspariMED @NicFlem @nature @benevolent_bio @bergpharma @Niven_Narain @BenchSci @WuXi_AppTec @Rbaltman @US_FDA @jsross119 @eturnermd1 @CommonsSTC @POST_UK Clinical study reports are not locked away. EMA provides access to clinical reports. Check out how we give online access to clinical data for human medicines: https://t.co/ZGZ3nrKF9W","id":"1007655291071188994","conversation_id":"1002540679640297472","entities":{"mentions":[{"start":0,"end":13,"username":"TranspariMED","id":"837335683215798272"},{"start":14,"end":22,"username":"NicFlem","id":"116916919"},{"start":23,"end":30,"username":"Nature","id":"15862891"},{"start":47,"end":58,"username":"bergpharma","id":"537318244"},{"start":59,"end":72,"username":"Niven_Narain","id":"2976864873"},{"start":73,"end":82,"username":"BenchSci","id":"2890046292"},{"start":83,"end":95,"username":"WuXi_AppTec","id":"2288833020"},{"start":96,"end":105,"username":"Rbaltman","id":"146978606"},{"start":106,"end":113,"username":"US_FDA","id":"208120290"},{"start":114,"end":124,"username":"jsross119","id":"185653786"},{"start":125,"end":136,"username":"eturnermd1","id":"4282193834"},{"start":137,"end":148,"username":"CommonsSTC","id":"988974846"},{"start":149,"end":157,"username":"POST_UK","id":"22506791"}],"hashtags":{},"urls":[{"start":317,"end":340,"url":"https://t.co/ZGZ3nrKF9W","expanded_url":"https://clinicaldata.ema.europa.eu/web/cdp/home","display_url":"clinicaldata.ema.europa.eu/web/cdp/home"}],"annotations":{}},"attachments":{"media_keys":{}},"in_reply_to_user_id":"837335683215798272"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2018-06-15T11:24:16.000Z","author_id":"116716199","text":"In June, our #Pharmacovigilance Risk Assessment Committee discussed 2 ongoing safety reviews and held a public hearing on #quinolone and #fluoroquinolone #antibiotics: https://t.co/LJ2OWiePGV #PRAC","id":"1007584571704082433","conversation_id":"1007584571704082433","entities":{"mentions":{},"hashtags":[{"start":13,"end":31,"tag":"Pharmacovigilance"},{"start":122,"end":132,"tag":"quinolone"},{"start":137,"end":153,"tag":"fluoroquinolone"},{"start":154,"end":166,"tag":"antibiotics"},{"start":192,"end":197,"tag":"PRAC"}],"urls":[{"start":168,"end":191,"url":"https://t.co/LJ2OWiePGV","expanded_url":"http://bit.ly/2JGfQzC","display_url":"bit.ly/2JGfQzC"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":11,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2018-06-15T08:40:00.000Z","author_id":"116716199","text":"Inspection and compliance activities play an important role in view of global supply chains for pharmaceuticals. The #AnnualReportEMA contains an extensive summary of our activities: https://t.co/Ah40V9aBxk https://t.co/cfLdJTIGyO","id":"1007543231482089472","conversation_id":"1007543231482089472","entities":{"mentions":{},"hashtags":[{"start":117,"end":133,"tag":"AnnualReportEMA"}],"urls":[{"start":183,"end":206,"url":"https://t.co/Ah40V9aBxk","expanded_url":"https://bit.ly/2rl0X9M","display_url":"bit.ly/2rl0X9M"},{"start":207,"end":230,"url":"https://t.co/cfLdJTIGyO","expanded_url":"https://twitter.com/EMA_News/status/1007543231482089472/photo/1","display_url":"pic.twitter.com/cfLdJTIGyO"}],"annotations":{}},"attachments":{"media_keys":["3_1007540472083025920"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":1,"like_count":16,"quote_count":1},"created_at":"2018-06-13T16:53:27.000Z","author_id":"116716199","text":"Thank you to all the participants who have shared today their experience and views on #quinolones and #fluoroquinolones during the EMA‚Äôs public hearing. A recording of the event and a summary report will be published shortly.","id":"1006942637490888705","conversation_id":"1006942637490888705","entities":{"mentions":{},"hashtags":[{"start":86,"end":97,"tag":"quinolones"},{"start":102,"end":119,"tag":"fluoroquinolones"}],"urls":{},"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1006877777688186880"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":1,"like_count":0,"quote_count":0},"created_at":"2018-06-13T12:39:44.000Z","author_id":"116716199","text":"@evamel5 The video that will be available on the EMA website will have only English subtitles generated by YouTube. We will not make available a transcript of the public hearing. However, a summary report will be published following the hearing.","id":"1006878785608830976","conversation_id":"1006822989097205760","entities":{"mentions":[{"start":0,"end":8,"username":"evamel5","id":"2793750781"}],"hashtags":{},"urls":{},"annotations":[{"start":49,"end":51,"probability":0.4858,"type":"Organization","normalized_text":"EMA"},{"start":107,"end":113,"probability":0.7468,"type":"Organization","normalized_text":"YouTube"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"2793750781"},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":39,"reply_count":0,"like_count":40,"quote_count":3},"created_at":"2018-06-13T10:30:01.000Z","author_id":"116716199","text":"Close interaction between regulators and HTAs is critical to support medicine development https://t.co/Ah40V9aBxk #AnnualReportEMA https://t.co/jLy9atxTVz","id":"1006846142339002369","conversation_id":"1006846142339002369","entities":{"mentions":{},"hashtags":[{"start":114,"end":130,"tag":"AnnualReportEMA"}],"urls":[{"start":90,"end":113,"url":"https://t.co/Ah40V9aBxk","expanded_url":"https://bit.ly/2rl0X9M","display_url":"bit.ly/2rl0X9M"},{"start":131,"end":154,"url":"https://t.co/jLy9atxTVz","expanded_url":"https://twitter.com/EMA_News/status/1006846142339002369/photo/1","display_url":"pic.twitter.com/jLy9atxTVz"}],"annotations":[{"start":41,"end":44,"probability":0.4723,"type":"Organization","normalized_text":"HTAs"}]},"attachments":{"media_keys":["3_1006817053796421634"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":2,"like_count":13,"quote_count":4},"created_at":"2018-06-13T08:58:01.000Z","author_id":"116716199","text":"You can watch the live broadcast of EMA's public hearing on #quinolones and #fluoroquinolenes, today from 13:00 to 18:00 (UK time). #EMAPublicHearing #antibiotics https://t.co/kdMl2jaJFz https://t.co/WWcGCziOEr","id":"1006822989097205760","conversation_id":"1006822989097205760","entities":{"mentions":{},"hashtags":[{"start":60,"end":71,"tag":"quinolones"},{"start":76,"end":93,"tag":"fluoroquinolenes"},{"start":132,"end":149,"tag":"EMAPublicHearing"},{"start":150,"end":162,"tag":"antibiotics"}],"urls":[{"start":163,"end":186,"url":"https://t.co/kdMl2jaJFz","expanded_url":"http://bit.ly/2LJZYZm","display_url":"bit.ly/2LJZYZm"},{"start":187,"end":210,"url":"https://t.co/WWcGCziOEr","expanded_url":"https://twitter.com/EMA_News/status/1006822989097205760/photo/1","display_url":"pic.twitter.com/WWcGCziOEr"}],"annotations":[{"start":122,"end":123,"probability":0.7596,"type":"Place","normalized_text":"UK"}]},"attachments":{"media_keys":["16_1006822845513650176"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":43,"reply_count":0,"like_count":41,"quote_count":3},"created_at":"2018-06-11T14:10:00.000Z","author_id":"116716199","text":"#EudraVigilance is a key tool for patient safety in Europe. Check out the key figures on #pharmacovigilance in 2017 https://t.co/Ah40V9aBxk #AnnualReportEMA https://t.co/IjslAHy25W","id":"1006176728417538048","conversation_id":"1006176728417538048","entities":{"mentions":{},"hashtags":[{"start":0,"end":15,"tag":"EudraVigilance"},{"start":89,"end":107,"tag":"pharmacovigilance"},{"start":140,"end":156,"tag":"AnnualReportEMA"}],"urls":[{"start":116,"end":139,"url":"https://t.co/Ah40V9aBxk","expanded_url":"https://bit.ly/2rl0X9M","display_url":"bit.ly/2rl0X9M"},{"start":157,"end":180,"url":"https://t.co/IjslAHy25W","expanded_url":"https://twitter.com/EMA_News/status/1006176728417538048/photo/1","display_url":"pic.twitter.com/IjslAHy25W"}],"annotations":[{"start":52,"end":57,"probability":0.9949,"type":"Place","normalized_text":"Europe"}]},"attachments":{"media_keys":["3_1006172225450528768"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":2,"like_count":6,"quote_count":2},"created_at":"2018-06-07T11:13:23.000Z","author_id":"116716199","text":"#EMAPublicHearing on #quinolones and #fluoroquinolones: 23 speakers from 11 EU countries to share their experience: https://t.co/ats76fB0F5 https://t.co/TwonULopzb","id":"1004682730607652864","conversation_id":"1004682730607652864","entities":{"mentions":{},"hashtags":[{"start":0,"end":17,"tag":"EMAPublicHearing"},{"start":21,"end":32,"tag":"quinolones"},{"start":37,"end":54,"tag":"fluoroquinolones"}],"urls":[{"start":116,"end":139,"url":"https://t.co/ats76fB0F5","expanded_url":"http://bit.ly/2LtQjWV","display_url":"bit.ly/2LtQjWV"},{"start":140,"end":163,"url":"https://t.co/TwonULopzb","expanded_url":"https://twitter.com/EMA_News/status/1004682730607652864/photo/1","display_url":"pic.twitter.com/TwonULopzb"}],"annotations":{}},"attachments":{"media_keys":["3_1004680073591615488"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":15,"reply_count":0,"like_count":13,"quote_count":0},"created_at":"2018-06-06T10:45:30.000Z","author_id":"116716199","text":"During its May 2018 meeting, our Committee for Medicinal Products for Human Use reviewed 8 recommendations for eligibility to #PRIME. See how many were granted: https://t.co/UlVwLDlfRz #CHMP https://t.co/LgIuS8u6Xt","id":"1004313326027984896","conversation_id":"1004313326027984896","entities":{"mentions":{},"hashtags":[{"start":126,"end":132,"tag":"PRIME"},{"start":185,"end":190,"tag":"CHMP"}],"urls":[{"start":161,"end":184,"url":"https://t.co/UlVwLDlfRz","expanded_url":"http://bit.ly/2LrKFEq","display_url":"bit.ly/2LrKFEq"},{"start":191,"end":214,"url":"https://t.co/LgIuS8u6Xt","expanded_url":"https://twitter.com/EMA_News/status/1004313326027984896/photo/1","display_url":"pic.twitter.com/LgIuS8u6Xt"}],"annotations":{}},"attachments":{"media_keys":["3_1004313167307132928"]}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":9,"reply_count":0,"like_count":10,"quote_count":1},"created_at":"2018-06-06T09:37:36.000Z","author_id":"116716199","text":"Companies are encouraged to report all suspected #SideEffects in #EudraVigilance #Veterinary, the EEA database of suspected adverse reaction reports for veterinary medicines: https://t.co/IC7nWNCiIT","id":"1004296235367485440","conversation_id":"1004296235367485440","entities":{"mentions":{},"hashtags":[{"start":49,"end":61,"tag":"SideEffects"},{"start":65,"end":80,"tag":"EudraVigilance"},{"start":81,"end":92,"tag":"Veterinary"}],"urls":[{"start":175,"end":198,"url":"https://t.co/IC7nWNCiIT","expanded_url":"http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2018/06/news_detail_002969.jsp&mid=WC0b01ac058004d5c1","display_url":"ema.europa.eu/ema/index.jsp?‚Ä¶"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":14,"reply_count":0,"like_count":15,"quote_count":3},"created_at":"2018-06-05T12:45:00.000Z","author_id":"116716199","text":"#AnnualReportEMA - Experts reflect on how EU #pharmacovigilance system has changed in the last five years https://t.co/Ah40V9scoS https://t.co/fO6leNqiqr","id":"1003981009405108225","conversation_id":"1003981009405108225","entities":{"mentions":{},"hashtags":[{"start":0,"end":16,"tag":"AnnualReportEMA"},{"start":45,"end":63,"tag":"pharmacovigilance"}],"urls":[{"start":106,"end":129,"url":"https://t.co/Ah40V9scoS","expanded_url":"https://bit.ly/2rl0X9M","display_url":"bit.ly/2rl0X9M"},{"start":130,"end":153,"url":"https://t.co/fO6leNqiqr","expanded_url":"https://twitter.com/EMA_News/status/1003981009405108225/photo/1","display_url":"pic.twitter.com/fO6leNqiqr"}],"annotations":{}},"attachments":{"media_keys":["3_1003977708995534850"]}},{"source":"Twitter Web Client","referenced_tweets":[{"type":"replied_to","id":"1003923568915369985"}],"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":0,"reply_count":0,"like_count":1,"quote_count":0},"created_at":"2018-06-05T10:49:07.000Z","author_id":"116716199","text":"@h0whardcanitbe Please send your questions to Recruitment@ema.europa.eu and we will get back to you with clarifications.","id":"1003951848192118785","conversation_id":"1003923568915369985","entities":{"mentions":[{"start":0,"end":15,"username":"h0whardcanitbe","id":"887738582651285504"}],"hashtags":{},"urls":{},"annotations":[{"start":46,"end":70,"probability":0.5806,"type":"Person","normalized_text":"Recruitment@ema.europa.eu"}]},"attachments":{"media_keys":{}},"in_reply_to_user_id":"887738582651285504"},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":7,"reply_count":0,"like_count":11,"quote_count":1},"created_at":"2018-06-01T13:32:54.000Z","author_id":"116716199","text":"Two more EU Member States benefit from EU-US mutual recognition agreement for inspections: https://t.co/Cbnip0aDO0\n@US_FDA @EU_Health","id":"1002543512775208960","conversation_id":"1002543512775208960","entities":{"mentions":[{"start":115,"end":122,"username":"US_FDA","id":"208120290"},{"start":123,"end":133,"username":"EU_Health","id":"606325697"}],"hashtags":{},"urls":[{"start":91,"end":114,"url":"https://t.co/Cbnip0aDO0","expanded_url":"http://bit.ly/2L9Cuwv","display_url":"bit.ly/2L9Cuwv"}],"annotations":[{"start":39,"end":43,"probability":0.4664,"type":"Organization","normalized_text":"EU-US"}]},"attachments":{"media_keys":{}}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":24,"reply_count":0,"like_count":16,"quote_count":3},"created_at":"2018-06-01T11:50:00.000Z","author_id":"116716199","text":"#CHMP recommends nine #medicines for approval at its May 2018 meeting https://t.co/zDnDGAch23 https://t.co/wex7fiucrT","id":"1002517617469542400","conversation_id":"1002517617469542400","entities":{"mentions":{},"hashtags":[{"start":0,"end":5,"tag":"CHMP"},{"start":22,"end":32,"tag":"medicines"}],"urls":[{"start":70,"end":93,"url":"https://t.co/zDnDGAch23","expanded_url":"https://bit.ly/2LO4dE5","display_url":"bit.ly/2LO4dE5"},{"start":94,"end":117,"url":"https://t.co/wex7fiucrT","expanded_url":"https://twitter.com/EMA_News/status/1002517617469542400/photo/1","display_url":"pic.twitter.com/wex7fiucrT"}],"annotations":{}},"attachments":{"media_keys":["3_1002514831889633280"]}},{"source":"TweetDeck","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":29,"reply_count":0,"like_count":35,"quote_count":0},"created_at":"2018-06-01T11:40:00.000Z","author_id":"116716199","text":"First monoclonal antibody therapy for prevention of #migraine recommended for approval https://t.co/ccLgRiS7Uc #CHMP","id":"1002515100778029056","conversation_id":"1002515100778029056","entities":{"mentions":{},"hashtags":[{"start":52,"end":61,"tag":"migraine"},{"start":111,"end":116,"tag":"CHMP"}],"urls":[{"start":87,"end":110,"url":"https://t.co/ccLgRiS7Uc","expanded_url":"https://bit.ly/2sxNY5c","display_url":"bit.ly/2sxNY5c"}],"annotations":{}},"attachments":{"media_keys":{}}},{"source":"Twitter Web Client","referenced_tweets":{},"possibly_sensitive":false,"lang":"en","public_metrics":{"retweet_count":13,"reply_count":1,"like_count":17,"quote_count":0},"created_at":"2018-06-01T11:39:27.000Z","author_id":"116716199","text":"#EMA recommends granting a marketing authorisation for a new medicine for the #RareDisease #TransthyretinAmyloidosis: https://t.co/VaJ9IpGQf6  \n#hATTR #CHMP","id":"1002514962240196608","conversation_id":"1002514962240196608","entities":{"mentions":{},"hashtags":[{"start":0,"end":4,"tag":"EMA"},{"start":78,"end":90,"tag":"RareDisease"},{"start":91,"end":116,"tag":"TransthyretinAmyloidosis"},{"start":144,"end":150,"tag":"hATTR"},{"start":151,"end":156,"tag":"CHMP"}],"urls":[{"start":118,"end":141,"url":"https://t.co/VaJ9IpGQf6","expanded_url":"http://bit.ly/2syLfIC","display_url":"bit.ly/2syLfIC"}],"annotations":{}},"attachments":{"media_keys":{}}}]
